0001171843-23-005467.txt : 20230829 0001171843-23-005467.hdr.sgml : 20230829 20230829160147 ACCESSION NUMBER: 0001171843-23-005467 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 90 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230829 DATE AS OF CHANGE: 20230829 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PORTAGE BIOTECH INC. CENTRAL INDEX KEY: 0001095435 STANDARD INDUSTRIAL CLASSIFICATION: CRUDE PETROLEUM & NATURAL GAS [1311] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40086 FILM NUMBER: 231221890 BUSINESS ADDRESS: STREET 1: 6 ADELAIDE ST. EAST STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5C 1H6 BUSINESS PHONE: 416-737-7600 MAIL ADDRESS: STREET 1: 6 ADELAIDE ST. EAST STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5C 1H6 FORMER COMPANY: FORMER CONFORMED NAME: BONTAN CORP INC DATE OF NAME CHANGE: 20030421 FORMER COMPANY: FORMER CONFORMED NAME: DEALCHECK COM INC DATE OF NAME CHANGE: 19990921 6-K 1 f6k_082923.htm FORM 6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August 2023

 

Commission File Number: 001-40086

 

Portage Biotech Inc.

(Translation of registrant’s name into English)

 

Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110

(Address of principal executive offices)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

 

 

 

EXHIBITS

 

Exhibit No.   Exhibit
     
99.1   Unaudited Condensed Consolidated Interim Financial Statements for the three months ended June 30, 2023. Unaudited - Prepared by Management as of August 29, 2023.
     
99.2   Management’s Discussion and Analysis for the three months ended June 30, 2023.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: August 29, 2023

 

PORTAGE BIOTECH INC.

 

By:  /s/ Allan Shaw  
  Allan Shaw  
  Chief Financial Officer  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

EX-99.1 2 exh_991.htm EXHIBIT 99.1
0001095435 false 6-K --03-31 2024 Q1 0001095435 2023-04-01 2023-06-30 0001095435 2023-06-30 0001095435 2023-03-31 0001095435 2022-04-01 2022-06-30 0001095435 ifrs-full:IssuedCapitalMember 2023-03-31 0001095435 ptgef:StockOptionReserveMember 2023-03-31 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001095435 ifrs-full:RetainedEarningsMember 2023-03-31 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2023-03-31 0001095435 ifrs-full:NoncontrollingInterestsMember 2023-03-31 0001095435 ifrs-full:IssuedCapitalMember 2022-03-31 0001095435 ptgef:StockOptionReserveMember 2022-03-31 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001095435 ifrs-full:RetainedEarningsMember 2022-03-31 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2022-03-31 0001095435 ifrs-full:NoncontrollingInterestsMember 2022-03-31 0001095435 2022-03-31 0001095435 ifrs-full:IssuedCapitalMember 2023-04-01 2023-06-30 0001095435 ptgef:StockOptionReserveMember 2023-04-01 2023-06-30 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001095435 ifrs-full:RetainedEarningsMember 2023-04-01 2023-06-30 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2023-04-01 2023-06-30 0001095435 ifrs-full:NoncontrollingInterestsMember 2023-04-01 2023-06-30 0001095435 ifrs-full:IssuedCapitalMember 2022-04-01 2022-06-30 0001095435 ptgef:StockOptionReserveMember 2022-04-01 2022-06-30 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001095435 ifrs-full:RetainedEarningsMember 2022-04-01 2022-06-30 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2022-04-01 2022-06-30 0001095435 ifrs-full:NoncontrollingInterestsMember 2022-04-01 2022-06-30 0001095435 ifrs-full:IssuedCapitalMember 2023-06-30 0001095435 ptgef:StockOptionReserveMember 2023-06-30 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001095435 ifrs-full:RetainedEarningsMember 2023-06-30 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2023-06-30 0001095435 ifrs-full:NoncontrollingInterestsMember 2023-06-30 0001095435 ifrs-full:IssuedCapitalMember 2022-06-30 0001095435 ptgef:StockOptionReserveMember 2022-06-30 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001095435 ifrs-full:RetainedEarningsMember 2022-06-30 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2022-06-30 0001095435 ifrs-full:NoncontrollingInterestsMember 2022-06-30 0001095435 2022-06-30 0001095435 ptgef:SalvaRxLimitedMember 2018-08-13 0001095435 2021-09-01 2021-09-30 0001095435 ifrs-full:BottomOfRangeMember 2021-09-01 2021-09-30 0001095435 ifrs-full:TopOfRangeMember 2021-09-01 2021-09-30 0001095435 2023-07-31 0001095435 ptgef:CountryOfBritishVirginIslandsMember 2023-04-01 2023-06-30 0001095435 ptgef:CountryOfDelawareMember 2023-04-01 2023-06-30 0001095435 ptgef:SubsidiariesTwoMember 2023-04-01 2023-06-30 0001095435 ptgef:StimunitySAMember 2023-04-01 2023-06-30 0001095435 ptgef:StimunitySAMember 2022-04-01 2023-03-31 0001095435 ptgef:StimunitySAMember 2022-04-01 2022-06-30 0001095435 2023-07-12 2023-07-13 0001095435 2022-09-11 2022-09-12 0001095435 2022-04-01 2023-03-31 0001095435 ptgef:IntensityMember ptgef:AcquisitionOfSalvaRxMember 2023-04-01 2023-06-30 0001095435 ptgef:IntensityMember ptgef:AcquisitionOfSalvaRxMember 2023-06-30 0001095435 ptgef:IntensityMember ptgef:AcquisitionOfIntensityHoldingLimitedMember 2019-07-11 0001095435 2022-10-31 0001095435 2022-11-30 0001095435 2022-12-31 0001095435 2023-04-30 0001095435 ifrs-full:BottomOfRangeMember 2023-04-30 0001095435 ifrs-full:TopOfRangeMember 2023-04-30 0001095435 ptgef:OCIMember 2022-04-01 2023-03-31 0001095435 ptgef:OCIMember 2023-03-31 0001095435 ptgef:IntensityMember 2023-07-04 2023-07-05 0001095435 ptgef:IntensityMember 2023-04-01 2023-06-30 0001095435 ptgef:IntensityMember 2023-07-06 2023-07-07 0001095435 ptgef:IntensityMember 2023-07-07 0001095435 ptgef:TarusAcquisitionMember 2023-04-01 2023-06-30 0001095435 2022-07-01 0001095435 ptgef:TarusAcquisitionMember 2023-06-30 0001095435 ptgef:TarusAcquisitionMember 2022-04-01 2022-06-30 0001095435 ptgef:IMM60IOXMelanomaLungCancersMember 2023-06-30 0001095435 ptgef:IMM60IOXMelanomaLungCancersMember 2023-03-31 0001095435 ptgef:IMM65IOXMelanomaLungCancersMember 2023-06-30 0001095435 ptgef:IMM65IOXMelanomaLungCancersMember 2023-03-31 0001095435 ptgef:IOXMember 2023-06-30 0001095435 ptgef:IOXMember 2023-03-31 0001095435 ptgef:OncomerSaugatuckDNAAptamersMember 2023-06-30 0001095435 ptgef:OncomerSaugatuckDNAAptamersMember 2023-03-31 0001095435 ptgef:TarusAdenosineReceptorsMember 2023-06-30 0001095435 ptgef:TarusAdenosineReceptorsMember 2023-03-31 0001095435 ptgef:TarusAdenosineReceptors1Member 2023-06-30 0001095435 ptgef:TarusAdenosineReceptors1Member 2023-03-31 0001095435 ptgef:TarusAdenosineReceptors2Member 2023-06-30 0001095435 ptgef:TarusAdenosineReceptors2Member 2023-03-31 0001095435 ptgef:TarusMember 2023-06-30 0001095435 ptgef:TarusMember 2023-03-31 0001095435 ptgef:IoxIPRAndDMember ifrs-full:TopOfRangeMember 2023-04-01 2023-06-30 0001095435 ptgef:IoxIPRAndDMember ifrs-full:BottomOfRangeMember 2023-04-01 2023-06-30 0001095435 ptgef:TrusIPRAndDMember ifrs-full:TopOfRangeMember 2023-04-01 2023-06-30 0001095435 ptgef:TrusIPRAndDMember ifrs-full:BottomOfRangeMember 2023-04-01 2023-06-30 0001095435 ptgef:IOXMember 2023-06-30 0001095435 ptgef:IOXMember 2023-03-31 0001095435 2021-04-01 2022-03-31 0001095435 ptgef:UnitedStateMember 2023-06-30 0001095435 ptgef:BVIMember 2023-06-30 0001095435 ptgef:CountryOfUnitedKingdomMember 2023-06-30 0001095435 ptgef:UnitedStateMember 2022-06-30 0001095435 ptgef:BVIMember 2022-06-30 0001095435 ptgef:CountryOfUnitedKingdomMember 2022-06-30 0001095435 2022-07-15 2022-07-18 0001095435 2022-07-18 0001095435 2022-07-05 2022-07-06 0001095435 ptgef:ATMMember 2022-04-01 2023-03-31 0001095435 ptgef:LincolnMember 2022-04-01 2023-03-31 0001095435 ptgef:ATMMember 2023-04-01 2023-06-30 0001095435 ptgef:N2021EquityIncentivePlanMember 2021-01-13 0001095435 ptgef:BoardOfDirectorsMember 2021-01-13 0001095435 ptgef:ConsultantsMember 2021-01-13 0001095435 ptgef:RestrictedStockUnitsMember 2021-01-12 2021-01-13 0001095435 ptgef:RestrictedStockUnitsMember 2020-04-01 2021-03-31 0001095435 ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-01-18 2022-01-19 0001095435 ptgef:TwoMembersMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-01-18 2022-01-19 0001095435 ptgef:EmployeesMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-01-18 2022-01-19 0001095435 ptgef:DirectorsMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-01-18 2022-01-19 0001095435 ptgef:DirectorsMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-02-14 2022-02-15 0001095435 ptgef:ExecutiveMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-06-07 2022-06-08 0001095435 ptgef:BoardOfDirectorsMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-07-26 2022-07-27 0001095435 ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2023-03-25 2023-03-30 0001095435 2023-03-25 2023-03-30 0001095435 ptgef:VestedOptionsMember 2023-06-30 0001095435 ptgef:VestedOptionsMember 2023-03-31 0001095435 ptgef:UnvestedOptionsMember 2023-06-30 0001095435 ptgef:UnvestedOptionsMember 2023-03-31 0001095435 ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2023-04-01 2023-06-30 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2023-03-31 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2022-03-31 0001095435 ptgef:StockOptionsTwoMember 2023-03-31 0001095435 ptgef:StockOptionsTwoMember 2022-03-31 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2023-04-01 2023-06-30 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2022-04-01 2022-06-30 0001095435 ptgef:StockOptionsTwoMember 2023-04-01 2023-06-30 0001095435 ptgef:StockOptionsTwoMember 2022-04-01 2022-06-30 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2023-06-30 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2022-06-30 0001095435 ptgef:StockOptionsTwoMember 2023-06-30 0001095435 ptgef:StockOptionsTwoMember 2022-06-30 0001095435 ifrs-full:ShareOptionsMember 2023-04-01 2023-06-30 0001095435 ifrs-full:ShareOptionsMember 2022-04-01 2022-06-30 0001095435 ifrs-full:RestrictedShareUnitsMember 2023-04-01 2023-06-30 0001095435 ifrs-full:RestrictedShareUnitsMember 2022-04-01 2022-06-30 0001095435 2022-07-13 0001095435 ptgef:LincolnMember 2022-07-05 2022-07-06 0001095435 ptgef:SalvaRxMember 2021-09-07 2021-09-08 0001095435 2021-12-14 2021-12-15 0001095435 2022-12-18 2022-12-19 0001095435 2022-12-25 2022-12-31 0001095435 ptgef:AmortizedCostMember 2023-06-30 0001095435 ptgef:FairValueToOtherComprehensiveIncomeMember 2023-06-30 0001095435 ptgef:FairValueThroughProfitOrLossMember 2023-06-30 0001095435 ptgef:AmortizedCostMember 2023-03-31 0001095435 ptgef:FairValueToOtherComprehensiveIncomeMember 2023-03-31 0001095435 ptgef:FairValueThroughProfitOrLossMember 2023-03-31 0001095435 ptgef:TarusMember 2023-04-01 2023-06-30 0001095435 ptgef:IOXMember 2023-04-01 2023-06-30 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2023-03-31 0001095435 ptgef:IOXMember 2023-04-01 2023-06-30 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2023-04-01 2023-06-30 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2023-06-30 0001095435 ptgef:IOXMember 2022-03-31 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2022-03-31 0001095435 ptgef:IOXMember 2022-04-01 2022-06-30 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2022-04-01 2022-06-30 0001095435 ptgef:IOXMember 2022-06-30 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2022-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:EUR iso4217:EUR xbrli:shares

Exhibit 99.1

 

 

 

 

 

 

 

 

 

Portage Biotech Inc.

 

Condensed Consolidated Interim Financial Statements

 

For the Three Months Ended June 30, 2023

 

(Unaudited – Prepared by Management as of August 29, 2023)

 

(U.S. Dollars)

 

 

 

 

 

 

 

 

 

 

 

 

 

Portage Biotech Inc.

Condensed Consolidated Interim Financial Statements

 

Index   Page
     
Notice to Reader   F-1
     
Condensed Consolidated Interim Statements of Financial Position
As of June 30, 2023 (Unaudited) and March 31, 2023
 
 
F-2
     
Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)
Three months ended June 30, 2023 and 2022
 
F-3
     
Condensed Consolidated Interim Statements of Changes in Shareholders’ Equity (Unaudited)
Three months ended June 30, 2023 and 2022
 
F-4
     
Condensed Consolidated Interim Statements of Cash Flows (Unaudited)
Three months ended June 30, 2023 and 2022
 
 
F-5
     
Notes to Condensed Consolidated Interim Financial Statements   F-6 to F-37

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NOTICE TO READER OF CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

 

The condensed consolidated interim financial statements of Portage Biotech Inc. are comprised of the condensed consolidated statements of financial position as of June 30, 2023 and March 31, 2023, the condensed consolidated interim statements of operations and other comprehensive income (loss) for the three months ended June 30, 2023 and 2022 and the statements of equity and cash flows for each of the three months ended June 30, 2023 and 2022 and are the responsibility of Portage Biotech Inc.’s management.

 

The condensed consolidated interim financial statements of Portage Biotech Inc. have been prepared by Portage Biotech Inc.’s management and include the selection of appropriate accounting principles, judgments and estimates necessary to prepare these condensed consolidated interim financial statements in accordance with International Financial Reporting Standards.

 

/s/ Allan Shaw /s/ Ian Walters
Allan Shaw, CFO Ian Walters, MD, Chairman of the Board and Chief Executive Officer
   
DATE: August 29, 2023  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 F-1 

 

Portage Biotech Inc.

Condensed Consolidated Interim Statements of Financial Position

(U.S. Dollars in thousands)

(Unaudited – see Notice to Reader dated August 29, 2023)

 

              
   Notes  June 30,
2023
  March 31,
2023
            (Audited) 
Assets             
Current assets             
Cash and cash equivalents     $7,698   $10,545 
Prepaid expenses and other receivables  5   2,752    2,689 
Convertible note receivable  6   442    442 
Total current assets      10,892    13,676 
Non-current assets             
Investment in associate  6   756    806 
Investment in public company  7   3,855    2,087 
In-process research and development  9, 10   81,683    81,683 
Deferred commitment fee  15   839    839 
Right to use asset  8   293    - 
Other assets, including equipment, net      51    38 
Total non-current assets      87,477    85,453 
Total assets     $98,369   $99,129 
              
Liabilities and Equity             
Current liabilities             
Accounts payable and accrued liabilities     $2,591   $1,865 
Lease liability - current, including interest  8   47    - 
Total current liabilities      2,638    1,865 
Non-current liabilities             
Lease liability - non-current  8   249    -   
Deferred tax liability  10, 11   10,416    10,564 
Deferred purchase price payable - Tarus  9, 17   7,864    7,179 
Deferred obligation - iOx milestone  16, 17   4,552    4,126 
Total non-current liabilities      23,081    21,869 
Total liabilities      25,719    23,734 
              
Shareholders’ Equity             
Capital stock  12   219,425    218,782 
Stock option reserve  13   21,973    21,204 
Accumulated other comprehensive loss      (2,556)   (4,325)
Accumulated deficit      (165,535)   (159,616)
Total equity attributable to owners of the Company      73,307    76,045 
Non-controlling interest  19   (657)   (650)
Total equity      72,650    75,395 
Total liabilities and equity     $98,369   $99,129 
Commitments and Contingent Liabilities (Note 15)       -    - 

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

 

 F-2 

Portage Biotech Inc.

Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss)

(U.S. Dollars in thousands, except per share amounts)

(Unaudited – see Notice to Reader dated August 29, 2023)

 

              
   Note  Three Months Ended June 30,
      2023  2022
Expenses             
Research and development      3,627    1,876 
General and administrative expenses      1,370    2,211 
Loss from operations      (4,997)   (4,087)
Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone  9, 16, 17   (1,111)   - 
Share of loss in associate accounted for using equity method  6   (50)   (60)
Change in fair value of warrant liability      -    1 
Foreign exchange transaction gain (loss)  11   18    (52)
Depreciation expense      (11)   - 
Interest income, net      80    21 
Loss before (provision) benefit for income taxes      (6,071)   (4,177)
Income tax benefit  11   145    2,552 
Net loss      (5,926)   (1,625)
Other comprehensive income (loss)             
Net unrealized gain on investments  6, 7   1,769    -   
Total comprehensive loss for period     $(4,157)  $(1,625)
              
Net (loss) income attributable to:             
Owners of the Company     $(5,919)  $(1,729)
Non-controlling interest  19   (7)   104 
Net loss     $(5,926)  $(1,625)
              
Comprehensive (loss) income attributable to:             
Owners of the Company     $(4,150)  $(1,729)
Non-controlling interest  19   (7)   104 
Total comprehensive loss for period     $(4,157)  $(1,625)
              
Loss per share  14          
Basic and diluted     $(0.33)  $(0.13)
              
Weighted average shares outstanding  14          
Basic and diluted      17,701    13,351 

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

 

 F-3 

Portage Biotech Inc.

Condensed Consolidated Interim Statements of Changes in Shareholders’ Equity

For the Three Months Ended June 30, 2023 and 2022

(U.S. Dollars)

(Unaudited – see Notice to Reader dated August 29, 2023)

 

                                         
            Accumulated     Equity      
   Number     Stock  Other     Attributable  Non-   
   of  Capital  Option  Comprehensive  (Accumulated  to Owners  Controlling  Total
   Shares  Stock  Reserve  Income (Loss)  Deficit)  of Company  Interest  Equity
Balance, April 1, 2023   17,606    218,782    21,204    (4,325)   (159,616)   76,045    (650)   75,395 
Share-based compensation expense   -    -    769    -    -    769    -    769 
Shares issued under ATM   171    632    -    -    -    632    -    632 
Share issuance costs   -    (19)   -    -    -    (19)   -    (19)
Shares issued or accrued for services   9    30    -    -    -    30    -    30 
Net unrealized gain on investments   -    -    -    1,769    -    1,769    -    1,769 
Net loss for period   -    -    -    -    (5,919)   (5,919)   (7)   (5,926)
Balance, June 30, 2023   17,786    219,425    21,973    (2,556)   (165,535)   73,307    (657)   72,650 
                                         
Balance, April 1, 2022   13,349    158,324    16,928    958    (55,005)   121,205    44,229    165,434 
Share-based compensation expense   -    -    1,176    -    -    1,176    -    1,176 
Shares issued or accrued for services   4    30    -    -    -    30    -    30 
Net (loss) income for period   -    -    -    -    (1,729)   (1,729)   104    (1,625)
Balance, June 30, 2022   13,353   $158,354   $18,104   $958   $(56,734)  $120,682   $44,333   $165,015 

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

 

 

 

 

 

 

 

 

 

 F-4 

Portage Biotech Inc.

Condensed Consolidated Interim Statements of Cash Flows

For the Three Months Ended June 30, 2023 and 2022

(U.S. Dollars in thousands)

(Unaudited – see Notice to Reader dated August 29, 2023)

 

 

           
   Three Months Ended June 30,
   2023  2022
Cash flows from operating activities:          
Net loss for the period  $(5,926)  $(1,625)
Adjustments for non-cash items:          
Share-based compensation expense   769    1,176 
Change in fair value of deferred purchase price payable – Tarus and deferred obligation – iOx milestone   1,111    - 
Decrease in deferred tax liability   (148)   (2,552)
Share of loss in associate   50    60 
Fair value of shares issued for services   30    30 
Depreciation   11    - 
Change in fair value of warrant liability   -    (1)
Changes in operating working capital:          
Accounts receivable   (17)   (44)
Prepaid expenses and other receivables   (50)   (408)
Other assets   (10)   - 
Accounts payable and accrued liabilities   726    1,188 
Other   1    - 
Net cash used in operating activities   (3,453)   (2,176)
           
Cash flows from financing activities:          
Proceeds from shares issued under ATM and Committed Purchase Agreement   632    - 
Share issuance costs   (19)   - 
Repayment of lease liability   (7)   - 
Net cash provided by financing activities   606    - 
           
Decrease in cash and cash equivalents during period   (2,847)   (2,176)
Cash and cash equivalents at beginning of period   10,545    23,352 
Cash and cash equivalents at end of period  $7,698   $21,176 
           
Supplemental disclosure of cash flow information:          
Net unrealized gain on investment in Intensity  $1,769   $- 
Cash paid for interest  $3   $- 
           
Supplemental disclosure of non-cash investing and financing activities:          
Right to use asset acquired  $303   $- 
Lease liability incurred  $303   $- 

 

The accompanying notes are an integral part of these condensed consolidated interim financial statements.

 

 F-5 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 1. NATURE OF OPERATIONS

 

Portage Biotech Inc. (the “Company” or “Portage”) is incorporated in the British Virgin Islands (“BVI”) with its registered office located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, BVI. Its USA agent, Portage Development Services Inc. (“PDS”), is located at 61 Wilton Road, Westport, CT, 06880, USA.

 

The Company is a foreign private issuer under the Securities and Exchange Commission (the “SEC”) rules. It is also a reporting issuer under the securities legislation of the provinces of Ontario and British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (“CSE”) under the symbol “PBT.U”. On February 25, 2021, the ordinary shares of the Company began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “PRTG”. As the principal market for the Company’s ordinary shares is Nasdaq, the Company voluntarily delisted from the CSE on April 23, 2021.

 

Portage is a clinical-stage immuno-oncology company advancing therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with invasive cancers. Portage’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enable the identification of clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage’s portfolio consists of four diverse platforms, with lead programs consisting of invariant natural killer T-cell (“iNKT”) engagers and a suite of treatments targeting the adenosine pathway. Additional programs leverage delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these four platforms, Portage has 9 product candidates currently in development with multiple clinical readouts expected through the end of calendar year 2024.

 

On August 13, 2018, the Company reached a definitive agreement to acquire 100% of SalvaRx Limited (“SalvaRx”) in exchange for 8,050,701 ordinary shares of the Company (the “SalvaRx Acquisition”). The SalvaRx Acquisition was completed on January 8, 2019 (the “Acquisition Date”) upon receiving shareholder and regulatory approval. In connection with the SalvaRx Acquisition, the Company acquired interests in SalvaRx’s five research and development invested entities and subsidiaries: iOx Therapeutics Ltd. (“iOx”) (60.49% interest), Nekonal Oncology Limited (“Nekonal”), Intensity Therapeutics, Inc. (“Intensity”), Saugatuck Therapeutics, Ltd. (“Saugatuck”) and Rift Biotherapeutics Inc.  The Company also acquired an option in Nekonal SARL, a Luxembourg-based company holding intellectual property rights for therapeutics and diagnostics in the field of autoimmune disorders and oncology, to participate in the funding of its autoimmune programs.

 

In September 2021, the Company, through SalvaRx, exchanged certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing 60.49% of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%. On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx,” for a further discussion.

 

NOTE 2. GOING CONCERN

 

As of June 30, 2023, the Company had cash and cash equivalents of approximately $7.7 million and total current liabilities of approximately $2.6 million. For the three months ended June 30, 2023, the Company is reporting a net loss of approximately $5.9 million and cash used in operating activities of approximately $3.5 million. As of July 31, 2023, the Company had approximately $6.4 million of cash and cash equivalents on hand.

 

 F-6 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 2. GOING CONCERN (Cont'd)

 

The Company’s cash and cash equivalents balance is decreasing, and the Company will not generate positive cash flows from operations for the fiscal year ending March 31, 2024.

 

The Company may have to delay, scale-back, or eliminate certain of its activities and other aspects of its operations until such time as the Company is successful in securing additional funding. The Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources. The future success of the Company is dependent upon its ability to obtain additional funding. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. As of the date of this filing, the Company currently anticipates that current cash and cash equivalents, excluding any potential proceeds from its ATM program and Committed Purchase Agreement with Lincoln Park, access to which are generally limited based on the Company’s Nasdaq trading volume, will be sufficient to meet its anticipated cash requirements through the end of October 2023. These factors raise significant doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued.

 

The Company has incurred significant operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result primarily from its conduct of research and development activities.

 

The Company historically has funded its operations principally from proceeds from issuances of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan, beyond the potential proceeds that could be reasonably generated from its ATM program and Committed Purchase Agreement with Lincoln Park given the Company’s current trading volume on Nasdaq. The Company's ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, future equity issuances would result in dilution to existing stockholders and any future debt securities may contain covenants that limit the Company's operations or ability to enter into certain transactions.

 

NOTE 3. BASIS OF PRESENTATION

 

Statement of Compliance and Basis of Presentation

 

These condensed consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”), IAS 34 Interim Financial Reporting and interpretations of the International Financial Reporting Interpretations Committee. These condensed consolidated interim financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the audited consolidated financial statements of the Company for the year ended March 31, 2023.

 

These condensed consolidated interim financial statements have been prepared on an historical cost basis except for items disclosed herein at fair value (see Note 17, “Financial Instruments and Risk Management”). In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

 

 F-7 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 3. BASIS OF PRESENTATION (Cont'd)

 

The Company has only one reportable operating segment.

 

These condensed consolidated interim financial statements were approved and authorized for issuance by the Audit Committee and Board of Directors (the “Board”) on August 29, 2023.

 

Consolidation

 

The condensed consolidated interim financial statements include the accounts of the Company and:

 

(a)SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;

 

(b)iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company, through SalvaRx, exchanged certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing 60.49% of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%. On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx,” for a further discussion;

 

(c)Saugatuck, a 70% owned subsidiary incorporated in the British Virgin Islands. Saugatuck and subsidiary refers to Saugatuck and Saugatuck Rx LLC;

 

(d)PDS, a 100% owned subsidiary incorporated in Delaware, which provides human resources, and other services to each operating subsidiary via a shared services agreement;

 

(e)SalvaRx LLC, a wholly-owned subsidiary through SalvaRx;

 

(f)Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck; and

 

(g)Tarus Therapeutics, LLC (“Tarus”), a wholly-owned subsidiary of Portage.

 

All inter-company balances and transactions have been eliminated in consolidation.

 

Non-controlling interest in the equity of a subsidiary is accounted for and reported as a component of stockholders’ equity. As of June 30, 2023, non-controlling interest represents the 30% shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx” for a discussion of the Company’s purchase of the balance of the non-controlling interest in iOx.

 

Functional and Presentation Currency

 

The Company’s functional and presentation currency is the U.S. Dollar.

 

Use of Estimates and Judgments

 

The preparation of the condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

 

 F-8 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 3. BASIS OF PRESENTATION (Cont'd)

 

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

 

Significant areas where estimates are made include valuation of financial instruments (including the Stimunity Convertible Note (as defined below), deferred tax assets and liabilities, research and development costs, fair value used for acquisition of intangible assets, contingent consideration assumed and measurement of share-based compensation. Significant areas where critical judgments are applied include assessment of impairment of investments, goodwill and in-process research and development and the determination of the accounting acquirer and acquiree in the business combination accounting.

 

NOTE 4.  SIGNIFICANT ACCOUNTING POLICIES

 

The accounting policies are set out in Note 4 to the Company’s audited consolidated financial statements for the fiscal year ended March 31, 2023 (“Fiscal 2023”). These policies have been applied consistently to all periods presented in these condensed consolidated interim financial statements.

 

Recent Accounting Pronouncements

 

IFRS Pronouncements Issued

 

Impact of Adoption of Significant New IFRS Standards in Fiscal 2023

 

(a)Annual Improvements to IFRS Standards 2018-2020

 

The annual improvements process addresses issues in the 2018-2020 reporting cycles including changes to IFRS 9, “Financial Instruments,” IFRS 1, “First Time Adoption of IFRS,” IFRS 16, “Leases,” and IAS 41, “Biological Assets”.

 

i)The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition of financial liabilities.

 

ii)The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent to also measure cumulative translation differences using the amounts reported by the parent based on the parent’s date of transition to IFRS.

 

iii)The amendment to IFRS 16’s illustrative example 13 removes the illustration of payments from the lessor related to leasehold improvements.

 

These amendments were effective for annual periods beginning on or after January 1, 2022. The adoption of these amendments did not have a material effect on the Company’s annual consolidated financial statements or the condensed consolidated interim financial statements for the three months ended June 30, 2023.

 

 F-9 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 4. SIGNIFICANT ACCOUNTING POLICIES (Cont'd)

 

New Accounting Standards, Interpretations and Amendments

 

Standards issued but not yet effective up to the date of issuance of the Company’s condensed consolidated interim financial statements are listed below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they become effective.

 

(a)IAS 1: Presentation of Financial Statements

 

The amendment to IAS 1 clarifies how to classify debt and other liabilities as either current or non-current. The amendment will be effective for annual periods beginning on or after January 1, 2024. The Company is currently evaluating the new guidance and impacts on its consolidated financial statements.

 

(b)Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture

 

The amendment addresses the conflict between IFRS 10, “Consolidated Financial Statements,” and IAS 28, “Investments in Associates and Joint Ventures,” in dealing with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, “Business Combinations,” between an investor and its associate or joint venture, is recognized in full. Any gain or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognized only to the extent of unrelated investors' interests in the associate or joint venture. The IASB has deferred the effective date of these amendments indefinitely, but an entity that early adopts the amendments must apply them prospectively. The Company is evaluating whether the adoption of the above amendment will have a material impact on its financial statements. 

 

NOTE 5. PREPAID EXPENSES AND OTHER RECEIVABLES

 

          
(In thousands)  As of
June 30, 2023
  As of
March 31, 2023
       
Prepaid clinical research costs  $1,783   $1,653 
Prepaid insurance   446    621 
Research & development tax credits   186    169 
Other prepaid expenses   151    56 
Tax deposits   115    119 
Other receivables   71    71 
Total prepaid expenses and other receivables  $2,752   $2,689 

 

 F-10 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 6. INVESTMENT IN ASSOCIATE

 

Details of the Company’s associate, Stimunity S.A. (“Stimunity”), as of June 30, 2023 and March 31, 2023 are as follows:

 

            
Name  Principal Activity  Place of Incorporation and
Principal Place of Business
  Voting Rights Held as
of June 30, 2023
  Voting Rights Held as
of March 31, 2023
Associate: Stimunity S.A.  Biotechnology  Paris, France  44.0%  44.0%

 

The following table is a roll-forward of the Company’s investment in Stimunity as of and for the three months ended June 30, 2023 and 2022:

 

          
   As of and for the Three Months Ended June 30,
(In thousands)  2023  2022
       
Balance, beginning of period  $806   $1,673 
Share of loss   (50)   (60)
Balance, end of period  $756   $1,613 

 

The Company accounts for its investment in Stimunity under the equity method and, accordingly, records its share of Stimunity’s earnings or loss based on its ownership percentage. The Company recorded loss in equity in Stimunity of $50,000 and $60,000 for the three months ended June 30, 2023 and 2022, respectively.

 

Under the Shareholders’ Agreement entered into on June 1, 2020, Portage has (i) a preferential subscription right to maintain its equity interest in Stimunity in the event of a capital increase from the issuance of new securities by Stimunity, except for issuances of new securities for stock options, under a merger plan or for an acquisition, and (ii) the right to vote against any (a) issuances of additional securities that would call for Portage to waive its preferential subscription right, or (b) any dilutive issuance.

 

On July 13, 2022, the Company entered into a commitment with Stimunity to provide €600,000 under a convertible note (the “Stimunity Convertible Note”) with a maturity date of September 1, 2023 (the “Maturity Date”). The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible Note is automatically converted into Series A shares of Stimunity upon Stimunity completing a Series A round for at least €20 million. If such subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into Series A shares of Stimunity at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares (other than Common Shares or Series A shares) for at least €5 million (the “Minimum Raise”), the Company will have the right to convert the Stimunity Convertible Note and the historical Series A shares of Stimunity owned into the new category of shares. In the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the right to convert the Stimunity Convertible Note into Series A shares at €363.00 per share or the raise price less 15%, whichever is lower. The Stimunity Convertible Note was funded on September 12, 2022. See Note 15, “Commitments and Contingent Liabilities – Stimunity Convertible Note,” for a further discussion.

 

 F-11 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 6. INVESTMENT IN ASSOCIATE (Cont’d)

 

The Stimunity Convertible Note was initially recorded at $0.614 million to record the translated value of the Stimunity Convertible Note on September 12, 2022. The Company recognized an unrealized gain of $0.039 million through other comprehensive income (“OCI”) in Fiscal 2023 to reflect the change in translation rate for the Stimunity Convertible Note settleable in euros, increasing the carrying value of the Stimunity Convertible Note to $0.653 million.

 

As of March 31, 2023, the Company determined that there were indications of impairment of both the investment in associate and the Stimunity Convertible Note receivable, based upon the inability of Stimunity to obtain financing. The Company performed an IAS 36 fair value analysis evaluating the likelihood of various scenarios given the then-current market conditions, the increasing cost of capital and development delays associated with Stimunity’s lack of liquidity. The Company recorded provisions of impairment of $0.607 million and $0.211 million, with respect to the investment in associate and the Stimunity Convertible Note receivable, respectively, decreasing the carrying value of the investment in associate and the Stimunity Convertible Note to $0.806 million and $0.442 million, respectively, as of March 31, 2023.

 

During the three months ended June 30, 2023, the Company recorded a loss of $0.05 million to recognize its share of Stimunity’s results of operations and recorded a marginal gain through OCI to reflect the translation rate effect on the Stimunity Convertible Note settleable in euros. The Company determined that there were no significant changes in the market or Stimunity’s outlook from March 31, 2023 to June 30, 2023, and, accordingly, determined that the carrying value at June 30, 2023 was not further impaired.

 

NOTE 7. INVESTMENT IN PUBLIC COMPANY

 

The following is a discussion of the Company’s investment in Intensity Therapeutics, Inc. (“Intensity”) as of June 30, 2023 and March 31, 2023.

 

Intensity Therapeutics, Inc.

 

In connection with the SalvaRx Acquisition in fiscal 2019, the Company acquired a $4.5 million interest in Intensity, a private clinical stage biotechnology company, of 1.0 million shares, which represented a 7.5% equity interest in Intensity. The investment was recorded at fair value (which approximates cost) at the acquisition date. The investment in Intensity has been irrevocably designated as a financial asset recorded at fair value with gains and losses recorded through OCI. Upon Intensity’s IPO discussed below, effective June 30, 2023, the fair value of the asset is determined by quoted market price.

 

On July 11, 2019, the Company entered into an agreement with Fast Forward Innovations Limited (“Fast Forward”) to purchase Intensity Holdings Limited (“IHL”), a wholly-owned subsidiary of Fast Forward. The Company paid $1.3 million for IHL through the issuance of 129,806 ordinary shares of the Company. The sole asset of IHL consists of 288,458 shares of Intensity. This transaction increased the Company’s ownership of Intensity to 1,288,458 shares.

 

 F-12 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 7. INVESTMENT IN PUBLIC COMPANY (Cont’d)

 

On October 28, 2021, Intensity filed a Form S-1 Registration Statement with the SEC to register shares for an initial public offering (“IPO”), which was declared effective by the SEC, but subsequently withdrawn prior to closing.

 

In October and November of 2022, Intensity filed amendments to its Form S-1 Registration Statement, which reflected a proposed offering price in the range of $4.00 - $5.00 per share, which is less than the Company’s carrying value, which was an external indication of impairment. Accordingly, the Company performed an IAS 36, “Impairment of Assets,” fair value analysis and determined a fair value of $3.363 million, which was $4.046 million less than the then carrying value at December 31, 2022. Intensity continued to seek a successful IPO during the fourth quarter of fiscal year ended March 31, 2023. At March 31, 2023, the Company undertook an IAS 36 fair value analysis based on the continued existence of external indications of impairment. The analysis included evaluating the likelihood of a successful IPO and the timing of such an event, as well as the then lack of marketability of the shares and the continued uncertainty surrounding an IPO, or any type of financing.

 

In April 2023, Intensity completed a 1:2 reverse stock split, which reduced the Company’s holdings to 644,229 shares. As the offering was priced at $4.00 to $5.00 per share, the Company determined the fair value of its interest to be $2.087 million. In total, the Company recorded an unrealized loss of $5.322 million with respect to Intensity for the fiscal year ended March 31, 2023, which was recognized through OCI, reducing the Company’s carrying value in Intensity to $2.087 million as of March 31, 2023.

 

On July 5, 2023, Intensity completed an IPO of its common stock selling 3,900,000 shares at a price of $5.00 per share generating net proceeds of approximately $16.2 million. In connection with the offering, Intensity’s common stock began trading on Nasdaq on June 30, 2023, under the ticker symbol “INTS.” The Intensity shares closed at a price of $5.96 on June 30, 2023. The Company received an additional 2,659 shares in connection with the offering pursuant to certain anti-dilution rights. Intensity sold its overallotment shares totaling 585,000 shares, which closed on July 7, 2023. At that date, the Company owned approximately 4.7% of the issued and outstanding shares of Intensity. The Company recorded unrealized gain of $1.768 million through OCI to reflect the difference between the market value of the Company’s ownership interest and its then carrying value, increasing the Company’s carrying value in Intensity to $3.855 million as of June 30, 2023. There was no unrealized gain or loss with respect to the Company’s investment in Intensity during the three months ended June 30, 2022.

 

NOTE 8. LEASE

 

The Company entered into a lease of office space, which commenced on May 1, 2023. The lease provides for an original term of two years with an option to renew the lease for an additional term of three years. The Company has included the extension option in the lease analysis under IFRS 16, based upon management’s intentions. The Company calculated the lease liability using its incremental borrowing rate of 13%. The Company provided a $0.013 million security deposit. The lease liability is payable as follows (in thousands):

 

     
Twelve Months Ended June 30,  Amount
2024  $79 
2025   81 
2026   83 
2027   84 
2028   71 
 Total   398 
Less: interest   (102)
Total lease liability   296 
Lease liability - current   47 
Lease liability - non-current  $249 

 

 F-13 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 9. ACQUISITION OF TARUS

 

On July 1, 2022, the Company, its wholly-owned subsidiary, Portage Merger Sub I, Inc., its wholly-owned subsidiary, Portage Merger Sub II, LLC and Tarus Therapeutics, Inc., a Delaware corporation advancing adenosine receptor antagonists for the treatment of solid tumors, entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). Under the structure of the Merger Agreement, Tarus Therapeutics, Inc. was ultimately merged into Portage Merger Sub II, LLC of the Company with the surviving entity renamed Tarus Therapeutics, LLC. The Tarus merger entitles the Company to the rights, know-how and/or ownership related to the assets developed by Tarus (the “Adenosine Compounds”), including:

 

1.All rights and obligations related to the License Agreement between Tarus and Impetis Biosciences Limited, dated October 29, 2019 (“Tarus License Agreement”), and the Call Option under the Tarus License Agreement, which was exercised on November 5, 2020;

 

2.All intellectual property and related documents owned or controlled by Tarus, including issued or pending patents, patent applications and trade secrets. Additionally, any draft submissions and/or correspondence with patent authorities;

 

3.All documents and supplies related to Adenosine Compounds (as defined in the Tarus License Agreement) including inventory, reagents, data, assays, reports, vendor agreements and other information related to the preclinical development;

 

4.All clinical supplies, manufacturing know-how, batch records, regulatory documents pertaining to the Adenosine Compounds, certain reservations for manufacturing campaigns and any related agreements;

 

5.All regulatory documents and correspondence pertaining to the Adenosine Compounds;

 

6.All Contract Research Organization (“CRO”) agreements and protocol related documents for Adenosine Compounds;

 

7.All current documents related to market research, forecasting, budgets and competitive intelligence; and

 

8.Rights to the use of Tarus Therapeutics’ name for regulatory purposes.

 

As consideration for Tarus, the Company issued to former Tarus shareholders an aggregate of 2,425,999 ordinary shares of Portage, calculated on the basis of $18 million divided by the 60-day volume weighted average price per share of ordinary shares of Portage. Such ordinary shares have not been registered with the SEC and were subject to lock-up agreements for terms ranging from six to twelve months, which expired on February 1, 2023 and July 1, 2023, respectively. Additionally, the ordinary shares that were subject to a twelve month lock-up period, are also subject to a three month dribble-out period, which commenced July 1, 2023. During the dribble out period, each holder may not sell more than 10% of the average trading volume of the Company’s ordinary shares for the rolling three month period prior to the date on which the holder executes a trade of the Company’s ordinary shares without its prior written consent (which the Company is permitted to withhold at its sole discretion). Additionally, milestone payments of up to $32 million in cash or Portage ordinary shares (at the discretion of the Company) would be triggered upon achievement of future development and sales milestones, as described below. As a result of the transaction:

 

 F-14 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 9. ACQUISITION OF TARUS (Cont’d)

 

·The Company also assumed $2 million in short-term debt held by Tarus and deferred license milestones obligations ($1 million plus interest). The short-term debt was repaid by the Company in July 2022.

 

·Upon enrolling the first patient in a Phase 2 clinical trial utilizing Tarus’s adenosine receptor antagonists, the Company will pay an additional one-time milestone payment of $15 million to the former Tarus shareholders. Payment will be in the form of cash or Portage ordinary shares (at the discretion of the Company). The remaining $17 million milestone is based on targeted commercial sales.

 

In connection with the acquisition of Tarus, the Company performed a fair value analysis of the assets acquired and liabilities assumed. The Company based the analysis on its clinical plan and timing of development events, and the probabilities of success determined primarily based upon empirical third party data and Company experience as well as the relevant cost of capital. In its fair value analysis, the Company used the Multi-Period Excess Earnings Method for PORT-6 and PORT-7 and the Replacement Cost Method for PORT-8 and PORT-9, determined based upon the maturity of the assets and the availability of sufficient data to measure fair value. The Company recorded the ordinary shares issued at $17.2 million, which represented the aggregate market value of the ordinary shares issued on July 1, 2022. The Company followed the guidance of IAS 3 and IAS 32 and recorded a deferred purchase price payable - Tarus of $8.538 million, which reflected the estimated acquisition date fair value of contractual milestone obligations incurred. The principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount rate used. The Company recorded the obligation as a non-current liability, in accordance with the provisions IAS 32 with respect to the classification of financial assets and financial liabilities.

 

The Company will determine the fair value of the shares issuable upon achievement of future development and sales milestones at each balance sheet date. Any change to the fair value will be recorded in the Company’s statements of operations and other comprehensive income (loss).

 

The following table summarizes the purchase price allocation to the fair value of assets acquired and liabilities assumed for Tarus:

 

     
Assets:  (In thousands)
Identifiable intangible assets  $28,200 
Goodwill   538 
Total assets  $28,738 
Consideration:     
Fair value of shares issued  $17,200 
Liabilities assumed   3,000 
Deferred purchase consideration at fair value   8,538 
Total liabilities  $28,738 

 

 F-15 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 9. ACQUISITION OF TARUS (Cont’d)

 

Pro forma Information

 

Summary unaudited pro forma condensed results of operations for the three months ended June 30, 2022, assuming the Tarus acquisition had occurred at the beginning of the earliest period presented, are as follows:

 

     
(In thousands) 

Three Months Ended

June 30, 2022

Loss from operations  $(3,788)
Loss before provision for income taxes  $(3,893)
Net loss  $(1,341)
Total comprehensive loss for period  $(1,341)
Loss per share  $(0.09)

 

These pro forma results are not necessarily indicative of what would have occurred if the acquisition had been in effect for the period presented, and they may not be indicative of results expected in the future.

 

NOTE 10. IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY

 

In-process research and development (“IPR&D”) consists of the following projects (in thousands):

 

             
      Value as of
Project #  Description  June 30, 2023  March 31, 2023
iOx:             
PORT 2 (IMM60)  Melanoma & Lung Cancers  $36,181   $36,181 
PORT 3 (IMM65)  Ovarian/Prostate Cancers   21,709    21,709 
       57,890    57,890 
              
Oncomer/Saugatuck  DNA Aptamers   178    178 
              
Tarus:             
PORT 6 & PORT 7  Adenosine Receptors   22,723    22,723 
PORT 8  Adenosine Receptors   420    420 
PORT 9  Adenosine Receptors   472    472 
       23,615    23,615 
              
In-process research and development     $81,683   $81,683 
              
Deferred tax liability     $13,510   $13,195 

 

At the end of each reporting period, the Company is required to assess whether there is any indication that an asset may be impaired. Pursuant to IAS 36, the Company evaluated the then-current capital markets, the increasing costs of capital, and the delays in the timing of asset development and concluded that provisions for impairment were required during the year ended March 31, 2023 with respect to the iOx IPR&D and the Tarus IPR&D. The Company recognized an impairment of $59.320 million with respect to the iOx assets, reducing the Company’s carrying value from $117.210 million to $57.890 million and an impairment of $4.585 million with respect to the Tarus assets, reducing the Company’s carrying value from $28.2 million to $23.615 million. The deferred tax liability in the U.K. was reduced as a result of the IPR&D impairment loss recognized by iOx for financial statement purposes.

 

Deferred tax liability represents iOx’s estimated tax on the difference between book and tax basis of the IPR&D, which is taxable in the U.K, and the effect of usable net operating loss carryforwards.

 

 F-16 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 11. INCOME TAXES

 

The Company is a BVI business company. The BVI government does not, under existing legislation, impose any income or corporate tax on corporations.

 

PDS is a U.S. corporation and is subject to U.S. federal, state and local income taxes, as applicable.

 

iOx is subject to U.K. taxes.

 

The (expense) benefit from income taxes consists of the following for the three months ended June 30, 2023 and 2022 (U.S. Dollars in thousands):

 

          
   For the Three Months Ended June 30,
(In thousands)  2023  2022
       
Current:          
Federal  $(3)  $- 
State and local   -    - 
Foreign   -    - 
Total current   (3)   - 
           
Deferred:          
Federal   -    - 
State and local   -    - 
Foreign   148    2,552 
Total deferred   148    2,552 
Benefit from income taxes  $145   $2,552 

 

The following is a reconciliation of the U.S. taxes to the effective income tax rates for the three months ended June 30, 2023 and 2022 (U.S. Dollars in thousands):

 

      
   Three Months Ended June 30,
   2023  2022
(Loss) income on ordinary activities before tax  $(605)  $34 
Statutory U.S. income tax rate   21.0%   21.0%
Income tax benefit (expense) at statutory income tax rate   127    (7)
Share-based compensation expense recognized for financial statement purposes   (142)   - 
Other losses recognized   -    7 
Utilization of losses not previously benefitted   12    - 
Income tax (expense)  $(3)  $- 

 

 F-17 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 11. INCOME TAXES (Cont’d)

 

As of June 30, 2023, the Company had $0.6 million of federal net operating losses, which carryforward indefinitely but are limited to 80% of taxable income when utilized and $0.4 million of items deducted for financial statements but not tax, excluding share-based compensation. As of each of June 30, 2023 and March 31, 2023, the Company had U.S. deferred tax assets of $0.2 million.

 

The following is a reconciliation of the U.K. taxes to the effective income tax rates for the three months ended June 30, 2023 and 2022 (U.S. Dollars in thousands):

 

      
   Three Months Ended June 30,
   2023  2022
Loss on ordinary activities before tax  $1,576   $1,743 
Statutory U.K. income tax rate   25.0%   19.0%
Loss at statutory income tax rate   394    331 
           
Change from increase in deferred income tax rate   -    105 
Recognition of deferred tax assets   -    - 
Foreign currency effect   (246)   2,116 
Income tax benefit  $148   $2,552 

 

Research and development credit receivables of $0.2 million were included in prepaid expenses and other receivables on the condensed consolidated interim statements of financial position as of each of June 30, 2023 and March 31, 2023. The receivable was collected in July 2023.

 

The following is a reconciliation of financial statement income (loss) to tax basis income (loss) (in thousands):

 

                                        
   Three Months Ended
   June 30, 2023  June 30, 2022
   United
States
  BVI  United
Kingdom
  Total  United
States
  BVI  Foreign  Total
                         
Pre-tax loss  $(609)  $(3,886)  $(1,576)  $(6,071)  $34   $(2,468)  $(1,743)  $(4,177)
Share-based compensation expense for financial statement purposes for which no benefit was taken   683    -    -    683    -    -    -    - 
Losses not subject to tax   -    3,886    -    3,886    -    2,468    -    2,468 
Utilization of losses not previously benefitted   (59)   -    -    (59)   (34)   -    -    (34)
Taxable income (loss)  $15   $-   $(1,576)  $(1,561)  $-   $-   $(1,743)  $(1,743)

 

 F-18 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 11. INCOME TAXES (Cont’d)

 

As of June 30, 2023 and March 31, 2023, the Company’s deferred tax assets and liabilities in the U.K. consisted of the effects of temporary differences attributable to the following (U.S. Dollars in thousands):

 

          
   As of June 30,  As of March 31,
   2023  2023
Deferred tax assets:          
Net operating loss  $(4,594)  $(4,131)
Deferred tax asset (unrecognized)   1,500    1,500 
Deferred tax asset   (3,094)   (2,631)
           
Deferred tax liabilities:          
In-process research and development   13,510    13,195 
Deferred tax liability   13,510    13,195 
           
Net deferred tax liability  $10,416   $10,564 

 

iOx generated no research and development cash credits recorded for the three months ended June 30, 2023.

 

As of June 30, 2023 and March 31, 2023, iOx had a net deferred tax liability of approximately $10.4 million and approximately $10.6 million, respectively. On January 8, 2019, the Company originally recognized a $19.8 million deferred tax liability, reflecting the then prevailing U.K. tax rate of 17% on the difference between the book and income tax basis of IPR&D acquired as part of the SalvaRx Acquisition. In the fiscal 2022, the Company recorded a $7.0 million increase in deferred income taxes to reflect a future change in the U.K. income tax rate to 25% effective April 1, 2023 and recognized $0.7 million of current year losses and $0.8 million of prior year losses. The Company also recognized a $1.1 million decrease in deferred tax liability in fiscal 2022 to reflect the effect of the change in exchange rates on the liability settleable in British pound sterling. For the year ended March 31, 2023, the Company recognized an aggregate reduction in net deferred tax liability of $17.9 million, comprised of $11.3 million to recognized the deferred tax effect of loss on impairment recognized with respect to the iOx IPR&D, $0.7 million related to other current year losses, $3.8 million to reflect the change related to the future U.K. tax rates and $2.1 million to reflect the effect of the change in exchange rates on the liability settleable in British pound sterling. For the three months ended June 30, 2023, the Company recognized a net decrease in the deferred tax liability of $0.1 million comprised of $0.3 million to reflect the effect of the change in exchange rates on the liability in the period and recognized $0.4 million of current period losses.

 

There is no expiration date for accumulated tax losses in the U.K. entities.

 

 F-19 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 12. CAPITAL STOCK

 

(a)Authorized ordinary shares: Unlimited number of Portage ordinary shares without par value.

 

(b)The following is a roll-forward of Portage ordinary shares for the years ended June 30, 2023 and 2022:

 

                    
   Three Months Ended June 30,
   2023  2022
   Ordinary
Shares
  Amount  Ordinary
Shares
  Amount
   In 000’  In 000’$  In 000’  In 000’$
Balance, beginning of period   17,606   $218,782    13,349   $158,324 
Shares issued under public offering and ATM, net of issue costs   171    613    -    - 
Shares issued or accrued for services   9    30    4    30 
Balance, end of period   17,786   $219,425    13,353   $158,354 

 

Portage filed a shelf registration statement with the SEC under which it may sell ordinary shares, debt securities, warrants and units in one or more offerings from time to time, which became effective on March 8, 2021 (“Registration Statement”). In connection with the Registration Statement, Portage has filed with the SEC:

 

·a base prospectus, which covers the offering, issuance and sale by Portage of up to $200,000,000 in the aggregate of the securities identified above from time to time in one or more offerings;

 

·a prospectus supplement, which covers the offer, issuance and sale by Portage in an “at-the-market” (“ATM”) offering of up to a maximum aggregate offering price of $50,000,000 of Portage’s ordinary shares that may be issued and sold from time to time under a Controlled Equity Offering Sales Agreement, dated February 24, 2021 (the “Sales Agreement”), with Cantor Fitzgerald & Co., the sales agent (“Cantor Fitzgerald”);

 

·a prospectus supplement dated June 24, 2021, for the offer, issuance and sale by Portage of 1,150,000 ordinary shares for gross proceeds of approximately $26.5 million in a firm commitment underwritten public offering with Cantor Fitzgerald; and

 

·a prospectus supplement dated August 19, 2022, for the resale of up to $30,000,000 in ordinary shares that Portage may sell from time to time to Lincoln Park Capital Fund, LLC (“Lincoln”) and an additional 94,508 shares that were issued to Lincoln.

 

 F-20 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 12. CAPITAL STOCK (Cont’d)

 

The Sales Agreement permits the Company to sell in an ATM program up to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered, issued and sold by the Company under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Upon termination of the Sales Agreement, any portion of the $50,000,000 included in the Sales Agreement prospectus that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus.

 

During Fiscal 2022, the Company sold 90,888 ordinary shares under the ATM program, generating gross proceeds of approximately $2.6 million ($2.5 million, net of commissions).

 

The Company has issued 2,425,999 ordinary shares in connection with the acquisition of Tarus Therapeutics, Inc. and in connection with the Tarus Therapeutics, Inc.’s acquisition it may issue additional ordinary shares. See Note 9, “Acquisition of Tarus,” for a further discussion.

 

On July 18, 2022, the Company entered into the iOx Share Exchange Agreement under which it exchanged 1,070,000 ordinary shares of the Company for the remaining minority interest of 21.68% of iOx. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx,” for a further discussion.

 

On July 6, 2022, the Company entered into a Purchase Agreement (the “Committed Purchase Agreement”) with Lincoln, under which it may require Lincoln to purchase ordinary shares of the Company having an aggregate value of up to $30 million (the “Purchase Shares”) over a period of 36 months. Upon execution of the Committed Purchase Agreement, the Company issued to Lincoln 94,508 ordinary shares, representing a 3% commitment fee. Pursuant to the Committed Purchase Agreement, Lincoln will be obligated to purchase the Purchase Shares in three different scenarios that are based on various market criteria and share amounts. The Company has the right to terminate the Committed Purchase Agreement for any reason, effective upon one business day prior written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The requirement that Lincoln must make a purchase will be suspended based on various criteria such as there not being an effective registration statement for Lincoln to be able to resell the ordinary shares it is committed to purchase and market criteria such as the Company continuing to be Depository Trust Company eligible, among other things. The Committed Purchase Agreement does not impose any financial or business covenants on the Company, and there are no limitations on the use of proceeds. The Company may raise capital from other sources in its sole discretion; provided, however, that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like securities until the three-year anniversary of the date of the Committed Purchase Agreement, excluding, however, an ATM transaction with a registered broker-dealer, which includes any sales under the Sales Agreement with Cantor Fitzgerald.

 

As discussed in Note 2, “Going Concern,” the Company’s access to the ATM program and the Committed Purchase Agreement is generally limited based on the Company’s trading volume on Nasdaq. See Note 15, “Commitments and Contingent Liabilities – Committed Purchase Agreement,” for a further discussion.

 

 F-21 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 12. CAPITAL STOCK (Cont’d)

 

In Fiscal 2023, the Company sold 166,145 ordinary shares under the ATM program, generating net proceeds of approximately $0.9 million. Separately, in Fiscal 2023, the Company sold 480,000 ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds totaling approximately $2.0 million. From April 1, 2023 through June 30, 2023, the Company sold 171,504 ordinary shares under the ATM program, generating net proceeds of approximately $0.6 million.

 

NOTE 13. STOCK OPTION RESERVE

 

(a)The following table provides the activity for the Company’s stock option reserve for the three months ended June 30, 2023 and 2022:

 

                    
   Three Months Ended June 30,
   2023  2022
(In thousands)  Non-Controlling Interest  Stock Option Reserve  Non-Controlling Interest  Stock Option Reserve
Balance, beginning of period  $-   $21,204   $11,659   $16,928 
Share-based compensation expense   -    769    -    1,176 
Balance, end of period  $-   $21,973   $11,659   $18,104 

 

Stock Options

 

On June 25, 2020, at the annual meeting of shareholders, the Company’s incentive stock option plan (the “2020 Stock Option Plan”) was approved, which authorized the Company’s directors to fix the option exercise price and to issue stock options under the plan as appropriate. The Company’s 2020 Stock Option Plan was a 10% rolling stock option plan under which the Company’s directors were authorized to grant up to a maximum of 10% of the issued and outstanding ordinary shares on the date of grant.

 

Effective January 13, 2021, the Company amended and restated its 2020 Stock Option Plan to permit the grant of additional types of equity compensation securities, including restricted stock units (“RSUs”) and dividend equivalent rights (the “2021 Equity Incentive Plan”). The aggregate number of equity securities, which may be issued under the 2021 Equity Incentive Plan has not been changed.  Pursuant to the 2021 Equity Incentive Plan, on January 13, 2021, the Company granted an aggregate of 868,000 stock options exercisable at a price of $17.75 per share, representing the closing price of the shares on the day immediately preceding the grant date, which expire on January 13, 2031 to various directors, officers and consultants of the Company. 350,000 options granted to members of the Board vest 1/3 on grant date, 1/3 on the first anniversary of the grant and 1/3 on the second anniversary of the grant. 518,000 options granted to consultants (one of whom is also a director of the Company) vest 1/3 on each of the first three anniversaries of the grant date.

 

Additionally, the Company granted 243,000 RSUs on January 13, 2021, with a fair value of $17.75 per share, which was the closing price on the day immediately preceding the grant date. The RSUs vested on the date of grant, but underlying shares cannot be sold until one of four of the following conditions are met: (1) a Change in Control (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)), (2) the participant’s Separation from Service (as defined in the Amended and Restated 2021 Equity Incentive Plan), (3) the participant’s death, or (4) the participant’s Disability (as defined in the Amended and Restated 2021 Equity Incentive Plan).  In accordance with IFRS 2, “Share-based Payment,” the Company recognized compensation expense of $4.3 million in the year ended March 31, 2021, in connection with the RSU grants.

 

 F-22 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 13. STOCK OPTION RESERVE (Cont’d)

 

Amended and Restated 2021 Equity Incentive Plan and Grants of Stock Options and Restricted Stock Units

 

On January 19, 2022, the Board unanimously approved the Amended and Restated 2021 Equity Incentive Plan (the “Amended and Restated 2021 Equity Incentive Plan”). The Amended and Restated 2021 Equity Incentive Plan provides for:

 

(1)An increase of aggregate number of ordinary shares available for awards to 2,001,812, which is equal to 15% of the issued and outstanding ordinary shares of the Company as of January 19, 2022 subject to discretionary annual increases (on a cumulative basis) as may be approved by the Board in future years by a number of ordinary shares not to exceed an additional 5% of the aggregate number of shares then outstanding;

 

(2)The authorization of incentive stock options under the Amended and Restated 2021 Equity Incentive Plan; and

 

(3)The provision of dividend equivalent rights to be issued when authorized.

 

Pursuant to the Amended and Restated 2021 Equity Incentive Plan, on January 19, 2022, the Company granted an aggregate of 302,000 stock options exercisable at a price of $10.22 per share, representing the average price of the Company’s ordinary shares on the grant date, which expire on January 19, 2032, to various directors, officers and consultants of the Company. A total of 13,800 of the 302,000 stock options were granted to two members of the Board and vest on the first anniversary of the grant date. The balance of 288,200 stock options was granted to employees (one of whom is also a director of the Company), and a consultant, and such stock options vest ratably on each of the first four annual anniversaries of the grant date.

 

Additionally, the Company granted 135,740 RSUs to employees (one of whom is also a director of the Company) on January 19, 2022, with a fair value of $10.22 per share, representing the average price of the shares on the grant date. The RSUs were fully vested and nonforfeitable as of the grant date and will expire on January 19, 2032.

 

On February 15, 2022, James Mellon, Linda Kozick and Mark Simon were appointed to the Board. Mr. Mellon owned approximately 23.9% of the Company’s outstanding shares at that date. Additionally, Mr. Mellon had previously served as a member of the Board from 2016 to August 14, 2020. On February 15, 2022, in connection with the appointments, each of these directors was granted 13,800 non-qualified stock options, which vest ratably monthly over a three-year period. The options have an exercise price of $8.59 per share, representing the average price of the shares on the grant date, and will expire, if unexercised, on February 15, 2032.

 

On June 8, 2022, the Company granted 50,000 options to purchase shares to an executive of the Company. The options have an exercise price of $11.00, the average price of the stock on that date, vest ratably on each of the first four anniversaries of the grant date and will expire, if unexercised, on June 8, 2032.

 

On July 27, 2022, the Company granted 15,900 options to purchase shares to a member of the Board. The options have an exercise price of $10.06, the average price of the stock on that date, vest ratably on each monthly anniversary of the grant date in the three year period following the grant date and will expire, if unexercised, on July 27, 2032.

 

On March 30, 2023, the Board unanimously approved to increase the maximum number of ordinary shares reserved for issuance under the Amended and Restated 2021 Equity Incentive Plan. The aggregate number of shares available for awards under the Amended and Restated 2021 Equity Incentive Plan was increased to 2,880,992, which represented a 5% increase (or 879,180 shares) based on ordinary shares outstanding on March 29, 2023, which is equal to 16% of the issued and outstanding ordinary shares in the capital of the Company as of this date.

 

 F-23 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 13. STOCK OPTION RESERVE (Cont’d)

 

On March 30, 2023, the Company granted an aggregate of 746,120 stock options exercisable at a price of $2.92 per share, representing the average price of the shares on the grant date, which expire on March 30, 2033, to various directors, officers and a consultant of the Company. 14,600 options to purchase ordinary shares, totaling 87,600, were granted to each non-executive member of the Board and vest on the first anniversary of the grant date. A total of 651,020 stock options were granted to employees (including Mr. Walters, who is Chairman of the Board of Directors), and a consultant, and such stock options vest ratably on each of the first four annual anniversaries of the grant date. The balance of 7,500 stock options were also granted to a consultant, which was fully vested as of the grant date.

 

(b)The changes in the number of options issued for the three months ended June 30, 2023 and 2022 were:

 

                    
   Three Months Ended June 30,
   2023  2022  2023  2022
   PBI Amended and Restated
2021 Equity Incentive Plan
  iOx Option Plan
(Subsidiary Plan)
Balance, beginning of period   1,963,420    1,151,400    -    1,275 
Granted   -    50,000    -    - 
Expired or forfeited   -    -    -    (1,275)
Balance, end of year   1,963,420    1,201,400    -    - 
Exercisable, end of period   764,438    410,600    -    - 

 

(c)The following is the weighted average exercise price and the remaining contractual life for outstanding options by plan as of June 30, 2023 and 2022:

 

                    
   As of June 30,
   2023  2022  2023  2022
   PBI Amended and Restated
2021 Equity Incentive Plan
  iOx Option Plan
(Subsidiary Plan)
Weighted average exercise price  $10.53    15.26   $-   $- 
Weighted average remaining contractual life (in years)   8.61    8.90    -    - 

 

 F-24 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 13. STOCK OPTION RESERVE (Cont’d)

 

The vested options can be exercised at any time in accordance with the applicable option agreement. The exercise price was greater than the market price for all options outstanding as of June 30, 2023 and March 31, 2023, except 7,500 vested options and 738,620 unvested options as of each date.

 

The Company recorded approximately $0.8 million and $1.2 million of share-based compensation expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the three months ended June 30, 2023 and 2022, respectively. The Company expects to record additional share-based compensation expense of approximately $3.4 million through March 2027 with respect to the Amended and Restated 2021 Equity Incentive Plan.

 

As of June 30, 2022, the Company’s iOx stock option plan was fully vested. The iOx stock option plan expired on May 5, 2022 and all outstanding stock option awards issued under the iOx stock option plan expired.

 

NOTE 14. (LOSS) PER SHARE

 

Basic earnings per share (“EPS”) is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period.

 

Diluted EPS is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

 

The following table reflects the loss and share data used in the basic and diluted EPS calculations (U.S. Dollars in thousands, except per share amounts):

 

          
   Three Months Ended June 30,
Numerator (in 000’$)  2023  2022
       
Net loss attributable to owners of the Company  $(5,919)  $(1,729)
Denominator (in 000’)          
Weighted average number of shares – Basic and Diluted   17,701    13,351 
Basic and diluted (loss) per share  $(0.33)  $(0.13)

 

 F-25 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 14. (LOSS) PER SHARE (Cont’d)

 

The inclusion of the Company’s stock options, RSUs and share purchase warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share for the three months ended June 30, 2023 and 2022. The following table reflects the Company's outstanding securities by year that would have an anti-dilutive effect on loss per share and, accordingly, were excluded from the calculation.

 

          
   As of June 30,
   2023  2022
Stock options   1,963,420    1,201,400 
Restricted stock units   378,740    378,740 

 

NOTE 15. COMMITMENTS AND CONTINGENT LIABILITIES

 

Effective March 15, 2022, iOx entered into a Master Services Agreement (the “MSA”) with Parexel International (IRE) Limited (“Parexel”) under which Parexel agreed to act as clinical service provider (CRO) pursuant to a work order (“Work Order”) effective June 1, 2022. Pursuant to such Work Order, Parexel will operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer (“NSCLC”). The MSA provides for a five-year term, and the Work Order provides for a term to be ended upon the completion of the services required. The budget provides for service fees and pass-through expenses and clinical sites totaling $11.5 million. During Fiscal 2023, the Company executed two change orders resulting in a $0.6 million increase in the overall estimated budgeted costs.

 

On March 1, 2023, the Company, through Tarus, entered into a clinical service agreement with Fortrea Inc. (formerly Labcorp Drug Development Inc.), a third-party CRO. The term of the agreement is through the earlier of August 14, 2025 or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services to be provided is approximately $12.1 million.

 

Stimunity Convertible Note

 

On July 13, 2022, the Company entered into a commitment with Stimunity to provide €600,000 under the Stimunity Convertible Note. The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible Note is automatically converted into Series A shares of Stimunity upon Stimunity completing a Series A round for at least €20 million. If such subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into Series A shares of Stimunity at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares (other than Common Shares or Series A shares of Stimunity) for at least €5 million (the “Minimum Raise”), the Company will have the right to convert the Stimunity Convertible Note and the historical Series A shares of Stimunity owned into the new category of shares. In the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the right to convert the Stimunity Convertible Note into Series A shares of Stimunity at €363.00 per share or the raise price less 15%, whichever is lower. The Stimunity Convertible Note was funded by the Company on September 12, 2022. In addition, the Company has not reflected the interest earned on the Stimunity Convertible Note in reporting its consolidated financial results. See Note 6, “Investment in Associate,” for a further discussion.

 

 F-26 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 15. COMMITMENTS AND CONTINGENT LIABILITIES (Cont’d)

 

Committed Purchase Agreement

 

On July 6, 2022 (the “Signing Date”), the Company entered into the Committed Purchase Agreement with Lincoln, pursuant to which the Company may require Lincoln to purchase ordinary shares having an aggregate value of up to $30 million over a period of 36 months. Pursuant to the Committed Purchase Agreement, Lincoln will be obligated to purchase the Company’s ordinary shares in three different scenarios that are based on various market criteria and share amounts.

 

Upon execution of the Committed Purchase Agreement, the Company issued to Lincoln 94,508 ordinary shares, representing a 3% commitment fee valued at $0.9 million. The Company has the right to terminate the Committed Purchase Agreement for any reason, effective upon one business day prior written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The Company is accounting for the commitment fee as a deferred commitment fee on the consolidated statement of financial position as of June 30, 2023 and March 31, 2023 and will amortize it pro-rata against equity sold under the Committed Purchase Agreement. Any unamortized balance will be written-off to operations at the expiration of the commitment.

 

The Committed Purchase Agreement does not impose any financial or business covenants on the Company and there are no limitations on the use of proceeds received by the Company from Lincoln. The Company may raise capital from other sources in its sole discretion; provided, however, that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like securities until the three-year anniversary of the Signing Date, excluding, however, an at-the-market transaction with a registered broker-dealer.

 

In connection with the Committed Purchase Agreement, the Company and Lincoln entered into a Registration Rights Agreement, dated July 6, 2022 (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company agreed to file with the SEC the prospectus supplement to the Company’s shelf registration statement pursuant to Rule 424(b) for the purpose of registering for resale the ordinary shares to be issued to Lincoln under the Committed Purchase Agreement. The prospectus supplement was filed on August 19, 2022.

 

The Company is obligated under the Tarus Merger Agreement and the iOx Share Exchange Agreement to pay certain third party earnouts based on the achievement of certain milestones. See Note 9, “Acquisition of Tarus,” and Note 16, “Related Party Transactions – Share Exchange Agreement – iOx,” respectively, for further discussions.

 

NOTE 16. RELATED PARTY TRANSACTIONS

 

SalvaRx Acquisition

 

Two of the Company’s directors are also directors of SalvaRx Group plc, a company which owns approximately 4.1% of the Company’s issued and outstanding ordinary shares as of June 30, 2023.

 

Investments

 

The Company has entered into related party transactions and certain services agreements with its investees.  Key management personnel of the Company have also entered into related party transactions with investees. Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the activities of the Company, including directors and senior management of the Company.

 

 F-27 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 16. RELATED PARTY TRANSACTIONS (Cont’d)

 

The following subsidiaries and associates are considered related parties:

 

(a)Stimunity. The CEO of Portage is one of three members of the board of directors of Stimunity (see Note 6, “Investment in Associate,” and Note 15, “Commitments and Contingent Liabilities – Stimunity Convertible Note”).
(b)iOx. Upon execution of the iOx Share Exchange on July 18, 2022, the non-Portage director resigned from the iOx board leaving two Portage insiders as directors. The CEO of Portage is also the CEO of iOx, and the management team of Portage comprises the management team of iOx. See below for a discussion of the Company’s purchase of the non-controlling interest in iOx through its wholly-owned subsidiary SalvaRx.
(c)Saugatuck. One of the three directorships on the board of directors of Saugatuck is controlled by Portage. Additionally, the CEO of Portage is also the CEO of Saugatuck, and the management team of Portage comprises the management team of Saugatuck.
(d)Intensity. The CEO of Portage previously served as a part-time officer of Intensity until becoming a consultant in 2023. Additionally, Intensity provided services (primarily rent) to Portage through April 2023.
(e)Portage Development Services Inc. PDS provides human resources and other services to each operating subsidiary of Portage through a shared services agreement.

 

The following are related party balances and transactions other than those disclosed elsewhere in the condensed consolidated interim financial statements:

 

Transactions between the parent company and its subsidiaries, which are related parties, have been eliminated in consolidation and are not disclosed in this note.

 

On September 8, 2021, the Company, through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price of £162. Simultaneously, the Company entered into an agreement with OSI, the holder of $0.15 million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for 820 shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets of IAS 39, “Financial Instruments: Recognition and Measurement,” and IFRIC 19, “Extinguishing Financial Liabilities with Equity Instruments,” and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%.

 

Share Exchange Agreement – iOx

 

On July 18, 2022, the Company and SalvaRx entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with each of the minority shareholders of iOx (the “Sellers”) resulting in the acquisition of the outstanding non-controlling ownership interest (approximately 22%) of iOx, which is developing the iNKT engager platform. The Company followed IFRS 3, “Business Combinations,” and IAS 27, “Separate Financial Statements,” (which substantially replaced IAS 3) to account for this transaction. The Company achieved control of iOx, as defined, on January 8, 2019 upon the completion of the SalvaRx Acquisition. Further transactions whereby the parent entity acquires further equity interests from non-controlling interests, or disposes of equity interests but without losing control, are accounted for as equity transactions (i.e., transactions with owners in their capacity as owners). As such:

 

 F-28 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 16. RELATED PARTY TRANSACTIONS (Cont’d)

 

·the carrying amounts of the controlling and non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiary;
·any difference between the amount by which the non-controlling interests is adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the parent; and
·there is no consequential adjustment to the carrying amount of goodwill, and no gain or loss is recognized in profit or loss.

 

The Company now owns the worldwide rights to its small molecule iNKT engagers, including lead programs PORT-2 and PORT-3. Under the terms of the Share Exchange Agreement, each Seller sold to the Company, and the Company acquired from each Seller, legal and beneficial ownership of the number of iOx shares held by each Seller, free and clear of any share encumbrances, in exchange for the issuance in an aggregate of 1,070,000 Portage ordinary shares to be allocated among the Sellers based upon their relative ownership. As a result of the Share Exchange Agreement, the Company owns 100% of the issued and outstanding shares of iOx through its wholly-owned subsidiary, SalvaRx.

 

As additional consideration for the sale of the iOx shares to the Company under the Share Exchange Agreement, the Sellers shall have the contingent right to receive additional shares (“Earnout Shares”) from the Company having an aggregate value equal to $25 million calculated at the Per Share Earnout Price, as defined in the Share Exchange Agreement, upon the achievement of certain milestones defined as the dosing of the first patient in a Phase 3 clinical trial for either PORT-2 (IMM60 iNKT cell activator/engager) or PORT-3 (PLGA-nanoparticle formulation of IMM60 combined with a NY-ESO-1 peptide vaccine). The Company shall have the option, in its sole and absolute discretion, to settle the Earnout Shares in cash. The Company followed IFRS 3 and IAS 32, “Financial Instruments: Presentation,” to account for the fair value of the Earnout Shares. The principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount rate used. The fundamental principle of IAS 32 is that a financial instrument should be classified as either a financial liability or an equity instrument according to the substance of the contract, not its legal form, and the definitions of financial liability and equity instrument. A financial instrument is an equity instrument if, and only if, both conditions (a) and (b) below are met:

 

(a)the instrument includes no contractual obligation to deliver cash or another financial asset to another entity, and
(b)if the instrument will or may be settled in the Company’s own equity instruments, it is either:
(i)a non-derivative that includes no contractual obligation for the Company to deliver a variable number of its own equity instruments; or
(ii)a derivative that will be settled only by the issuer exchanging a fixed amount of cash or another financial asset for a fixed number of its own equity instruments.

 

When a derivative financial instrument gives one party a choice over how it is settled (for instance, the Company or the holder can choose settlement net in cash or by exchanging shares for cash), it is a financial asset or a financial liability unless all of the settlement alternatives would result in it being an equity instrument. The financial instrument includes the exclusive right of the Company to settle the obligation with cash or equity and, accordingly, accounted for the fair value of the Earnout Shares as a non-current liability.

 

The Company recorded $5.478 million as the fair value estimate of the Earnout Shares, which is reflected as deferred obligation - iOx milestone on the condensed consolidated interim statements of financial position included herein. The Company will determine the fair value of the Earnout Shares at each balance sheet date. Any change to the fair value will be recorded in the Company’s statements of operations and other comprehensive income (loss). The Company recorded a (loss) from the change (increase) in fair value of the liability of $0.685 million for the three months ended June 30, 2023.

 

 F-29 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 16. RELATED PARTY TRANSACTIONS (Cont’d)

 

Employment Agreements

 

PDS entered into a Services Agreement with the Company’s CEO effective December 15, 2021 (the “CEO Services Agreement”). The CEO Services Agreement originally provided for a base salary of $618,000, plus cost-of-living increases. On December 19, 2022, the Compensation Committee approved the CEO’s compensation of $642,700 for Fiscal 2024. The CEO Services Agreement provides for annual increases based upon the review of the base salary by the Board prior to the anniversary of the CEO Services Agreement provided that the annual increase cannot be less than the cost-of-living increase. The CEO Services Agreement also provides that the CEO is eligible to receive an annual performance-based bonus targeted at 59% of the applicable year’s base salary, which bonus is earned based on the achievement of performance targets, as determined annually by the Board and communicated to the CEO in the first quarter of the year. Any annual bonus, to the extent earned, is to be paid no later than March 15 of the following year. The CEO Services Agreement is for an initial term of three years, after which it will automatically renew annually unless terminated in accordance with the CEO Services Agreement.

 

Under the CEO Services Agreement, the CEO may terminate his employment with PDS at any time for Good Reason (as defined in the CEO Services Agreement). PDS may terminate the CEO’s employment immediately upon his death, upon a period of disability or without Just Cause (as defined in the CEO Services Agreement). In the event that the CEO’s employment is terminated due to his death or Disability (as defined in the CEO Services Agreement), for Good Reason or without Just Cause, he will be entitled to accrued obligations (accrued unpaid portion of base salary, accrued unused vacation time and any unpaid expenses). Additionally, he may be entitled to Severance Benefits (as defined in the CEO Services Agreement), which include his then current base salary and the average of his annual bonus for the prior two completed performance years, paid over 12 monthly installments. Additionally, the CEO will be entitled to life insurance benefits and medical and dental benefits for a period of 12 months at the same rate the CEO and PDS shared such costs during his period of employment.

 

Additionally, all stock options (and any other unvested equity incentive award) held by the CEO relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as defined in the CEO Services Agreement), and the exercise period for such stock options will be increased by a period of two years from the Termination Date.

 

If the CEO’s employment by PDS is terminated by PDS or any successor entity without Just Cause (not including termination by virtue of the CEO’s death or Disability) or by the CEO for Good Reason within 12 months following the effective date of a Change in Control (as defined in the CEO Services Agreement), then, in addition to paying or providing the CEO with the Accrued Obligations (as defined in the CEO Services Agreement), the Company will provide the following Change in Control Severance Benefits (as defined in the CEO Services Agreement):

 

(1)PDS will pay the base salary continuation benefit for 18 months;

 

(2)PDS will pay the life insurance benefit for 18 months;

 

(3)PDS will pay an additional amount equivalent to the CEO’s target annual bonus calculated using the bonus percentage for the performance year in which the CEO’s termination occurs. This bonus will be paid in 12 equal installments commencing on the first payroll date that is more than 60 days following the date of termination of the CEO’s employment, with the remaining installments occurring on the first day of the month for the 11 months thereafter;

 

(4)PDS will provide the CEO with continued medical and dental benefits, as described above, for 18 months; and

 

 F-30 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 16. RELATED PARTY TRANSACTIONS (Cont’d)

 

(5)All stock options (and any other unvested equity incentive award) held by the CEO relating to shares of PDS or the Company will be deemed fully vested and exercisable on the Termination Date, as defined, and the exercise period for such stock options will be increased by a period of two years from the Termination Date.

 

PDS entered into services agreements (individually, an “Executive Service Agreement,” and collectively, the “Executive Service Agreements”) with each of the Company’s five other members of senior management (individually, “Executive” and collectively, “Executives”), three of which are dated as of December 1, 2021, one of which is dated December 15, 2021 and one of which is dated June 1, 2022. Each of the Executive Services Agreements provides for an initial term of two years that is automatically renewed for one-year periods (except two of the Executive Services Agreement, which provides for an initial term of one year and that is automatically renewed for one-year periods). The Executive Services Agreements initially provided for annual base salaries ranging from $175,000 to $348,000 (pro-rated for services rendered) and annual bonus targets ranging from 30% to 40%. They also provide for long-term incentives in the form of equity awards from time to time under the Portage Biotech Inc. Amended and Restated 2021 Equity Incentive Plan.

 

On December 19, 2022, the Compensation Committee approved executive compensation for Fiscal 2024 for annual base salaries ranging from $183,750 to $469,000 (pro-rated for services rendered) and annual bonus targets ranging from 30% to 40%.

 

The Executive Services Agreements can be terminated by PDS without Just Cause, by death or Disability, or by the Executive (except one) for Good Reason (each as defined in the respective Executive Services Agreements). In such instances, the Executive Services Agreements provide for the payment of accrued obligations (accrued unpaid portion of base salary, accrued unused vacation time and any unpaid expenses). Additionally, the Executives (except two) are entitled to 50% of base salary plus 50% of average annual bonus earned over the prior two performance years, as well as prevailing life insurance benefits for a period of six months and medical and dental benefits for a period of six months at the prevailing rate PDS and the Executive were sharing such expenses.

 

Additionally, all stock options (and any other unvested equity incentive award) held by the Executives relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as defined in the respective Executive Services Agreements), and the exercise period for such stock options will be increased by a period of two years from the Termination Date.

 

If an Executive’s employment by PDS is terminated by the Company or any successor entity without Just Cause (not including termination by virtue of the Executive’s death or Disability) or by the Executive (except one) for Good Reason within 12 months following the effective date of a Change in Control (as defined in the respective Executive Services Agreements), then, in addition to paying or providing the Executive with the Accrued Obligations (as defined in the respective Executive Services Agreements), the Company will provide the following Change in Control Severance Benefits (as defined in the respective Executive Services Agreements), except in two cases in which the Executive is entitled to Item (5) and 50% of Items (1) and (3) below:

 

(1)PDS will pay the Base Salary continuation benefit for 12 months;

 

(2)PDS will pay the life insurance benefit for 12 months;

 

(3)The Company will pay an additional amount equivalent to the Executive’s target annual bonus calculated using the bonus percentage for the performance year in which the Executive’s termination occurs. This bonus will be payable in 12 equal installments commencing on the first payroll date that is more than 60 days following the date of termination of the Executive’s employment, with the remaining installments occurring on the first day of the month for the 11 months thereafter;

 

 F-31 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 16. RELATED PARTY TRANSACTIONS (Cont’d)

 

(4)PDS will provide the Executive with continued medical and dental benefits, as described above, for 12 months; and

 

(5)All stock options (and any other unvested equity incentive award) held by the Executive relating to shares of PDS or the Company will be deemed fully vested and exercisable on the Termination Date and the exercise period for such stock options will be increased by a period of two years from the Termination Date.

 

The Executive Services Agreements also include customary confidentiality, as well as provisions relating to assignment of inventions. The Executive Services Agreements also includes non-competition and non-solicitation of employees and customers provision that run during the Executive’s employment with PDS and for a period of one year after termination of employment.

 

Bonuses & Board Compensation Arrangements

 

In December 2022, the Board approved executive performance bonuses, as recommended by the Compensation Committee, totaling $0.6 million, which is equivalent to 73.5% of original annual targets established by the Board in December 2021. The bonuses were approved based upon the original performance targets established. The Board further approved a payment structure of 25% of approved bonuses, which were paid in January 2023, with the balance of amounts due payable upon a new financing. The accrued, unpaid amount of approximately $0.4 million is included in accounts payable and accrued expenses on the condensed consolidated statements of financial position as of each of June 30, 2023 and March 31, 2023.

 

Effective January 1, 2022, each non-employee Board member are entitled to receive cash Board fees of $40,000 per annum, payable quarterly in arrears. Additionally, each non-employee Board member is entitled to an annual grant of 6,900 options to purchase Portage ordinary shares, which would vest the first annual anniversary of the grant date. The Company incurred Board fees totaling $82,500 and $75,000 during the three months ended June 30, 2023 and 2022, respectively.

 

Non-employee Board chairpersons are entitled to an annual cash fee of $30,000, payable quarterly in arrears. In lieu of a non-executive chairperson, the lead director is entitled to an annual cash fee of $20,000 per annum paid quarterly in arrears. Additionally, the chairperson of each of the Audit Committee, Compensation Committee and Nominating Committee is entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members of those committees will be entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.

 

NOTE 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

 

The Company’s financial instruments recognized in the Company’s condensed consolidated interim statements of financial position consist of the following:

 

Fair value estimates are made at a specific point in time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties and matters of significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could significantly affect these estimates.

 

 F-32 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Cont’d)

 

The following table summarizes the Company’s financial instruments as of June 30, 2023 and March 31, 2023:

 

                              
   As of June 30, 2023  As of March 31, 2023
   Amortized
Cost
  FVTOCI  FVTPL  Amortized
Cost
  FVTOCI  FVTPL
                   
Financial assets                              
Cash and cash equivalents  $7,698   $-   $-   $10,545   $-   $- 
Prepaid expenses and other receivables  $2,752   $-   $-   $2,689   $-   $- 
Convertible note receivable, including accrued interest, net of impairment  $-   $-   $442   $-   $-   $442 
Investment in associate  $-   $-   $756   $-   $-   $806 
Investment in public company  $-   $3,855   $-   $-   $2,087   $- 

 

                     
   As of June 30, 2023  As of March 31, 2023
   Amortized
Cost
  FVTPL  Amortized
Cost
  FVTPL
Financial liabilities                    
Accounts payable and accrued liabilities  $2,591   $-   $1,865   $- 
Lease liability - current  $47   $-   $-   $- 
Lease liability - non-current  $249   $-   $-   $- 
Deferred purchase price payable - Tarus  $-   $7,864   $-   $7,179 
Deferred obligation - iOx milestone  $-   $4,552   $-   $4,126 

 

A summary of the Company’s risk exposures as it relates to financial instruments are reflected below.

 

Fair value of Financial Instruments

 

The Company’s financial assets and liabilities are comprised of cash and cash equivalents, receivables and investments in equities and private and public entities, accounts payable, lease liability, deferred purchase price payable, deferred obligation and unsecured notes payable.

 

The Company classifies the fair value of these transactions according to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:

 

·Level 1 – Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of the reporting date.

 

·Level 2 – Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of the reporting date.

 

·Level 3 – Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified as Level 3 financial instrument.

 

Assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy.

 

 F-33 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Cont’d)

 

Management has assessed that the fair values of cash and cash equivalents, other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.

 

The following methods and assumptions were used to estimate their fair values:

 

Investment in Associate: The fair value of the Stimunity investment was determined based on an IAS 36 fair value analysis evaluating the likelihood of various scenarios given the then-current market conditions, the increasing cost of capital and development delays associated with Stimunity’s lack of liquidity (Level 3). The Company recorded a provision of impairment of $0.607 million with respect to the investment in associate decreasing the carrying value of the investment in associate to $0.806 million as of March 31, 2023. There was no provision for impairment recorded in the three months ended June 30, 2023. See Note 6, “Investment in Associate,” for a further discussion.

 

Convertible Note Receivable: The fair value of the Stimunity Convertible Note receivable denominated in euros at initial recognition is the transaction price for the instrument adjusted for the effect of the currency translation rate on the reporting date (Level 3) (see Note 15, “Commitments and Contingent Liabilities – Stimunity Convertible Note”). The Stimunity Convertible Note was initially recorded at $0.614 million to record the translated value of the Stimunity Convertible Note on September 12, 2022. The Company recognized an unrealized gain of $0.039 million through OCI in Fiscal 2023 to reflect the change in translation rate for the Stimunity Convertible Note settleable in euros, increasing the carrying value of the Stimunity Convertible Note to $0.653 million. As of March 31, 2023, the Company determined that there were indications of impairment, based upon the inability of Stimunity to obtain financing. The Company performed an IAS 36 fair value analysis evaluating the likelihood of various scenarios given the then-current market conditions, the increasing cost of capital and development delays associated with Stimunity’s lack of liquidity. The Company recorded an impairment of $0.211 million resulting from the impairment analysis decreasing the carrying value of the Stimunity Convertible Note to $0.442 million as of March 31, 2023. The Company recorded a nominal unrealized gain in the three months ended June 30, 2023 with respect to the Stimunity Convertible Note.

 

Investment in Public Company: Upon Intensity’s IPO effective June 30, 2023, the fair value of the investment is determined by the quoted market price (Level 1).

 

Accrued Equity Issuable: The fair value is estimated based on the average of the quoted market prices for the period in which the shares were earned (Level 1).

 

Lease Liability - Current: The lease liability - current represents the present value of the lease payments due over the next twelve months discounted at the Company’s incremental borrowing rate (Level 2).

 

Lease Liability - Non-Current: The lease liability - non-current represents the present value of the lease payments due under the lease less the current portion of such payments discounted at the Company’s incremental borrowing rate (Level 2).

 

Deferred Purchase Price Payable - Tarus: The fair value is the estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 at acquisition date, adjusted at each reporting date for any change in fair value (Level 3) (see Note 9, “Acquisition of Tarus”). The fair value was determined using the Income Approach and was based upon the analysis on the Tarus clinical plan, the timing of development events and the probabilities of success determined primarily based upon empirical third party data and Company experience, as well as the relevant cost of capital. The Company recorded a (loss) from the change (increase) in fair value of the liability of $0.685 million for the three months ended June 30, 2023.

 

 F-34 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Cont’d)

 

Deferred Obligation - iOx Milestone: The fair value is the estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 as of July 18, 2022, the date of the Share Exchange Agreement, adjusted at each reporting date for any change in fair value (Level 3) (see Note 16, “Related Party Transactions – Share Exchange Agreement – iOx”). The fair value was determined using the Income Approach and based on factors including the clinical plan, the timing of development events and the probabilities of success determined primarily based upon empirical third party data and Company experience, as well as the relevant cost of capital. The Company recorded a (loss) from the change (increase) in fair value of the liability of $0.426 million for the three months ended June 30, 2023.

 

Fair Value Hierarchy

 

The investment in public company (Intensity) was transferred from Level 3 to Level 1 of the fair value hierarchy for the three months ended June 30, 2023 as the result of Intensity’s IPO. For the year ended March 31, 2023, the fair value of the investment was determined based on an IAS 36 impairment analysis after determining there were external indications of impairment (Level 3). See Note 7, “Investment in Public Company.”

 

The Company’s financial instruments are exposed to certain financial risks: Credit Risk, Liquidity Risk and Foreign Currency Risk.

 

Credit Risk

 

Credit risk is the risk of loss associated with a counterparty’s inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit risk is limited to the carrying value as reflected in the Company’s condensed consolidated interim statements of financial position.

 

Cash and cash equivalents. Cash and cash equivalents comprise cash on hand and amounts invested in underlying Treasury and money market funds that are readily convertible to a known amount of cash with three months or less from date of acquisition and are subject to an insignificant risk of change in value. As of June 30, 2023 and March 31, 2023, cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. Cash and cash equivalents are held with major international financial institutions and therefore the risk of loss is minimal.

 

Liquidity Risk

 

Liquidity risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due.

 

The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without incurring unacceptable losses or risking harm to the Company’s reputation. The Company holds sufficient cash and cash equivalents to satisfy current obligations under accounts payable and accruals.

 

The Company monitors its liquidity position regularly to assess whether it has the funds necessary to meet its operating needs and needs for investing in new projects.

 

As a biotech company at an early stage of development and without significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty in global markets could have an impact on the Company’s future ability to access capital on terms that are acceptable to the Company. There can be no assurance that required financing will be available to the Company. See Note 2, “Going Concern,” and Note 12, “Capital Stock,” for a discussion of the Company’s share offering and Note 15, “Commitments and Contingent Liabilities – Committed Purchase Agreement,” for a further discussion.

 

 F-35 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Cont’d)

 

Foreign Currency Risk

 

While the Company operates in various jurisdictions, substantially all of the Company’s transactions are denominated in the U.S. Dollar, except the deferred tax liability in the U.K. settleable in British pound sterling and the Stimunity Convertible Note receivable settleable in euros.

 

NOTE 18. CAPITAL DISCLOSURES

 

The Company considers the items included in shareholders’ equity as capital. The Company had accounts payable and accrued liabilities of approximately $2.6 million and lease liability - current of $0.047 million as of June 30, 2023 (accounts payable and accrued liabilities of approximately $1.9 million as of March 31, 2023) and current assets of approximately $10.9 million as of June 30, 2023 (approximately $13.7 million as of March 31, 2023). The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern in order to pursue new business opportunities and to maintain a flexible capital structure, which optimizes the costs of capital at an acceptable risk.

 

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets.

 

As of June 30, 2023, shareholders’ equity attributable to the owners of the company was approximately $73.3 million (approximately $76.0 million as of March 31, 2023).

 

The Company is not subject to any externally imposed capital requirements and does not presently utilize any quantitative measures to monitor its capital. There have been no changes to the Company’s approach to capital management during the three months ended June 30, 2023 and 2022.

 

 

 

 

 

 

 F-36 

Portage Biotech Inc.

Notes to Condensed Consolidated Interim Financial Statements

(U.S. Dollars)

(Unaudited – See Notice to Reader dated August 29, 2023)

 

NOTE 19. NON-CONTROLLING INTEREST

 

               
(In thousands)  iOx  Saugatuck
and subsidiary
  Total
Non-controlling interest as of April 1, 2023  $-   $(650)  $(650)
Net loss attributable to non-controlling interest   -    (7)   (7)
Non-controlling interest as of June 30, 2023  $-   $(657)  $(657)

 

(In thousands)  iOx  Saugatuck
and subsidiary
  Total
Non-controlling interest as of April 1, 2022  $44,701   $(472)  $44,229 
Net income (loss) attributable to non-controlling interest   175    (71)   104 
Non-controlling interest as of June 30, 2022  $44,876   $(543)  $44,333 

 

On September 8, 2021, the Company, through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price of £162. On July 18, 2022, the Company completed the acquisition of the remaining non-controlling interest in iOx, by issuing 1,070,000 shares of its ordinary shares and assuming certain milestone obligations. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx” for a discussion of the Company’s purchase of the balance of the non-controlling interest in iOx.

 

Saugatuck and subsidiary includes Saugatuck and its wholly-owned subsidiary, Saugatuck Rx LLC.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

F-37

 

 

 

 

 

 

 

EX-99.2 3 exh_992.htm EXHIBIT 99.2

Exhibit 99.2

 

 

 

 

 

 

 

PORTAGE BIOTECH INC.

 

THREE MONTHS ENDED JUNE 30, 2023

 

 

 

 

 

MANAGEMENT’S DISCUSSION AND ANALYSIS

 

Prepared as of August 29, 2023

 

 

 

 

 

 

 

 

 

 

TABLE OF CONTENTS

 

 

  Page No.
Forward-Looking Statements 3
Nature of Operations and Overview 4
Summary of Results 8
Number of Ordinary Shares 8
Business Environment – Risk Factors 9
Our Programs and Technology – Recent Developments 9
Results of Operations 15
Liquidity and Capital Resources 17
Key Contractual Obligations 21
Off-balance Sheet Arrangements 24
Transactions with Related Parties 24
Financial and Derivative Instruments 24
Use of Estimates and Judgments 27
New Accounting Standards, Interpretations and Amendments 27
Internal Control over Financial Reporting 28
Public Securities Filings 28

 

 

 

 

 

 

 

 

 

 

 

 

 2 

 

Management Discussion and Analysis

 

The following discussion and analysis by management of the financial condition and financial results for Portage Biotech Inc. for the three months ended June 30, 2023, should be read in conjunction with the unaudited condensed consolidated interim financial statements for the three months ended June 30, 2023, together with the related Management’s Discussion and Analysis and audited consolidated financial statements for the year ended March 31, 2023, and the annual report on Form 20-F (“Annual Report”) for the year ended March 31, 2023.

 

Forward-Looking Statements

 

This document includes “forward-looking statements.” All statements, other than statements of historical facts, included herein or incorporated by reference herein, including without limitation, statements regarding our business strategy, plans and objectives of management for future operations and those statements preceded by, followed by or that otherwise include the words “believe,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “should,” “could,” “targets,” “projects,” “predicts,” “plans,” “potential,” or “continue,” or similar expressions or variations on such expressions are forward-looking statements. We can give no assurances that such forward-looking statements will prove to be correct.

 

Each forward-looking statement reflects our current view of future events and is subject to risks, uncertainties and other factors that could cause actual results to differ materially from any results expressed or implied by our forward-looking statements.

 

Risks and uncertainties include, but are not limited to:

 

·our need for financing and our estimates regarding our capital requirements and future revenues and profitability;

 

·our plans and ability to develop and commercialize product candidates and the timing of these development programs;

 

·clinical development of our product candidates, including the timing for availability and release of results of current and future clinical trials;

 

·our expectations regarding regulatory communications, submissions or approvals;

 

·the potential functionality, capabilities, benefits and risks of our product candidates as compared to others;

 

·our maintenance and establishment of intellectual property rights in our product candidates;

 

·our estimates of the size of the potential markets for our product candidates; and

 

·our selection and licensing of product candidates.

 

Our business focus is that of being primarily a pharmaceutical development business subject to all of the risks of a pharmaceutical development business. We do not anticipate directly engaging in the commercialization of the product candidates we develop.

 

These statements are based on assumptions and analyses made by us in light of our experience and our perception of historical trends, current conditions and expected future developments based on the focus of our business activities on biotechnology, as well as other factors we believe are appropriate in particular circumstances. However, whether actual results and developments will meet our expectations and predictions depends on a number of risks and uncertainties, which could cause actual results to differ materially from our expectations, including the risks set forth in “Item 3 - Key Information - Risk Factors” in our Annual Report on Form 20-F for the year ended March 31, 2023.

 

Consequently, all of the forward-looking statements made in this Management’s Discussion and Analysis are qualified by these cautionary statements. We cannot assure you that the actual results or developments anticipated by us will be realized or, even if substantially realized, that they will have the expected effect on us or our business or operations.

 

 3 

 

Unless the context indicates otherwise the terms “Portage Biotech Inc.,” “the Company,” “our Company,” “Portage,” “we,” “us” or “our” are used interchangeably in this Management’s Discussion and Analysis and mean Portage Biotech Inc. and its subsidiaries. Capitalized terms used but not defined herein have the meaning ascribed to such terms in our unaudited condensed consolidated interim financial statements for the three months ended June 30, 2023.

 

Nature of Operations and Overview

 

Portage is a clinical stage immune-oncology company advancing treatments it believes will be first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with invasive cancers. Our access to next-generation technologies coupled with a deep understanding of biological mechanisms enables the identification of clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. We currently are working on 9 immuno-oncology assets, of which five are pre-clinical and four of which are clinical stage. This excludes backup compounds. We source, nurture and develop the creation of early- to mid-stage treatments that we believe will be first-in-class therapies for a variety of cancers, by funding, implementing viable, cost effective product development strategies, clinical counsel/trial design, shared services, financial and project management to enable efficient, turnkey execution of commercially informed development plans. Our drug development pipeline portfolio encompasses product candidates or technologies based on biology addressing known resistance pathways/mechanisms of current checkpoint inhibitors with established scientific rationales, including intratumoral delivery, nanoparticles, liposomes, aptamers, and virus-like particles.

 

The Portage Approach

 

Our mission is to advance and grow a portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance and expanding the addressable patient population. Given these foundations, we manage capital allocation and risk as much as we oversee drug development. By focusing our efforts on translational medicine and pipeline diversification, we seek to mitigate overall exposure to many of the inherent risks of drug development.

 

Our approach is guided by the following core elements:

 

·Portfolio diversification to mitigate risk and maximize optionality;

 

·Capital allocation based on risk-adjusted potential, including staged funding to pre-specified scientific and clinical results;

 

·Virtual infrastructure and key external relationships to maintain a lean operating base;

 

·Internal development capabilities complemented by external business development;

 

·Rigorous asset selection for broad targets with disciplined ongoing evaluation;

 

·Focus on translational medicine and therapeutic candidates with single agent activity;

 

·Conduct randomized trials early and test non-overlapping mechanisms of action; and

 

·Improve potential outcomes for patients with invasive cancers.

 

Our execution is achieved, in part, through our internal core team and our large network of experts, contract labs, and academic partners.

 

 

 4 

 

Our Science Strategy

 

Our goal is to develop immuno-oncology therapeutics that will dramatically improve the standard-of-care for patients with cancer. The key elements of our scientific strategy are to:

 

·Build a pipeline of differentiated oncology therapeutic candidates that are diversified by mechanism, broad targets, therapeutic approach, modality, stage of development, leading to a variety of deal types that can be executed with partners;

 

·Expand our pipeline through research collaborations, business development and internally designed programs;

 

·Continue to advance and evolve our pipeline with a goal of advancing one therapeutic candidate into the clinic and one program into Investigational New Drug (“IND”)-enabling studies each year; and

 

·Evaluate strategic opportunities to accelerate development timelines and maximize the value of our portfolio.

 

Our Pipeline

 

We have built a pipeline of immuno-oncology therapeutic candidates and programs that are diversified by mechanism, therapeutic approach, modality and stage of development. On an ongoing basis, we rigorously assess each of our programs using internally defined success criteria to justify continued investment and determine proper capital allocation. When certain programs do not meet our de-risking criteria for advancement, we look to monetize or terminate those programs and preserve our capital and resources to invest in programs with greater potential. As a result, our pipeline will continue to be dynamic.

 

The charts below set forth, as of August 29, 2023, the current state of our immuno-oncology therapeutic candidates and programs.  The chart contains forward-looking information and projections based on management’s current estimates. The chart information is based on and subject to many assumptions, as determined by management and not verified by any independent third party, which may change or may not occur as modeled. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  Before you make an investment decision regarding us, you should make your own analysis of forward-looking statements and our projections about candidate and program development and results.

 

 

 5 

 

 

 

Our Business Model

 

We are a development organization that is structured to facilitate flexibility in financing and ease of partnering, licensing, and merger/acquisition of individual assets and or technology platforms.  The intellectual property (“IP”) for each platform is held in separate private entities.  Our employees and consultants work across the pipeline of assets and we believe that this can (i) enhance operational efficiency, (ii) maintain an optimal cost structure, (iii) attract leading collaborators, and (iv) promote asset flexibility, as further described below.

 

·Enhance operational efficiency: We allocate resources while empowering managers to make program-level decisions in order to increase productivity and speed. We believe this model enables a flexible organizational structure that can achieve scale through the addition of programs without increasing burdensome bureaucracy or redundant infrastructure.

 

·Maintain an optimal cost structure: We have a relatively small number of employees and have partnered with a number of service providers to leverage their infrastructure and expertise as needed instead of embarking on capital-intensive lab, manufacturing, and equipment expenditures. By reducing overhead costs, we believe we can increase the likelihood that we can generate a return on invested capital.

 

·Attract leading collaborators and licensors: Our pipeline is comprised of therapies we believe will be first-in-class therapies for a variety of cancers sourced via our extensive industry contacts and relationships (including academia and pharmaceutical industry executives). On preclinical programs/technology, we initially established development structures enabling us to keep licensors economically incentivized at the program level. We believe that our experienced drug development leadership team and approach to resource allocation differentiate us from other potential licensees.

 

 6 

 

·Leverage the commoditized checkpoint marketplace and explore the potential to further enhance long-term clinical benefits for patients with cancer and also expand the eligible population to include those who do not currently receive anti-PD-1 therapy: Presently there are multiple approved checkpoint therapeutics that lack differentiation, resulting in a competitive market dynamic, which will favor combination therapy. There is substantial opportunity for potential expansion in the PD-1 market with our iNKT engagers and adenosine antagonists. Studies show that 70-80% of patients do not respond or have a limited response to existing monotherapies, such as PD-1 checkpoint inhibitors. We see potential for our unique approach of using iNKT engagers and adenosine antagonists to initiate an immune response in tumors that have become refractory to checkpoint therapy or to increase the number of front-line patients achieving more durable responses. Combinations can improve this but often come at the cost of significant additional toxicity. The market is saturated with 14 approved PD-1 antibodies, and every major pharmaceutical company competes in this space. One illustrative example of potentially expanding eligible patients is with iNKT engagers upregulating expression of PD-L1. Patient populations that are typically not good candidates for PD-1 antibodies due to their lack or low expression of PD-L1 may be able to utilize iNKTs to sensitize tumors to PD-1 agents. Extending the use of PD-1 antibodies represents a significant potential upside for one of these companies competing for market share, should they choose to partner with Portage.

 

·Promote asset flexibility: Our structure is designed to maximize flexibility and cost efficiency. This allows us to efficiently pursue various subsidiary-level transactions, such as stock or asset sales, licensing transactions, strategic partnerships and/or co-development arrangements. It also provides us with the flexibility to terminate programs with minimal costs if results do not meet our de-risking criteria for advancement.

 

We are a BVI business company incorporated under the BVI Act with our registered office located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110. Our U.S. agent, Portage Development Services Inc. (“PDS”), is located at 61 Wilton Road, Westport, CT 06880.

 

We currently are a foreign private issuer under the United States Securities and Exchange Commission (“SEC”) rules. We are also a reporting issuer under the securities legislation of the provinces of Ontario and British Columbia. Our ordinary shares were listed on the Canadian Securities Exchange (“CSE”) under the symbol “PBT.U”. On February 25, 2021, our ordinary shares began trading on the Nasdaq Capital Market under the symbol “PRTG”. As the principal market for our ordinary shares is Nasdaq, we voluntarily delisted from the CSE on April 23, 2021.

 

 

 7 

 

Summary of Results

 

The following table summarizes financial information for the quarter ended June 30, 2023, and the preceding eight quarters (all amounts in 000’US$ except net loss per share, which are actual amounts). All share and per share amounts reflect the 1:100 reverse stock split effected June 5, 2020.

 

   June 30,  Mar. 31,  Dec. 31,  Sept. 30  June 30,  Mar. 31,  Dec. 31,  Sept. 30,  June 30,
Quarter ended  2023  2023  2022  2022  2022  2022  2021  2021  2021
    
Net loss attributable to owners of the Company   (5,919)   (94,448)   (7,485)   (949)   (1,729)   (7,317)   (3,512)   (2,975)   (3,066)
Comprehensive loss attributable to the owners of the Company   (4,150)   (95,714)   (11,502)   (949)   (1,729)   (7,317)   (3,512)   (2,975)   (3,066)
Working capital (1) to (8)   8,254    11,811    13,110    15,737    21,138    24,049    25,639    27,301    28,106 
Equity attributable to owners of the Company   73,307    76,045    168,945    178,434    120,682    121,205    125,789    127,140    127,711 
Net loss per share - Basic   (0.33)   (5.45)   (0.44)   (0.06)   (0.13)   (0.55)   (0.26)   (0.22)   (0.25)
Net loss per share - Diluted   (0.33)   (5.45)   (0.44)   (0.06)   (0.13)   (0.55)   (0.26)   (0.22)   (0.25)

 

(1)September 30, 2022 working capital is net of warrant liability of $8 settleable on a non-cash basis.

 

(2)June 30, 2022 working capital is net of warrant liability of $32 settleable on a non-cash basis.

 

(3)March 31, 2022 working capital is net of warrant liability of $33 settleable on a non-cash basis.

 

(4)December 31, 2021 working capital is net of warrant liability of $159 settleable on a non-cash basis.

 

(5)September 30, 2021 working capital is net of warrant liability of $535 settleable on a non-cash basis.

 

(6)June 30, 2021 working capital is net of warrant liability of $751 settleable on a non-cash basis.

 

(7)March 31, 2021 working capital is net of warrant liability of $1,120 settleable on a non-cash basis.

 

(8)December 31, 2020 working capital is net of warrant liability of $771 settleable on a non-cash basis.

 

Number of Ordinary Shares

 

The following table summarizes the number of our ordinary shares issued and outstanding at June 30, 2023 and August 29, 2023:

 

As of,  June 30, 2023  August 29, 2023
Shares issued and outstanding (a) (b)   17,786,290    17,801,390 

 

(a)This amount excludes an aggregate of 243,000 restricted stock units granted to our executive chairman and an employee on January 13, 2021, which vested immediately on the date of grant and are subject to certain restrictions and 135,740 restricted stock units granted to employees (one of whom is also a director) on January 19, 2022, which vested immediately on the date of grant and are subject to certain restrictions.

 

(b)The June 30, 2023 amount includes 9,038 shares earned for services rendered from April 1, 2023 to June 30, 2023, accrued at June 30, 2023 for financial statement purposes and issued in July 2023. The August 29, 2023 amount excludes 3,019 shares earned for services rendered in July 2023, accrued at July 31, 2023 but not yet issued.

 

 8 

 

Business Environment – Risk Factors

 

Please refer to the Annual Report on Form 20-F for the year ended March 31, 2023 for detailed information as the economic and industry factors that are substantially unchanged as of the date hereof.

 

Our Programs and Technology – Recent Developments

 

Invariant Natural Killer T-cells (iNKT cells) Platform

 

iNKT cells play an important role in anti-tumor immune responses and are a distinct class of T lymphocyte displaying a limited diversity of T-cell receptors. They recognize lipid antigens on the surface of tumor cells and produce large amounts of cytokines within hours of stimulation without the need for clonal expansion. Furthermore, iNKT cells activate multiple immune system components, including dendritic cells (“DC”), T-cells and B-cells and stimulate an antigen-specific expansion of these cells. Our operating subsidiary, iOx Therapeutics Ltd. (“iOx”), holds an exclusive license (with the right to sub-license) from the Ludwig Institute for Cancer Research (the "Ludwig Institute") to use, research, develop and commercialize iNKT cell engagers, for the treatment of various forms of human disease, including cancer, under the Ludwig Institute’s intellectual property and know-how.

 

PORT-2 (IMM60)

 

PORT-2 is an iNKT cell engager formulated in a liposome with a six-member carbon head structure that has been shown to activate both human and murine iNKT cells, resulting in DC maturation and the priming of Ag-specific T and B cells.

 

In animal models, PORT-2 enhanced the frequency of tumor specific immune responses. iNKT cells are unique lymphocytes defined by their co-expression of surface markers associated with NK cells along with a T-cell antigen receptor. They recognize amphipathic ligands such as glycolipids or phospholipids presented in the context of the non-polymorphic, MHC class I-like molecule CD1d. Activated iNKT cells rapidly produce IFN-gamma and IL-4 and induce DC maturation and IL-12 production.

 

In August 2021, we dosed the first patient in the IMP-MEL PORT-2 clinical trial, a Phase 1/2 dose escalation and randomized expansion trial. The PORT-2 trial is expected to enroll up to 88 patients with melanoma or non-small cell lung carcinoma (“NSCLC”) in order to evaluate safety and efficacy. In November 2022, we announced that we had entered into a clinical trial collaboration with Merck to evaluate PORT-2 in combination with pembrolizumab for patients with NSCLC. Under the terms of the collaboration, Merck will supply pembrolizumab for our Phase 1/2 trial of PORT-2 in patients with NSCLC and melanoma.

 

Preliminary Phase 1 data, presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting in June 2023, suggests PORT-2 was well tolerated when administered as a monotherapy, with no related severe or serious adverse events. All possibly related adverse events were mild to moderate and did not limit dosing. This enabled the opening of the combination safety cohort with pembrolizumab, in parallel with the ongoing high dose monotherapy cohort. As of August 2023, two patients have received the combination with pembrolizumab, and no related severe or serious adverse events were reported. The adverse event profile was consistent with pembrolizumab. Previously reported biomarker data confirmed the mechanism of action (i.e., both activation of the innate and adaptive arms of the immune system). The following figure illustrates the different lesion responses. Although these are preliminary results, several lesions showed shrinkage, and the responses in liver metastases were encouraging.

 

 9 

 

 

We are encouraged by the growing patient data set that supports proof of concept for using an iNKT engager in cancer treatment. Preliminary Phase 1 data suggests that PORT-2 has a favorable safety and tolerability profile as a monotherapy at all doses tested to date (as noted above), has demonstrated evidence of single agent activity, and biomarkers confirm mechanistic potential of PORT-2 to activate both the adaptive and innate immune systems.

 

To accelerate development, we have transitioned sponsorship and have expanded the PORT-2 trial beyond the U.K. while addressing COVID-19 headwinds. The Clinical Trial Agreement with CRO Parexel, our clinical research organization in the U.K., has been transferred from the University of Oxford to us through our iOx subsidiary and the trial is being converted to a program sponsored by iOx. Sites in the U.K. will continue to enroll, as we bring on sites in the U.S. and in Spain. Should there be delays in recruiting patients, this could result in increasing overall costs of program administration and ultimately, slow down the completion of the trial and achievement of results.

 

Given the safety data shown at the highest planned doses, the trial protocol is being amended to escalate patient dosing to include one additional higher dose, and we anticipate the Phase 2 portion of the trial to commence in the first half of calendar 2024.

 

 

 10 

 

PORT-3 (IMM65)

 

PORT-3 is a poly(lactide-co-glycolide) (“PLGA”)-nanoparticle formulation of PORT-2 (IMM60) combined with a NY-ESO-1 peptide vaccine. Biodegradable PLGA-nanoparticles function as a delivery platform for immunomodulators and tumor antigens to induce a specific anti-tumor immune response. PLGA has minimal (systemic) toxicity and is used in various drug-carrying platforms as an encapsulating agent. Furthermore, co-formulating an iNKT engager with a peptide vaccine in a particle has shown to be approximately five times more potent in killing cancer cells and generating an antigen-specific CD8 T-cell response than giving the two agents individually.

 

NY-ESO-1 is a cancer-testis antigen expressed during embryogenesis and in the testis, an immune privileged site. Furthermore, NY-ESO-1 expression is observed in several advanced cancers: Lung (2-32%), melanoma (40%), bladder (32-35%), prostate (38%), ovarian (30%), esophageal (24-33%), and gastric cancers (8-12%). Clinical trials have shown the safety and tolerability of Good Manufacturing Practices (“GMP”)-grade NY-ESO-1 peptides in patients with cancer.

 

The first patient was dosed in 2021 and patients continue to enroll in the PRECIOUS Phase 1 trial of PORT-3 in patients with solid tumors. The Phase 1 portion of the trial is expected to enroll 15 patients. The trial was having difficulty identifying tumors that expressed NY-ESO-1, so the trial protocol was amended to include all solid tumors regardless of expression to facilitate assessment of safety. This platform is designed to demonstrate proof of concept. The combination of NY-ESO-1 and IMM-60 is being evaluated to determine its ability to prime and boost an anti-tumor immune response. Our patent position extends to other known tumor antigens, and we are prepared to rapidly launch other assets into the clinic if we see strong activity of this formulation. Preliminary safety data for repeat dosing of PORT-3 in the PRECIOUS Phase 1 trial shows a favorable safety profile. The investigator trial has paused while we await more data. It is our understanding that the investigators with who we work with have continued to explore next generation targeted nanoparticles.

 

Adenosine Receptor Antagonist Platform

 

A critical mechanism of cancer immune evasion is the generation of high levels of immunosuppressive adenosine within the tumor microenvironment (“TME”). Research suggests that the TME has significantly elevated concentrations of extracellular adenosine. Engagement with adenosine receptors A2A and A2B triggers a dampening effect on the immune response, suppressing effector cell function and stabilizing immunosuppressive regulatory cells. Over-expression of the A2A and A2B receptors leads to a poor prognosis in multiple cancers, including prostate cancer, colorectal cancer and lung adenocarcinoma, driven by a reduced ability to generate an immune response against the tumor.

 

These findings have made A2A and A2B high-priority targets for immunotherapeutic intervention. We are advancing four adenosine antagonists that we believe to be first-in-class, which together represent a broad suite of adenosine-targeting approaches and are expected to enable a comprehensive exploration of how targeting the adenosine pathway could potentially improve response in multiple cancer and non-cancer indications. By modulating the adenosine pathway in four different ways, we expect to determine the optimal approach to maximize the impact of the mechanism of action on different tumors.

 

We have designed the ADPORT-601 clinical trial to evaluate the activity and safety of PORT-6 and PORT-7 alone and in combination. This trial will adapt over time and also include safety cohorts for these two agents with other immune activating agents including others from our internal pipeline. Depending on the data, it can be expanded to evaluate either agent as monotherapy or a randomized comparison of either agent plus standard of care versus standard of care alone.

 

 

 11 

 

PORT-6 (TT-10)

 

PORT-6 is an adenosine receptor type 2A (“A2A”) antagonist being studied for the treatment of A2A expressing solid tumors. We believe PORT-6 is more potent, more durable and more selective than other clinical stage A2A agents.

 

The ADPORT-601 portion of the Phase 1 trial for PORT-6, dosed its first patient in June 2023. We have activated 6 sites in the U.S. to complete the Phase 1 including: MD Anderson Cancer Center, UC San Francisco, University of Southern California, Thomas Jefferson University, Virginia Cancer Specialists and Sarah Canon Research Institute.

 

PORT-7 (TT-4)

 

PORT-7 is an adenosine receptor type 2B (“A2B”) antagonist that we expect to study for the treatment of solid tumors. PORT-7 has a very selective profile that focuses on A2B. We expect, based upon available liquidity, to commence a Phase 1 trial in late calendar 2023 or early calendar 2024.

 

PORT-8 (TT-53)

 

PORT-8 is a dual antagonist of adenosine receptors 2A and 2B (A2A/A2B) that we expect to study for the treatment of solid tumors. We have the ability to combine these two adenosine receptors to titrate the levels of A2A and A2B or has the ability to give the dual antagonist (PORT-08). The PORT-8 program is a pre-clinical stage program.

 

PORT-9 (TT-3)

 

PORT-9 is an A2B antagonist to treat colorectal and gastrointestinal cancers.

 

In connection with the adenosine programs, we will focus on solid tumor types with high adenosine expression of receptors A2A and A2B and enrich for patients that have high adenosine expression and therefore have potential to benefit most from treatment. The PORT-9 program is currently in the pre-clinical stage.

 

Other Programs and Investee Programs in Development

 

We are focused on delivering clinical data with the iNKT and adenosine programs and prioritizing the allocation of financial resources to these programs. Developmental work continues on some of the other developmental assets, through collaborations such as that with the U.S. National Cancer Institute (“NCI”) and other academic groups, as further described below. These developmental assets may be re-evaluated at a future point depending on market conditions, ongoing data, funding priorities and status.

 

Amphiphilic platform

 

DfuseRx SM, identifies combinations of anti cancer agents with amphiphilic diffuse enhancers that can passively enter into cancer cells.  These novel formulations with unique IP can be directly injected into any solid tumors, and the payloads will diffuse across the membrane and disperse throughout the tumor, while sparing healthy cells. Once inside the cells, the technology is diluted away and the payloads are stuck inside the cells. The payloads are able to disperse to areas of the tumor that do not have blood supply and hence oral or IV drugs will not reach.

 

 

 12 

 

PORT-1 (INT230-6)

 

Intensity Therapeutics, Inc., (“Intensity”), which we have an investment in, is developing INT230-6 (“PORT-1”) as a fixed dose formulation of cisplatin, vinblastine and a penetration enhancer.  In animal models, the drug has shown efficacy in the majority of the animals, by a combination of direct killing of the cancer cells, and also a CD4 and CD8 T-cell response.  Interim safety and survival data from the Phase 1/2 IT-01 trial exploring the safety and efficacy of PORT-1 in patients with refractory or metastatic cancers presented at ASCO Annual Meeting in 2021 demonstrated that both PORT-1 monotherapy and combination therapy with immune checkpoint drugs are well-tolerated. The mechanism of action includes direct tumor-killing effects, as well as responses generated in non-injected tumors (abscopal responses) resulting from antigen presentation and immune activation. The specific rapid local killing in the normal three-dimensional environment inside the body we believe is critical for robust antigen presentation and immune activation.  Animal studies also showed synergy when combined with checkpoint inhibition. PORT-1 has shown proof of concept in humans in that the vast majority of the drug has been shown to stay in the tumor, and a dose equivalent to three times the approved dose of the cytotoxic agent was well tolerated without the typical chemotherapy side effects.  The most common adverse event related to the treatment was pain at the injection site.  As a result, PORT-1 is being studied in nine Phase 2 trials including seven clinical collaborations with the two largest immuno-oncology drug manufacturers, Bristol Myers Squibb (“BMS”) and Merck, in combination with their respective checkpoints in high unmet need medical types (including pancreatic, gall bladder, sarcoma, non-microsatellite unstable colorectal).

 

Intensity has also launched a randomized Phase 2 trial of PORT-1 for the treatment in early stage breast cancer for patients who are ineligible or chose not to have presurgical chemotherapy (compared to no treatment, which is the standard of care) (the “INVINCIBLE Trial”) and has expanded its collaboration efforts with the INVINCIBLE Trial, conducted by the Ottawa Hospital and the Ontario Institute for Cancer Research. The INVINCIBLE Trial suggests that one treatment with PORT-1, can result in near complete necrosis of breast tumors greater than 3 cm with an influx of key immune cells to process the dying tumor. Intensity presented clinical data from the PORT-1 INVINCIBLE Trial at the ASCO Annual Meeting in June 2023, which demonstrated significant necrosis of presurgical breast cancer tumors in the majority of patients injected with PORT-1 in the window period from diagnosis to surgery and a pathway enrichment analysis that demonstrated changes in T-cell activation, lymphocyte activation and inflammatory response from the INVINCIBLE Trial.

 

On July 5, 2023, Intensity completed an IPO of its common stock selling 3,900,000 shares at a price of $5.00 per share generating net proceeds of approximately $16.2 million. In connection with the offering, Intensity’s common stock began trading on Nasdaq on June 30, 2023, under the ticker symbol “INTS.” The Intensity shares closed at a price of $5.96 on June 30, 2023. We received an additional 2,659 shares in connection with the offering pursuant to certain anti-dilution rights. Intensity sold its overallotment shares totaling 585,000 shares, which closed on July 7, 2023. As of that date, we owned approximately 4.7% of the issued and outstanding shares of Intensity.

 

PORT-4, Nanolipogel (“NLG”) co-formulation Platform

 

Scientists are interested in novel ways to deliver multiple signals to the immune system in order to better activate an anti-tumor response.  We have been impressed with a platform from Yale University that allows different types of agents to be packaged together and will concentrate them in tumors.  We have licensed the platform for delivery of DNA aptamers and certain aptamer-small molecule-based combination products. In order to have multiple proprietary agents with known mechanisms of action, we have licensed rights to create DNA aptamers for immune-oncology targets and the first one developed is a proprietary PD1 aptamer, which has been placed in the NLG formulation.  Early testing has shown the formulation properly modulates PD1 signaling in vitro similar to a PD1 antibody I.  In non-clinical, in vivo experiments, the NLG-PD1 performed favorably compared to a mouse PD1 antibody.  The current level of funding is expected to support exploration of multiple PD1 based co-formulations with small molecules and other DNA aptamers. We have conducted further research with the technology licensed from Yale University to co-deliver a PD1 blocking signal with a small molecule vascular endothelial growth factor inhibitor.

 

As of June 30, 2023, we owned approximately 70% of the outstanding shares of Saugatuck Therapeutics, Ltd. (“Saugatuck”), the subsidiary on which the PORT-4 platform is managed.

 

 

 13 

 

PORT-5, STING Agonist Platform

 

Proprietary immune priming and boosting technology (using a STING agonist delivered in a virus-like particle) has shown proof of concept in animal models and Stimunity S.A. (“Stimunity”) is beginning to progress its lead asset towards the clinic.  This platform offers multiple ways to target immune stimulation towards the cancer, as well as to co-deliver multiple signals in a single product.  The PORT-5 STING platform provides distinct advantages over chemical intratumoral approaches by offering a potent immune priming and boosting pathway within a virus-like particle to enable convenient systemic administration and traffic to the correct targets. This technology preferentially targets dendritic cells, which is differentiated from other chemical STING approaches.  Stimunity is progressing this project towards clinical trials as well as developing next generation compounds.  To that end, Stimunity has received grant funding to study this technology with any COVID-19 vaccine to evaluate if it is possible to boost the immune response for immunocompromised or elderly patients. During April 2022, the American Association for Cancer Research showcased PORT-5 preclinical data at a late-breaking session that shows that one or more targeted immunotherapy agents could be packaged within a virus-like particle to increase potency, while enabling a selective immune activation. Advancing the program to an IND for PORT-5 is subject to Stimunity securing additional financing.

 

As of June 30, 2023, we owned approximately 44% of the outstanding shares of Stimunity, the subsidiary on which the PORT-5 platform is managed.

 

Early-Stage Research and Development Collaborations

 

We continue to evaluate and test new antibody targets.  Our interest here lies in the suppressive tumor microenvironment, and how we can down regulate or remove MDSC, TAMs, Tregs and other signals that impede the immune response from clearing cancer cells.

 

·We are collaborating with Dr. Robert Negrin and his team at Stanford University in an IST study to evaluate the use of PORT-2 with iNKT cell therapies in animals. This work will evaluate if an engager co-administered with expanded or transformed iNKT cells can further activate the transplanted and endogenous cells inside the patient. The Stanford collaboration will also study the impact iNKT engagers have on driving an adaptive immune response and correcting the suppressive tumor microenvironment.

 

·We have entered into a Cooperative Research and Development Agreement (“CRADA”) with the NCI. We and NCI will advance preclinical and potential clinical development of STING agonists and anti-RAGE agents for cancer vaccines. We and NCI will develop agents to enhance the efficacy of proprietary cancer vaccines and mouse model cancer vaccines developed by NCI. After the Tarus acquisition, we amended the CRADA to include exploration of the different adenosine compounds.

 

 

 14 

 

Three Months Ended June 30, 2023 Compared to the Three Months Ended June 30, 2022

(All Amounts in 000’$)

 

Results of Operations

 

The following details major expenses for the three months ended June 30, 2023, compared to the three months ended June 30, 2022:

 

Three months ended June 30,  2023  2022
   In 000’$  In 000’$
Operating expenses  $(4,997)  $(4,087)
Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone   (1,111)   - 
Share of loss in associate accounted for using equity method   (50)   (60)
Change in fair value of warrant liability   -    1 
Foreign exchange transaction gain (loss)   18    (52)
Depreciation expense   (11)   - 
Interest income, net   80    21 
Loss before (provision) benefit for income taxes   (6,071)   (4,177)
Income tax benefit   145    2,552 
Net loss   (5,926)   (1,625)
Other comprehensive income (loss)          
Net unrealized gain on investments   1,769    - 
Total comprehensive loss for period  $(4,157)  $(1,625)
           
Comprehensive (loss) income attributable to:          
Owners of the Company  $(4,150)  $(1,729)
Non-controlling interest   (7)   104 
Total comprehensive loss for period  $(4,157)  $(1,625)

 

Results of Operations for the Three Months Ended June 30, 2023 Compared to the Three Months Ended June 30, 2022

 

We incurred a net loss of approximately $5.9 million and total comprehensive loss of approximately $4.2 million during the three months ended June 30, 2023 (the “Fiscal 2024 Quarter”), which include approximately $1.7 million of non-cash expenses, net, compared to a net loss and total comprehensive loss of approximately $1.6 million during the three months ended June 30, 2022 (the “Fiscal 2023 Quarter”), an increase in net loss of $4.3 million and an increase in total comprehensive loss of $2.6 million, quarter-over-quarter.

 

The components of the change in net loss and total comprehensive loss are as follows:

 

·Operating expenses, which include R&D and general and administrative (“G&A”) expenses, were $5.0 million in the Fiscal 2024 Quarter, compared to $4.1 million in the Fiscal 2023 Quarter, an increase of $0.9 million, which is discussed more fully below.

 

·Our other items of income and expense were substantially non-cash in nature and aggregated approximately $1.074 million net loss in the Fiscal 2024 Quarter, compared to approximately $0.090 million net loss in the Fiscal 2023 Quarter, a change in other items of income and expense of approximately $0.984 million, quarter-over-quarter. The primary reason for the quarter-over-quarter difference in other items of income and expense were (a) the non-cash loss from the change (increase) in fair value of the deferred purchase price payable to the former Tarus shareholders and (b) the deferred obligation - iOx milestone totaling $1.111 million, partially offset by the increase in our net interest income from investments in short-term investments in the Fiscal 2024 Quarter. The deferred purchase price payable - Tarus and the deferred obligation - iOx milestone were incurred subsequent to the prior year period.

 

 15 

 

 

·Additionally, we reflected a non-cash net deferred income tax benefit of $0.1 million in the Fiscal 2024 Quarter, compared to a net deferred income tax benefit of $2.6 million in the Fiscal 2023 Quarter. For the Fiscal 2024 Quarter, we recognized an increase in net deferred tax liability of $0.3 million to reflect the effect of the change in exchange rates on the liability during the period and the recognition $0.4 million of current period losses in the U.K. The Fiscal 2023 Quarter includes the foreign currency effect on deferred tax liability balance settleable in British pound sterling of $2.2 million and the recognition of current period losses in the U.K. of $0.4 million.

 

Operating Expenses

 

Total operating expenses are comprised of the following:

 

Three months ended June 30,  2023  2022
   In 000’$  In 000’$
Research and development  $3,627   $1,876 
General and administrative expenses   1,370    2,211 
Total operating expenses  $4,997   $4,087 

 

Research and Development Costs

 

R&D costs are comprised of the following:

 

Three months ended June 30,  2023  2022
   In 000’$  In 000’$
Research and development – Clinical  $1,496   $642 
Contractual milestone   500    - 
Payroll-related expenses   480    406 
Share-based compensation expense   423   $552 
Manufacturing costs   345    - 
Consulting fees   213    24 
Licensing fees   112    24 
Research and development – CRADA   31    69 
Research and development services and storage   19    119 
Legal regarding patents’ registration   8    40 
Total research and development costs  $3,627   $1,876 

 

R&D costs increased by approximately $1.7 million, or approximately 89%, from approximately $1.9 million in the Fiscal 2023 Quarter, to approximately $3.6 million in the Fiscal 2024 Quarter. The increase was primarily attributable to an overall increase in clinical trial costs of $0.8 million, part of $1.4 million of start-up and manufacturing costs associated with the adenosine assets (PORT-6 and PORT-7) acquired in the Tarus acquisition, and the clinical trial costs and other R&D costs associated with the iNKT clinical trial for PORT-2 totaling $1.7 million. Additionally, we incurred a contractual milestone obligation of $0.5 million upon the dosing of the first patients under the adenosine program. These increases reflect the increase in clinical activity and manufacturing costs related to accelerating the development of our adenosine and iNKT programs. Non-cash share-based compensation expense aggregated $0.4 million in the Fiscal 2024 Quarter (allocated equally to each of the adenosine and iNKT programs), as compared to approximately $0.6 million in the Fiscal 2023 quarter, due to the continued vesting of options, as well as recent grants having a lower grant date fair value.

 

 16 

 

General and Administrative Expenses

 

Key components of G&A expenses are the following:

 

Three months ended June 30,  2023  2022
   In 000’$  In 000’$
Professional fees  $469   $903 
Share-based compensation expense   347    624 
Payroll-related expenses   225    251 
D&O insurance   175    307 
Directors fees   83    75 
Office and general expenses   68    51 
Consulting fees   3    - 
Total general and administrative expenses  $1,370   $2,211 

 

G&A expenses decreased by approximately $0.8 million, or approximately 36%, from approximately $2.2 million in the Fiscal 2023 Quarter, to approximately $1.4 million in the Fiscal 2024 Quarter. Professional fees decreased by $0.4 million, primarily attributable to legal fees associated with the Tarus acquisition in the Fiscal 2023 Quarter. Additionally, non-cash share-based compensation expense decreased by $0.3 million attributable to the vesting of certain stock options granted in prior years, lower fair value associated with more recent grants and D&O insurance expense decreased by $0.1 million due to the decrease in the D&O premium market year-over-year.

 

Liquidity and Capital Resources

 

Capital Resources

 

We filed a Registration statement with the SEC under which we may sell ordinary shares, debt securities, warrants and units in one or more offerings from time to time, which became effective on March 8, 2021. In connection with the Registration Statement, we have filed with the SEC:

 

·a base prospectus, which covers the offering, issuance and sale by us of up to $200,000,000 in the aggregate of the securities identified above from time to time in one or more offerings;
·a prospectus supplement, which covers the offer, issuance and sale by us in an “at-the-market” (“ATM”) offering program of up to a maximum aggregate offering price of $50,000,000 of our ordinary shares that may be issued and sold from time to time under a Controlled Equity Offering Sales Agreement, dated February 24, 2021, with Cantor Fitzgerald & Co., the sales agent;
·a prospectus supplement dated June 24, 2021, for the offer, issuance and sale by us of 1,150,000 ordinary shares for gross proceeds of approximately $26.5 million in a firm commitment underwritten public offering with Cantor Fitzgerald; and
·a prospectus supplement dated August 19, 2022, for the resale of up to $30,000,000 in ordinary shares that we may sell from time to time to Lincoln and an additional 94,508 shares that were issued to Lincoln.

 

The Sales Agreement permits us to sell in an ATM program up to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered, issued and sold by us under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act. Upon termination of the Sales Agreement, any portion of the $50,000,000 included in the Sales Agreement prospectus that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus.

 

 

 17 

 

On June 24, 2021, we completed the sale of 1,150,000 ordinary shares, including the underwriters’ option, at a price of $23.00 per share, which generated gross proceeds of approximately $26.5 million and net proceeds of approximately $25.0 million, and was settled June 28, 2021.

 

On July 6, 2022 (the “Signing Date”), we entered into the Committed Purchase Agreement with Lincoln, pursuant to which we may require Lincoln to purchase our ordinary shares having an aggregate value of up to $30 million over a period of 36 months. Pursuant to the Committed Purchase Agreement, Lincoln will be obligated to purchase the Purchase Shares in three different scenarios as described below.

 

Regular Purchase – At any time after the Closing Date (as defined below) and provided that the closing sale price of the ordinary shares is not less than $0.25 per share, from time to time on any business day selected by us (the “Purchase Date”), we shall have the right, but not the obligation, to require Lincoln to purchase up to 30,000 ordinary shares (the “Regular Purchase Amount”) at the Purchase Price (as defined below) per purchase notice (each such purchase, a “Regular Purchase”). Lincoln’s committed obligation under each Regular Purchase shall not exceed $1,500,000; provided, that the parties may mutually agree at any time to increase the dollar amount of any Regular Purchase on any Purchase Date above and beyond the forgoing amounts that Lincoln is committed to purchase. The purchase price for Regular Purchases (the “Purchase Price”) shall be equal to the lesser of: (i) the lowest sale price of the ordinary shares during the Purchase Date, and (ii) the average of the three (3) lowest closing sale prices of the ordinary shares during the ten (10) business days prior to the Purchase Date. We shall have the right to submit a Regular Purchase notice to Lincoln as often as every business day. “Closing Date” shall mean the date that customary conditions to closing have been satisfied, including that our shelf registration statement for the ordinary shares to be issued pursuant to the Committed Purchase Agreement is effective and available for use and any listing application and/or exchange approvals, to the extent applicable, have been approved.

 

·Accelerated Purchase – In addition to Regular Purchases and provided that we have directed a Regular Purchase in full, we in our sole discretion may require Lincoln on each Purchase Date to purchase on the following business day (“Accelerated Purchase Date”) up to the lesser of (i) three (3) times the number of ordinary shares purchased pursuant to such Regular Purchase, and (ii) 25% of the trading volume on the Accelerated Purchase Date at a purchase price equal to the lesser of 97% of (i) the closing sale price on the Accelerated Purchase Date, and (ii) the Accelerated Purchase Date’s volume weighted average price (the “Accelerate Purchase Price”). The parties may mutually agree to increase the number of ordinary shares sold to Lincoln on any Accelerated Purchase Date at the Accelerated Purchase Price. We shall have the right in our sole discretion to set a minimum price threshold for each Accelerated Purchase in the notice provided with respect to such Accelerated Purchase and we may direct multiple Accelerated Purchases in a day; provided, that delivery of ordinary shares has been completed with respect to any prior Regular Purchases and Accelerated Purchases Lincoln has purchased.

 

·Tranche Purchase – In addition to Regular Purchases and Accelerated Purchases and provided that the closing price of the ordinary shares is not below $0.25, at any time beginning five (5) business days from the Closing Date, we shall have the option to require Lincoln to purchase up to $3,000,000 in separate purchases of up to $1,000,000 of ordinary shares for each purchase (the “Tranche Purchases”, and with Regular Purchases and Accelerated Purchases, the “Committed Purchases”). The purchase price for each Tranche Purchase shall be equal to 90% of the Purchase Price. We may deliver notice to Lincoln for a Tranche Purchase so long as at least twenty (20) business days have passed since any Tranche Purchase was completed.

 

Upon execution of the Committed Purchase Agreement, we issued to Lincoln 94,508 ordinary shares, representing a 3% commitment fee. We have the right to terminate the Committed Purchase Agreement for any reason, effective upon one (1) business day prior written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement.

 

 

 18 

 

Committed Purchases shall be suspended if any of the following occur: (i) the shelf registration statement is not available for the sale of all of the ordinary shares issued pursuant to the Committed Purchase Agreement for ten (10) consecutive trading days or for a total of thirty (30) trading days out of the preceding 365 days; (ii) the ordinary shares cease to be DTC authorized and participating in the D.W.A.C./F.A.S.T. systems; (iii) suspension of the ordinary shares from trading for one (1) trading day; (iv) any breach of the representations and warranties or covenants contained in any related agreements with Lincoln which has or which could have a material adverse effect on us, Lincoln or the value of the ordinary shares, subject to reasonable cure periods to be agreed upon for curable breaches of covenants; (v) if we are listed on a national exchange or market (excluding the OTC Markets, OTC Bulletin Board or comparable market), at any time prior to shareholder approval of the Committed Purchase Agreement more than 19.99% of our aggregate ordinary shares, determined as of the Signing Date, would be issuable to Lincoln in violation of the principal securities exchange or market rules; (vi) if the ordinary shares cease to be eligible for trading on the Nasdaq Capital Market, our principal market, and is not immediately thereafter trading on the Nasdaq Global Select Market, the Nasdaq Global Market, the NYSE, the NYSE American, or the OTC Markets; or (vii) our insolvency or our participation or threatened participation in insolvency or bankruptcy proceedings by or against us. The Committed Purchases may resume following the resolution of any of the forgoing events.

 

The Committed Purchase Agreement does not impose any financial or business covenants on us and there are no limitations on the use of proceeds received by us from Lincoln. We may raise capital from other sources in our sole discretion; provided, however, that we shall not enter into any similar agreement for the issuance of variable priced equity-like securities until the three-year anniversary of the Signing Date, excluding, however, an ATM transaction with a registered broker-dealer, which includes any sales under the Sales Agreement with Cantor Fitzgerald.

 

In connection with the Committed Purchase Agreement, we and Lincoln entered into a Registration Rights Agreement (the “Registration Rights Agreement”), dated July 6, 2022. Pursuant to the Registration Rights Agreement, we agreed, within the time required under Rule 424(b) under the Securities Act, to file with the SEC an initial prospectus supplement to our shelf registration statement pursuant to Rule 424(b) for the purpose of registering for resale the ordinary shares to be issued to Lincoln under the Committed Purchase Agreement. All reasonable expenses of ours incurred through the registration of the ordinary shares under the Committed Purchase Agreement shall be paid by us.

 

In October 2022, we began selling shares pursuant to the ATM program and the Sales Agreement. From October 2022 through March 31, 2023, we sold 166,145 ordinary shares under the ATM program, generating net proceeds of approximately $0.9 million. Separately, between October 2022 and March 31, 2023, we sold 480,000 ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds totaling approximately $2.0 million. From April 1, 2023 through June 30, 2023, we sold 171,504 ordinary shares under the ATM program, generating net proceeds of approximately $0.6 million.

 

On March 1, 2023, we, through Tarus, entered into a clinical service agreement with a third-party service provider. The term of the agreement is through the earlier of August 14, 2025 or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services to be provided is approximately $12.1 million.

 

Going Concern

 

The accompanying condensed consolidated interim financial statements for the three months ended June 30, 2023 have been prepared on a basis that assumes that we will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying condensed consolidated interim financial statements for the three months ended June 30, 2023 do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty.

 

As of June 30, 2023, we had cash and cash equivalents of approximately $7.7 million and total current liabilities of approximately $2.6 million. For the three months ended June 30, 2023, we are reporting a net loss of approximately $5.9 million and cash used in operating activities of approximately $3.5 million. As of July 31, 2023, we had approximately $6.4 million of cash and cash equivalents on hand.

 

 

 19 

 

Our cash and cash equivalents balance is decreasing and we will not generate positive cash flows from operations for the fiscal year ending March 31, 2024.

 

We have and may continue to delay, scale-back, or eliminate certain of our activities and other aspects of our operations until such time as we are successful in securing additional funding. We are exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources. Our future success is dependent upon our ability to obtain additional funding. There can be no assurance, however, that we will be successful in obtaining such funding in sufficient amounts, on terms acceptable to us, or at all. As of the date of this filing, we currently anticipate that current cash and cash equivalents, excluding any potential proceeds from our ATM program and Committed Purchase Agreement with Lincoln, will be sufficient to meet our anticipated cash requirements through the end of October 2023. Access to our Committed Purchase Agreement with Lincoln is generally limited based on, among other things, our trading volume. Furthermore, under General Instruction I.B.5 to Form F-3 (the “Baby Shelf Rule”), the amount of funds we can raise through primary public offerings of securities in any 12-month period using our registration statement on Form F-3 is limited to one-third of the aggregate market value of the ordinary shares held by our non-affiliates, which limitation may change over time based on our stock price, number of ordinary shares outstanding and the percentage of ordinary shares held by non-affiliates. We therefore are limited by the Baby Shelf Rule as of the filing of this Form 6-K, until such time as our non-affiliate public float exceeds $75 million. These factors raise significant doubt about our ability to continue as a going concern within one year after the date that the financial statements are issued.

 

We have incurred significant operating losses since inception and expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result primarily from our conduct of research and development activities.

 

We historically have funded our operations principally from proceeds from issuances of equity and debt securities. We will require significant additional capital to make the investments we need to execute our longer-term business plan. Our ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, future equity issuances would result in dilution to existing stockholders and any future debt securities may contain covenants that limit our operations or ability to enter into certain transactions.

 

Cash Flows From Operating Activities

 

During the Fiscal 2024 Quarter, we used cash of approximately $3.5 million to fund operating activities, compared to approximately $2.2 million used during the Fiscal 2023 Quarter. Operations in both the Fiscal 2024 Quarter and the Fiscal 2023 Quarter were funded by cash raised from the ATM program, the public offering in June 2021 and the ordinary shares issued to Lincoln under the Committed Purchase Agreement, described above under “Capital Resources.”

 

Our continuing operations are dependent upon any one of:

 

1.the development and identification of economically recoverable therapeutic solutions;
2.the ability of us to obtain the necessary financing to complete the research and development; or
3.the future profitable production, or proceeds, from the disposition of intellectual property.

 

We have incurred significant operating losses since inception due to significant R&D spending and corporate overhead, and we expect to continue to incur significant operating losses for the foreseeable future and may never become profitable. As of June 30, 2023, we had cash and cash equivalents of approximately $7.7 million, working capital of approximately $8.3 million (including prepaid expenses of $2.8 million) and an accumulated deficit of approximately $165.5 million.  We have funded our operations primarily from proceeds from the sale of equity and debt securities. We will require significant additional capital to make the investments that we need to execute our longer-term business plan. Our ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, even if it were successful, future equity issuances would result in dilution to our existing stockholders and any future debt securities may contain covenants that limit our operations or ability to enter into certain transactions.

 

 

 20 

 

Cash Flows From Investing Activities

 

There were no cash flows from investing activities during both the Fiscal 2024 Quarter and the Fiscal 2023 Quarter.

 

Cash Flows From Financing Activities

 

During the Fiscal 2024 Quarter, we generated net cash of $0.6 million from financing activities. During the Fiscal 2023 Quarter, there were no financing cash flow activities.

 

In October 2022, we began selling shares pursuant to the ATM program and the Sales Agreement. From April 1, 2023 through June 30, 2023, we sold 171,504 ordinary shares under the ATM program, generating net proceeds of approximately $0.6 million. Additionally, the Fiscal 2024 Quarter reflects a small repayment of the lease liability.

 

Key Contractual Obligations

 

Details of contractual obligations, commitments and contingent liabilities are provided in Note 15, “Commitments and Contingent Liabilities,” to the unaudited condensed consolidated interim financial statements for the three months ended June 30, 2023.

 

Acquisition of Tarus

 

On July 1, 2022, we, our wholly-owned subsidiary, Portage Merger Sub I, Inc., our wholly-owned subsidiary, Portage Merger Sub II, LLC and Tarus Therapeutics, Inc., a Delaware corporation advancing adenosine receptor antagonists for the treatment of solid tumors, entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). Under the structure of the Merger Agreement, Tarus Therapeutics, Inc. was ultimately merged into Portage Merger Sub II, LLC with the surviving entity renamed Tarus Therapeutics, LLC (“Tarus”).

 

As consideration for Tarus, we issued to the former Tarus shareholders an aggregate of 2,425,999 ordinary shares of Portage, calculated on the basis of $18 million divided by the 60-day volume weighted average price per share of ordinary shares of Portage. Such ordinary shares have not been registered with the SEC and were subject to lock-up agreements for terms ranging from six to twelve months, which expired on February 1, 2023 and July 1, 2023, respectively. Additionally, the ordinary shares that were subject to a twelve month lock-up period, are also subject to a three month dribble-out period which commenced July 1, 2023. During the dribble out period, each holder may not sell more than 10% of the average trading volume of our ordinary shares for the rolling three month period prior to the date on which the holder executes a trade of our ordinary shares without our prior written consent (which we are permitted to withhold at our sole discretion). Additionally, payments of up to $32 million in cash or our ordinary shares (at our discretion) would be triggered upon achievement of future development and sales milestones, as described below. As a result of the transaction:

 

·We also assumed $2 million in short-term debt held by Tarus and deferred license milestones obligations ($1 million plus interest), for an aggregate of $3 million in liabilities. We repaid the short-term debt in July 2022.

 

·Upon enrolling the first patient in a Phase 2 clinical trial utilizing Tarus’s adenosine receptor antagonists, we will pay an additional one-time payment of $15 million to the former Tarus shareholders. Payment will be in the form of cash or our ordinary shares (at our discretion). The remaining $17 million milestone is based on target commercial sales.

 

Additionally, in connection with the acquisition of Tarus, we initially recorded a deferred purchase price payable of $8.538 million, which reflected the estimated acquisition date fair value of contractual milestone obligations incurred.

 

We recognized a loss of $0.685 million in the Fiscal 2024 Quarter to reflect the estimated fair value of the obligation at June 30, 2023 and the carrying value of the liability of $4.552 million is reflected on the condensed consolidated interim statements of financial position as of June 30, 2023.

 

 21 

 

Stimunity Convertible Note

 

On July 13, 2022, we entered into a commitment with Stimunity to provide €600,000 under a convertible note (the “Stimunity Convertible Note”) with a maturity date of September 1, 2023 (the “Maturity Date”). The Stimunity Convertible Note provides for interest at 7% per annum. The Stimunity Convertible Note is automatically converted into Series A shares upon Stimunity completing a Series A round for at least €20 million. If such subscription round is completed prior to the Maturity Date, we will be entitled to convert the Stimunity Convertible Note into Series A shares of Stimunity at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares (other than Common Shares or Series A shares) for at least €5 million (the “Minimum Raise”), we will have the right to convert the Stimunity Convertible Note and the historical Series A shares owned into the new category of shares of Stimunity. In the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, we will have the right to convert the Stimunity Convertible Note into Series A shares at €363.00 per share or the raise price less 15%, whichever is lower. The Stimunity Convertible Note was funded by us on September 12, 2022 by existing cash and cash provided under the Committed Purchase Agreement described above.

 

iOx Share Exchange Agreement

 

On July 18, 2022, we and our wholly-owned subsidiary, SalvaRx, entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with each of the minority shareholders of iOx (the “Sellers”) resulting in the acquisition of the outstanding non-controlling ownership interest (approximately 22%) of iOx, which is developing the iNKT engager platform. We followed IFRS 3, “Business Combinations,” and IAS 27, “Separate Financial Statements,” (which substantially replaced IAS 3) to account for this transaction. We achieved control of iOx on January 8, 2019 upon the completion of our acquisition of SalvaRx. See our Annual Report on Form 20-F for the year ended March 31, 2023 for additional information. Further transactions whereby we acquire further equity interests from non-controlling interests, or disposes of equity interests but without losing control, are accounted for as equity transactions (i.e., transactions with owners in their capacity as owners). As such:

 

·the carrying amounts of the controlling and non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiary;
·any difference between the amount by which the non-controlling interests is adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to us; and
·there is no consequential adjustment to the carrying amount of goodwill, and no gain or loss is recognized in profit or loss.

 

We now own the worldwide rights to iOx’s small molecule iNKT engagers, including lead programs PORT-2 and PORT-3. Under the terms of the Share Exchange Agreement, each Seller sold to us, and we acquired from each Seller, legal and beneficial ownership of the number of iOx shares held by each Seller, free and clear of any share encumbrances, in exchange for the issuance in an aggregate of 1,070,000 of our ordinary shares to be allocated among the Sellers based upon their relative ownership. As a result of the Share Exchange Agreement, we own 100% of the issued and outstanding shares of iOx through our wholly-owned subsidiary, SalvaRx.

 

As additional consideration for the sale of the iOx shares to us under the Share Exchange Agreement, the Sellers shall have the contingent right to receive additional shares (“Earnout Shares”) from us having an aggregate value equal to $25 million calculated at the Per Share Earnout Price, as defined in the Share Exchange Agreement, upon the achievement of certain milestones defined as the dosing of the first patient in a Phase 3 clinical trial for either PORT-2 (IMM60 iNKT cell activator/engager) or PORT-3 (PLGA-nanoparticle formulation of IMM60 combined with a NY-ESO-1 peptide vaccine). We shall have the option, in our sole and absolute discretion, to settle the Earnout Shares in cash.

 

We initially recorded $5.478 million as the fair value estimate of the Earnout Shares, which is reflected as deferred obligation - iOx milestone. We recognized a loss of $0.426 million in the Fiscal 2024 Quarter to reflect the estimated fair value of the obligation as of June 30, 2023 and the carrying value of the liability of $4.552 million is reflected on the condensed consolidated interim statements of financial position as of June 30, 2023.

 

 

 22 

 

Master Services Agreement

 

Effective March 15, 2022, through iOx, we entered into a Master Services Agreement (the “MSA”) with Parexel International (IRE) Limited (“Parexel”) under which Parexel agreed to act as clinical service provider (CRO) pursuant to a work order (“Work Order”) effective June 1, 2022. Pursuant to such Work Order, Parexel will operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer (“NSCLC”). The MSA provides for a five-year term, and the Work Order provides for a term to be ended upon the completion of the services required. The budget provides for service fees and pass-through expenses and clinical sites totaling $11.5 million. During Fiscal 2023, we executed two change orders resulting in a $0.6 million increase in the overall estimated budgeted costs.

 

Clinical Service Agreement

 

On March 1, 2023, we, through Tarus, entered into a clinical service agreement with Fortrea Inc. (formerly Labcorp Drug Development Inc.), a third-party CRO. The term of the agreement is through the earlier of August 14, 2025, or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services to be provided is approximately $12.1 million.

 

iOx License

 

On July 1, 2015, iOx entered into a licensing agreement with Ludwig Institute for Cancer Research Ltd. (“LICR”), which covers certain technology, intellectual property and know-how and development with respect to iNKT cell agonists to treat human diseases. Under the terms of the licensing agreement (“LICR License”), LICR granted to iOx an exclusive worldwide license, with the right to grant sublicenses, under the Licensed Patent and Licensed Technology, each as defined in the LICR License, in each case, to development, make, have made, use, sell, offer for sale and import Licensed Products, as defined in the LICR License, subject to certain rights retained by LICR for academic and research purposes. The LICR License provides for a royalty term of ten years after the first commercial sale, on a Licensed Product by Licensed Product, country by country basis. Upon the expiration of the applicable royalty term, the license with respect to such Licensed Product in such country will convert to a non-exclusive, fully paid-up license.

 

LICR is entitled to 15,000 GBP as an annual license fee on each annual anniversary of the effective date of the LICR License until royalties become duly payable and 15,000 GBP as a patent reimbursement fee until LICR has been fully reimbursed for all patent costs incurred prior to the LICR License.

 

Additionally, LICR is entitled to milestone payments totaling up to 20.45 million GBP based upon the first Licensed Product achieving specific clinical, regulatory and sales based milestones. LICR is also entitled to milestone payment totaling up to 10.25 million GBP based upon a second Licensed Product achieving specific clinical, regulatory and sales based milestones.

 

Finally, LICR is entitled to a low-single digit royalty on net sales of Licensed Products that marginally escalates upon sales levels all determined by territory. LICR is also entitled to a percentage of any sublicensing income that gradually decreases based on the stage of development of the most advanced Licensed Product that is the subject of the applicable sublicense agreement.

 

Pursuant to the terms and conditions of the LICR License, LICR is responsible for managing the preparation, filing, prosecution and maintenance of all Licensed Patent Rights, as defined in the LICR License. iOx will reimburse LICR for all reasonable patent costs it incurs after the effective date of the LICR License. Further, the LICR License provides that both parties have the right to termination for material breach or default in the performance of obligations under the LICR License by the other party and in the event of insolvency of the other party.

 

Tarus License

 

On July 1, 2022, we acquired Tarus Therapeutics, Inc. Pursuant to the license agreement entered into by Tarus Therapeutics, Inc. and Impetis Biosciences Limited (“Impetis”) dated October 29, 2019 (“Impetis License”), Impetis granted to Tarus an exclusive sublicensable worldwide license to develop and commercialize the adenosine receptor antagonists for all indications and certain other assets which were granted upon exercise of a call option on November 5, 2020.

 

 23 

 

Under the terms of the Impetis License, Impetis is eligible to receive payments totaling up to $38 million on an Impetis Compound (as defined in the Impetis License) based upon achievement of certain clinical and commercial milestones. Milestone payments due in the amount of USD $1 million for achievement of certain regulatory milestones were paid in July 2022.

 

Additionally, commencing upon the First Commercial Sale (as defined in the Impetis License) of a Licensed Product (as defined in the Impetis License), Impetis is entitled to royalties on worldwide net sales that begin in the mid-single digits and escalate through multiple tiers, with net sales over $1 billion receiving low double digit royalties.

 

Pursuant to the terms and conditions of the Impetis License, Tarus has exclusive and full authority to manage all intellectual property (whether licensed or not) underlying the assets covered by the Impetis License and any other aspects related to exploitation, development and commercialization thereof at its own cost, and Impetis must provide Tarus reasonable assistance as requested at Tarus’ cost and expense. Further, the Impetis License provides that both parties have the right to termination for material breach by the other party and in the event that the other party undergoes certain events such as a voluntary winding-up, a liquidation or entry into receivership.

 

Off-balance Sheet Arrangements

 

As of June 30, 2023 and March 31, 2023, we did not have any off-balance sheet arrangements, including any relationships with unconsolidated entities or financial partnership to enhance perceived liquidity.

 

Transactions with Related Parties

 

Significant related party transactions are detailed in Note 16, “Related Party Transactions,” to the unaudited condensed consolidated interim financial statements for the three months ended June 30, 2023.

 

Financial and Derivative Instruments

 

Our financial instruments recognized in our condensed consolidated interim statements of financial position consist of the following:

 

Fair value estimates are made at a specific point in time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties and matters of significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could significantly affect these estimates.

 

The following table summarizes our financial instruments as of June 30, 2023 and March 31, 2023:

 

   As of June 30, 2023  As of March 31, 2023
   Amortized
Cost
  FVTOCI  FVTPL  Amortized
Cost
  FVTOCI  FVTPL
                   
Financial assets                              
Cash and cash equivalents  $7,698   $-   $-   $10,545   $-   $- 
Prepaid expenses and other receivables  $2,752   $-   $-   $2,689   $-   $- 
Convertible note receivable, including accrued interest, net of impairment  $-   $-   $442   $-   $-   $442 
Investment in associate  $-   $-   $756   $-   $-   $806 
Investment in public company  $-   $3,855   $-   $-   $2,087   $- 

 

 

 24 

 

   As of June 30, 2023  As of March 31, 2023
   Amortized
Cost
  FVTPL  Amortized
Cost
  FVTPL
Financial liabilities                    
Accounts payable and accrued liabilities  $2,591   $-   $1,865   $- 
Lease liability - current  $47   $-   $-   $- 
Lease liability - non-current  $249   $-   $-   $- 
Deferred purchase price payable - Tarus  $-   $7,864   $-   $7,179 
Deferred obligation - iOx milestone  $-   $4,552   $-   $4,126 

 

A summary of our risk exposures as it relates to financial instruments are reflected below.

 

Fair value of Financial Instruments

 

Our financial assets and liabilities are comprised of cash and cash equivalents, receivables and investments in equities and private and public entities, accounts payable, lease liability, deferred purchase price payable, deferred obligation and unsecured notes payable.

 

We classify the fair value of these transactions according to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:

 

·Level 1 – Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of the reporting date.

 

·Level 2 – Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of the reporting date.

 

·Level 3 – Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified as Level 3 financial instrument.

 

Assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy.

 

Management has assessed that the fair values of cash and cash equivalents, other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.

 

The following methods and assumptions were used to estimate their fair values:

 

Investment in Associate: The fair value of the Stimunity investment was determined based on an IAS 36 fair value analysis evaluating the likelihood of various scenarios given the then-current market conditions, the increasing cost of capital and development delays associated with Stimunity’s lack of liquidity (Level 3). We recorded a provision of impairment of $0.607 million with respect to the investment in associate decreasing the carrying value of the investment in associate to $0.806 million as of March 31, 2023. There was no provision for impairment recorded in the three months ended June 30, 2023.

 

 

 25 

 

Convertible Note Receivable: The fair value of the Stimunity Convertible Note receivable denominated in euros at initial recognition is the transaction price for the instrument adjusted for the effect of the currency translation rate on the reporting date (Level 3). The Stimunity Convertible Note was initially recorded at $0.614 million to record the translated value of the Stimunity Convertible Note on September 12, 2022. We recognized an unrealized gain of $0.039 million through other comprehensive income in fiscal 2023 to reflect the change in translation rate for the Stimunity Convertible Note settleable in euros, increasing the carrying value of the Stimunity Convertible Note to $0.653 million. As of March 31, 2023, we determined that there were indications of impairment, based upon the inability of Stimunity to obtain financing. We performed an IAS 36 fair value analysis evaluating the likelihood of various scenarios given the then-current market conditions, the increasing cost of capital and development delays associated with Stimunity’s lack of liquidity. We recorded an impairment of $0.211 million resulting from the impairment analysis decreasing the carrying value of the Stimunity Convertible Note to $0.442 million as of March 31, 2023. We recorded a nominal unrealized gain in the three months ended June 30, 2023 with respect to the Stimunity Convertible Note.

 

Investment in Public Company: Upon Intensity’s IPO effective June 30, 2023, the fair value of the investment is determined by the quoted market price (Level 1).

 

Accrued Equity Issuable: The fair value is estimated based on the average of the quoted market prices for the period in which the shares were earned (Level 1).

 

Lease Liability - Current: The lease liability - current represents the present value of the lease payments due over the next twelve months discounted at the Company’s incremental borrowing rate (Level 2).

 

Lease Liability - Non-Current: The lease liability - non-current represents the present value of the lease payments due under the lease less the current portion of such payments discounted at the Company’s incremental borrowing rate (Level 2).

 

Deferred Purchase Price Payable - Tarus: The fair value is the estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 at acquisition date, adjusted at each reporting date for any change in fair value (Level 3). The fair value was determined using the Income Approach and was based upon the analysis on the Tarus clinical plan, the timing of development events and the probabilities of success determined primarily based upon empirical third party data and our experience, as well as the relevant cost of capital. We recorded a (loss) from the change (increase) in fair value of the liability of $0.685 million for the three months ended June 30, 2023.

 

Deferred Obligation - iOx Milestone: The fair value is the estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 as of July 18, 2022, the date of the Share Exchange Agreement, adjusted at each reporting date for any change in fair value (Level 3). The fair value was determined using the Income Approach and based on factors including the clinical plan, the timing of development events and the probabilities of success determined primarily based upon empirical third party data and our experience, as well as the relevant cost of capital. We recorded a (loss) from the change (increase) in fair value of the liability of $0.426 million for the three months ended June 30, 2023.

 

Fair Value Hierarchy

 

The investment in public company (Intensity) was transferred from Level 3 to Level 1 of the fair value hierarchy for the three months ended June 30, 2023 as the result of Intensity’s IPO. For the year ended March 31, 2023, the fair value of the investment was determined based on an IAS 36 impairment analysis after determining there were external indications of impairment (Level 3).

 

Our financial instruments are exposed to certain financial risks: Credit Risk, Liquidity Risk and Foreign Currency Risk.

 

Credit Risk

 

Credit risk is the risk of loss associated with a counterparty’s inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit risk is limited to the carrying value as reflected in our condensed consolidated interim statements of financial position.

 

 26 

 

Cash and cash equivalents. Cash and cash equivalents comprise cash on hand and amounts invested in underlying Treasury and money market funds that are readily convertible to a known amount of cash with three months or less from date of acquisition and are subject to an insignificant risk of change in value. As of June 30, 2023 and March 31, 2023, cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. Cash and cash equivalents are held with major international financial institutions and therefore the risk of loss is minimal.

 

Liquidity Risk

 

Liquidity risk is the risk that we will encounter difficulty in satisfying financial obligations as they become due.

 

Our approach to managing liquidity is to ensure, as far as possible, that we will have sufficient liquidity to meet our liabilities when due, under both normal and stressed conditions without incurring unacceptable losses or risking harm to our reputation. We hold sufficient cash and cash equivalents to satisfy current obligations under accounts payable and accruals.

 

We monitor our liquidity position regularly to assess whether we have the funds necessary to meet our operating needs and needs for investing in new projects.

 

As a biotech company at an early stage of development and without significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may not be available to us, or that actual drug development expenditures may exceed those planned. The current uncertainty in global markets could have an impact on our future ability to access capital on terms that are acceptable to us. There can be no assurance that required financing will be available to us.

 

Foreign Currency Risk

 

While we operate in various jurisdictions, substantially all of our transactions are denominated in the U.S. Dollar, except the deferred tax liability in the U.K. settleable in British pound sterling and the Stimunity Convertible Note receivable settleable in euros.

 

Use of Estimates and Judgments

 

The preparation of the condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

 

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

 

Significant areas where estimates are made include valuation of financial instruments (including the Stimunity Convertible Note, deferred tax assets and liabilities, R&D costs, fair value used for acquisition of intangible assets, contingent consideration assumed and measurement of share-based compensation. Significant areas where critical judgments are applied include assessment of impairment of investments, goodwill and in-process research and development and the determination of the accounting acquirer and acquiree in the business combination accounting.

 

New Accounting Standards, Interpretations and Amendments

 

We are also unaware of any applicable but not-yet-adopted standards that are expected to materially affect our financial statements for future periods.

 

 

 27 

 

Internal Control Over Financial Reporting

 

The management of the Company, including the Chief Executive Officer and Chief Financial Officer, is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Securities Exchange Act of 1934, as amended). The Company’s internal control system was designed to provide reasonable assurance to the Company’s management and the Company’s Board of Directors regarding the reliability of financial reporting and preparation and fair presentation of published financial statements for external purposes in accordance with IFRS. Internal control over financial reporting includes those policies and procedures that:

 

1.pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;

 

2.provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with IFRS, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and the directors of the Company; and

 

3.provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

 

All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.

 

Management assessed the effectiveness of the Company’s internal control over financial reporting as of June 30, 2023. In making this assessment, it used the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on the evaluation under these criteria, management identified material weaknesses in the Company’s internal control over financial reporting and, as a result, management concluded that the Company’s internal control over financial reporting was not effective as of June 30, 2023.

 

Management identified the following material weaknesses in our internal control over financial reporting.

 

·Management was unable to perform an effective risk assessment or monitor internal controls over financial reporting;

 

·Management lacks the number of skilled persons that it requires given the complexity of the reporting requirements that it has to make, which more specifically include the staff and expertise to (i) properly segregate duties and perform oversight of work performed and to perform compensating controls over the finance and accounting functions, (ii) establish and perform fair value estimates or subsequently monitor fluctuations in fair value estimates, and (iii) apply complex accounting principles, including those relating to business combination accounting, income taxes and fair value estimates; and

 

·There are insufficient written policies and procedures in place to ensure the correct application of accounting and financial reporting with respect to the current requirements of IFRS and SEC disclosure requirements, some of which specifically relate to investment accounting and fair value measures, assessment of in-process R&D assets, share-based payments, carrying amounts of goodwill and intangible assets and business combination accounting.

 

Public Securities Filings

 

Additional information, including our annual information in the Annual Report on Form 20-F, is filed with the Canadian Securities Administrators at www.sedar.com and with the SEC at www.edgar.com.

 

 

 

28

 

EX-101.SCH 4 ptgef-20230630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - NATURE OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - INVESTMENT IN ASSOCIATE link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - INVESTMENT IN PUBLIC COMPANY link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - LEASE link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - ACQUISITION OF TARUS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - CAPITAL STOCK link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - STOCK OPTION RESERVE link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - (LOSS) PER SHARE link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - CAPITAL DISCLOSURES link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - NON-CONTROLLING INTEREST link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - INVESTMENT IN ASSOCIATE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - LEASE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - ACQUISITION OF TARUS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - CAPITAL STOCK (Tables) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - STOCK OPTION RESERVE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - (LOSS) PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - NON-CONTROLLING INTEREST (Tables) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - NATURE OF OPERATIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - BASIS OF PRESENTATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - INVESTMENT IN ASSOCIATE (Details) link:presentationLink link:calculationLink link:definitionLink 00000043 - Disclosure - INVESTMENT IN ASSOCIATE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000044 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000045 - Disclosure - INVESTMENT IN PUBLIC COMPANY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000046 - Disclosure - LEASE (Details) link:presentationLink link:calculationLink link:definitionLink 00000047 - Disclosure - LEASE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000048 - Disclosure - ACQUISITION OF TARUS (Details) link:presentationLink link:calculationLink link:definitionLink 00000049 - Disclosure - ACQUISITION OF TARUS (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000050 - Disclosure - ACQUISITION OF TARUS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000051 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details) link:presentationLink link:calculationLink link:definitionLink 00000052 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000053 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 00000054 - Disclosure - INCOME TAXES (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000055 - Disclosure - INCOME TAXES (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000056 - Disclosure - INCOME TAXES (Details 3) link:presentationLink link:calculationLink link:definitionLink 00000057 - Disclosure - INCOME TAXES (Details 4) link:presentationLink link:calculationLink link:definitionLink 00000058 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000059 - Disclosure - CAPITAL STOCK (Details) link:presentationLink link:calculationLink link:definitionLink 00000060 - Disclosure - CAPITAL STOCK (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000061 - Disclosure - STOCK OPTION RESERVE (Details) link:presentationLink link:calculationLink link:definitionLink 00000062 - Disclosure - STOCK OPTION RESERVE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000063 - Disclosure - STOCK OPTION RESERVE (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000064 - Disclosure - STOCK OPTION RESERVE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000065 - Disclosure - (LOSS) PER SHARE (Details) link:presentationLink link:calculationLink link:definitionLink 00000066 - Disclosure - (LOSS) PER SHARE (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000067 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000068 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000069 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details) link:presentationLink link:calculationLink link:definitionLink 00000070 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000071 - Disclosure - CAPITAL DISCLOSURES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000072 - Disclosure - NON-CONTROLLING INTEREST (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 5 ptgef-20230630_cal.xml XBRL CALCULATION FILE EX-101.DEF 6 ptgef-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 7 ptgef-20230630_lab.xml XBRL LABEL FILE Components of equity [axis] Issued capital [member] Stock Option Reserve [Member] Accumulated other comprehensive income [member] Retained earnings [member] Equity attributable to owners of parent [member] Non-controlling interests [member] Categories of related parties [axis] Salva Rx Limited [Member] Range [axis] Bottom of range [member] Top of range [member] Geographical areas [axis] Country Of British Virgin Islands [Member] Country Of Delaware [Member] Subsidiaries Two [Member] Associates [axis] Stimunity S A [Member] Types of investment property [axis] Intensity [Member] Business combinations [axis] Acquisition Of Salva Rx [Member] Acquisition Of Intensity Holding Limited [Member] Classes of intangible assets and goodwill [axis] O C I [Member] Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [axis] Tarus Acquisition [Member] Counterparties [axis] I M M 60 I O X Melanoma Lung Cancers [Member] I M M 65 I O X Melanoma Lung Cancers [Member] I O X [Member] Oncomer Saugatuck D N A Aptamers [Member] Tarus Adenosine Receptors [Member] Tarus Adenosine Receptors 1 [Member] Tarus Adenosine Receptors 2 [Member] Tarus [Member] Iox I P R And D [Member] Borrowings by name [axis] Trus I P R And D [Member] United State [Member] B V I [Member] United Kingdom [Member] A T M [Member] Lincoln [Member] Defined benefit plans [axis] N 2021 Equity Incentive Plan [Member] Board Of Directors [Member] Consultants [Member] Restricted Stock Units [Member] Amended And Restated 2021 Equity Incentive Plan [Member] Two Members [Member] Employees [Member] Directors [Member] Executive [Member] Measurement [axis] Vested Options [Member] Unvested Options [Member] P B I 2021 Equity Incentive Plan [Member] Types of antidilutive instruments [axis] Stock Options Two [Member] Share options [member] Restricted share units [member] Salva Rx [Member] Levels of fair value hierarchy [axis] Amortized Cost [Member] Fair Value To Other Comprehensive Income [Member] Fair Value Through Profit Or Loss [Member] Saugatuck And Subsidiary [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of financial position [abstract] Assets Current assets Cash and cash equivalents Prepaid expenses and other receivables Convertible note receivable Total current assets Non-current assets Investment in associate Investment in public company In-process research and development Deferred commitment fee Right to use asset Other assets, including equipment, net Total non-current assets Total assets Liabilities and Equity Current liabilities Accounts payable and accrued liabilities Lease liability - current, including interest Total current liabilities Non-current liabilities Lease liability - non-current Deferred tax liability Deferred purchase price payable - Tarus Deferred obligation - iOx milestone Total non-current liabilities Total liabilities Shareholders’ Equity Capital stock Stock option reserve Accumulated other comprehensive loss Accumulated deficit Total equity attributable to owners of the Company Non-controlling interest Total equity Total liabilities and equity Commitments and Contingent Liabilities (Note 15) Profit or loss [abstract] Expenses Research and development General and administrative expenses Loss from operations Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone Share of loss in associate accounted for using equity method Change in fair value of warrant liability Foreign exchange transaction gain (loss) Depreciation expense Interest income, net Loss before (provision) benefit for income taxes Income tax benefit Net loss Other comprehensive income (loss) Net unrealized gain on investments Total comprehensive loss for period Net (loss) income attributable to: Owners of the Company Non-controlling interest Comprehensive (loss) income attributable to: Owners of the Company Non-controlling interest Loss per share Weighted average shares outstanding Basic earnings (loss) per share Diluted earnings (loss) per share Weighted average shares outstanding, basic Weighted average shares outstanding, diluted Statement of changes in equity [table] IfrsStatementLineItems [Line Items] Beginning balance, value Beginning balance, shares Share-based compensation expense Shares issued under ATM Shares issued under ATM, shares Share issuance costs Shares issued or accrued for services Shares issued or accrued for services, shares Net unrealized gain on investments Net (loss) income for period Ending balance, value Ending balance, shares Statement of cash flows [abstract] Cash flows from operating activities: Net loss for the period Adjustments for non-cash items: Share-based compensation expense Change in fair value of deferred purchase price payable – Tarus and deferred obligation – iOx milestone Decrease in deferred tax liability Share of loss in associate Fair value of shares issued for services Depreciation Change in fair value of warrant liability Changes in operating working capital: Accounts receivable Prepaid expenses and other receivables Other assets Accounts payable and accrued liabilities Other Net cash used in operating activities Cash flows from financing activities: Proceeds from shares issued under ATM and Committed Purchase Agreement Share issuance costs Repayment of lease liability Net cash provided by financing activities Decrease in cash and cash equivalents during period Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental disclosure of cash flow information: Net unrealized gain on investment in Intensity Cash paid for interest Supplemental disclosure of non-cash investing and financing activities: Right to use asset acquired Lease liability incurred Nature Of Operations NATURE OF OPERATIONS Notes and other explanatory information [abstract] GOING CONCERN BASIS OF PRESENTATION Significant Accounting Policies SIGNIFICANT ACCOUNTING POLICIES Prepaid Expenses And Other Receivables PREPAID EXPENSES AND OTHER RECEIVABLES Investment In Associate INVESTMENT IN ASSOCIATE Investment In Public Company INVESTMENT IN PUBLIC COMPANY LEASE Acquisition Of Tarus ACQUISITION OF TARUS In-process Research And Development And Deferred Tax Liability IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY INCOME TAXES Capital Stock CAPITAL STOCK STOCK OPTION RESERVE (LOSS) PER SHARE COMMITMENTS AND CONTINGENT LIABILITIES Related party transactions [abstract] RELATED PARTY TRANSACTIONS FINANCIAL INSTRUMENTS AND RISK MANAGEMENT Capital Disclosures CAPITAL DISCLOSURES NON-CONTROLLING INTEREST Recent Accounting Pronouncements Schedule of prepaid expenses and other receivables Schedule of investment associate Schedule of investment in Stimunity S.A. Schedule of lease liability Schedule of fair value of assets acquired and liabilities assumed Schedule of Pro forma Information Schedule of in-process research and development Schedule of income taxes benefit Schedule of reconciliation income tax rates Schedule of effective income tax rates Schedule of reconciliation of financial statement loss to tax basis loss Schedule of deferred tax assets and liabilities Schedule of unlimited number of common shares without par value Schedule of terms stock option reserve explanatory Schedule of outstanding stock options Schedule of weighted average exercise price and remaining contractual life Schedule of basic and diluted EPS calculations Schedule of anti-dilutive share Schedule of financial instruments Schedule of non-controlling interest Disclosure of transactions between related parties [table] Percentage of acquire Exchange of ordinary shares Percentage of outstanding shares Percentage of ownership subsidiary Cash and cash equivalents Total current liabilities Net (loss) income Cash used in operating activities Cash on hand Disclosure of detailed information about borrowings [table] Non-controlling interest Prepaid clinical research costs Prepaid insurance Research & development tax credits Other prepaid expenses Tax deposits Other receivables Total prepaid expenses and other receivables Disclosure of associates [table] Name Principal activity Place of Incorporation and principal place of business Voting rights held Beginning balance Share of loss Ending balance Equity in (loss) income Convertible Note description Translated value Unrealized gain Increasing the carrying value Impairment analysis Stimunity convertible note receivable Decreasing the carrying value Stimunity convertible note Loss on shares recognize Changes in the market Disclosure of detailed information about investment property [table] Investment Number of shares purchased Percentage of equity held Equity interests of acquirer Number of ordinary shares issued in acquisition Number of private company share consists in sole asset Number of shares outstanding Per share price Impairment asset fair value Impairment assets carring value Holding shares Offering price Fair value interest Impairment loss Cash carrying value Number of shares sold Price per share Proceeds from sales of biological assets Additional antidilution shares Percentage of voting equity interests acquired Unrealized gain or loss 2024 2025 2026 2027 2028  Total Less: interest Total lease liability Lease liability - current Security deposit Disclosure of transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [table] Assets: Identifiable intangible assets Goodwill Total assets Consideration: Fair value of shares issued Liabilities assumed Deferred purchase consideration at fair value Total liabilities Loss from operations Loss before provision for income taxes Net loss Total comprehensive loss for period Loss per share Number of share issued Ordinary shares value Proceeds from offering Short term debt Milestone payment Ordinary shares issued Value Deferred purchase price payable Disclosure of offsetting of financial assets [table] Deferred tax liability Recognized an impairment Carrying value Impairment Current: Federal State and local Foreign Total current Deferred: Federal State and local Foreign Total deferred Benefit from income taxes (Loss) income on ordinary activities before tax Statutory U.S. income tax rate Income tax benefit (expense) at statutory income tax rate Share-based compensation expense recognized for financial statement purposes Other losses recognized Utilization of losses not previously benefitted Income tax (expense) Loss on ordinary activities before tax Statutory U.K. income tax rate Loss at statutory income tax rate Change from increase in deferred income tax rate Recognition of deferred tax assets Foreign currency effect Income tax benefit Disclosure of disaggregation of revenue from contracts with customers [table] Pre-tax loss Share-based compensation expense for financial statement purposes for which no benefit was taken Losses not subject to tax Utilization of losses not previously benefitted Taxable income (loss) Deferred tax assets: Net operating loss Deferred tax asset (unrecognized) Deferred tax asset Deferred tax liabilities: In-process research and development Deferred tax liability Net deferred tax liability Federal net operating losses Deferred tax assets Research and development credit receivables Deferred tax liabilities Deferred income taxes Current year losses Increase (Decrease) in deferred tax liability Deferred tax liability Change in exchange rates on the liability Exchange rates losses Beginning balance, Shares Beginning balance, Amount Shares issued under public offering and ATM, net of issue cost, shares Shares issued under public offering and ATM, net of issue costs Shares issued or accrued for services, shares Shares issued or accrued for services Ending balance, Shares Ending balance, Amount Maximum aggregate offering price Issuance and sales, shares Gross proceeds from stock Cash fund, description Number of stock sold Gross proceeds from stock sold Net proceeds from stock sold Number of shares exchanged Minority interest, percentage Number of ordinary share issued Net proceeds from sale Begiining balance Stock based compensation expense Ending balance Disclosure of defined benefit plans [table] Beginning balance Granted Expired or forfeited Ending balance Exercisable as at end Weighted average exercise price Weighted average remaining contractual life (in years) Option issued Exercise price Number of shares available for awards Fair value per share Compensation expense Exercisable price Number of shares available for awards Expiration date Number of shares purchased Number of shares available for granted Total of stock options granted to employees Stock options granted to consultant Options outstanding Share based compensation expense Numerator (in 000’$) Net loss attributable to owners of the Company Denominator (in 000’) Weighted average number of shares, Basic Weighted average number of shares, Diluted Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [table] Anti-dilutive effect on loss per share Budget cost related to services Convertible note Interest rate Conversion of debt Conversion of debt into shares Share price, per share Aggregate value Number of ordinary shares issued Commitment fee Issuance of unsecured notes, description Portage ordinary shares Base salary Annual base salary Compensation committee Original annual targets percentage Accounts payable and accrued expenses Annual fees description Disclosure of fair value measurement of assets [table] Financial assets Prepaid expenses and other receivables Convertible note receivable, including accrued interest, net of impairment Investment in associate Investment in public company Financial liabilities Accounts payable and accrued liabilities Notes receivable Unrealized gain Increasing carrying value Impairment of convertible note Decreasing impairment carrying value Loss on decrease in fair value of the liability Accounts payable and accrued liabilities Lease liability current Current assets Shareholders' equity attributable to owners Non-controlling interest, at beginning Net (loss) attributable to non-controlling interest Non-controlling interest, at ending Current assets [Default Label] Non-current assets [Default Label] Assets [Default Label] Current liabilities [Default Label] Non-current liabilities [Default Label] Liabilities Equity attributable to owners of parent Equity Equity and liabilities Profit (loss) from operating activities ForeignExchangeTransactionGainLoss Depreciation and amortisation expense Tax expense (income) Profit (loss), attributable to non-controlling interests Comprehensive income, attributable to owners of parent Comprehensive income, attributable to non-controlling interests NetUnrealizedGainOnInvestment ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone Increase (decrease) in deferred tax liability (asset) IncreaseDecreaseInShareOfLossInAssociate IncomeOnFairValueOfWarrantLiability IncreasingDecreasingAccountsReceivable Adjustments for decrease (increase) in prepaid expenses Adjustments for increase (decrease) in trade accounts payable Cash flows from (used in) operating activities Payments for share issue costs RepaymentOfLeaseLiability Cash flows from (used in) financing activities Increase (decrease) in cash and cash equivalents after effect of exchange rate changes Cash Proportion of ownership interests held by non-controlling interests Current prepayments Unrecognised share of losses of associates EarningLossPerShare DeferredTaxesLiability Deferred Federal Income Tax Benefit Deferred State And Local Income Tax Benefit Deferred Foreign Income Tax Benefit UtilizationOfLossNotPreviouslyBenefitted Net deferred tax assets Deferred Tax Liabilities In Process R And D Deferred Tax Liability1 DeferredTaxLiability CommonStockShares Common Stock Values Increase (decrease) in number of ordinary shares issued Sale or issue of treasury shares Stock Option Reserve Number Of Outstanding Share Option NumberOfShareOptionsAvailableInSharebasedPaymentArrangement NumberOfSharesPurchased Prepaid Expenses And Other Receivable Current investments InvestmentInPrivateCompany Accounts Payable And Accrued Liabilities UnrealizedGains AccountsPayableAndAccruedLiability Current Asset EX-101.PRE 8 ptgef-20230630_pre.xml XBRL PRESENTATION FILE GRAPHIC 9 pipe.jpg GRAPHIC begin 644 pipe.jpg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end GRAPHIC 10 dev.jpg GRAPHIC begin 644 dev.jpg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

BD8Z,%D[]0/6@#=HKS2'X@'5-2T;4/L#+%/;ZK-9LMRP62&%HPKL@&#O'S M#.=H/'4U8T7XAZU=:;X:U'4-(L[2U\07-O#:QPW3221I)!)*6?* 9^1< $\- MRVC^(-)AMQ'=,B()((#N7:>5RVXKT;//6F^!_B*TFO:QH$3?;;NWU;4 M;B]FN9B%M+5)V "]2S<00V]M M?^;>V^X$QM-'MP < $ _*6'7FNH\1>*M8M?%UEX?T?3;6ZGN+*2\:YO+AHXX ME1U7D*I)SN' H Z^BO-[CXJ7?]CVT_V;3-*G6YN+.^EU;45BM[::%MI13C=( M7/*X4<L?"W]C:/:2WVN17C?Z3=LL$#6[JK'<$)922G45X_K7BC7+6;XCMJD<4^FZ=! 8X+6]DC=,M=OM4UJ+0-%MM0M='E6WG^T71BEN9MBR-'$-I485UY8@$G' YH [>BO)]1 M^(3>#=8\97-P1(SZI8V=I#>7/E0Q/):1,=S\A%'S,< ]#ZTC?&\Q:?J0,6F7 M=U936Z->6-VTMBL:[A-RA2A##!ZKS@Y !ZS16!X)\13>*-#%[.+$GS&1 M9=-NQ(PZY+X9FUG6?#$.O-X>L=%N;BXCUS[5Y+7*X, M0B^T'?G ?=CY<8[UO7'@$VW@N36DUS5/^$GCLS>?VJ;Z0HTH3?@Q;O+\K/&S M;C;[\T >H45\_:AXLT_6/$#ZMX@M?$,UI)X>T^_6/1);I4M6D$K2,XA=0/X> M6_N^QK1U;0[JZ^!]]KNIW>I?VI:V-S/I]PNJ2B18"S/ 9#%($D?85R3F@9[A M17&6,_A;X9Z?!]LU==+^WJ'!U;5))#(R@9VF9SC&X9"^HKB_%37=GXH\1ZWK M6E^()?#]K-#Y=U8ZM);Q0P+%'OD$*2*9!O+D\=!WY% CV>BN.L;Y].^)4]@D MK26&L:?_ &C$I8D)+$R1R;?0,KQ''JI/\U>_U#2M0L<3.RMGJ2=_ M/TK(OOA6MU]N5-6F2.755UBWC>"-U@N!DMD$?.IR>#TXP:[RB@#S'7/AS-IN MEZI?"YU+7=3NK^UU#SK?RH[B"6(!/,B4C8V$'^K/4 C))JGX=\ WGBBX\57> MLSZI$NI?8?LMU>)'#XF18E5E$4$:KDY6->-Q)Y8Y)P!P!BLC_A7#S:U97=YK=W?V5C>M?VMK M<(C21R-N^7SB-Y0;CA?0 $D#%=I10!P/B3POJVJ?$S3M1T^\GTN.WTF:+[8D M2R1EVFC/ENK=00">,'*CF@_#&WTNSBGM[FXNKVVMM0WM( 6NYKK:SNV,8.Y! M@#C!QVKOJ* /-?!/PTN5T#PHFNZE=7EOI=K%)%I4\2*(9_)V$.P&7"!G50>G M?.*V/#_P^N?#[:=;)XBOY=%TTDVFGX5,+@JJ22+\TB*#PI]!G.*[*B@#@;?X M16=OH\>GC4)RB:%/H6_8,[)2"9/]X8Z=*V=0\"V>J76E27,C2PV-C<6!A(^6 M:.98U;)[<1]O4UTM% ')>'?!%[H=QIXG\27]_8:=&8K6T95C!7;M'G%0/-*K MP,X'?!/-/\0>!WU;Q)#K=GJLVEWJVAL7>.&.0^47W93<#L?.?FY]QP*ZJB@# MA-)^%%MI-E9VT6JWR?9=(ETB.>!O*E5'D5Q(''1UV@"HY/A+%J4E]PP1P/"89/-C< ##.' .6R.,8 )%=_10!S7A_P?+IFM7&LZEJDNL: MK+ MJLSQ)$D4(8MM5%[ECDDDYP.@%5M;^'=MK=UK4[W:@]W:?8D81)$D2;@Q;8O#.2!ECZ8 '.>YHH X7Q)\,7UR MZU\V^NW6FVFNPB*_MHHHVWD1^6"K,,KE0 1WQQBIKOX6L5 MK?+#$C^<(U**ZE@=C[3C(R, <9&:[2B@#@K'X6R:%#IQT37;C3+JWTV'2YYO M(CE6XCB!V,588#KN;!'][!!J36/AG-J5@;!/$FI"QFLEL;J&\VW?G*,_O 9 M=DAW'+ 8/'' KN:* ,'5O"-OJFF:38B62"'3;JVN8L?,3Y+!E4D^N,$UE>(O MAG:^(KG6+B2\EAEU V3C"*RQO;.SH2IX8$GE3U KLZ* .!;X4_:O[9DO=;N; MRXU5K)YG:%$5#;2^8@15& I&%P(?AY8^)M0U2XO)IME_IT>GLD9" MF/RY7D613_>#/D=OE%=510!PT_PSEU9=1DUK7+C5+NYTV?2X9C!'$MO%*,.P M51@N<+DG^Z *RO'OPWDF\-ZV-/DN;FZU$:7;F.( ,B6]PI+J?7:S-[;:].H MH X6X^%L6M'4)-?U:YU>ZN;/[#%.(T@-O'O$F4"C&_>J,6/=%X XIM[\.9+Z M'4[K6[V;Q3>2:;-806\BI:H(W +*"HX=RJ OVP, 5WE% 'CWA[PMJOB3Q1IL MNKC6I],L]-N;2==:CAB_UH1/+7R\&1MH;=)T.%QUKK--^'MY9P06ESXEU"]T M^UMGM;:V*I'\K)L!E*@>:57IG SR03S7:T4 <%??"V2YT6#28=?NX-._LV+3 M+BVDB2:.1$7:'17!$VMOG+2B+Y M6C!/\31EU&>Y%=?10!BZ1X=BT_7M9U=)9&?5O(9XG7 C\N/8,=^1ZU!XH\'K MX@NK+4+:^GTG6+'<+>^MPK$(V-\;JP(=#@'![@$$5T-% '%P_#<3KJMQJVK7 M&K:M?V,FG?;)(TC6WA8'*QQJ,#)P23DD@"['X?Q^)=7T#2H9-0 MOL/!:VUND>UA&B+$" ,(64,>PRQK2T+P;#IG@&V\,SRM)&+'[)/-&=K,64AV M![$DL?QKI** //\ 3_A2]M<:=)JBL0\49C!93P05+ CWKK:* .'M?AMV.:E>7ANY(SQ M\L9^M0_\*OLU:*:.[DCO(M4N-22X" G$[DRP,.Z,IVGZ ]17:T4 <;X?^'US MX?;3K9/$5_+HNFDFTT_"IA<$*DDB_-(B@\*?09SBJ?B3PQJVJ?$S3M1T^\GT MN.WTF:+[8D2R1EVFC/ENK=00">,'*CFN^HH X"'X2QZ?-I]YI^KW%MJMM]I, MM]-#',T[3NKRR;6&%?-R,QL44 D9Z C!YKLJ* .+U#X8 MV=])J"-3FM9WF\5ZD=3D MGBF2YBQ'%'L! 00CY2C9.X');CG@8Z^B@# \'^$8_"=M?*+AKNYOKIKRYF\M M8E:0JJ_*BC"C"+[GDDDFN]>A44 175K#?6LUM<1K-!,C1R1N,AE(P0?8@UPI^%MR^F#1'\4ZD_ MAG;Y1TXI'YAA_P">)GV[]F/E_O8XW5W]% &%IOA.UTOQ%?:K"VT75G;V7V8* M D:1&0KC_OX1CV%9:?#>WC\!ZIX32]F&G7:SQ0G:"UM%(21&OJ%R0,]L#M78 MT4 5OL$#0112Q).(U"J9$![8_I7):[\-Y=<;4K8Z_?0Z)J<@DO-."JV[@!D2 M0CX8\PNRR2N!_=&V)1[ MJU=7110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45\[Z;KGC<^!=6\0 MK>ZE'8II%_))+KO3_"^EV&DWTUMJ^J MR*B7-G ]Q)#&B[Y'"(K,>BKP#CS,T#/3:*\M:K9V^JZ=< M7=W81S!4BN(&@1HPI7( 9I 1W]JQM'\3>*-/^&NH^)I+C4C.8BD=Y=74%^+O$FK>%X_$&F:5XFN];A728;Y;N22)IK: M9KE(]HD10 )$)(!'&TD<&L35_&'B[289UBU.]ADL-;PVGWR7&E2BWN=-A886*!I+A%('^ MTL2M^->K4""BBB@ HHHH ***X7XRF\L_ ][J5AJ=YIMU9A61K20*'W.JX;(. M>": .ZHKR&\768/B4VBP:CK%[I]G8VDK,-1BB(+S3;FDW+\_"@8'9:E\(:]< M:M>V^KZCXPDLKZ;5[BP;066,P[4=T6 )@.'VJK[\]^1@T >LT5\^1_$+Q5)X M?\+O+]HMHYX]4+:A]H1OM1CM[ADRHY&UE4C/]VJB?%?Q38Z>]I=7+1ZOI^A^ M9/.T8:-UDGMA'>8(P<12.3VW(V>*!GT=17AWB?Q+JGA5MEF^6>TDB M1[B;S"I&]U8;44!BH_OC/% CTBBO"--\=:UXJMM+AU#5[W3U_L9[]'TKR()M M1D6X>(.IE^4 (J2;00#YGH!5O2_$?B'7K[PS:V>LW$FF^*+=+HWDZ)%<6PML M?: BJ64>;E. Q"EG([4 >V4444 %%%% !1110 45XYXH^)UYIOQ7MXXKBX'A M_3YH-.OHUMI&@:2<,6D:4*44QEK?@L#\[5GV/C76K+Q%>?;->8QW@U)+.[26 M*>P#1*[H&B"B6$Q*GS9W!L'DY% 'N=%?.[>--?M?#NH6$NJ:BVK,^F3(RWEO M,KQS7"QN\,Z*-H?D;74;>HX-=7X@L]6M='\-2?VSKFG7%UJ\-C/$=0CF;RY' M.265<9QC'I0,]=HJ*U@^RVL,/F23>6@3S)3EVP,98]R:EH$%%%% !1110 44 M44 %%%% !1110 445R?Q5U2[T7P%JEY8SM;74?E;)4ZC,J _H30!UE%>"R_$ M+Q%IOBJXTZZNI6L+_P 41VNGW"C_ %:I<(LULW'0HP8?1Z@M?%>MZ;X;T/4X M_$5Y>WNK1:@EQ93NCB-8XIW26,;=R;6C0=<'=]*!GT#17B5AXFOM9;4)M3\9 MS>&ETG3[":'"QE)?,@5WFE5ES("Y*;01]T]S4GB[XE7EO\3(;>&]NXO#]F\. MFWWD6TGEF2X5LRF;:40QEK?ACGYFXH ]IHKQ**\U?2M+UF['B#5+F2V\36^E M1K<3!E$!N8 >-HY(9@3Z$TV/QAJ[6">(CXBF_M9M>_LT^&_W7E"/[5Y/D[-N M_?Y?[S?G/X4 >WT5X+H/Q"\0Q^)-,TK4;J5X=1\1W'V*X4=7&M:GJ7@)[E-:7\58++[??77AV"9="?SX'9'G* M[O/:;9LW>;MBQNSU.*K^'O'E])_PCNK7NN:I+=ZQ--!/8QK;-:02?O L!0LL ML;)M!W -G'/WJ /'[34=5GU">2ZLH91)=WT25;.Y2FS&#DY&.'[@3Z7X5;39P&42 M6>AM$V#C(RL8Z[1GZ#TKM** .6MK[1+.X6XM]!N8+A3(PECT>16!D(:0Y"9^ M8@%O4@9J6VUK2[.Q%E;Z/>P68!46\>E2K'@Y)&T)CG)_.NDHH XZU7PS86$] MC;>%WM[*=@\MM%HCK'(P.0641X)R!U]*FFNM!N+UKR7P_<2W;$%KA]&D,APK M(,L4SPKNOT8CH375T4 H6^D>&5OKN3RK6ULQ/-)M+;45-S' &3@ ]*K:7XWT/7( M-$GL-0CNH=:A:XL)(U8K/&JAF.)Q'(INLJEK6LV?AW2;S4]0F^SV-I$TTTNUFV M(!DG"@D_@* .?,_A]K>W@/AV"'VC9@;@S XZACGK4BZAHJ MS+,-"NA,MO\ 9!(-(DW"'.?*SL^YG^'I5OQ'XWTCPK/;V]]+3LBX#/Y4*.^T$@%L8!(&>:TM'UBR\0:7;:CIUS'=V5PF^*:,Y##^ASP0>0 M00: .8MX?"]KIMSIT/A9H=/N3F>TCT-EBE/JR"/#?B*A_LSP>+!;$>#D%DLA MF6V_L ^6)" "X7R\;L #/7@5N^*/&6E^#TL6U)[K=?3FVMHK.RGNY99 CR%0 MD*.W"1N&WU+P[-J$$!S%%=:,\JQG&/E#(0./2K']KZ2)K68:->>=:HT=O)_9 M,NZ%6 #*AV?*" ,@=<"NEHH Q/\ A++;_GRU3_P73?\ Q-'_ EEM_SY:I_X M+IO_ (FKSZS9QZU#I+38U":W>Z2':W,:,BLV<8X,B#&<\^QHU#6+/2V1;B;; M+(DCQP(I>64(NYMB*"SD#LH)Y [B@"C_ ,)9;?\ /EJG_@NF_P#B:/\ A++; M_GRU3_P73?\ Q-;,;B2-7 (##(W @_B#R*=0!B?\)9;?\^6J?^"Z;_XFD_X2 M^U+%19ZGN !(_L^;(S_P'VK@# DO=#EM+NU?0+E[6[< MRW$+:/(4FC.$R?Q- M=;10!Q*6?A./3[FQ3PEMLKEP\]LN@L(Y6!R&9?+PQ!YR:GLF\.:;9Q6EIX:E MM;6*87$<$.BNB)*.D@4)@-_M=:Z^B@#$_P"$LMO^?+5/_!=-_P#$T?\ "66W M_/EJG_@NF_\ B:VZ* ,3_A++;_GRU3_P73?_ !-'_"66W_/EJG_@NF_^)K;H MH Q/^$LMO^?+5/\ P73?_$T?\)9;?\^6J?\ @NF_^)K;HH Q/^$LMO\ GRU3 M_P %TW_Q-'_"66W_ #Y:I_X+IO\ XFMNB@#$_P"$LMO^?+5/_!=-_P#$T?\ M"66W_/EJG_@NF_\ B:VZ* ,3_A++;_GRU3_P73?_ !-'_"66W_/EJG_@NF_^ M)K;HH PG\7VL:,[6>IJJC))T^8 #_OFHKW7M-U*U>VN]*O[JW?&Z&;2Y71L' M(R"F#R ?PK7U;_D%7O\ UQ?_ -!-6Z .5>\T.0 /H%RP6Y^V -H\AQ/_ ,]? MN??_ -KK[U4L;7PII'+ MR:SFN/#4L\MDH6UDDT1V: #H$)3Y0/:I9+W0Y;2[M7T"Y>UNW,MS"VCR%)G. M,LZ[,,3@9KB' M_B3R?NY6)+2+\G#$LV6')W'UJ_\ \)9;?\^6J?\ @NF_^)K;HH Q/^$LMO\ MGRU3_P %TW_Q-'_"66W_ #Y:I_X+IO\ XFMNB@#$_P"$LMO^?+5/_!=-_P#$ MT?\ "66W_/EJG_@NF_\ B:VZ* ,3_A++;_GRU3_P73?_ !-'_"66W_/EJG_@ MNF_^)K;HH Q/^$LMO^?+5/\ P73?_$T?\)9;?\^6J?\ @NF_^)K;HH Q/^$L MMO\ GRU3_P %TW_Q--?Q?:QKN:SU-1ZG3YA_[+6[535/^/%_]Y?_ $(4 9%] MKVFZG:2VMYI5_=VTHVR0SZ7*Z./0J4P156&YT"VTV/3H?#UQ%I\;K(EJFC2" M)65@RL$"8!# $''! -=910!RIO-#-DUF= N3:-+Y[6_]CR>69-^_>5V8W;OF MSUSSUJ*-_#D.J2ZFGAJ5-2E!$EXNBN)GR,'+[,GCWKKZ* .-T6+PQX;GDFTG MPLVES2+L>2RT-X69#Q-;W$T<2V>I*78*&DL)E49[DE< > MYK8HHH **** "BBB@ HHHH **** /,M(^-D<]MIFH:OHLVC:+J:W#6NH-=IC:KX(-8L+G3M)E6XC:SM7CFO)51DC:7+D( 6W%5SN8#E M0"I *GAWXP7_ (@@T4CPM+;SZ[IIU/2XVOXF$T8$;,KDNM M)AT^SN(='32]9-K;B(7[HJ;)^!]\.KY)Y(D.1R:9J-S9 ^=<22@.(I%W@!P,/D<'CF@"YH/Q L?$GC+7?#]G%,[:1%"\M MX1^ZE9WE1D0_Q;&A96/0-E>JFNIKSWP/\(X/ ?BRYU*QU.^FT]M+M]/AL[JY M:79Y?XJ]"H **** .:\0:?<:O\-]2L;2/S;JZTF2"&/<%W M.T)51DG R2.M>8S?#7Q1X=UNS.AV4=SI']E7LZVQN_(-GJ,L"JT:LK!@DKC? MN0_*_F'(W#'KC:K;Z%X3.I7;;+6SLOM$S8SA$CW,?R!KS[3?BQK5KXZM-(U[ M3[.UTVZTNSF^U0;MUM?7#3E('R2"A6'8&XRX _Y:* ZK$5V]CN:3\5-=\3:#9WL%_P"' M_#D=MH>GZIJ>H:Q#(]OYUTA81(/.C\M1M^^S-]]1@X)KJ/ GCZY\7:]>6C_V M<]K%H^G:@LNG3_:(VEG>Y60+*#M=!Y"[2 .ISZ \O\ &'A7Q+H.CZE=7,%P M;62XN@WV6\6%IFGU>T>+:5?*%XQ)AN-N2"16W_PAFNAC*?#FJ-X5_M)IAX6& MI1?:=GV94#Y\_P K9YH9O*\W'._&[BNLO?B]97&@ZQJND0SW%IHY,]U//;.L M4EO'(5N/+?H'55@]: /E[Q1#J7A^,:1KIN]0\1W<%F-&CBUA5 MFLE-RX\HJTJR3,%*JSQK)OVD.0 #6O:7%I\E MM9301SP/%+)(K 321J583,#\V047@YXY#Q9X5\6ZTL\UQH^+O#>G:'H7=U'8Z?-JD#:FLDMS M=0W2/(H:27:7\K>,E@I "[NE>]T4 >"W7A'QK>76I:H=!G$ERM\J6DU]'YBQ M2WMHZIF.=03Y4270;N:^MWU>&S5KJ!9+6.XM MQY##]^551)N&U68J3QD*-X+\4G6MQT^^.J?;HYTUT:BGV9+(1*&M M3%YN[)PR[1&4W,)-V>F8?A7XCTWPYI]K:VFIMYFCZ>-2AAU%)'FO8WS+N$LH M63@G=\RA@,;N *]^HH YOXI:?X+TNVU>V6TOXD97A65I-JAVV EI)#G9M MR-[A3D!B #6S#_R%+G_KE'_-ZMU4A_Y"ES_URC_F] ')3?$USXJU#2;+0KO4 M8=-NH+2^N+>6,R1-*L;!Q!NWM&HE0L^!T; ;::MP_$:SF\ MFJNTM';RJ1P2K88\C>00XXIEO\&#;QV&IKJ,S>)XM4;4[BX:\N#:R&5V$Z+ M7V*##(\:L%R,*>QH V9OBOIMGX;\(ZW=PR6MCX@A^T;W8'[+&+*6[9GQUPD1 M''UDM%:0LQ52(I7SM!RQ!^4#;6 MII7P[UZ3Q9H6KZSJ6G32:.I07-C!+'-?+Y,D0$JF0H@_>%R &RRC!&* .CU3 MQU:Z9XTT;PT;2[ENM2$C?:%A86\06-W ,A&"Q"'Y5R0!DXR,UO'GQ$MO ]G? M2M:2WTMGIESJTT43!=L,('!)_B9B ![,?X:T-<\.R:MXB\-ZDDRQII4\TSHP M.7#P/& /H7!_"N4^(W@.]\47VNVUMA(/$7AV;1GN6&5MI5,C1,P'.UA-+D^J M*.] ":I\8+O0WN;+4/#,]OK*M9>1:K>1O'.MS0RCC&,\XT5^* M4=E:ZXNKZ+J%AJND113RZ=;J+MYHY2XB>(QYW!FC=?FV[2C%L+\U5_$7PGL5 M\/-;>&+*PTO4?M]C?--,C$3?9KE)E1V&6(^5@/3'=83Q%X?TS58XVACOK6* MZ6-CDJ'0, ?<9J.V\01:KX976=*C;4(9K8W-M&,HTWRY5?F'!/ Y'>J>D^#[ M./P+IGAO5[:UU>UM[*"UGAN(5DAF,:J,E&!!&5!&?:D\"^ =#^'.@P:3H5A; MV5O&JAY(H8XWG8#&^0HH#-@=<4 <[X@^-&FZ/X6T_6[6TFU**\TBXUM8HV"L MEM#"KL6ST.YXH\>K^QK1NO'FHZ-IZS:OX=DM[RYN([33[*UNXYWNYG#':#\J MH%52Q+' 4$]L'F;GX)32:#X\TY-1A9=;LKC3]+62,[;&&9I965N>?WL[=/X$ MC':I[/X57<&GP_8M/\,^%K^POHM1L7T6R(ADE5)(W$Z )N#1R,N0C&JZW M_8!NCH*C5-V!I_VU<$9QGS-N.G/3VKSM_@;-K5_)=ZV=)GANM0M+RYTF.!Y; M1A#YY8D2LVYW,XS\J@"-1@XS7JFD:/8>']/BL-+L;;3;&'/EVMG"L429))PJ M@ 9))X[DT >?:;\:XQH>@ZSKFD_V#I>L2,(;F:\218XUMIIV=\ 8P(2,>K"M M)?B?(&MDE\/WT$USIEYJT-M(5$Y@@DA4 I_#(ZS!@A.1C!P?M%TLLMN]NLC'C'9;RUE6>VN+4RQ2KT M=&3*D>Q!%0>,/%%MX,\-7^M7<@>' MSX3^'.G:&9?/.FZ5'9F7^_Y<(3/XXK1\3:;>:OH=W:6%ZNG7DBCR[B2!9D!! M!VNA^\C %6&0<,<$'! !CZ3X_C;3[R[\0VB^&(+7RR;N\NHC:2J_W6CG!VGD M8(."#CC!!*?\+&TV;68K*SEMKR":WM;J*^6[C$$J3SM$H1LX8Y3( ^]D /3F=([B-W=0V#3[/ MX*WT-Z+N74[9II;JVO)UAB9$61-1DO)%C&3A?WFT9.WN9Y_LEU'(;8PO$A215)*L3+W_N&LQOB-J5MXRET.\T".SMXD MBF?4)M2C""*69HHVP1]XLOWK>&=<\.275YIL^G>'](GTBU: MWMW2XF1V@*O(2Q ($'('5B3GG T/&7P\O/$FJ:G?6M[!;2SV5G# )HV=5EM[ MIK@%@",JQ*J<'/6@#>U?QWX:\/F0:IXATK33'(8G^V7L46UPJ,5.YA@A9(SC MT=3W%-7X@>%Y+.]O%\2:0UI8R"&ZN!?1&.WZ?+<7)K(WFCZG9ZM:;RGVBQN$FCW#JN MY21D9Z5Y]HOP=GLEU][R[L;F?6--N+253;,88Y)[BXFD 3<"8LS@8W MM))! M/'1?#CPEJ?A.SU!-2OQ>-+_[R_P#H0H Y+XJ> M.)?!^DPQV>W^T+LE8V89$:C&6QZ\C'_UJ\2MI]8\2S74TNJ/^Y3S99;FX8* M6"_S85Z3\?-&GFM]-U.-2\$.Z*7 ^YD@J?IU'Y5YCX?UB+2;75A)&DLEQ;K' M&DB;D+"5&.1]%-?(JRS!TJTFH):=MK_GI^!# MJ2ZEI-SY,]S(25616CF+*ZD9# @\@BJG]I7?_/U-_P!_#_C6_#XRF_LV=))& M626XAWPP#RT:W1&4Q\?P\@8[]ZM>)O%EEJ1@*017Z+*\BQ7"S*$0C 3/FDCZ M(0O Z]*]92FFHRI_-'@RC3E%SA6MY/U]?T.8COKR2146ZFW,<#]X?\:L:@U_ MIMP\$MXYEC=HW5)B=I5BI!_*MF3Q%;2Z?"D=U-9PI&$;3(4)B+[]V_+$]NY^ M;C'O5W4/&D AOVL+B>"YE64121Y1ANNO,ZCI\G^%2YSYE:G_ %]W]=RE3I\K MO6UM?_@6O^=O0Y-KR[6%)/MDAW$C:)3N&,=1^/Z5'_:5W_S]3?\ ?P_XUV=Q MXNL)6D\F>:UFD,Y2[2,[H69SCZEJ_A^^ M"?;9DE54DP)"RD,H89!X/!%>I>%-?'B+25N"H293LE4=-P[CV(KR?Q#?1:EJ MAGA),?DPI\PQRL2J?U!KT+X::?+9Z))-*I7[1)O0'^Z #^/->7FM*G]6C4D MK3T_X*/?X?KUECI4(2;IZ^?HSKZ***^//TL**** "BBB@ HHHH **** "BBB M@ HHHH *='(\3!D9D;U4XIM% '5Z#J37T+)*HK5K!\+VKHDL[#"OA5 M]_4UO5C+< HHHJ0"BBB@ HHHH ***A:%V8D3R*/0!<#]* )J*@^SO_S\R_DG M_P 31]G?_GYE_)/_ (F@">BH/L[_ //S+^2?_$T?9W_Y^9?R3_XF@">BH/L[ M_P#/S+^2?_$T?9W_ .?F7\D_^)H GHJ#[.__ #\R_DG_ ,31]G?_ )^9?R3_ M .)H SVTJWUWPF=-NUWVMY9?9YESC*/'M8?D37.VOPQM]1T:_A\02M>7NI:7 M;:7>O ^$(MS*8YH_E#)(3*7ZG:P7'W5U9C-!(VXF>3)! M'4<<5W'V=_\ GYE_)/\ XFC[._\ S\R_DG_Q- 'G&J?!*UE.LRVM_<3W&LPM MI]U)>^4-EG+*&G0-'&KR,5!56E9BN>#]X-Z;TXJ'[.__ #\R_DG_ ,31]G?_ M )^9?R3_ .)H GHJ#[.__/S+^2?_ !-'V=_^?F7\D_\ B: )Z*@^SO\ \_,O MY)_\31]G?_GYE_)/_B: )Z*@^SO_ ,_,OY)_\31]G?\ Y^9?R3_XF@">BH/L M[_\ /S+^2?\ Q-'V=_\ GYE_)/\ XF@">BH/L[_\_,OY)_\ $T?9W_Y^9?R3 M_P")H GHJ#[._P#S\R_DG_Q-'V=_^?F7\D_^)H GJI#_ ,A2Y_ZY1_S>I/L[ M_P#/S+^2?_$U5BA?^TKD?:)/]7'SA?5_:@#1HJ#[._\ S\R_DG_Q-'V=_P#G MYE_)/_B: )Z*@^SO_P _,OY)_P#$T?9W_P"?F7\D_P#B: )Z*@^SO_S\R_DG M_P 31]G?_GYE_)/_ (F@">BH/L[_ //S+^2?_$T?9W_Y^9?R3_XF@">BH/L[ M_P#/S+^2?_$T?9W_ .?F7\D_^)H GHJ#[.__ #\R_DG_ ,31]G?_ )^9?R3_ M .)H GHJ#[.__/S+^2?_ !-'V=_^?F7\D_\ B: )Z*@^SO\ \_,OY)_\31]G M?_GYE_)/_B: (]6_Y!5[_P!<7_\ 035NL[587&EWA-Q(?W+\$+_=/M5K[.__ M #\R_DG_ ,30!/14'V=_^?F7\D_^)H^SO_S\R_DG_P 30!/14'V=_P#GYE_) M/_B:/L[_ //S+^2?_$T 3T5!]G?_ )^9?R3_ .)H^SO_ ,_,OY)_\30!/14' MV=_^?F7\D_\ B:/L[_\ /S+^2?\ Q- $]%0?9W_Y^9?R3_XFC[.__/S+^2?_ M !- $]%0?9W_ .?F7\D_^)H^SO\ \_,OY)_\30!/14'V=_\ GYE_)/\ XFC[ M._\ S\R_DG_Q- $]%0?9W_Y^9?R3_P")H^SO_P _,OY)_P#$T 3U4U3_ (\7 M_P!Y?_0A4GV=_P#GYE_)/_B:JZG"XLW_ -(D/S+U"_WA[4 7;BWBNH7AFC66 M*0;6C< JP/8BN+N?@UX7N)FD%I+#NYV1S,%_#.:['[.__/S+^2?_ !-'V=_^ M?F7\D_\ B:WI5ZM'^')KT.6MA:&)M[:"E;NCB?\ A2?AG_GE<_\ ?\T?\*3\ M,_\ /*Y_[_FNV^SO_P _,OY)_P#$T?9W_P"?F7\D_P#B:Z/K^*_Y^/[SE_LO M _\ /F/W(XG_ (4GX9_YY7/_ '_-'_"D_#/_ #RN?^_YKMOL[_\ /S+^2?\ MQ-'V=_\ GYE_)/\ XFCZ_BO^?C^\/[+P/_/F/W(XG_A2?AG_ )Y7/_?\T?\ M"D_#/_/*Y_[_ )KMOL[_ //S+^2?_$T?9W_Y^9?R3_XFCZ_BO^?C^\/[+P/_ M #YC]R.1LO@]X8LYA*;*2X(Y"S3,5_+C/XUTB^']/4 "WP!T =O\:M?9W_Y^ M9?R3_P")H^SO_P _,OY)_P#$USU*]6L[U)-^IUT<-1PR:HP4;]E8K?V!8?\ M/#_Q]O\ &C^P+#_GA_X^W^-6?L[_ //S+^2?_$T?9W_Y^9?R3_XFL;LZ2M_8 M%A_SP_\ 'V_QH_L"P_YX?^/M_C5G[.__ #\R_DG_ ,31]G?_ )^9?R3_ .)H MNP*W]@6'_/#_ ,?;_&C^P+#_ )X?^/M_C5G[._\ S\R_DG_Q-'V=_P#GYE_) M/_B:+L"M_8%A_P \/_'V_P :/[ L/^>'_C[?XU9^SO\ \_,OY)_\31]G?_GY ME_)/_B:+L"M_8%A_SP_\?;_&C^P+#_GA_P"/M_C5G[.__/S+^2?_ !-'V=_^ M?F7\D_\ B:+L"M_8%A_SP_\ 'V_QH_L"P_YX?^/M_C5G[.__ #\R_DG_ ,31 M]G?_ )^9?R3_ .)HNP*W]@6'_/#_ ,?;_&C^P+#_ )X?^/M_C5G[._\ S\R_ MDG_Q-'V=_P#GYE_)/_B:+L"M_8%A_P \/_'V_P :5-#L8V!%N,^[$_S-6/L[ M_P#/S+^2?_$T?9W_ .?F7\D_^)HNP)@ H P!2U"L+A@3<2$>A"\_I4U( HH MHH **** "BBB@ HHHH **^:_ ^@^*O\ A"K+Q+X?TW[#J%M87\[71U%YGU:0 MQ3+!&8,%?]:8WRQR-@ SN..AMY]!T]O!MSX0UV;4M8U"8"]']H/)&UNRU:QN;S2+*Y^Q7B 06 M0$]TJQIACR5VY;^)E<\#:![/0 4444 JQZ?;ZOX96QNX_-M;JS$$T>XKN1DVL,@Y&03TKG;KPKX%\7:I M$LD>GZEJ%EIDMB$CNMTB64V8W5@K9*,8F4%NA5L$'- &'I_QSCU2'R[/1)+O M4&U"'3T@M[R)XG,L+RHXESM*@1L&QTP<;N,RK\;4FT^\N;;P]>W!TNVDN]7B M$T0-HD<\\#ANGZQ=:Q9VPOIHKVTU#5==DE M^U.D;+&Z232GS,)*P&"00P]%Q>E^&_@K5[J:U$"O.$::YM[;49D,L5Q-+,1. MB2#S(GD:SW*WNL,MQ?K;6ML(8UDC74(;:)>5! MW@3* 2P!&[=DX(Z(?%6=KXZ,/#UP?$PNC;G3OM,?E[1")O-\W.-FU@.F[<<8 MQ\U.\8?"KPWJVES6Y*:5->3[?M#2N=QDNHKB6-07',CPC&.5_A]#I?\ "J_# M?V/R/LUYYGVDW?VT:E=?;/-*>66^T^9YWW $QOQM&.G% '-M\=(KC3[N_P!/ M\/7UY:Z>L8U(M+%&]K*TC1F/!;YRA4EBIQC&TL>*QM?^/G]H>'_$9T6POK.2 M"RNY;'5&A#QEX1S126[7DYA193F7RH M]^V$N>28PI- %/7+S5_$'Q E\-V.M7'AZTL]+BU"6YLH89+B=Y998U4&:.1 MJB$D_+DEUY&.:5Q\3+KPW93VTUO_ ,)3=:/8?;]6O]-:.*-81)*@949OFD_< M2Y0$ %",C(%=5XD\#Z1XJGM[B_BN$N[=&CCNK&]GLYU1B"R>9"Z-M)525SC( M!QQ6?>?"?PK?6]M;MI?DV\%N+,0VMS-!'+ &+>5*L;J)4RS';(&!WMD?,<@' M(?$'XF"_NO#EEX8UC4T,VKM9W_\ 8]G%)?8_LOA.ZE^WZER\Z6)C)%/.L.Y@K M':59@<9.01SG(':6O@W1['^SO(L]G]GW,]Y;?O7/ERS>9YKQU<,K*ZJ0X.[CK0!S&H?%N M2U\670$973+"TODFMY988A)/%;(0%7$S=6Z'H3@5F:C\<;R^M;2XT_ M3F@L?*U07TL(RSS,S:C_F M;F#J.0Q()YQGF@#/7XN1QL)3I%Y)HZ7:::^J-)'_ ,?+*N!Y8.=N]E0L!]X_ M=V_-69#\=B=%BOKGPS?6K7-E:ZC;1F9) 8)VVAY&3/EA3C=P< CKR!UO_"L? M#?\ :@U#[!()MXE\K[7-]G,@01B4P;_+,@4 >85W<#GBBX^&7ARXM;2 V,L: MV=I#96[P7\+' M/'.HY(.'C9E89'4'\CQ5J'_D*7/_ %RC_F]1Z'H=EX;TN'3M.A,%I$6*JSL[ M%F8LS,S$LS,S,Q8DDDDDY-20_P#(4N?^N4?\WH MT5X'XSOK?2_'>L:K+J$> MI&UU.S3R8]4FLM3L#MA A@@93'<1R$EL?+O\QQEB!4UCXKU5OB _BA[+4E\. MZM>2Z'%=O-#]C\GB.UD51+OW-]T5YC\&TM;JZUG5-(E:W M\/W<=NMEI\UTTTQV!]UW(K,3&TNY1M.&Q$&;#,0."CAN_%NL>")KC26\13ZI MHVJ:E^IR1-%)YE[YCQR;E8L-J#?]X[5)YKH-#;7KJ_^$&J:UJ=\+V[LBEYI MS[8XO.-C([R.@ )D+8X)(7!P!DD@'L=%7.I0Z2L[6[?:I M)(;*;R$+);R9Y48!*AF"L6''0='I_P#97@OXL-IL=Q#I>FC0$>.":XVIO-S) MN(W'K0!Z=17AMWXNU)?B0_BY+/47\,6]^N@M>+-#]B^S;C%)*4\W?O%XP!;8 M1LC//6H=(U35_%7Q2U2WUNVUO1DU'1+E(89 (XK&-)E$ZF3&-KO$K,,?4FM^@"IJW_(*O?\ MKB__ *":MU4U;_D%7O\ UQ?_ -!-<_\ %218_A_K)?56T-#$JG4%5R(07498 MH0RISAF!!52S9&,@ ZNBO O#OC27PIJ4^AZ=_9FG7%W>6D+WB:E)J>CVHDBN M6#J&\MTDW"VMXV_3[ M;[Q:S8U>> W$* M[\C<%##+, >"6 R0#W^BO%? WC?4_&/Q$\(7EYJ>E/'?:!?WG]E:>'6:S)EL M_P!W/F1M[+RN[:GS*XV^D'C#3=)\&_$;4]8ALX%:VLM.NRUS+)Y4;RZ@\.WWQ6U[6/%&J:5X=NM#^SVMS>1I>3V\ERK+!:6)FN=,L;V30[2;5[?3;R&_:VE%O8I=1W;^7*# M-F1@;0(K!HPS2K\HQ@@'MU%>+:=\5O%6L'4WMI?#Z6VD:90K%F\S;EAEN&'8_"OQK>>,M-U(:DT!U"QN1#*MO (@H:))%!V MSSH3A^JRL,8Z'B@#N**** "BBB@ HHHH **** "JFJ?\>+_[R_\ H0JW535/ M^/%_]Y?_ $(4 &J:K:Z+8RWE[,MO;1#+.W\O<^U><7GQ\TR*9EM]-N9XP>'9 MU3/XF:CYMU:W*PG?#;"*UA+1/<.A) MP68%4RIYYZ\#%5]6\&BQ:-+?4+:XD,K0NLL\,05@,YSYA '!^]M/3CFO0C@, MO=DXM/S;/)EFV;I-QDFEU2CZ'HO_ T!:?\ 0'F_[_C_ H_X: M/^@/-_W_ M !_A7FC^'8++R$N+LM>NBS>3%$)(BI;&/,5CS@$\#'O6KK'A:T2:^GDN/L=I M;F9PEO;!WP+DQ!>7&>W.1P,4G@,O32Y7KZA'-LVDF^9:>4?Z7YG;?\- 6G_0 M'F_[_C_"C_AH"T_Z \W_ '_'^%<%=^#4L[>1I[P+;6S3-)+';YD*@Q!<#<,D MF5>,C'/)J'3?!\6I>:8[YT0DB!Y( @DP@?GFSRA)M.GMP?XRX8#ZX&:Z^'QBEQ$DD=NLD;#O2 MOG3Q/:Q6>K&*%!''Y$#;5]3$A)_$DFN\^%]U+-HL\+DE(9<)GL" CIMIZGLY1G&(Q&*>$Q-F];-:;'J7_"6?].O_D3_ .M1_P )9_TZ M_P#D3_ZU<_17SG*C[%2-0JCZ 5#!I=G:W%Q/#:00SW!S-+'&JM) M_O$#)_&G_:T_NR_]^G_PH^UI_=E_[]/_ (4 "6-M&MNJ6\2BW&(0J >4,;<+ MZ<<<=J?##';Q[(HUB3);:B@#)))/XDD_C3/M:?W9?^_3_P"%'VM/[LO_ 'Z? M_"@!X@C69IA&HF90C2;1N*@D@$^@)/YFI*@^UI_=E_[]/_A1]K3^[+_WZ?\ MPH GHJ#[6G]V7_OT_P#A1]K3^[+_ -^G_P * ,36O[0_X5Y?_P!DY_M7^RY/ MLF.OG>2=G_CV*\EA\+7":[_PEWA6QFE.F>&M)73U5"$U"T_THSVBL>"Q0Q,/ M1Q%G )S[7I5TBZ79@K)Q"G2)C_"/:I;7[)8PB&VMS;P@EA'%;LJ@DDDX [DD M_4T >&>"[?4_!>C:=-J.EWL-Q>^$])L+6Y?0[G4A:O%&WGVTUO#B1,E@>2H) M."#_$DDFO>']0TPW7A[2K:*'2=#NY[:-HI;S,8\I91'M5XOE9 M\C<*]H^UI_=E_P"_3_X4?:T_NR_]^G_PH \!U#4?$KZ)XYMM2.L74GV.9[&Z MO('MXDOQ< 6:(CQ!=YW,XC<2IYENS M;7'1AD<$>M2_:T_NR_\ ?I_\* )Z*@^UI_=E_P"_3_X4?:T_NR_]^G_PH GH MJ#[6G]V7_OT_^%'VM/[LO_?I_P#"@">BH/M:?W9?^_3_ .%'VM/[LO\ WZ?_ M H GHJ#[6G]V7_OT_\ A1]K3^[+_P!^G_PH GHJ#[6G]V7_ +]/_A1]K3^[ M+_WZ?_"@">BH/M:?W9?^_3_X4?:T_NR_]^G_ ,* )ZJ0_P#(4N?^N4?\WJ3[ M6G]V7_OT_P#A56*Z3^TKD[9/]7'_ ,LF]7]J )Y=,LY[V*\DM()+N$%8[AHU M,B ]0&QD?A3OL%K]E2V^S0_9DV[8=@V+M(*X'08(!'IBE^UI_=E_[]/_ (4? M:T_NR_\ ?I_\* &6^EV5I=3W,%I!#H5GRQ'3) M^F+?VM/[LO\ WZ?_ H^UI_=E_[]/_A0!7NM!TR^O8[RYTZTN+N/&RXE@5I$ MP*[@>&>))H9!M>.10RL/0@]13/M:?W9?^_3_X4?:T_NR_]^G_ M ,* &QZ;:16(LDM84LPNP6ZQ@1[?3;C&/:H-2\/:5K,B2:AIEG?2(-JMG\ZL_:T_NR_]^G_PH^UI M_=E_[]/_ (4 21QI#&D<:JD: *JJ, = !3Z@^UI_=E_[]/_ (4?:T_NR_\ M?I_\* (]6_Y!5[_UQ?\ ]!-6F4,I!&0>"#6?JMTC:7> +)S"_6)A_"?:K7VM M/[LO_?I_\* ((]#TV'3WL(]/M4L9,[[98%$;9ZY7@TNS7RP+2 "-45/W: M_*$.4 XX /(]*?\ :T_NR_\ ?I_\*/M:?W9?^_3_ .% $<.DV5M=274-G;Q7 M,A)>9(E#MG&@.Y.?E/J.3Q[FD^UI_=E_[ M]/\ X4?:T_NR_P#?I_\ "@"*WT>PLU M[&V@"@J!'"JX! 4C@>BJ/HH]*632 M+&:%X9+*W>%XUA:-HE*M&N=J$8Y49.!T&34GVM/[LO\ WZ?_ H^UI_=E_[] M/_A0 0V-M;X\JWBCVQB(;$ P@Z+]!D\4ECI]KI=N(+.VAM( 21'!&$7)ZG % M+]K3^[+_ -^G_P */M:?W9?^_3_X4 3T5!]K3^[+_P!^G_PH^UI_=E_[]/\ MX4 3T5!]K3^[+_WZ?_"C[6G]V7_OT_\ A0!/14'VM/[LO_?I_P#"C[6G]V7_ M +]/_A0!/14'VM/[LO\ WZ?_ H^UI_=E_[]/_A0!/535/\ CQ?_ 'E_]"%2 M?:T_NR_]^G_PJKJ=TC6;C;)]Y>L3?WA[4 8WQ#\#IXVT=85D6&]@)>"1NF3U M4^QP/R%>*R?#GQ;IK7-NFF3%)5V2&%E974,&'(/J ?PKZ-^UI_=E_P"_3_X4 M?:T_NR_]^G_PKU\+F=;"P]FDG'S/G\?DN'Q]3VTFXR[KKZGS:O@'Q8MNUNNE M70A9Q(4P,;@" >OH3^=3ZAX/\::HJ"[T^]G"$D;\=3U)YY)P.3SQ7T7]K3^[ M+_WZ?_"C[6G]V7_OT_\ A7;_ &Y5O?DC?YGF_P"K%"W+[65OE_D?.J>$O&L= MF+1;"]%N. G' SG'7IGG'3/-%QX1\:W4.D@(<$#G+[S_X]S7T5]K3^ M[+_WZ?\ PH^UI_=E_P"_3_X4O[:J;^SB5_JU1M;VT_O7^1\\CPSXY659/L5] MO4L0<#^( -D=P0HZ^E/B\/\ CR%G9+6_#.V\G@G) !QZ9 X[ "OH/[6G]V7 M_OT_^%'VM/[LO_?I_P#"I_MF?_/N/W#_ -7*2VK3^_\ X!\Z1_#7Q;K-X#-I MTJN0JF6X95 []@!TKT_P[X$NO#^F):1P[VSN=]RC'_CZ_P"-=3]K3^[+_P!^G_PH^UI_=E_[ M]/\ X4VTS4-7T6; M1M%U-;AK74&N4E7]S%)*_F*,,G[N&1@<$?+@XR,Z=E\3IO.TQM5\.7^BV&K- MLL+JXDB8LYC,BI*BL3$S*K8SD9&"0Q (!W5%>9>'?C!?^((-%(\+2V\^NZ:= M3TN-K^)A-&!&S*Y',9VRJ>A'!&0<9Z'X?^,M0\:V$U[_%2W^(6IZC;VD5FD5FTBGR]2BFG&V4HI>%?F MC#!2PW=L5W= !1110!4TG_D%67_7%/\ T$5;K"OM7?P_X)FU..TDOWLK W M M82 \NR/=M7/\1Q@>]87B;XM:;H*V3V\#ZI#U?1M+T_1VU>^U,3LB?:5@5%B52Q+,#_>%,M?B183?# MV]\736MU;VEC#=275JRJTT;6[.DR##;20T;@$'!X.<4 =;17G-U\4M7M?#^H MZF?"$[QV5K]O9TOX7@EM]KL3',N59UV8*?[2D$@TS5OC!-X>TN:YU7P_-;SI MHM[KBV\-TDI>*W\GY=V S>>,>FT^M 'I-%<(WQBT-+&QU!A,FGW&D7>KO*R M?/"MN\*20M'U\P--MV]0R$=:T_#_ (LU34]46SU/POJ&B":!KB">22.:/ *@ MQR-&Q$@"W17"W/Q.D_P"$HU+2;#0;O4X],N8;2]FMYH_, MC>5$97$.=[1@2IN? _BP&VFLNX^+VJ:;:^*[K4/"C6UMX;@>:\=-0CD)(MQ, MJJ-HSD%1GL30!Z=17"6OQ7UJ'2/C%9ZI;^"RVDW\%QXF.%C,>Z.T_=ROB24?+G]TP"@Y/7&!F@#T&BJ M6JZQ::+#!+>2&))KB*U0A2V9)'"(./5F S2:QKFG>'K%KW5=0M=,LU(5KB\F M6*,$G !9B!R: +U%8%U\0?"UC]C%SXETBW-ZB2VOFW\2^>CDA&3+?,&(.".N M*F7QGX?;73H@UW33K(.TZ<+R/[1G;NQY>=WW>>G3F@#9HKF6^)W@Y;.6[/BS M0Q:12B"20:G9F-)EMV;[0F%E8*5C)S MPQ#J0.I##U% &C16!#\0?"UQI5QJ<7B72)--MW$4UXE_$88G.,*S[L G(X)[ MBJ^@_$31M;\,7/B![VULM(ANKBV-[/BL&[\ M?>&+#3[*_N?$>DV]C?9^RW4U]$L5QCKY;%L-^&:E3QIX?DU2/34UW36U&6(3 MQV:WD9F>,KN#A,Y*[>1@@X(..,$$I_P +&TV;68K*SEMKR":W MM;J*^6[C$$J3SM$H1LX8Y3( ^]D ?[)=1R&V,+Q(4D522K$R]_[AK,;XC:E;>,I=#O- CL[>)(IGU";4HP@BEF: M*-L$?>++]W.%Y+.]O%\2:0UI8R"&ZN!?1&.W MK6F\I]HL;A)H]PZKN4D9&>E &A1110 4444 %%%% !1110 54U3_ (\7_P!Y M?_0A5NJFJ?\ 'B_^\O\ Z$* +=%<%\6O'$_A/2H(+%ME]>%@LF,^6@QDCWY M'XUXA:6MUXDDO+BZU%4%O&)I;B\:1^"RJ/NJQ)RP[5[F$RN6)I>VE+ECTTN? M,9AGD,'6^KTX<\NNMDNN^O34^K**^3=0T*ZT^8IM%S'Y:S+-;AF1D(R&Y (& M/4 U2EMY8 AEB>,.-R[E(R/45Z$1+BF4&U+#[?WO_M3Z_HKY M"BLYIE5UC;RV<)YFT[21F00JC;@1CVP>O8D\;B"0^5_K,(?D^OI3_L%?\ /W\/^"+_ %JE_P! _P#Y-_\ :GU[17R; M,+WPWJ 2.Y,4RHDFZ%CC#*&'Z$9KU7P?X@;Q!I"S2 "XC;RY,="1W_$&O-QF M5RPL%5C+FBSV\MSNGCZKH2AR372]]ON/7:*\_HKR.0^D/0**\_HHY /0**\_ MHHY /0**\_HHY /0**\_HHY /0**\_HHY /0**\_HHY /0**\_ITYO[FRN+&YU"-3YA28,)-A;.S(;!QUP*LKX'\2ZQ)I%MX@U MBPN=.TF5;B-K.U>.:\E5&2-I MNM)AT^SN(='32]9-K;B(7[HJ;)^!]\.KY)Y(D.V;!R=FZ09']X>E M>HZ3_P @JR_ZXI_Z"*MT >=:I\.[_P <:UH5[XKCTR6'3#<_Z-9-+MD$B(%. M3@@@J?S%;%]\.;%;0V_BHM_8NCR:SI!FN8R>.1;QDJ>-R[NK-6EHG@36SXWM?$>M M7FF_:+:"2!_[,AF0WA8*H=P\A5 O"@-R?O>OH-% !1110 4444 %%%% !11 M10 4444 %5(?^0I<_P#7*/\ F]6ZJ0_\A2Y_ZY1_S>@#SSQE\+-2\5Z\T\ES MI+P_:8Y[74IK'_B9Z:J[2T=O*I'!*MACR-Y!#CBM#Q)\.+G7-&^(EE'>11-X MHA,4+,I(@/V58,MZ\KGCL:[ZB@#R_4_@_<:AXFGU1=1CACNM8%W629;/R M;0-;GGJTME$2>FTL.]:FE?#FYT_0/!&GM>1._A^]^U2N%.)1Y,\>%]#F8'GT M-=Y10!R_C;X9^&_B$ME_;NDV>H26<\KZ)I5CH4MOID=A<(XMUWP(T*Q/&(T>+#PXW*04P<+MX#&NOHH \)L?A'X MFTUKC0K>?39+6?PY_9-QJ5W;22*?,N;EF*9UM="7Q%:ZG'-)"QO)A;P6NTJV[!#/%M+$9 #C!SD>O44 >9Z=\,]6\. M:9X3;2KO3Y-1T33[C3WCO(7-O*LQB9I!M.58-$/J&8'&:\NH9%BBN(MKM-,[+D74C*%X0@?>R:U+?X;:U:_#_\ L>/4;&/4 MFU:?4Y'MXGAA<273SF-""7B^_C>IW CCK7I=% 'S_J?P\\2>!=%6#3;<>(=0 MO;/5+*5OL[W$(%SZ7>VSS:BDML)8[U MU>YNR5G6W6/8(A*(2 RY$A3.WY<'[U>TT4 >2W'P;U"/2=$@L[ZS2YTK3-+L MT\R-A&\EG=1SY..0K>65]1NS7K-+10!4U;_D%7O_ %Q?_P!!-5O$VFWFKZ'= MVEA>KIUY(H\NXD@69 00=KH?O(P!5AD'#'!!P19U;_D%7O\ UQ?_ -!-6Z / M(-/^#.I:;J2ZS9OH>DWD%Y#>0Z/IUH\>G,Z1W$;NZYSYCBY)+JHP8H\AL&GV M?P5OH;T73K#$R(LB:C)>2+&,G"_O-HR0EB 0(.0.K$G/.!H>,OAY>>)- M4U.^M;V"VEGLK.& 31LZK+;W37 + $95B54X.>M=W10!Y;IOPKU9_$U]K>K7 MNGRW%W)>2F*VB<)'YUK:0*!N))VBV;)XSNZ#I5>'X-ZCIM_H6HV-_9"ZT;3] M,MH;>:%O)EDMH[R)]V#D K>94C)5D!P>E>M44 >7:+\'9[)=?>\N[&YGUC3; MBTE4VS&&.2>XN)I $W F+,X&-P+;2203QT7PX\):GX3L]034K\7C7-P)8HA+ M+/Y"B-$V^=,QDDR5)RY.,@#@5U]% !1110 4444 %%%% !1110 54U3_ (\7 M_P!Y?_0A5NJFJ?\ 'B_^\O\ Z$* /,OCQH-Q=V=AJD*-)%;;HYL<[0V"&^F< MC\17E>@ZX-%M]3 17EN8%BC\R))4!$B,=RMD8PI['G'UKZJDC61&1U#HPP58 M9!'H:Y6Y^%7A6ZF:5](C#,MSXS,LCK8C M$O%8::3>][]K:6OT/"8_%T[:?-'.\DL\EU#*RKA(VB167RR!C Y' &,5=\0> M,H-1:-H8S=?OWG,=Y;J%7<,8X8EC[\=!Q7LG_"H?"7_0)_\ )F;_ .+H_P"% M0^$O^@3_ .3,W_Q==O\ :N"YE+DE]R_S/-_L+,^1P]I'7S?>_8\4E\2VUQ:0 M$R7EO)'"(39VX5;<@^UV_G^<&N(U4R)O,)R!N&23&P/(X; MK1I?B[3;%G,LFHSMO)WS 2&13&J9(\P!3P>S<8&>,GUS_A4/A+_H$_\ DS-_ M\71_PJ'PE_T"?_)F;_XNI_M+!JGKMQ@'\>?TKT&U^%OA M:RF$L6DIO7D;Y9''Y,QK;_L"P_YX?^/M_C7+CLTIUZ2H4HM+S\CT!S(^O./HKL/ M[ L/^>'_ (^W^-']@6'_ #P_\?;_ !HYD!Q]%=A_8%A_SP_\?;_&C^P+#_GA M_P"/M_C1S(#CZ*[#^P+#_GA_X^W^-']@6'_/#_Q]O\:.9 '_C[?XT'_C[?XT?V!8?\\/_ !]O\:.9 M '_C[?XTJ: M'8QL"+<9]V)_F:.9 4/"]JZ)+.PPKX5??U-;U( % & *6LV[L HHHI %%%% M !1110 5DW6ASW%Q)(NM:A K'(CB,6U?89C)_6M:B@#$_P"$=N?^@_JGYP__ M !JC_A';G_H/ZI^U0KQQF'US_SSK>HH Q/^$=N? M^@_JGYP__&J/^$=N?^@_JGYP_P#QJMNB@#$_X1VY_P"@_JGYP_\ QJC_ (1V MY_Z#^J?G#_\ &JVZ* ,3_A';G_H/ZI^G)JC-X@TNW8K+J5I$WH\Z@_J:X6R\%Z]XID\_Q%J$T$&>+6-A MD_@/E7]370IX+LM-58=,TZS23O=WJ>=M^BYR3^*@>_2NATZ4'9RN_+;[SBC7 MKU5S1IV7GO\ =_FSZ2UPESJ"R:O,#&I_V8E C!YZA<^I-2MX!T%=Y@TJ MS@+G+*MNC(Q]T(Q^6#[TDJ">K?\ 7]=C5O$VT2_'^OQ&Z7\2?".MRK'IWBG1 M;^1N EKJ$,A/X*QKHZ\N\6?LV_#SQM;R)J/A:QL[EAQ>:4GV63/][Y, GV8, M/K7B^J_ OXN_!34HKCX8>);KQ!HK.%_LF]F3,8]&20B-A_M+M;V&,UWTL+A, M1[M.MRR[25E_X$OU1PU<7B\-[U2CSQ[P=W_X"U^39]&"=O^Z2?J:ZFO)G!TY.+=[=G=?>CUJY+;6/T !R2*L6-P]W8V\\D+6\D ML:NT,GWHR0"5/N.E1:GI5MK$"0W2,Z(ZR+M=D(8=""I!XJS%&(8TC7=M4!1N M8L>/4GD_C0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ M KF/[0U_5-6U>WT^33;6WT^X6$-GJ /MO%-_KS6]IIT$%G>E M)'NWN@TL=L4D:(J I4R$NC@'*\+GN!46H^+M2T6QO8;BT@N]6M9K-56 E(KB M.XG$2N 22ASO&"6QMSD@U>;P>MG'9MI=Y)87ELCI]H91+YP=MS^:I^\2WS9! M!R3@X)!5?!Z26\QNKV:ZO9[FWN);IE4$^3*LB1JH&%0%3QU^9CDDYH S+]O$ MW_"5:/!%J&GQ-)876^G/8VT M=BZPRSW4#R>?+L5V"*'7:H# ;B6YSQQDWM:T.74+JUO+2\:POK99(TE\L2*4 M?:65E/491#P0Z*M, !@3M/&"-O!'.:^A^%[S5+359]:FN$GOIHI(6PD'_$FKWNK16UQ:M=V?F&, M''&#D==6=I-GJ%H)/M^HK?DX";;<1;0,]<$Y)_ <=!6C0 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 ,0 4444 %%%% '__9 end GRAPHIC 11 imm60.jpg GRAPHIC begin 644 imm60.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
3 Months Ended
Jun. 30, 2023
Cover [Abstract]  
Document Type 6-K
Amendment Flag false
Document Period End Date Jun. 30, 2023
Document Fiscal Period Focus Q1
Document Fiscal Year Focus 2024
Current Fiscal Year End Date --03-31
Entity File Number 001-40086
Entity Registrant Name Portage Biotech Inc.
Entity Central Index Key 0001095435
Entity Address, Address Line One Clarence Thomas Building
Entity Address, Address Line Two P.O. Box 4649
Entity Address, Address Line Three Road Town
Entity Address, City or Town Tortola
Entity Address, Postal Zip Code VG1110

XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Interim Statements of Financial Position (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Mar. 31, 2023
Current assets    
Cash and cash equivalents $ 7,698 $ 10,545
Prepaid expenses and other receivables 2,752 2,689
Convertible note receivable 442 442
Total current assets 10,892 13,676
Non-current assets    
Investment in associate 756 806
Investment in public company 3,855 2,087
In-process research and development 81,683 81,683
Deferred commitment fee 839 839
Right to use asset 293
Other assets, including equipment, net 51 38
Total non-current assets 87,477 85,453
Total assets 98,369 99,129
Current liabilities    
Accounts payable and accrued liabilities 2,591 1,865
Lease liability - current, including interest 47
Total current liabilities 2,638 1,865
Non-current liabilities    
Lease liability - non-current 249
Deferred tax liability 10,416 10,564
Deferred purchase price payable - Tarus 7,864 7,179
Deferred obligation - iOx milestone 4,552 4,126
Total non-current liabilities 23,081 21,869
Total liabilities 25,719 23,734
Shareholders’ Equity    
Capital stock 219,425 218,782
Stock option reserve 21,973 21,204
Accumulated other comprehensive loss (2,556) (4,325)
Accumulated deficit (165,535) (159,616)
Total equity attributable to owners of the Company 73,307 76,045
Non-controlling interest (657) (650)
Total equity 72,650 75,395
Total liabilities and equity 98,369 99,129
Commitments and Contingent Liabilities (Note 15)
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Expenses    
Research and development $ 3,627 $ 1,876
General and administrative expenses 1,370 2,211
Loss from operations (4,997) (4,087)
Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone (1,111)
Share of loss in associate accounted for using equity method (50) (60)
Change in fair value of warrant liability 1
Foreign exchange transaction gain (loss) 18 (52)
Depreciation expense (11)
Interest income, net 80 21
Loss before (provision) benefit for income taxes (6,071) (4,177)
Income tax benefit 145 2,552
Net loss (5,926) (1,625)
Other comprehensive income (loss)    
Net unrealized gain on investments 1,769
Total comprehensive loss for period (4,157) (1,625)
Net (loss) income attributable to:    
Owners of the Company (5,919) (1,729)
Non-controlling interest (7) 104
Comprehensive (loss) income attributable to:    
Owners of the Company (4,150) (1,729)
Non-controlling interest $ (7) $ 104
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) (Parenthetical) - $ / shares
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Profit or loss [abstract]    
Basic earnings (loss) per share $ (0.33) $ (0.13)
Diluted earnings (loss) per share $ (0.33) $ (0.13)
Weighted average shares outstanding, basic 17,701 13,351
Weighted average shares outstanding, diluted 17,701 13,351
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Issued capital [member]
Stock Option Reserve [Member]
Accumulated other comprehensive income [member]
Retained earnings [member]
Equity attributable to owners of parent [member]
Non-controlling interests [member]
Total
Beginning balance, value at Mar. 31, 2022 $ 158,324 $ 16,928 $ 958 $ (55,005) $ 121,205 $ 44,229 $ 165,434
Beginning balance, shares at Mar. 31, 2022 13,349            
IfrsStatementLineItems [Line Items]              
Share-based compensation expense 1,176 1,176 1,176
Shares issued or accrued for services $ 30 30 30
Shares issued or accrued for services, shares 4            
Net (loss) income for period (1,729) (1,729) 104 (1,625)
Ending balance, value at Jun. 30, 2022 $ 158,354 18,104 958 (56,734) 120,682 44,333 165,015
Ending balance, shares at Jun. 30, 2022 13,353            
Beginning balance, value at Mar. 31, 2023 $ 218,782 21,204 (4,325) (159,616) 76,045 (650) 75,395
Beginning balance, shares at Mar. 31, 2023 17,606            
IfrsStatementLineItems [Line Items]              
Share-based compensation expense 769 769 769
Shares issued under ATM $ 632 632 632
Shares issued under ATM, shares 171            
Share issuance costs $ (19) (19) (19)
Shares issued or accrued for services $ 30 30 30
Shares issued or accrued for services, shares 9            
Net unrealized gain on investments 1,769 1,769 1,769
Net (loss) income for period (5,919) (5,919) (7) (5,926)
Ending balance, value at Jun. 30, 2023 $ 219,425 $ 21,973 $ (2,556) $ (165,535) $ 73,307 $ (657) $ 72,650
Ending balance, shares at Jun. 30, 2023 17,786            
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Interim Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Cash flows from operating activities:    
Net loss for the period $ (5,926) $ (1,625)
Adjustments for non-cash items:    
Share-based compensation expense 769 1,176
Change in fair value of deferred purchase price payable – Tarus and deferred obligation – iOx milestone 1,111
Decrease in deferred tax liability (148) (2,552)
Share of loss in associate 50 60
Fair value of shares issued for services 30 30
Depreciation 11
Change in fair value of warrant liability (1)
Changes in operating working capital:    
Accounts receivable (17) (44)
Prepaid expenses and other receivables (50) (408)
Other assets (10)
Accounts payable and accrued liabilities 726 1,188
Other 1
Net cash used in operating activities (3,453) (2,176)
Cash flows from financing activities:    
Proceeds from shares issued under ATM and Committed Purchase Agreement 632
Share issuance costs (19)
Repayment of lease liability (7)
Net cash provided by financing activities 606
Decrease in cash and cash equivalents during period (2,847) (2,176)
Cash and cash equivalents at beginning of period 10,545 23,352
Cash and cash equivalents at end of period 7,698 21,176
Supplemental disclosure of cash flow information:    
Net unrealized gain on investment in Intensity 1,769
Cash paid for interest 3
Supplemental disclosure of non-cash investing and financing activities:    
Right to use asset acquired 303
Lease liability incurred $ 303
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.2
NATURE OF OPERATIONS
3 Months Ended
Jun. 30, 2023
Nature Of Operations  
NATURE OF OPERATIONS

NOTE 1. NATURE OF OPERATIONS

 

Portage Biotech Inc. (the “Company” or “Portage”) is incorporated in the British Virgin Islands (“BVI”) with its registered office located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, BVI. Its USA agent, Portage Development Services Inc. (“PDS”), is located at 61 Wilton Road, Westport, CT, 06880, USA.

 

The Company is a foreign private issuer under the Securities and Exchange Commission (the “SEC”) rules. It is also a reporting issuer under the securities legislation of the provinces of Ontario and British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (“CSE”) under the symbol “PBT.U”. On February 25, 2021, the ordinary shares of the Company began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “PRTG”. As the principal market for the Company’s ordinary shares is Nasdaq, the Company voluntarily delisted from the CSE on April 23, 2021.

 

Portage is a clinical-stage immuno-oncology company advancing therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with invasive cancers. Portage’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enable the identification of clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage’s portfolio consists of four diverse platforms, with lead programs consisting of invariant natural killer T-cell (“iNKT”) engagers and a suite of treatments targeting the adenosine pathway. Additional programs leverage delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these four platforms, Portage has 9 product candidates currently in development with multiple clinical readouts expected through the end of calendar year 2024.

 

On August 13, 2018, the Company reached a definitive agreement to acquire 100% of SalvaRx Limited (“SalvaRx”) in exchange for 8,050,701 ordinary shares of the Company (the “SalvaRx Acquisition”). The SalvaRx Acquisition was completed on January 8, 2019 (the “Acquisition Date”) upon receiving shareholder and regulatory approval. In connection with the SalvaRx Acquisition, the Company acquired interests in SalvaRx’s five research and development invested entities and subsidiaries: iOx Therapeutics Ltd. (“iOx”) (60.49% interest), Nekonal Oncology Limited (“Nekonal”), Intensity Therapeutics, Inc. (“Intensity”), Saugatuck Therapeutics, Ltd. (“Saugatuck”) and Rift Biotherapeutics Inc.  The Company also acquired an option in Nekonal SARL, a Luxembourg-based company holding intellectual property rights for therapeutics and diagnostics in the field of autoimmune disorders and oncology, to participate in the funding of its autoimmune programs.

 

In September 2021, the Company, through SalvaRx, exchanged certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing 60.49% of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%. On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx,” for a further discussion.

 

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.2
GOING CONCERN
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
GOING CONCERN

NOTE 2. GOING CONCERN

 

As of June 30, 2023, the Company had cash and cash equivalents of approximately $7.7 million and total current liabilities of approximately $2.6 million. For the three months ended June 30, 2023, the Company is reporting a net loss of approximately $5.9 million and cash used in operating activities of approximately $3.5 million. As of July 31, 2023, the Company had approximately $6.4 million of cash and cash equivalents on hand.

 

The Company’s cash and cash equivalents balance is decreasing, and the Company will not generate positive cash flows from operations for the fiscal year ending March 31, 2024.

 

The Company may have to delay, scale-back, or eliminate certain of its activities and other aspects of its operations until such time as the Company is successful in securing additional funding. The Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources. The future success of the Company is dependent upon its ability to obtain additional funding. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. As of the date of this filing, the Company currently anticipates that current cash and cash equivalents, excluding any potential proceeds from its ATM program and Committed Purchase Agreement with Lincoln Park, access to which are generally limited based on the Company’s Nasdaq trading volume, will be sufficient to meet its anticipated cash requirements through the end of October 2023. These factors raise significant doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued.

 

The Company has incurred significant operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result primarily from its conduct of research and development activities.

 

The Company historically has funded its operations principally from proceeds from issuances of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan, beyond the potential proceeds that could be reasonably generated from its ATM program and Committed Purchase Agreement with Lincoln Park given the Company’s current trading volume on Nasdaq. The Company's ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, future equity issuances would result in dilution to existing stockholders and any future debt securities may contain covenants that limit the Company's operations or ability to enter into certain transactions.

 

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.2
BASIS OF PRESENTATION
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
BASIS OF PRESENTATION

NOTE 3. BASIS OF PRESENTATION

 

Statement of Compliance and Basis of Presentation

 

These condensed consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”), IAS 34 Interim Financial Reporting and interpretations of the International Financial Reporting Interpretations Committee. These condensed consolidated interim financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the audited consolidated financial statements of the Company for the year ended March 31, 2023.

 

These condensed consolidated interim financial statements have been prepared on an historical cost basis except for items disclosed herein at fair value (see Note 17, “Financial Instruments and Risk Management”). In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.

 

The Company has only one reportable operating segment.

 

These condensed consolidated interim financial statements were approved and authorized for issuance by the Audit Committee and Board of Directors (the “Board”) on August 29, 2023.

 

Consolidation

 

The condensed consolidated interim financial statements include the accounts of the Company and:

 

(a)SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;

 

(b)iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company, through SalvaRx, exchanged certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing 60.49% of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%. On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx,” for a further discussion;

 

(c)Saugatuck, a 70% owned subsidiary incorporated in the British Virgin Islands. Saugatuck and subsidiary refers to Saugatuck and Saugatuck Rx LLC;

 

(d)PDS, a 100% owned subsidiary incorporated in Delaware, which provides human resources, and other services to each operating subsidiary via a shared services agreement;

 

(e)SalvaRx LLC, a wholly-owned subsidiary through SalvaRx;

 

(f)Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck; and

 

(g)Tarus Therapeutics, LLC (“Tarus”), a wholly-owned subsidiary of Portage.

 

All inter-company balances and transactions have been eliminated in consolidation.

 

Non-controlling interest in the equity of a subsidiary is accounted for and reported as a component of stockholders’ equity. As of June 30, 2023, non-controlling interest represents the 30% shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx” for a discussion of the Company’s purchase of the balance of the non-controlling interest in iOx.

 

Functional and Presentation Currency

 

The Company’s functional and presentation currency is the U.S. Dollar.

 

Use of Estimates and Judgments

 

The preparation of the condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

 

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

 

Significant areas where estimates are made include valuation of financial instruments (including the Stimunity Convertible Note (as defined below), deferred tax assets and liabilities, research and development costs, fair value used for acquisition of intangible assets, contingent consideration assumed and measurement of share-based compensation. Significant areas where critical judgments are applied include assessment of impairment of investments, goodwill and in-process research and development and the determination of the accounting acquirer and acquiree in the business combination accounting.

 

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.2
SIGNIFICANT ACCOUNTING POLICIES
3 Months Ended
Jun. 30, 2023
Significant Accounting Policies  
SIGNIFICANT ACCOUNTING POLICIES

NOTE 4.  SIGNIFICANT ACCOUNTING POLICIES

 

The accounting policies are set out in Note 4 to the Company’s audited consolidated financial statements for the fiscal year ended March 31, 2023 (“Fiscal 2023”). These policies have been applied consistently to all periods presented in these condensed consolidated interim financial statements.

 

Recent Accounting Pronouncements

 

IFRS Pronouncements Issued

 

Impact of Adoption of Significant New IFRS Standards in Fiscal 2023

 

(a)Annual Improvements to IFRS Standards 2018-2020

 

The annual improvements process addresses issues in the 2018-2020 reporting cycles including changes to IFRS 9, “Financial Instruments,” IFRS 1, “First Time Adoption of IFRS,” IFRS 16, “Leases,” and IAS 41, “Biological Assets”.

 

i)The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition of financial liabilities.

 

ii)The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent to also measure cumulative translation differences using the amounts reported by the parent based on the parent’s date of transition to IFRS.

 

iii)The amendment to IFRS 16’s illustrative example 13 removes the illustration of payments from the lessor related to leasehold improvements.

 

These amendments were effective for annual periods beginning on or after January 1, 2022. The adoption of these amendments did not have a material effect on the Company’s annual consolidated financial statements or the condensed consolidated interim financial statements for the three months ended June 30, 2023.

 

New Accounting Standards, Interpretations and Amendments

 

Standards issued but not yet effective up to the date of issuance of the Company’s condensed consolidated interim financial statements are listed below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they become effective.

 

(a)IAS 1: Presentation of Financial Statements

 

The amendment to IAS 1 clarifies how to classify debt and other liabilities as either current or non-current. The amendment will be effective for annual periods beginning on or after January 1, 2024. The Company is currently evaluating the new guidance and impacts on its consolidated financial statements.

 

(b)Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture

 

The amendment addresses the conflict between IFRS 10, “Consolidated Financial Statements,” and IAS 28, “Investments in Associates and Joint Ventures,” in dealing with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, “Business Combinations,” between an investor and its associate or joint venture, is recognized in full. Any gain or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognized only to the extent of unrelated investors' interests in the associate or joint venture. The IASB has deferred the effective date of these amendments indefinitely, but an entity that early adopts the amendments must apply them prospectively. The Company is evaluating whether the adoption of the above amendment will have a material impact on its financial statements. 

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.2
PREPAID EXPENSES AND OTHER RECEIVABLES
3 Months Ended
Jun. 30, 2023
Prepaid Expenses And Other Receivables  
PREPAID EXPENSES AND OTHER RECEIVABLES

NOTE 5. PREPAID EXPENSES AND OTHER RECEIVABLES

 

          
(In thousands)  As of
June 30, 2023
  As of
March 31, 2023
       
Prepaid clinical research costs  $1,783   $1,653 
Prepaid insurance   446    621 
Research & development tax credits   186    169 
Other prepaid expenses   151    56 
Tax deposits   115    119 
Other receivables   71    71 
Total prepaid expenses and other receivables  $2,752   $2,689 

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT IN ASSOCIATE
3 Months Ended
Jun. 30, 2023
Investment In Associate  
INVESTMENT IN ASSOCIATE

NOTE 6. INVESTMENT IN ASSOCIATE

 

Details of the Company’s associate, Stimunity S.A. (“Stimunity”), as of June 30, 2023 and March 31, 2023 are as follows:

 

            
Name  Principal Activity  Place of Incorporation and
Principal Place of Business
  Voting Rights Held as
of June 30, 2023
  Voting Rights Held as
of March 31, 2023
Associate: Stimunity S.A.  Biotechnology  Paris, France  44.0%  44.0%

 

The following table is a roll-forward of the Company’s investment in Stimunity as of and for the three months ended June 30, 2023 and 2022:

 

          
   As of and for the Three Months Ended June 30,
(In thousands)  2023  2022
       
Balance, beginning of period  $806   $1,673 
Share of loss   (50)   (60)
Balance, end of period  $756   $1,613 

 

The Company accounts for its investment in Stimunity under the equity method and, accordingly, records its share of Stimunity’s earnings or loss based on its ownership percentage. The Company recorded loss in equity in Stimunity of $50,000 and $60,000 for the three months ended June 30, 2023 and 2022, respectively.

 

Under the Shareholders’ Agreement entered into on June 1, 2020, Portage has (i) a preferential subscription right to maintain its equity interest in Stimunity in the event of a capital increase from the issuance of new securities by Stimunity, except for issuances of new securities for stock options, under a merger plan or for an acquisition, and (ii) the right to vote against any (a) issuances of additional securities that would call for Portage to waive its preferential subscription right, or (b) any dilutive issuance.

 

On July 13, 2022, the Company entered into a commitment with Stimunity to provide €600,000 under a convertible note (the “Stimunity Convertible Note”) with a maturity date of September 1, 2023 (the “Maturity Date”). The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible Note is automatically converted into Series A shares of Stimunity upon Stimunity completing a Series A round for at least €20 million. If such subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into Series A shares of Stimunity at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares (other than Common Shares or Series A shares) for at least €5 million (the “Minimum Raise”), the Company will have the right to convert the Stimunity Convertible Note and the historical Series A shares of Stimunity owned into the new category of shares. In the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the right to convert the Stimunity Convertible Note into Series A shares at €363.00 per share or the raise price less 15%, whichever is lower. The Stimunity Convertible Note was funded on September 12, 2022. See Note 15, “Commitments and Contingent Liabilities – Stimunity Convertible Note,” for a further discussion.

 

The Stimunity Convertible Note was initially recorded at $0.614 million to record the translated value of the Stimunity Convertible Note on September 12, 2022. The Company recognized an unrealized gain of $0.039 million through other comprehensive income (“OCI”) in Fiscal 2023 to reflect the change in translation rate for the Stimunity Convertible Note settleable in euros, increasing the carrying value of the Stimunity Convertible Note to $0.653 million.

 

As of March 31, 2023, the Company determined that there were indications of impairment of both the investment in associate and the Stimunity Convertible Note receivable, based upon the inability of Stimunity to obtain financing. The Company performed an IAS 36 fair value analysis evaluating the likelihood of various scenarios given the then-current market conditions, the increasing cost of capital and development delays associated with Stimunity’s lack of liquidity. The Company recorded provisions of impairment of $0.607 million and $0.211 million, with respect to the investment in associate and the Stimunity Convertible Note receivable, respectively, decreasing the carrying value of the investment in associate and the Stimunity Convertible Note to $0.806 million and $0.442 million, respectively, as of March 31, 2023.

 

During the three months ended June 30, 2023, the Company recorded a loss of $0.05 million to recognize its share of Stimunity’s results of operations and recorded a marginal gain through OCI to reflect the translation rate effect on the Stimunity Convertible Note settleable in euros. The Company determined that there were no significant changes in the market or Stimunity’s outlook from March 31, 2023 to June 30, 2023, and, accordingly, determined that the carrying value at June 30, 2023 was not further impaired.

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT IN PUBLIC COMPANY
3 Months Ended
Jun. 30, 2023
Investment In Public Company  
INVESTMENT IN PUBLIC COMPANY

NOTE 7. INVESTMENT IN PUBLIC COMPANY

 

The following is a discussion of the Company’s investment in Intensity Therapeutics, Inc. (“Intensity”) as of June 30, 2023 and March 31, 2023.

 

Intensity Therapeutics, Inc.

 

In connection with the SalvaRx Acquisition in fiscal 2019, the Company acquired a $4.5 million interest in Intensity, a private clinical stage biotechnology company, of 1.0 million shares, which represented a 7.5% equity interest in Intensity. The investment was recorded at fair value (which approximates cost) at the acquisition date. The investment in Intensity has been irrevocably designated as a financial asset recorded at fair value with gains and losses recorded through OCI. Upon Intensity’s IPO discussed below, effective June 30, 2023, the fair value of the asset is determined by quoted market price.

 

On July 11, 2019, the Company entered into an agreement with Fast Forward Innovations Limited (“Fast Forward”) to purchase Intensity Holdings Limited (“IHL”), a wholly-owned subsidiary of Fast Forward. The Company paid $1.3 million for IHL through the issuance of 129,806 ordinary shares of the Company. The sole asset of IHL consists of 288,458 shares of Intensity. This transaction increased the Company’s ownership of Intensity to 1,288,458 shares.

 

On October 28, 2021, Intensity filed a Form S-1 Registration Statement with the SEC to register shares for an initial public offering (“IPO”), which was declared effective by the SEC, but subsequently withdrawn prior to closing.

 

In October and November of 2022, Intensity filed amendments to its Form S-1 Registration Statement, which reflected a proposed offering price in the range of $4.00 - $5.00 per share, which is less than the Company’s carrying value, which was an external indication of impairment. Accordingly, the Company performed an IAS 36, “Impairment of Assets,” fair value analysis and determined a fair value of $3.363 million, which was $4.046 million less than the then carrying value at December 31, 2022. Intensity continued to seek a successful IPO during the fourth quarter of fiscal year ended March 31, 2023. At March 31, 2023, the Company undertook an IAS 36 fair value analysis based on the continued existence of external indications of impairment. The analysis included evaluating the likelihood of a successful IPO and the timing of such an event, as well as the then lack of marketability of the shares and the continued uncertainty surrounding an IPO, or any type of financing.

 

In April 2023, Intensity completed a 1:2 reverse stock split, which reduced the Company’s holdings to 644,229 shares. As the offering was priced at $4.00 to $5.00 per share, the Company determined the fair value of its interest to be $2.087 million. In total, the Company recorded an unrealized loss of $5.322 million with respect to Intensity for the fiscal year ended March 31, 2023, which was recognized through OCI, reducing the Company’s carrying value in Intensity to $2.087 million as of March 31, 2023.

 

On July 5, 2023, Intensity completed an IPO of its common stock selling 3,900,000 shares at a price of $5.00 per share generating net proceeds of approximately $16.2 million. In connection with the offering, Intensity’s common stock began trading on Nasdaq on June 30, 2023, under the ticker symbol “INTS.” The Intensity shares closed at a price of $5.96 on June 30, 2023. The Company received an additional 2,659 shares in connection with the offering pursuant to certain anti-dilution rights. Intensity sold its overallotment shares totaling 585,000 shares, which closed on July 7, 2023. At that date, the Company owned approximately 4.7% of the issued and outstanding shares of Intensity. The Company recorded unrealized gain of $1.768 million through OCI to reflect the difference between the market value of the Company’s ownership interest and its then carrying value, increasing the Company’s carrying value in Intensity to $3.855 million as of June 30, 2023. There was no unrealized gain or loss with respect to the Company’s investment in Intensity during the three months ended June 30, 2022.

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.2
LEASE
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
LEASE

NOTE 8. LEASE

 

The Company entered into a lease of office space, which commenced on May 1, 2023. The lease provides for an original term of two years with an option to renew the lease for an additional term of three years. The Company has included the extension option in the lease analysis under IFRS 16, based upon management’s intentions. The Company calculated the lease liability using its incremental borrowing rate of 13%. The Company provided a $0.013 million security deposit. The lease liability is payable as follows (in thousands):

 

     
Twelve Months Ended June 30,  Amount
2024  $79 
2025   81 
2026   83 
2027   84 
2028   71 
 Total   398 
Less: interest   (102)
Total lease liability   296 
Lease liability - current   47 
Lease liability - non-current  $249 

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.2
ACQUISITION OF TARUS
3 Months Ended
Jun. 30, 2023
Acquisition Of Tarus  
ACQUISITION OF TARUS

NOTE 9. ACQUISITION OF TARUS

 

On July 1, 2022, the Company, its wholly-owned subsidiary, Portage Merger Sub I, Inc., its wholly-owned subsidiary, Portage Merger Sub II, LLC and Tarus Therapeutics, Inc., a Delaware corporation advancing adenosine receptor antagonists for the treatment of solid tumors, entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). Under the structure of the Merger Agreement, Tarus Therapeutics, Inc. was ultimately merged into Portage Merger Sub II, LLC of the Company with the surviving entity renamed Tarus Therapeutics, LLC. The Tarus merger entitles the Company to the rights, know-how and/or ownership related to the assets developed by Tarus (the “Adenosine Compounds”), including:

 

1.All rights and obligations related to the License Agreement between Tarus and Impetis Biosciences Limited, dated October 29, 2019 (“Tarus License Agreement”), and the Call Option under the Tarus License Agreement, which was exercised on November 5, 2020;

 

2.All intellectual property and related documents owned or controlled by Tarus, including issued or pending patents, patent applications and trade secrets. Additionally, any draft submissions and/or correspondence with patent authorities;

 

3.All documents and supplies related to Adenosine Compounds (as defined in the Tarus License Agreement) including inventory, reagents, data, assays, reports, vendor agreements and other information related to the preclinical development;

 

4.All clinical supplies, manufacturing know-how, batch records, regulatory documents pertaining to the Adenosine Compounds, certain reservations for manufacturing campaigns and any related agreements;

 

5.All regulatory documents and correspondence pertaining to the Adenosine Compounds;

 

6.All Contract Research Organization (“CRO”) agreements and protocol related documents for Adenosine Compounds;

 

7.All current documents related to market research, forecasting, budgets and competitive intelligence; and

 

8.Rights to the use of Tarus Therapeutics’ name for regulatory purposes.

 

As consideration for Tarus, the Company issued to former Tarus shareholders an aggregate of 2,425,999 ordinary shares of Portage, calculated on the basis of $18 million divided by the 60-day volume weighted average price per share of ordinary shares of Portage. Such ordinary shares have not been registered with the SEC and were subject to lock-up agreements for terms ranging from six to twelve months, which expired on February 1, 2023 and July 1, 2023, respectively. Additionally, the ordinary shares that were subject to a twelve month lock-up period, are also subject to a three month dribble-out period, which commenced July 1, 2023. During the dribble out period, each holder may not sell more than 10% of the average trading volume of the Company’s ordinary shares for the rolling three month period prior to the date on which the holder executes a trade of the Company’s ordinary shares without its prior written consent (which the Company is permitted to withhold at its sole discretion). Additionally, milestone payments of up to $32 million in cash or Portage ordinary shares (at the discretion of the Company) would be triggered upon achievement of future development and sales milestones, as described below. As a result of the transaction:

 

·The Company also assumed $2 million in short-term debt held by Tarus and deferred license milestones obligations ($1 million plus interest). The short-term debt was repaid by the Company in July 2022.

 

·Upon enrolling the first patient in a Phase 2 clinical trial utilizing Tarus’s adenosine receptor antagonists, the Company will pay an additional one-time milestone payment of $15 million to the former Tarus shareholders. Payment will be in the form of cash or Portage ordinary shares (at the discretion of the Company). The remaining $17 million milestone is based on targeted commercial sales.

 

In connection with the acquisition of Tarus, the Company performed a fair value analysis of the assets acquired and liabilities assumed. The Company based the analysis on its clinical plan and timing of development events, and the probabilities of success determined primarily based upon empirical third party data and Company experience as well as the relevant cost of capital. In its fair value analysis, the Company used the Multi-Period Excess Earnings Method for PORT-6 and PORT-7 and the Replacement Cost Method for PORT-8 and PORT-9, determined based upon the maturity of the assets and the availability of sufficient data to measure fair value. The Company recorded the ordinary shares issued at $17.2 million, which represented the aggregate market value of the ordinary shares issued on July 1, 2022. The Company followed the guidance of IAS 3 and IAS 32 and recorded a deferred purchase price payable - Tarus of $8.538 million, which reflected the estimated acquisition date fair value of contractual milestone obligations incurred. The principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount rate used. The Company recorded the obligation as a non-current liability, in accordance with the provisions IAS 32 with respect to the classification of financial assets and financial liabilities.

 

The Company will determine the fair value of the shares issuable upon achievement of future development and sales milestones at each balance sheet date. Any change to the fair value will be recorded in the Company’s statements of operations and other comprehensive income (loss).

 

The following table summarizes the purchase price allocation to the fair value of assets acquired and liabilities assumed for Tarus:

 

     
Assets:  (In thousands)
Identifiable intangible assets  $28,200 
Goodwill   538 
Total assets  $28,738 
Consideration:     
Fair value of shares issued  $17,200 
Liabilities assumed   3,000 
Deferred purchase consideration at fair value   8,538 
Total liabilities  $28,738 

 

Pro forma Information

 

Summary unaudited pro forma condensed results of operations for the three months ended June 30, 2022, assuming the Tarus acquisition had occurred at the beginning of the earliest period presented, are as follows:

 

     
(In thousands) 

Three Months Ended

June 30, 2022

Loss from operations  $(3,788)
Loss before provision for income taxes  $(3,893)
Net loss  $(1,341)
Total comprehensive loss for period  $(1,341)
Loss per share  $(0.09)

 

These pro forma results are not necessarily indicative of what would have occurred if the acquisition had been in effect for the period presented, and they may not be indicative of results expected in the future.

 

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.2
IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY
3 Months Ended
Jun. 30, 2023
In-process Research And Development And Deferred Tax Liability  
IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY

NOTE 10. IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY

 

In-process research and development (“IPR&D”) consists of the following projects (in thousands):

 

             
      Value as of
Project #  Description  June 30, 2023  March 31, 2023
iOx:             
PORT 2 (IMM60)  Melanoma & Lung Cancers  $36,181   $36,181 
PORT 3 (IMM65)  Ovarian/Prostate Cancers   21,709    21,709 
       57,890    57,890 
              
Oncomer/Saugatuck  DNA Aptamers   178    178 
              
Tarus:             
PORT 6 & PORT 7  Adenosine Receptors   22,723    22,723 
PORT 8  Adenosine Receptors   420    420 
PORT 9  Adenosine Receptors   472    472 
       23,615    23,615 
              
In-process research and development     $81,683   $81,683 
              
Deferred tax liability     $13,510   $13,195 

 

At the end of each reporting period, the Company is required to assess whether there is any indication that an asset may be impaired. Pursuant to IAS 36, the Company evaluated the then-current capital markets, the increasing costs of capital, and the delays in the timing of asset development and concluded that provisions for impairment were required during the year ended March 31, 2023 with respect to the iOx IPR&D and the Tarus IPR&D. The Company recognized an impairment of $59.320 million with respect to the iOx assets, reducing the Company’s carrying value from $117.210 million to $57.890 million and an impairment of $4.585 million with respect to the Tarus assets, reducing the Company’s carrying value from $28.2 million to $23.615 million. The deferred tax liability in the U.K. was reduced as a result of the IPR&D impairment loss recognized by iOx for financial statement purposes.

 

Deferred tax liability represents iOx’s estimated tax on the difference between book and tax basis of the IPR&D, which is taxable in the U.K, and the effect of usable net operating loss carryforwards.

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
INCOME TAXES

NOTE 11. INCOME TAXES

 

The Company is a BVI business company. The BVI government does not, under existing legislation, impose any income or corporate tax on corporations.

 

PDS is a U.S. corporation and is subject to U.S. federal, state and local income taxes, as applicable.

 

iOx is subject to U.K. taxes.

 

The (expense) benefit from income taxes consists of the following for the three months ended June 30, 2023 and 2022 (U.S. Dollars in thousands):

 

          
   For the Three Months Ended June 30,
(In thousands)  2023  2022
       
Current:          
Federal  $(3)  $- 
State and local   -    - 
Foreign   -    - 
Total current   (3)   - 
           
Deferred:          
Federal   -    - 
State and local   -    - 
Foreign   148    2,552 
Total deferred   148    2,552 
Benefit from income taxes  $145   $2,552 

 

The following is a reconciliation of the U.S. taxes to the effective income tax rates for the three months ended June 30, 2023 and 2022 (U.S. Dollars in thousands):

 

      
   Three Months Ended June 30,
   2023  2022
(Loss) income on ordinary activities before tax  $(605)  $34 
Statutory U.S. income tax rate   21.0%   21.0%
Income tax benefit (expense) at statutory income tax rate   127    (7)
Share-based compensation expense recognized for financial statement purposes   (142)   - 
Other losses recognized   -    7 
Utilization of losses not previously benefitted   12    - 
Income tax (expense)  $(3)  $- 

 

As of June 30, 2023, the Company had $0.6 million of federal net operating losses, which carryforward indefinitely but are limited to 80% of taxable income when utilized and $0.4 million of items deducted for financial statements but not tax, excluding share-based compensation. As of each of June 30, 2023 and March 31, 2023, the Company had U.S. deferred tax assets of $0.2 million.

 

The following is a reconciliation of the U.K. taxes to the effective income tax rates for the three months ended June 30, 2023 and 2022 (U.S. Dollars in thousands):

 

      
   Three Months Ended June 30,
   2023  2022
Loss on ordinary activities before tax  $1,576   $1,743 
Statutory U.K. income tax rate   25.0%   19.0%
Loss at statutory income tax rate   394    331 
           
Change from increase in deferred income tax rate   -    105 
Recognition of deferred tax assets   -    - 
Foreign currency effect   (246)   2,116 
Income tax benefit  $148   $2,552 

 

Research and development credit receivables of $0.2 million were included in prepaid expenses and other receivables on the condensed consolidated interim statements of financial position as of each of June 30, 2023 and March 31, 2023. The receivable was collected in July 2023.

 

The following is a reconciliation of financial statement income (loss) to tax basis income (loss) (in thousands):

 

                                        
   Three Months Ended
   June 30, 2023  June 30, 2022
   United
States
  BVI  United
Kingdom
  Total  United
States
  BVI  Foreign  Total
                         
Pre-tax loss  $(609)  $(3,886)  $(1,576)  $(6,071)  $34   $(2,468)  $(1,743)  $(4,177)
Share-based compensation expense for financial statement purposes for which no benefit was taken   683    -    -    683    -    -    -    - 
Losses not subject to tax   -    3,886    -    3,886    -    2,468    -    2,468 
Utilization of losses not previously benefitted   (59)   -    -    (59)   (34)   -    -    (34)
Taxable income (loss)  $15   $-   $(1,576)  $(1,561)  $-   $-   $(1,743)  $(1,743)

 

As of June 30, 2023 and March 31, 2023, the Company’s deferred tax assets and liabilities in the U.K. consisted of the effects of temporary differences attributable to the following (U.S. Dollars in thousands):

 

          
   As of June 30,  As of March 31,
   2023  2023
Deferred tax assets:          
Net operating loss  $(4,594)  $(4,131)
Deferred tax asset (unrecognized)   1,500    1,500 
Deferred tax asset   (3,094)   (2,631)
           
Deferred tax liabilities:          
In-process research and development   13,510    13,195 
Deferred tax liability   13,510    13,195 
           
Net deferred tax liability  $10,416   $10,564 

 

iOx generated no research and development cash credits recorded for the three months ended June 30, 2023.

 

As of June 30, 2023 and March 31, 2023, iOx had a net deferred tax liability of approximately $10.4 million and approximately $10.6 million, respectively. On January 8, 2019, the Company originally recognized a $19.8 million deferred tax liability, reflecting the then prevailing U.K. tax rate of 17% on the difference between the book and income tax basis of IPR&D acquired as part of the SalvaRx Acquisition. In the fiscal 2022, the Company recorded a $7.0 million increase in deferred income taxes to reflect a future change in the U.K. income tax rate to 25% effective April 1, 2023 and recognized $0.7 million of current year losses and $0.8 million of prior year losses. The Company also recognized a $1.1 million decrease in deferred tax liability in fiscal 2022 to reflect the effect of the change in exchange rates on the liability settleable in British pound sterling. For the year ended March 31, 2023, the Company recognized an aggregate reduction in net deferred tax liability of $17.9 million, comprised of $11.3 million to recognized the deferred tax effect of loss on impairment recognized with respect to the iOx IPR&D, $0.7 million related to other current year losses, $3.8 million to reflect the change related to the future U.K. tax rates and $2.1 million to reflect the effect of the change in exchange rates on the liability settleable in British pound sterling. For the three months ended June 30, 2023, the Company recognized a net decrease in the deferred tax liability of $0.1 million comprised of $0.3 million to reflect the effect of the change in exchange rates on the liability in the period and recognized $0.4 million of current period losses.

 

There is no expiration date for accumulated tax losses in the U.K. entities.

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.2
CAPITAL STOCK
3 Months Ended
Jun. 30, 2023
Capital Stock  
CAPITAL STOCK

NOTE 12. CAPITAL STOCK

 

(a)Authorized ordinary shares: Unlimited number of Portage ordinary shares without par value.

 

(b)The following is a roll-forward of Portage ordinary shares for the years ended June 30, 2023 and 2022:

 

                    
   Three Months Ended June 30,
   2023  2022
   Ordinary
Shares
  Amount  Ordinary
Shares
  Amount
   In 000’  In 000’$  In 000’  In 000’$
Balance, beginning of period   17,606   $218,782    13,349   $158,324 
Shares issued under public offering and ATM, net of issue costs   171    613    -    - 
Shares issued or accrued for services   9    30    4    30 
Balance, end of period   17,786   $219,425    13,353   $158,354 

 

Portage filed a shelf registration statement with the SEC under which it may sell ordinary shares, debt securities, warrants and units in one or more offerings from time to time, which became effective on March 8, 2021 (“Registration Statement”). In connection with the Registration Statement, Portage has filed with the SEC:

 

·a base prospectus, which covers the offering, issuance and sale by Portage of up to $200,000,000 in the aggregate of the securities identified above from time to time in one or more offerings;

 

·a prospectus supplement, which covers the offer, issuance and sale by Portage in an “at-the-market” (“ATM”) offering of up to a maximum aggregate offering price of $50,000,000 of Portage’s ordinary shares that may be issued and sold from time to time under a Controlled Equity Offering Sales Agreement, dated February 24, 2021 (the “Sales Agreement”), with Cantor Fitzgerald & Co., the sales agent (“Cantor Fitzgerald”);

 

·a prospectus supplement dated June 24, 2021, for the offer, issuance and sale by Portage of 1,150,000 ordinary shares for gross proceeds of approximately $26.5 million in a firm commitment underwritten public offering with Cantor Fitzgerald; and

 

·a prospectus supplement dated August 19, 2022, for the resale of up to $30,000,000 in ordinary shares that Portage may sell from time to time to Lincoln Park Capital Fund, LLC (“Lincoln”) and an additional 94,508 shares that were issued to Lincoln.

 

The Sales Agreement permits the Company to sell in an ATM program up to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered, issued and sold by the Company under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Upon termination of the Sales Agreement, any portion of the $50,000,000 included in the Sales Agreement prospectus that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus.

 

During Fiscal 2022, the Company sold 90,888 ordinary shares under the ATM program, generating gross proceeds of approximately $2.6 million ($2.5 million, net of commissions).

 

The Company has issued 2,425,999 ordinary shares in connection with the acquisition of Tarus Therapeutics, Inc. and in connection with the Tarus Therapeutics, Inc.’s acquisition it may issue additional ordinary shares. See Note 9, “Acquisition of Tarus,” for a further discussion.

 

On July 18, 2022, the Company entered into the iOx Share Exchange Agreement under which it exchanged 1,070,000 ordinary shares of the Company for the remaining minority interest of 21.68% of iOx. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx,” for a further discussion.

 

On July 6, 2022, the Company entered into a Purchase Agreement (the “Committed Purchase Agreement”) with Lincoln, under which it may require Lincoln to purchase ordinary shares of the Company having an aggregate value of up to $30 million (the “Purchase Shares”) over a period of 36 months. Upon execution of the Committed Purchase Agreement, the Company issued to Lincoln 94,508 ordinary shares, representing a 3% commitment fee. Pursuant to the Committed Purchase Agreement, Lincoln will be obligated to purchase the Purchase Shares in three different scenarios that are based on various market criteria and share amounts. The Company has the right to terminate the Committed Purchase Agreement for any reason, effective upon one business day prior written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The requirement that Lincoln must make a purchase will be suspended based on various criteria such as there not being an effective registration statement for Lincoln to be able to resell the ordinary shares it is committed to purchase and market criteria such as the Company continuing to be Depository Trust Company eligible, among other things. The Committed Purchase Agreement does not impose any financial or business covenants on the Company, and there are no limitations on the use of proceeds. The Company may raise capital from other sources in its sole discretion; provided, however, that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like securities until the three-year anniversary of the date of the Committed Purchase Agreement, excluding, however, an ATM transaction with a registered broker-dealer, which includes any sales under the Sales Agreement with Cantor Fitzgerald.

 

As discussed in Note 2, “Going Concern,” the Company’s access to the ATM program and the Committed Purchase Agreement is generally limited based on the Company’s trading volume on Nasdaq. See Note 15, “Commitments and Contingent Liabilities – Committed Purchase Agreement,” for a further discussion.

 

In Fiscal 2023, the Company sold 166,145 ordinary shares under the ATM program, generating net proceeds of approximately $0.9 million. Separately, in Fiscal 2023, the Company sold 480,000 ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds totaling approximately $2.0 million. From April 1, 2023 through June 30, 2023, the Company sold 171,504 ordinary shares under the ATM program, generating net proceeds of approximately $0.6 million.

 

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK OPTION RESERVE
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
STOCK OPTION RESERVE

NOTE 13. STOCK OPTION RESERVE

 

(a)The following table provides the activity for the Company’s stock option reserve for the three months ended June 30, 2023 and 2022:

 

                    
   Three Months Ended June 30,
   2023  2022
(In thousands)  Non-Controlling Interest  Stock Option Reserve  Non-Controlling Interest  Stock Option Reserve
Balance, beginning of period  $-   $21,204   $11,659   $16,928 
Share-based compensation expense   -    769    -    1,176 
Balance, end of period  $-   $21,973   $11,659   $18,104 

 

Stock Options

 

On June 25, 2020, at the annual meeting of shareholders, the Company’s incentive stock option plan (the “2020 Stock Option Plan”) was approved, which authorized the Company’s directors to fix the option exercise price and to issue stock options under the plan as appropriate. The Company’s 2020 Stock Option Plan was a 10% rolling stock option plan under which the Company’s directors were authorized to grant up to a maximum of 10% of the issued and outstanding ordinary shares on the date of grant.

 

Effective January 13, 2021, the Company amended and restated its 2020 Stock Option Plan to permit the grant of additional types of equity compensation securities, including restricted stock units (“RSUs”) and dividend equivalent rights (the “2021 Equity Incentive Plan”). The aggregate number of equity securities, which may be issued under the 2021 Equity Incentive Plan has not been changed.  Pursuant to the 2021 Equity Incentive Plan, on January 13, 2021, the Company granted an aggregate of 868,000 stock options exercisable at a price of $17.75 per share, representing the closing price of the shares on the day immediately preceding the grant date, which expire on January 13, 2031 to various directors, officers and consultants of the Company. 350,000 options granted to members of the Board vest 1/3 on grant date, 1/3 on the first anniversary of the grant and 1/3 on the second anniversary of the grant. 518,000 options granted to consultants (one of whom is also a director of the Company) vest 1/3 on each of the first three anniversaries of the grant date.

 

Additionally, the Company granted 243,000 RSUs on January 13, 2021, with a fair value of $17.75 per share, which was the closing price on the day immediately preceding the grant date. The RSUs vested on the date of grant, but underlying shares cannot be sold until one of four of the following conditions are met: (1) a Change in Control (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)), (2) the participant’s Separation from Service (as defined in the Amended and Restated 2021 Equity Incentive Plan), (3) the participant’s death, or (4) the participant’s Disability (as defined in the Amended and Restated 2021 Equity Incentive Plan).  In accordance with IFRS 2, “Share-based Payment,” the Company recognized compensation expense of $4.3 million in the year ended March 31, 2021, in connection with the RSU grants.

 

Amended and Restated 2021 Equity Incentive Plan and Grants of Stock Options and Restricted Stock Units

 

On January 19, 2022, the Board unanimously approved the Amended and Restated 2021 Equity Incentive Plan (the “Amended and Restated 2021 Equity Incentive Plan”). The Amended and Restated 2021 Equity Incentive Plan provides for:

 

(1)An increase of aggregate number of ordinary shares available for awards to 2,001,812, which is equal to 15% of the issued and outstanding ordinary shares of the Company as of January 19, 2022 subject to discretionary annual increases (on a cumulative basis) as may be approved by the Board in future years by a number of ordinary shares not to exceed an additional 5% of the aggregate number of shares then outstanding;

 

(2)The authorization of incentive stock options under the Amended and Restated 2021 Equity Incentive Plan; and

 

(3)The provision of dividend equivalent rights to be issued when authorized.

 

Pursuant to the Amended and Restated 2021 Equity Incentive Plan, on January 19, 2022, the Company granted an aggregate of 302,000 stock options exercisable at a price of $10.22 per share, representing the average price of the Company’s ordinary shares on the grant date, which expire on January 19, 2032, to various directors, officers and consultants of the Company. A total of 13,800 of the 302,000 stock options were granted to two members of the Board and vest on the first anniversary of the grant date. The balance of 288,200 stock options was granted to employees (one of whom is also a director of the Company), and a consultant, and such stock options vest ratably on each of the first four annual anniversaries of the grant date.

 

Additionally, the Company granted 135,740 RSUs to employees (one of whom is also a director of the Company) on January 19, 2022, with a fair value of $10.22 per share, representing the average price of the shares on the grant date. The RSUs were fully vested and nonforfeitable as of the grant date and will expire on January 19, 2032.

 

On February 15, 2022, James Mellon, Linda Kozick and Mark Simon were appointed to the Board. Mr. Mellon owned approximately 23.9% of the Company’s outstanding shares at that date. Additionally, Mr. Mellon had previously served as a member of the Board from 2016 to August 14, 2020. On February 15, 2022, in connection with the appointments, each of these directors was granted 13,800 non-qualified stock options, which vest ratably monthly over a three-year period. The options have an exercise price of $8.59 per share, representing the average price of the shares on the grant date, and will expire, if unexercised, on February 15, 2032.

 

On June 8, 2022, the Company granted 50,000 options to purchase shares to an executive of the Company. The options have an exercise price of $11.00, the average price of the stock on that date, vest ratably on each of the first four anniversaries of the grant date and will expire, if unexercised, on June 8, 2032.

 

On July 27, 2022, the Company granted 15,900 options to purchase shares to a member of the Board. The options have an exercise price of $10.06, the average price of the stock on that date, vest ratably on each monthly anniversary of the grant date in the three year period following the grant date and will expire, if unexercised, on July 27, 2032.

 

On March 30, 2023, the Board unanimously approved to increase the maximum number of ordinary shares reserved for issuance under the Amended and Restated 2021 Equity Incentive Plan. The aggregate number of shares available for awards under the Amended and Restated 2021 Equity Incentive Plan was increased to 2,880,992, which represented a 5% increase (or 879,180 shares) based on ordinary shares outstanding on March 29, 2023, which is equal to 16% of the issued and outstanding ordinary shares in the capital of the Company as of this date.

 

On March 30, 2023, the Company granted an aggregate of 746,120 stock options exercisable at a price of $2.92 per share, representing the average price of the shares on the grant date, which expire on March 30, 2033, to various directors, officers and a consultant of the Company. 14,600 options to purchase ordinary shares, totaling 87,600, were granted to each non-executive member of the Board and vest on the first anniversary of the grant date. A total of 651,020 stock options were granted to employees (including Mr. Walters, who is Chairman of the Board of Directors), and a consultant, and such stock options vest ratably on each of the first four annual anniversaries of the grant date. The balance of 7,500 stock options were also granted to a consultant, which was fully vested as of the grant date.

 

(b)The changes in the number of options issued for the three months ended June 30, 2023 and 2022 were:

 

                    
   Three Months Ended June 30,
   2023  2022  2023  2022
   PBI Amended and Restated
2021 Equity Incentive Plan
  iOx Option Plan
(Subsidiary Plan)
Balance, beginning of period   1,963,420    1,151,400    -    1,275 
Granted   -    50,000    -    - 
Expired or forfeited   -    -    -    (1,275)
Balance, end of year   1,963,420    1,201,400    -    - 
Exercisable, end of period   764,438    410,600    -    - 

 

(c)The following is the weighted average exercise price and the remaining contractual life for outstanding options by plan as of June 30, 2023 and 2022:

 

                    
   As of June 30,
   2023  2022  2023  2022
   PBI Amended and Restated
2021 Equity Incentive Plan
  iOx Option Plan
(Subsidiary Plan)
Weighted average exercise price  $10.53    15.26   $-   $- 
Weighted average remaining contractual life (in years)   8.61    8.90    -    - 

 

The vested options can be exercised at any time in accordance with the applicable option agreement. The exercise price was greater than the market price for all options outstanding as of June 30, 2023 and March 31, 2023, except 7,500 vested options and 738,620 unvested options as of each date.

 

The Company recorded approximately $0.8 million and $1.2 million of share-based compensation expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the three months ended June 30, 2023 and 2022, respectively. The Company expects to record additional share-based compensation expense of approximately $3.4 million through March 2027 with respect to the Amended and Restated 2021 Equity Incentive Plan.

 

As of June 30, 2022, the Company’s iOx stock option plan was fully vested. The iOx stock option plan expired on May 5, 2022 and all outstanding stock option awards issued under the iOx stock option plan expired.

 

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.2
(LOSS) PER SHARE
3 Months Ended
Jun. 30, 2023
Profit or loss [abstract]  
(LOSS) PER SHARE

NOTE 14. (LOSS) PER SHARE

 

Basic earnings per share (“EPS”) is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period.

 

Diluted EPS is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.

 

The following table reflects the loss and share data used in the basic and diluted EPS calculations (U.S. Dollars in thousands, except per share amounts):

 

          
   Three Months Ended June 30,
Numerator (in 000’$)  2023  2022
       
Net loss attributable to owners of the Company  $(5,919)  $(1,729)
Denominator (in 000’)          
Weighted average number of shares – Basic and Diluted   17,701    13,351 
Basic and diluted (loss) per share  $(0.33)  $(0.13)

 

The inclusion of the Company’s stock options, RSUs and share purchase warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share for the three months ended June 30, 2023 and 2022. The following table reflects the Company's outstanding securities by year that would have an anti-dilutive effect on loss per share and, accordingly, were excluded from the calculation.

 

          
   As of June 30,
   2023  2022
Stock options   1,963,420    1,201,400 
Restricted stock units   378,740    378,740 

 

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENT LIABILITIES
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
COMMITMENTS AND CONTINGENT LIABILITIES

NOTE 15. COMMITMENTS AND CONTINGENT LIABILITIES

 

Effective March 15, 2022, iOx entered into a Master Services Agreement (the “MSA”) with Parexel International (IRE) Limited (“Parexel”) under which Parexel agreed to act as clinical service provider (CRO) pursuant to a work order (“Work Order”) effective June 1, 2022. Pursuant to such Work Order, Parexel will operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer (“NSCLC”). The MSA provides for a five-year term, and the Work Order provides for a term to be ended upon the completion of the services required. The budget provides for service fees and pass-through expenses and clinical sites totaling $11.5 million. During Fiscal 2023, the Company executed two change orders resulting in a $0.6 million increase in the overall estimated budgeted costs.

 

On March 1, 2023, the Company, through Tarus, entered into a clinical service agreement with Fortrea Inc. (formerly Labcorp Drug Development Inc.), a third-party CRO. The term of the agreement is through the earlier of August 14, 2025 or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services to be provided is approximately $12.1 million.

 

Stimunity Convertible Note

 

On July 13, 2022, the Company entered into a commitment with Stimunity to provide €600,000 under the Stimunity Convertible Note. The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible Note is automatically converted into Series A shares of Stimunity upon Stimunity completing a Series A round for at least €20 million. If such subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into Series A shares of Stimunity at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares (other than Common Shares or Series A shares of Stimunity) for at least €5 million (the “Minimum Raise”), the Company will have the right to convert the Stimunity Convertible Note and the historical Series A shares of Stimunity owned into the new category of shares. In the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the right to convert the Stimunity Convertible Note into Series A shares of Stimunity at €363.00 per share or the raise price less 15%, whichever is lower. The Stimunity Convertible Note was funded by the Company on September 12, 2022. In addition, the Company has not reflected the interest earned on the Stimunity Convertible Note in reporting its consolidated financial results. See Note 6, “Investment in Associate,” for a further discussion.

 

Committed Purchase Agreement

 

On July 6, 2022 (the “Signing Date”), the Company entered into the Committed Purchase Agreement with Lincoln, pursuant to which the Company may require Lincoln to purchase ordinary shares having an aggregate value of up to $30 million over a period of 36 months. Pursuant to the Committed Purchase Agreement, Lincoln will be obligated to purchase the Company’s ordinary shares in three different scenarios that are based on various market criteria and share amounts.

 

Upon execution of the Committed Purchase Agreement, the Company issued to Lincoln 94,508 ordinary shares, representing a 3% commitment fee valued at $0.9 million. The Company has the right to terminate the Committed Purchase Agreement for any reason, effective upon one business day prior written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The Company is accounting for the commitment fee as a deferred commitment fee on the consolidated statement of financial position as of June 30, 2023 and March 31, 2023 and will amortize it pro-rata against equity sold under the Committed Purchase Agreement. Any unamortized balance will be written-off to operations at the expiration of the commitment.

 

The Committed Purchase Agreement does not impose any financial or business covenants on the Company and there are no limitations on the use of proceeds received by the Company from Lincoln. The Company may raise capital from other sources in its sole discretion; provided, however, that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like securities until the three-year anniversary of the Signing Date, excluding, however, an at-the-market transaction with a registered broker-dealer.

 

In connection with the Committed Purchase Agreement, the Company and Lincoln entered into a Registration Rights Agreement, dated July 6, 2022 (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company agreed to file with the SEC the prospectus supplement to the Company’s shelf registration statement pursuant to Rule 424(b) for the purpose of registering for resale the ordinary shares to be issued to Lincoln under the Committed Purchase Agreement. The prospectus supplement was filed on August 19, 2022.

 

The Company is obligated under the Tarus Merger Agreement and the iOx Share Exchange Agreement to pay certain third party earnouts based on the achievement of certain milestones. See Note 9, “Acquisition of Tarus,” and Note 16, “Related Party Transactions – Share Exchange Agreement – iOx,” respectively, for further discussions.

 

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED PARTY TRANSACTIONS
3 Months Ended
Jun. 30, 2023
Related party transactions [abstract]  
RELATED PARTY TRANSACTIONS

NOTE 16. RELATED PARTY TRANSACTIONS

 

SalvaRx Acquisition

 

Two of the Company’s directors are also directors of SalvaRx Group plc, a company which owns approximately 4.1% of the Company’s issued and outstanding ordinary shares as of June 30, 2023.

 

Investments

 

The Company has entered into related party transactions and certain services agreements with its investees.  Key management personnel of the Company have also entered into related party transactions with investees. Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the activities of the Company, including directors and senior management of the Company.

 

The following subsidiaries and associates are considered related parties:

 

(a)Stimunity. The CEO of Portage is one of three members of the board of directors of Stimunity (see Note 6, “Investment in Associate,” and Note 15, “Commitments and Contingent Liabilities – Stimunity Convertible Note”).
(b)iOx. Upon execution of the iOx Share Exchange on July 18, 2022, the non-Portage director resigned from the iOx board leaving two Portage insiders as directors. The CEO of Portage is also the CEO of iOx, and the management team of Portage comprises the management team of iOx. See below for a discussion of the Company’s purchase of the non-controlling interest in iOx through its wholly-owned subsidiary SalvaRx.
(c)Saugatuck. One of the three directorships on the board of directors of Saugatuck is controlled by Portage. Additionally, the CEO of Portage is also the CEO of Saugatuck, and the management team of Portage comprises the management team of Saugatuck.
(d)Intensity. The CEO of Portage previously served as a part-time officer of Intensity until becoming a consultant in 2023. Additionally, Intensity provided services (primarily rent) to Portage through April 2023.
(e)Portage Development Services Inc. PDS provides human resources and other services to each operating subsidiary of Portage through a shared services agreement.

 

The following are related party balances and transactions other than those disclosed elsewhere in the condensed consolidated interim financial statements:

 

Transactions between the parent company and its subsidiaries, which are related parties, have been eliminated in consolidation and are not disclosed in this note.

 

On September 8, 2021, the Company, through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price of £162. Simultaneously, the Company entered into an agreement with OSI, the holder of $0.15 million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for 820 shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets of IAS 39, “Financial Instruments: Recognition and Measurement,” and IFRIC 19, “Extinguishing Financial Liabilities with Equity Instruments,” and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%.

 

Share Exchange Agreement – iOx

 

On July 18, 2022, the Company and SalvaRx entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with each of the minority shareholders of iOx (the “Sellers”) resulting in the acquisition of the outstanding non-controlling ownership interest (approximately 22%) of iOx, which is developing the iNKT engager platform. The Company followed IFRS 3, “Business Combinations,” and IAS 27, “Separate Financial Statements,” (which substantially replaced IAS 3) to account for this transaction. The Company achieved control of iOx, as defined, on January 8, 2019 upon the completion of the SalvaRx Acquisition. Further transactions whereby the parent entity acquires further equity interests from non-controlling interests, or disposes of equity interests but without losing control, are accounted for as equity transactions (i.e., transactions with owners in their capacity as owners). As such:

 

·the carrying amounts of the controlling and non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiary;
·any difference between the amount by which the non-controlling interests is adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the parent; and
·there is no consequential adjustment to the carrying amount of goodwill, and no gain or loss is recognized in profit or loss.

 

The Company now owns the worldwide rights to its small molecule iNKT engagers, including lead programs PORT-2 and PORT-3. Under the terms of the Share Exchange Agreement, each Seller sold to the Company, and the Company acquired from each Seller, legal and beneficial ownership of the number of iOx shares held by each Seller, free and clear of any share encumbrances, in exchange for the issuance in an aggregate of 1,070,000 Portage ordinary shares to be allocated among the Sellers based upon their relative ownership. As a result of the Share Exchange Agreement, the Company owns 100% of the issued and outstanding shares of iOx through its wholly-owned subsidiary, SalvaRx.

 

As additional consideration for the sale of the iOx shares to the Company under the Share Exchange Agreement, the Sellers shall have the contingent right to receive additional shares (“Earnout Shares”) from the Company having an aggregate value equal to $25 million calculated at the Per Share Earnout Price, as defined in the Share Exchange Agreement, upon the achievement of certain milestones defined as the dosing of the first patient in a Phase 3 clinical trial for either PORT-2 (IMM60 iNKT cell activator/engager) or PORT-3 (PLGA-nanoparticle formulation of IMM60 combined with a NY-ESO-1 peptide vaccine). The Company shall have the option, in its sole and absolute discretion, to settle the Earnout Shares in cash. The Company followed IFRS 3 and IAS 32, “Financial Instruments: Presentation,” to account for the fair value of the Earnout Shares. The principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount rate used. The fundamental principle of IAS 32 is that a financial instrument should be classified as either a financial liability or an equity instrument according to the substance of the contract, not its legal form, and the definitions of financial liability and equity instrument. A financial instrument is an equity instrument if, and only if, both conditions (a) and (b) below are met:

 

(a)the instrument includes no contractual obligation to deliver cash or another financial asset to another entity, and
(b)if the instrument will or may be settled in the Company’s own equity instruments, it is either:
(i)a non-derivative that includes no contractual obligation for the Company to deliver a variable number of its own equity instruments; or
(ii)a derivative that will be settled only by the issuer exchanging a fixed amount of cash or another financial asset for a fixed number of its own equity instruments.

 

When a derivative financial instrument gives one party a choice over how it is settled (for instance, the Company or the holder can choose settlement net in cash or by exchanging shares for cash), it is a financial asset or a financial liability unless all of the settlement alternatives would result in it being an equity instrument. The financial instrument includes the exclusive right of the Company to settle the obligation with cash or equity and, accordingly, accounted for the fair value of the Earnout Shares as a non-current liability.

 

The Company recorded $5.478 million as the fair value estimate of the Earnout Shares, which is reflected as deferred obligation - iOx milestone on the condensed consolidated interim statements of financial position included herein. The Company will determine the fair value of the Earnout Shares at each balance sheet date. Any change to the fair value will be recorded in the Company’s statements of operations and other comprehensive income (loss). The Company recorded a (loss) from the change (increase) in fair value of the liability of $0.685 million for the three months ended June 30, 2023.

 

Employment Agreements

 

PDS entered into a Services Agreement with the Company’s CEO effective December 15, 2021 (the “CEO Services Agreement”). The CEO Services Agreement originally provided for a base salary of $618,000, plus cost-of-living increases. On December 19, 2022, the Compensation Committee approved the CEO’s compensation of $642,700 for Fiscal 2024. The CEO Services Agreement provides for annual increases based upon the review of the base salary by the Board prior to the anniversary of the CEO Services Agreement provided that the annual increase cannot be less than the cost-of-living increase. The CEO Services Agreement also provides that the CEO is eligible to receive an annual performance-based bonus targeted at 59% of the applicable year’s base salary, which bonus is earned based on the achievement of performance targets, as determined annually by the Board and communicated to the CEO in the first quarter of the year. Any annual bonus, to the extent earned, is to be paid no later than March 15 of the following year. The CEO Services Agreement is for an initial term of three years, after which it will automatically renew annually unless terminated in accordance with the CEO Services Agreement.

 

Under the CEO Services Agreement, the CEO may terminate his employment with PDS at any time for Good Reason (as defined in the CEO Services Agreement). PDS may terminate the CEO’s employment immediately upon his death, upon a period of disability or without Just Cause (as defined in the CEO Services Agreement). In the event that the CEO’s employment is terminated due to his death or Disability (as defined in the CEO Services Agreement), for Good Reason or without Just Cause, he will be entitled to accrued obligations (accrued unpaid portion of base salary, accrued unused vacation time and any unpaid expenses). Additionally, he may be entitled to Severance Benefits (as defined in the CEO Services Agreement), which include his then current base salary and the average of his annual bonus for the prior two completed performance years, paid over 12 monthly installments. Additionally, the CEO will be entitled to life insurance benefits and medical and dental benefits for a period of 12 months at the same rate the CEO and PDS shared such costs during his period of employment.

 

Additionally, all stock options (and any other unvested equity incentive award) held by the CEO relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as defined in the CEO Services Agreement), and the exercise period for such stock options will be increased by a period of two years from the Termination Date.

 

If the CEO’s employment by PDS is terminated by PDS or any successor entity without Just Cause (not including termination by virtue of the CEO’s death or Disability) or by the CEO for Good Reason within 12 months following the effective date of a Change in Control (as defined in the CEO Services Agreement), then, in addition to paying or providing the CEO with the Accrued Obligations (as defined in the CEO Services Agreement), the Company will provide the following Change in Control Severance Benefits (as defined in the CEO Services Agreement):

 

(1)PDS will pay the base salary continuation benefit for 18 months;

 

(2)PDS will pay the life insurance benefit for 18 months;

 

(3)PDS will pay an additional amount equivalent to the CEO’s target annual bonus calculated using the bonus percentage for the performance year in which the CEO’s termination occurs. This bonus will be paid in 12 equal installments commencing on the first payroll date that is more than 60 days following the date of termination of the CEO’s employment, with the remaining installments occurring on the first day of the month for the 11 months thereafter;

 

(4)PDS will provide the CEO with continued medical and dental benefits, as described above, for 18 months; and

 

(5)All stock options (and any other unvested equity incentive award) held by the CEO relating to shares of PDS or the Company will be deemed fully vested and exercisable on the Termination Date, as defined, and the exercise period for such stock options will be increased by a period of two years from the Termination Date.

 

PDS entered into services agreements (individually, an “Executive Service Agreement,” and collectively, the “Executive Service Agreements”) with each of the Company’s five other members of senior management (individually, “Executive” and collectively, “Executives”), three of which are dated as of December 1, 2021, one of which is dated December 15, 2021 and one of which is dated June 1, 2022. Each of the Executive Services Agreements provides for an initial term of two years that is automatically renewed for one-year periods (except two of the Executive Services Agreement, which provides for an initial term of one year and that is automatically renewed for one-year periods). The Executive Services Agreements initially provided for annual base salaries ranging from $175,000 to $348,000 (pro-rated for services rendered) and annual bonus targets ranging from 30% to 40%. They also provide for long-term incentives in the form of equity awards from time to time under the Portage Biotech Inc. Amended and Restated 2021 Equity Incentive Plan.

 

On December 19, 2022, the Compensation Committee approved executive compensation for Fiscal 2024 for annual base salaries ranging from $183,750 to $469,000 (pro-rated for services rendered) and annual bonus targets ranging from 30% to 40%.

 

The Executive Services Agreements can be terminated by PDS without Just Cause, by death or Disability, or by the Executive (except one) for Good Reason (each as defined in the respective Executive Services Agreements). In such instances, the Executive Services Agreements provide for the payment of accrued obligations (accrued unpaid portion of base salary, accrued unused vacation time and any unpaid expenses). Additionally, the Executives (except two) are entitled to 50% of base salary plus 50% of average annual bonus earned over the prior two performance years, as well as prevailing life insurance benefits for a period of six months and medical and dental benefits for a period of six months at the prevailing rate PDS and the Executive were sharing such expenses.

 

Additionally, all stock options (and any other unvested equity incentive award) held by the Executives relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as defined in the respective Executive Services Agreements), and the exercise period for such stock options will be increased by a period of two years from the Termination Date.

 

If an Executive’s employment by PDS is terminated by the Company or any successor entity without Just Cause (not including termination by virtue of the Executive’s death or Disability) or by the Executive (except one) for Good Reason within 12 months following the effective date of a Change in Control (as defined in the respective Executive Services Agreements), then, in addition to paying or providing the Executive with the Accrued Obligations (as defined in the respective Executive Services Agreements), the Company will provide the following Change in Control Severance Benefits (as defined in the respective Executive Services Agreements), except in two cases in which the Executive is entitled to Item (5) and 50% of Items (1) and (3) below:

 

(1)PDS will pay the Base Salary continuation benefit for 12 months;

 

(2)PDS will pay the life insurance benefit for 12 months;

 

(3)The Company will pay an additional amount equivalent to the Executive’s target annual bonus calculated using the bonus percentage for the performance year in which the Executive’s termination occurs. This bonus will be payable in 12 equal installments commencing on the first payroll date that is more than 60 days following the date of termination of the Executive’s employment, with the remaining installments occurring on the first day of the month for the 11 months thereafter;

 

(4)PDS will provide the Executive with continued medical and dental benefits, as described above, for 12 months; and

 

(5)All stock options (and any other unvested equity incentive award) held by the Executive relating to shares of PDS or the Company will be deemed fully vested and exercisable on the Termination Date and the exercise period for such stock options will be increased by a period of two years from the Termination Date.

 

The Executive Services Agreements also include customary confidentiality, as well as provisions relating to assignment of inventions. The Executive Services Agreements also includes non-competition and non-solicitation of employees and customers provision that run during the Executive’s employment with PDS and for a period of one year after termination of employment.

 

Bonuses & Board Compensation Arrangements

 

In December 2022, the Board approved executive performance bonuses, as recommended by the Compensation Committee, totaling $0.6 million, which is equivalent to 73.5% of original annual targets established by the Board in December 2021. The bonuses were approved based upon the original performance targets established. The Board further approved a payment structure of 25% of approved bonuses, which were paid in January 2023, with the balance of amounts due payable upon a new financing. The accrued, unpaid amount of approximately $0.4 million is included in accounts payable and accrued expenses on the condensed consolidated statements of financial position as of each of June 30, 2023 and March 31, 2023.

 

Effective January 1, 2022, each non-employee Board member are entitled to receive cash Board fees of $40,000 per annum, payable quarterly in arrears. Additionally, each non-employee Board member is entitled to an annual grant of 6,900 options to purchase Portage ordinary shares, which would vest the first annual anniversary of the grant date. The Company incurred Board fees totaling $82,500 and $75,000 during the three months ended June 30, 2023 and 2022, respectively.

 

Non-employee Board chairpersons are entitled to an annual cash fee of $30,000, payable quarterly in arrears. In lieu of a non-executive chairperson, the lead director is entitled to an annual cash fee of $20,000 per annum paid quarterly in arrears. Additionally, the chairperson of each of the Audit Committee, Compensation Committee and Nominating Committee is entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members of those committees will be entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.

 

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.2
FINANCIAL INSTRUMENTS AND RISK MANAGEMENT
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

NOTE 17. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

 

The Company’s financial instruments recognized in the Company’s condensed consolidated interim statements of financial position consist of the following:

 

Fair value estimates are made at a specific point in time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties and matters of significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could significantly affect these estimates.

 

The following table summarizes the Company’s financial instruments as of June 30, 2023 and March 31, 2023:

 

                              
   As of June 30, 2023  As of March 31, 2023
   Amortized
Cost
  FVTOCI  FVTPL  Amortized
Cost
  FVTOCI  FVTPL
                   
Financial assets                              
Cash and cash equivalents  $7,698   $-   $-   $10,545   $-   $- 
Prepaid expenses and other receivables  $2,752   $-   $-   $2,689   $-   $- 
Convertible note receivable, including accrued interest, net of impairment  $-   $-   $442   $-   $-   $442 
Investment in associate  $-   $-   $756   $-   $-   $806 
Investment in public company  $-   $3,855   $-   $-   $2,087   $- 

 

                     
   As of June 30, 2023  As of March 31, 2023
   Amortized
Cost
  FVTPL  Amortized
Cost
  FVTPL
Financial liabilities                    
Accounts payable and accrued liabilities  $2,591   $-   $1,865   $- 
Lease liability - current  $47   $-   $-   $- 
Lease liability - non-current  $249   $-   $-   $- 
Deferred purchase price payable - Tarus  $-   $7,864   $-   $7,179 
Deferred obligation - iOx milestone  $-   $4,552   $-   $4,126 

 

A summary of the Company’s risk exposures as it relates to financial instruments are reflected below.

 

Fair value of Financial Instruments

 

The Company’s financial assets and liabilities are comprised of cash and cash equivalents, receivables and investments in equities and private and public entities, accounts payable, lease liability, deferred purchase price payable, deferred obligation and unsecured notes payable.

 

The Company classifies the fair value of these transactions according to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:

 

·Level 1 – Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of the reporting date.

 

·Level 2 – Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of the reporting date.

 

·Level 3 – Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified as Level 3 financial instrument.

 

Assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy.

 

Management has assessed that the fair values of cash and cash equivalents, other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.

 

The following methods and assumptions were used to estimate their fair values:

 

Investment in Associate: The fair value of the Stimunity investment was determined based on an IAS 36 fair value analysis evaluating the likelihood of various scenarios given the then-current market conditions, the increasing cost of capital and development delays associated with Stimunity’s lack of liquidity (Level 3). The Company recorded a provision of impairment of $0.607 million with respect to the investment in associate decreasing the carrying value of the investment in associate to $0.806 million as of March 31, 2023. There was no provision for impairment recorded in the three months ended June 30, 2023. See Note 6, “Investment in Associate,” for a further discussion.

 

Convertible Note Receivable: The fair value of the Stimunity Convertible Note receivable denominated in euros at initial recognition is the transaction price for the instrument adjusted for the effect of the currency translation rate on the reporting date (Level 3) (see Note 15, “Commitments and Contingent Liabilities – Stimunity Convertible Note”). The Stimunity Convertible Note was initially recorded at $0.614 million to record the translated value of the Stimunity Convertible Note on September 12, 2022. The Company recognized an unrealized gain of $0.039 million through OCI in Fiscal 2023 to reflect the change in translation rate for the Stimunity Convertible Note settleable in euros, increasing the carrying value of the Stimunity Convertible Note to $0.653 million. As of March 31, 2023, the Company determined that there were indications of impairment, based upon the inability of Stimunity to obtain financing. The Company performed an IAS 36 fair value analysis evaluating the likelihood of various scenarios given the then-current market conditions, the increasing cost of capital and development delays associated with Stimunity’s lack of liquidity. The Company recorded an impairment of $0.211 million resulting from the impairment analysis decreasing the carrying value of the Stimunity Convertible Note to $0.442 million as of March 31, 2023. The Company recorded a nominal unrealized gain in the three months ended June 30, 2023 with respect to the Stimunity Convertible Note.

 

Investment in Public Company: Upon Intensity’s IPO effective June 30, 2023, the fair value of the investment is determined by the quoted market price (Level 1).

 

Accrued Equity Issuable: The fair value is estimated based on the average of the quoted market prices for the period in which the shares were earned (Level 1).

 

Lease Liability - Current: The lease liability - current represents the present value of the lease payments due over the next twelve months discounted at the Company’s incremental borrowing rate (Level 2).

 

Lease Liability - Non-Current: The lease liability - non-current represents the present value of the lease payments due under the lease less the current portion of such payments discounted at the Company’s incremental borrowing rate (Level 2).

 

Deferred Purchase Price Payable - Tarus: The fair value is the estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 at acquisition date, adjusted at each reporting date for any change in fair value (Level 3) (see Note 9, “Acquisition of Tarus”). The fair value was determined using the Income Approach and was based upon the analysis on the Tarus clinical plan, the timing of development events and the probabilities of success determined primarily based upon empirical third party data and Company experience, as well as the relevant cost of capital. The Company recorded a (loss) from the change (increase) in fair value of the liability of $0.685 million for the three months ended June 30, 2023.

 

Deferred Obligation - iOx Milestone: The fair value is the estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 as of July 18, 2022, the date of the Share Exchange Agreement, adjusted at each reporting date for any change in fair value (Level 3) (see Note 16, “Related Party Transactions – Share Exchange Agreement – iOx”). The fair value was determined using the Income Approach and based on factors including the clinical plan, the timing of development events and the probabilities of success determined primarily based upon empirical third party data and Company experience, as well as the relevant cost of capital. The Company recorded a (loss) from the change (increase) in fair value of the liability of $0.426 million for the three months ended June 30, 2023.

 

Fair Value Hierarchy

 

The investment in public company (Intensity) was transferred from Level 3 to Level 1 of the fair value hierarchy for the three months ended June 30, 2023 as the result of Intensity’s IPO. For the year ended March 31, 2023, the fair value of the investment was determined based on an IAS 36 impairment analysis after determining there were external indications of impairment (Level 3). See Note 7, “Investment in Public Company.”

 

The Company’s financial instruments are exposed to certain financial risks: Credit Risk, Liquidity Risk and Foreign Currency Risk.

 

Credit Risk

 

Credit risk is the risk of loss associated with a counterparty’s inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit risk is limited to the carrying value as reflected in the Company’s condensed consolidated interim statements of financial position.

 

Cash and cash equivalents. Cash and cash equivalents comprise cash on hand and amounts invested in underlying Treasury and money market funds that are readily convertible to a known amount of cash with three months or less from date of acquisition and are subject to an insignificant risk of change in value. As of June 30, 2023 and March 31, 2023, cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. Cash and cash equivalents are held with major international financial institutions and therefore the risk of loss is minimal.

 

Liquidity Risk

 

Liquidity risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due.

 

The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without incurring unacceptable losses or risking harm to the Company’s reputation. The Company holds sufficient cash and cash equivalents to satisfy current obligations under accounts payable and accruals.

 

The Company monitors its liquidity position regularly to assess whether it has the funds necessary to meet its operating needs and needs for investing in new projects.

 

As a biotech company at an early stage of development and without significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty in global markets could have an impact on the Company’s future ability to access capital on terms that are acceptable to the Company. There can be no assurance that required financing will be available to the Company. See Note 2, “Going Concern,” and Note 12, “Capital Stock,” for a discussion of the Company’s share offering and Note 15, “Commitments and Contingent Liabilities – Committed Purchase Agreement,” for a further discussion.

 

Foreign Currency Risk

 

While the Company operates in various jurisdictions, substantially all of the Company’s transactions are denominated in the U.S. Dollar, except the deferred tax liability in the U.K. settleable in British pound sterling and the Stimunity Convertible Note receivable settleable in euros.

 

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.2
CAPITAL DISCLOSURES
3 Months Ended
Jun. 30, 2023
Capital Disclosures  
CAPITAL DISCLOSURES

NOTE 18. CAPITAL DISCLOSURES

 

The Company considers the items included in shareholders’ equity as capital. The Company had accounts payable and accrued liabilities of approximately $2.6 million and lease liability - current of $0.047 million as of June 30, 2023 (accounts payable and accrued liabilities of approximately $1.9 million as of March 31, 2023) and current assets of approximately $10.9 million as of June 30, 2023 (approximately $13.7 million as of March 31, 2023). The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern in order to pursue new business opportunities and to maintain a flexible capital structure, which optimizes the costs of capital at an acceptable risk.

 

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets.

 

As of June 30, 2023, shareholders’ equity attributable to the owners of the company was approximately $73.3 million (approximately $76.0 million as of March 31, 2023).

 

The Company is not subject to any externally imposed capital requirements and does not presently utilize any quantitative measures to monitor its capital. There have been no changes to the Company’s approach to capital management during the three months ended June 30, 2023 and 2022.

 

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.2
NON-CONTROLLING INTEREST
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
NON-CONTROLLING INTEREST

NOTE 19. NON-CONTROLLING INTEREST

 

               
(In thousands)  iOx  Saugatuck
and subsidiary
  Total
Non-controlling interest as of April 1, 2023  $-   $(650)  $(650)
Net loss attributable to non-controlling interest   -    (7)   (7)
Non-controlling interest as of June 30, 2023  $-   $(657)  $(657)

 

(In thousands)  iOx  Saugatuck
and subsidiary
  Total
Non-controlling interest as of April 1, 2022  $44,701   $(472)  $44,229 
Net income (loss) attributable to non-controlling interest   175    (71)   104 
Non-controlling interest as of June 30, 2022  $44,876   $(543)  $44,333 

 

On September 8, 2021, the Company, through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price of £162. On July 18, 2022, the Company completed the acquisition of the remaining non-controlling interest in iOx, by issuing 1,070,000 shares of its ordinary shares and assuming certain milestone obligations. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx” for a discussion of the Company’s purchase of the balance of the non-controlling interest in iOx.

 

Saugatuck and subsidiary includes Saugatuck and its wholly-owned subsidiary, Saugatuck Rx LLC.

 

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.2
SIGNIFICANT ACCOUNTING POLICIES (Policies)
3 Months Ended
Jun. 30, 2023
Significant Accounting Policies  
Recent Accounting Pronouncements

Recent Accounting Pronouncements

 

IFRS Pronouncements Issued

 

Impact of Adoption of Significant New IFRS Standards in Fiscal 2023

 

(a)Annual Improvements to IFRS Standards 2018-2020

 

The annual improvements process addresses issues in the 2018-2020 reporting cycles including changes to IFRS 9, “Financial Instruments,” IFRS 1, “First Time Adoption of IFRS,” IFRS 16, “Leases,” and IAS 41, “Biological Assets”.

 

i)The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition of financial liabilities.

 

ii)The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent to also measure cumulative translation differences using the amounts reported by the parent based on the parent’s date of transition to IFRS.

 

iii)The amendment to IFRS 16’s illustrative example 13 removes the illustration of payments from the lessor related to leasehold improvements.

 

These amendments were effective for annual periods beginning on or after January 1, 2022. The adoption of these amendments did not have a material effect on the Company’s annual consolidated financial statements or the condensed consolidated interim financial statements for the three months ended June 30, 2023.

 

New Accounting Standards, Interpretations and Amendments

 

Standards issued but not yet effective up to the date of issuance of the Company’s condensed consolidated interim financial statements are listed below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they become effective.

 

(a)IAS 1: Presentation of Financial Statements

 

The amendment to IAS 1 clarifies how to classify debt and other liabilities as either current or non-current. The amendment will be effective for annual periods beginning on or after January 1, 2024. The Company is currently evaluating the new guidance and impacts on its consolidated financial statements.

 

(b)Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture

 

The amendment addresses the conflict between IFRS 10, “Consolidated Financial Statements,” and IAS 28, “Investments in Associates and Joint Ventures,” in dealing with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, “Business Combinations,” between an investor and its associate or joint venture, is recognized in full. Any gain or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognized only to the extent of unrelated investors' interests in the associate or joint venture. The IASB has deferred the effective date of these amendments indefinitely, but an entity that early adopts the amendments must apply them prospectively. The Company is evaluating whether the adoption of the above amendment will have a material impact on its financial statements. 

 

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.2
PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)
3 Months Ended
Jun. 30, 2023
Prepaid Expenses And Other Receivables  
Schedule of prepaid expenses and other receivables
          
(In thousands)  As of
June 30, 2023
  As of
March 31, 2023
       
Prepaid clinical research costs  $1,783   $1,653 
Prepaid insurance   446    621 
Research & development tax credits   186    169 
Other prepaid expenses   151    56 
Tax deposits   115    119 
Other receivables   71    71 
Total prepaid expenses and other receivables  $2,752   $2,689 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT IN ASSOCIATE (Tables)
3 Months Ended
Jun. 30, 2023
Investment In Associate  
Schedule of investment associate
            
Name  Principal Activity  Place of Incorporation and
Principal Place of Business
  Voting Rights Held as
of June 30, 2023
  Voting Rights Held as
of March 31, 2023
Associate: Stimunity S.A.  Biotechnology  Paris, France  44.0%  44.0%
Schedule of investment in Stimunity S.A.
          
   As of and for the Three Months Ended June 30,
(In thousands)  2023  2022
       
Balance, beginning of period  $806   $1,673 
Share of loss   (50)   (60)
Balance, end of period  $756   $1,613 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.2
LEASE (Tables)
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
Schedule of lease liability
     
Twelve Months Ended June 30,  Amount
2024  $79 
2025   81 
2026   83 
2027   84 
2028   71 
 Total   398 
Less: interest   (102)
Total lease liability   296 
Lease liability - current   47 
Lease liability - non-current  $249 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.2
ACQUISITION OF TARUS (Tables)
3 Months Ended
Jun. 30, 2023
Acquisition Of Tarus  
Schedule of fair value of assets acquired and liabilities assumed
     
Assets:  (In thousands)
Identifiable intangible assets  $28,200 
Goodwill   538 
Total assets  $28,738 
Consideration:     
Fair value of shares issued  $17,200 
Liabilities assumed   3,000 
Deferred purchase consideration at fair value   8,538 
Total liabilities  $28,738 
Schedule of Pro forma Information
     
(In thousands) 

Three Months Ended

June 30, 2022

Loss from operations  $(3,788)
Loss before provision for income taxes  $(3,893)
Net loss  $(1,341)
Total comprehensive loss for period  $(1,341)
Loss per share  $(0.09)
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.2
IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)
3 Months Ended
Jun. 30, 2023
In-process Research And Development And Deferred Tax Liability  
Schedule of in-process research and development
             
      Value as of
Project #  Description  June 30, 2023  March 31, 2023
iOx:             
PORT 2 (IMM60)  Melanoma & Lung Cancers  $36,181   $36,181 
PORT 3 (IMM65)  Ovarian/Prostate Cancers   21,709    21,709 
       57,890    57,890 
              
Oncomer/Saugatuck  DNA Aptamers   178    178 
              
Tarus:             
PORT 6 & PORT 7  Adenosine Receptors   22,723    22,723 
PORT 8  Adenosine Receptors   420    420 
PORT 9  Adenosine Receptors   472    472 
       23,615    23,615 
              
In-process research and development     $81,683   $81,683 
              
Deferred tax liability     $13,510   $13,195 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Tables)
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
Schedule of income taxes benefit
          
   For the Three Months Ended June 30,
(In thousands)  2023  2022
       
Current:          
Federal  $(3)  $- 
State and local   -    - 
Foreign   -    - 
Total current   (3)   - 
           
Deferred:          
Federal   -    - 
State and local   -    - 
Foreign   148    2,552 
Total deferred   148    2,552 
Benefit from income taxes  $145   $2,552 
Schedule of reconciliation income tax rates
      
   Three Months Ended June 30,
   2023  2022
(Loss) income on ordinary activities before tax  $(605)  $34 
Statutory U.S. income tax rate   21.0%   21.0%
Income tax benefit (expense) at statutory income tax rate   127    (7)
Share-based compensation expense recognized for financial statement purposes   (142)   - 
Other losses recognized   -    7 
Utilization of losses not previously benefitted   12    - 
Income tax (expense)  $(3)  $- 
Schedule of effective income tax rates
      
   Three Months Ended June 30,
   2023  2022
Loss on ordinary activities before tax  $1,576   $1,743 
Statutory U.K. income tax rate   25.0%   19.0%
Loss at statutory income tax rate   394    331 
           
Change from increase in deferred income tax rate   -    105 
Recognition of deferred tax assets   -    - 
Foreign currency effect   (246)   2,116 
Income tax benefit  $148   $2,552 
Schedule of reconciliation of financial statement loss to tax basis loss
                                        
   Three Months Ended
   June 30, 2023  June 30, 2022
   United
States
  BVI  United
Kingdom
  Total  United
States
  BVI  Foreign  Total
                         
Pre-tax loss  $(609)  $(3,886)  $(1,576)  $(6,071)  $34   $(2,468)  $(1,743)  $(4,177)
Share-based compensation expense for financial statement purposes for which no benefit was taken   683    -    -    683    -    -    -    - 
Losses not subject to tax   -    3,886    -    3,886    -    2,468    -    2,468 
Utilization of losses not previously benefitted   (59)   -    -    (59)   (34)   -    -    (34)
Taxable income (loss)  $15   $-   $(1,576)  $(1,561)  $-   $-   $(1,743)  $(1,743)
Schedule of deferred tax assets and liabilities
          
   As of June 30,  As of March 31,
   2023  2023
Deferred tax assets:          
Net operating loss  $(4,594)  $(4,131)
Deferred tax asset (unrecognized)   1,500    1,500 
Deferred tax asset   (3,094)   (2,631)
           
Deferred tax liabilities:          
In-process research and development   13,510    13,195 
Deferred tax liability   13,510    13,195 
           
Net deferred tax liability  $10,416   $10,564 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.2
CAPITAL STOCK (Tables)
3 Months Ended
Jun. 30, 2023
Capital Stock  
Schedule of unlimited number of common shares without par value
                    
   Three Months Ended June 30,
   2023  2022
   Ordinary
Shares
  Amount  Ordinary
Shares
  Amount
   In 000’  In 000’$  In 000’  In 000’$
Balance, beginning of period   17,606   $218,782    13,349   $158,324 
Shares issued under public offering and ATM, net of issue costs   171    613    -    - 
Shares issued or accrued for services   9    30    4    30 
Balance, end of period   17,786   $219,425    13,353   $158,354 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK OPTION RESERVE (Tables)
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
Schedule of terms stock option reserve explanatory
                    
   Three Months Ended June 30,
   2023  2022
(In thousands)  Non-Controlling Interest  Stock Option Reserve  Non-Controlling Interest  Stock Option Reserve
Balance, beginning of period  $-   $21,204   $11,659   $16,928 
Share-based compensation expense   -    769    -    1,176 
Balance, end of period  $-   $21,973   $11,659   $18,104 
Schedule of outstanding stock options
                    
   Three Months Ended June 30,
   2023  2022  2023  2022
   PBI Amended and Restated
2021 Equity Incentive Plan
  iOx Option Plan
(Subsidiary Plan)
Balance, beginning of period   1,963,420    1,151,400    -    1,275 
Granted   -    50,000    -    - 
Expired or forfeited   -    -    -    (1,275)
Balance, end of year   1,963,420    1,201,400    -    - 
Exercisable, end of period   764,438    410,600    -    - 
Schedule of weighted average exercise price and remaining contractual life
                    
   As of June 30,
   2023  2022  2023  2022
   PBI Amended and Restated
2021 Equity Incentive Plan
  iOx Option Plan
(Subsidiary Plan)
Weighted average exercise price  $10.53    15.26   $-   $- 
Weighted average remaining contractual life (in years)   8.61    8.90    -    - 
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.2
(LOSS) PER SHARE (Tables)
3 Months Ended
Jun. 30, 2023
Profit or loss [abstract]  
Schedule of basic and diluted EPS calculations
          
   Three Months Ended June 30,
Numerator (in 000’$)  2023  2022
       
Net loss attributable to owners of the Company  $(5,919)  $(1,729)
Denominator (in 000’)          
Weighted average number of shares – Basic and Diluted   17,701    13,351 
Basic and diluted (loss) per share  $(0.33)  $(0.13)
Schedule of anti-dilutive share
          
   As of June 30,
   2023  2022
Stock options   1,963,420    1,201,400 
Restricted stock units   378,740    378,740 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.2
FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
Schedule of financial instruments
                              
   As of June 30, 2023  As of March 31, 2023
   Amortized
Cost
  FVTOCI  FVTPL  Amortized
Cost
  FVTOCI  FVTPL
                   
Financial assets                              
Cash and cash equivalents  $7,698   $-   $-   $10,545   $-   $- 
Prepaid expenses and other receivables  $2,752   $-   $-   $2,689   $-   $- 
Convertible note receivable, including accrued interest, net of impairment  $-   $-   $442   $-   $-   $442 
Investment in associate  $-   $-   $756   $-   $-   $806 
Investment in public company  $-   $3,855   $-   $-   $2,087   $- 

 

                     
   As of June 30, 2023  As of March 31, 2023
   Amortized
Cost
  FVTPL  Amortized
Cost
  FVTPL
Financial liabilities                    
Accounts payable and accrued liabilities  $2,591   $-   $1,865   $- 
Lease liability - current  $47   $-   $-   $- 
Lease liability - non-current  $249   $-   $-   $- 
Deferred purchase price payable - Tarus  $-   $7,864   $-   $7,179 
Deferred obligation - iOx milestone  $-   $4,552   $-   $4,126 
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.2
NON-CONTROLLING INTEREST (Tables)
3 Months Ended
Jun. 30, 2023
Notes and other explanatory information [abstract]  
Schedule of non-controlling interest
               
(In thousands)  iOx  Saugatuck
and subsidiary
  Total
Non-controlling interest as of April 1, 2023  $-   $(650)  $(650)
Net loss attributable to non-controlling interest   -    (7)   (7)
Non-controlling interest as of June 30, 2023  $-   $(657)  $(657)

 

(In thousands)  iOx  Saugatuck
and subsidiary
  Total
Non-controlling interest as of April 1, 2022  $44,701   $(472)  $44,229 
Net income (loss) attributable to non-controlling interest   175    (71)   104 
Non-controlling interest as of June 30, 2022  $44,876   $(543)  $44,333 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.2
NATURE OF OPERATIONS (Details Narrative) - shares
1 Months Ended
Sep. 30, 2021
Aug. 13, 2018
IfrsStatementLineItems [Line Items]    
Percentage of outstanding shares 60.49%  
Bottom of range [member]    
IfrsStatementLineItems [Line Items]    
Percentage of ownership subsidiary 60.49%  
Top of range [member]    
IfrsStatementLineItems [Line Items]    
Percentage of ownership subsidiary 78.32%  
Salva Rx Limited [Member]    
IfrsStatementLineItems [Line Items]    
Percentage of acquire   100.00%
Exchange of ordinary shares   8,050,701
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.2
GOING CONCERN (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jul. 31, 2023
Notes and other explanatory information [abstract]    
Cash and cash equivalents $ 7,700  
Total current liabilities 2,600  
Net (loss) income 5,900  
Cash used in operating activities $ 3,500  
Cash on hand   $ 6,400
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.2
BASIS OF PRESENTATION (Details Narrative)
1 Months Ended 3 Months Ended
Sep. 30, 2021
Jun. 30, 2023
IfrsStatementLineItems [Line Items]    
Percentage of outstanding shares 60.49%  
Subsidiaries Two [Member]    
IfrsStatementLineItems [Line Items]    
Non-controlling interest   30.00%
Country Of British Virgin Islands [Member]    
IfrsStatementLineItems [Line Items]    
Percentage of ownership subsidiary   70.00%
Country Of Delaware [Member]    
IfrsStatementLineItems [Line Items]    
Percentage of ownership subsidiary   100.00%
Bottom of range [member]    
IfrsStatementLineItems [Line Items]    
Percentage of ownership subsidiary 60.49%  
Top of range [member]    
IfrsStatementLineItems [Line Items]    
Percentage of ownership subsidiary 78.32%  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.2
PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Mar. 31, 2023
Prepaid Expenses And Other Receivables    
Prepaid clinical research costs $ 1,783 $ 1,653
Prepaid insurance 446 621
Research & development tax credits 186 169
Other prepaid expenses 151 56
Tax deposits 115 119
Other receivables 71 71
Total prepaid expenses and other receivables $ 2,752 $ 2,689
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT IN ASSOCIATE (Details) - Stimunity S A [Member]
3 Months Ended 12 Months Ended
Jun. 30, 2023
Mar. 31, 2023
IfrsStatementLineItems [Line Items]    
Name Associate: Stimunity S.A.  
Principal activity Biotechnology  
Place of Incorporation and principal place of business Paris, France  
Voting rights held 44.00% 44.00%
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT IN ASSOCIATE (Details 1) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Investment In Associate    
Beginning balance $ 806 $ 1,673
Share of loss (50) (60)
Ending balance $ 756 $ 1,613
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT IN ASSOCIATE (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jul. 13, 2023
Sep. 12, 2022
Jun. 30, 2023
Jun. 30, 2022
Mar. 31, 2023
IfrsStatementLineItems [Line Items]          
Convertible Note description the Company entered into a commitment with Stimunity to provide €600,000 under a convertible note (the “Stimunity Convertible Note”) with a maturity date of September 1, 2023 (the “Maturity Date”). The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible Note is automatically converted into Series A shares of Stimunity upon Stimunity completing a Series A round for at least €20 million. If such subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into Series A shares of Stimunity at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares (other than Common Shares or Series A shares) for at least €5 million (the “Minimum Raise”), the Company will have the right to convert the Stimunity Convertible Note and the historical Series A shares of Stimunity owned into the new category of shares. In the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the right to convert the Stimunity Convertible Note into Series A shares at €363.00 per share or the raise price less 15%, whichever is lower. The Stimunity Convertible Note was funded on September 12, 2022. See Note 15, “Commitments and Contingent Liabilities – Stimunity Convertible Note,” for a further discussion.        
Translated value   $ 614      
Unrealized gain         $ 39
Increasing the carrying value         653
Impairment analysis         607
Stimunity convertible note receivable         211
Decreasing the carrying value         806
Stimunity convertible note         $ 442
Loss on shares recognize     $ 50    
Changes in the market     0    
Stimunity S A [Member]          
IfrsStatementLineItems [Line Items]          
Equity in (loss) income     $ 50,000 $ 60,000  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.2
INVESTMENT IN PUBLIC COMPANY (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Jul. 07, 2023
Jul. 05, 2023
Jun. 30, 2023
Jun. 30, 2022
Mar. 31, 2023
Apr. 30, 2023
Dec. 31, 2022
Nov. 30, 2022
Oct. 31, 2022
Jul. 11, 2019
IfrsStatementLineItems [Line Items]                    
Per share price               $ 5.00 $ 4.00  
Impairment asset fair value             $ 3,363      
Impairment assets carring value             $ 4,046      
Holding shares           644,229        
Fair value interest     $ 2,087              
Cash carrying value     $ 3,855              
Number of shares sold     2,425,999              
Unrealized gain or loss     $ 1,768 $ 0            
O C I [Member]                    
IfrsStatementLineItems [Line Items]                    
Impairment loss         $ 5,322          
Cash carrying value         $ 2,087          
Bottom of range [member]                    
IfrsStatementLineItems [Line Items]                    
Offering price           $ 4.00        
Top of range [member]                    
IfrsStatementLineItems [Line Items]                    
Offering price           $ 5.00        
Intensity [Member]                    
IfrsStatementLineItems [Line Items]                    
Number of shares sold 585,000 3,900,000                
Price per share   5.00 5.96              
Proceeds from sales of biological assets   $ 16,200                
Additional antidilution shares     2,659              
Percentage of voting equity interests acquired 4.70%                  
Intensity [Member] | Acquisition Of Salva Rx [Member]                    
IfrsStatementLineItems [Line Items]                    
Investment     $ 4,500              
Number of shares purchased     1,000.0              
Percentage of equity held     7.50%              
Intensity [Member] | Acquisition Of Intensity Holding Limited [Member]                    
IfrsStatementLineItems [Line Items]                    
Equity interests of acquirer                   $ 1,300
Number of ordinary shares issued in acquisition                   129,806
Number of private company share consists in sole asset                   288,458
Number of shares outstanding                   1,288,458
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.2
LEASE (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Mar. 31, 2023
Notes and other explanatory information [abstract]    
2024 $ 79  
2025 81  
2026 83  
2027 84  
2028 71  
 Total 398  
Less: interest (102)  
Total lease liability 296  
Lease liability - current 47
Lease liability - non-current $ 249
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.2
LEASE (Details Narrative)
$ in Thousands
Jun. 30, 2023
USD ($)
Notes and other explanatory information [abstract]  
Security deposit $ 13
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.2
ACQUISITION OF TARUS (Details) - Tarus Acquisition [Member]
$ in Thousands
Jun. 30, 2023
USD ($)
Assets:  
Identifiable intangible assets $ 28,200
Goodwill 538
Total assets 28,738
Consideration:  
Fair value of shares issued 17,200
Liabilities assumed 3,000
Deferred purchase consideration at fair value 8,538
Total liabilities $ 28,738
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.23.2
ACQUISITION OF TARUS (Details 1) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
IfrsStatementLineItems [Line Items]    
Loss before provision for income taxes $ (6,071) $ (4,177)
Net loss (5,926) (1,625)
Total comprehensive loss for period $ (4,157) (1,625)
Tarus Acquisition [Member]    
IfrsStatementLineItems [Line Items]    
Loss from operations   (3,788)
Loss before provision for income taxes   (3,893)
Net loss   (1,341)
Total comprehensive loss for period   $ (1,341)
Loss per share   $ (0.09)
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.2
ACQUISITION OF TARUS (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jul. 01, 2022
IfrsStatementLineItems [Line Items]    
Number of share issued 2,425,999  
Ordinary shares value $ 18,000  
Proceeds from offering 32,000  
Short term debt 2,000  
Milestone payment 17,000  
Ordinary shares issued Value   $ 17,200
Deferred purchase price payable 8,538  
Tarus Acquisition [Member]    
IfrsStatementLineItems [Line Items]    
Milestone payment $ 15,000  
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.23.2
IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Mar. 31, 2023
IfrsStatementLineItems [Line Items]    
In-process research and development $ 81,683 $ 81,683
Deferred tax liability 13,510 13,195
I M M 60 I O X Melanoma Lung Cancers [Member]    
IfrsStatementLineItems [Line Items]    
In-process research and development 36,181 36,181
I M M 65 I O X Melanoma Lung Cancers [Member]    
IfrsStatementLineItems [Line Items]    
In-process research and development 21,709 21,709
I O X [Member]    
IfrsStatementLineItems [Line Items]    
In-process research and development 57,890 57,890
Oncomer Saugatuck D N A Aptamers [Member]    
IfrsStatementLineItems [Line Items]    
In-process research and development 178 178
Tarus Adenosine Receptors [Member]    
IfrsStatementLineItems [Line Items]    
In-process research and development 22,723 22,723
Tarus Adenosine Receptors 1 [Member]    
IfrsStatementLineItems [Line Items]    
In-process research and development 420 420
Tarus Adenosine Receptors 2 [Member]    
IfrsStatementLineItems [Line Items]    
In-process research and development 472 472
Tarus [Member]    
IfrsStatementLineItems [Line Items]    
In-process research and development $ 23,615 $ 23,615
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.2
IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)
$ in Thousands
3 Months Ended
Jun. 30, 2023
USD ($)
IfrsStatementLineItems [Line Items]  
Recognized an impairment $ 59,320
Impairment 4,585
Iox I P R And D [Member] | Top of range [member]  
IfrsStatementLineItems [Line Items]  
Carrying value 117,210
Iox I P R And D [Member] | Bottom of range [member]  
IfrsStatementLineItems [Line Items]  
Carrying value 57,890
Trus I P R And D [Member] | Top of range [member]  
IfrsStatementLineItems [Line Items]  
Carrying value 28,200
Trus I P R And D [Member] | Bottom of range [member]  
IfrsStatementLineItems [Line Items]  
Carrying value $ 23,615
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Current:    
Federal $ (3)
State and local
Foreign
Total current (3)
Deferred:    
Federal
State and local
Foreign 148 2,552
Total deferred 148 2,552
Benefit from income taxes $ 145 $ 2,552
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details 1) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Notes and other explanatory information [abstract]    
(Loss) income on ordinary activities before tax $ (605) $ 34
Statutory U.S. income tax rate 21.00% 21.00%
Income tax benefit (expense) at statutory income tax rate $ 127 $ (7)
Share-based compensation expense recognized for financial statement purposes (142)
Other losses recognized 7
Utilization of losses not previously benefitted 12
Income tax (expense) $ (3)
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details 2) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Notes and other explanatory information [abstract]    
Loss on ordinary activities before tax $ 1,576 $ 1,743
Statutory U.K. income tax rate 25.00% 19.00%
Loss at statutory income tax rate $ 394 $ 331
Change from increase in deferred income tax rate 105
Recognition of deferred tax assets
Foreign currency effect (246) 2,116
Income tax benefit $ 148 $ 2,552
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details 3) - USD ($)
$ in Thousands
Jun. 30, 2023
Jun. 30, 2022
IfrsStatementLineItems [Line Items]    
Pre-tax loss $ (6,071) $ (4,177)
Share-based compensation expense for financial statement purposes for which no benefit was taken 683
Losses not subject to tax 3,886 2,468
Utilization of losses not previously benefitted (59) (34)
Taxable income (loss) (1,561) (1,743)
United State [Member]    
IfrsStatementLineItems [Line Items]    
Pre-tax loss (609) 34
Share-based compensation expense for financial statement purposes for which no benefit was taken 683
Losses not subject to tax
Utilization of losses not previously benefitted (59) (34)
Taxable income (loss) 15
B V I [Member]    
IfrsStatementLineItems [Line Items]    
Pre-tax loss (3,886) (2,468)
Share-based compensation expense for financial statement purposes for which no benefit was taken
Losses not subject to tax 3,886 2,468
Utilization of losses not previously benefitted
Taxable income (loss)
United Kingdom [Member]    
IfrsStatementLineItems [Line Items]    
Pre-tax loss (1,576) (1,743)
Share-based compensation expense for financial statement purposes for which no benefit was taken
Losses not subject to tax
Utilization of losses not previously benefitted
Taxable income (loss) $ (1,576) $ (1,743)
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details 4) - USD ($)
$ in Thousands
Jun. 30, 2023
Mar. 31, 2023
Deferred tax assets:    
Net operating loss $ (4,594) $ (4,131)
Deferred tax asset (unrecognized) 1,500 1,500
Deferred tax asset (3,094) (2,631)
Deferred tax liabilities:    
In-process research and development 13,510 13,195
Deferred tax liability 13,510 13,195
Net deferred tax liability $ 10,416 $ 10,564
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Mar. 31, 2022
Mar. 31, 2023
IfrsStatementLineItems [Line Items]        
Federal net operating losses $ 600      
Deferred tax assets 200     $ 200
Research and development credit receivables 200     200
Deferred tax liabilities 10,416     10,564
Deferred income taxes   $ 7,000    
Current year losses 700      
Increase (Decrease) in deferred tax liability     $ 1,100  
Deferred tax liability 100      
Change in exchange rates on the liability 300      
Exchange rates losses 400      
I O X [Member]        
IfrsStatementLineItems [Line Items]        
Deferred tax liabilities $ 10,400     $ 10,600
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.23.2
CAPITAL STOCK (Details) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Capital Stock    
Beginning balance, Shares 17,606 13,349
Beginning balance, Amount $ 218,782 $ 158,324
Shares issued under public offering and ATM, net of issue cost, shares 171
Shares issued under public offering and ATM, net of issue costs $ 613
Shares issued or accrued for services, shares 9 4
Shares issued or accrued for services $ 30 $ 30
Ending balance, Shares 17,786 13,353
Ending balance, Amount $ 219,425 $ 158,354
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.23.2
CAPITAL STOCK (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Jul. 18, 2022
Jul. 06, 2022
Jun. 30, 2023
Mar. 31, 2023
Mar. 31, 2022
IfrsStatementLineItems [Line Items]          
Maximum aggregate offering price     $ 50,000,000    
Issuance and sales, shares     1,150,000    
Gross proceeds from stock     $ 26,500    
Cash fund, description     The Sales Agreement permits the Company to sell in an ATM program up to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered, issued and sold by the Company under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Upon termination of the Sales Agreement, any portion of the $50,000,000 included in the Sales Agreement prospectus that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus.    
Number of stock sold         90,888
Gross proceeds from stock sold         $ 2,600
Net proceeds from stock sold         $ 2,500
Number of shares sold     2,425,999    
Number of shares exchanged 1,070,000        
Minority interest, percentage 21.68%        
Number of ordinary share issued   94,508      
A T M [Member]          
IfrsStatementLineItems [Line Items]          
Number of shares sold     171,504 166,145  
Net proceeds from sale     $ 600 $ 900  
Lincoln [Member]          
IfrsStatementLineItems [Line Items]          
Number of shares sold       480,000  
Net proceeds from sale       $ 2,000  
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK OPTION RESERVE (Details) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
IfrsStatementLineItems [Line Items]    
Stock based compensation expense $ 769 $ 1,176
Non-controlling interests [member]    
IfrsStatementLineItems [Line Items]    
Begiining balance 11,659
Stock based compensation expense
Ending balance 11,659
Stock Option Reserve [Member]    
IfrsStatementLineItems [Line Items]    
Begiining balance 21,204 16,928
Stock based compensation expense 769 1,176
Ending balance $ 21,973 $ 18,104
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK OPTION RESERVE (Details 1) - shares
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Stock Options Two [Member]    
IfrsStatementLineItems [Line Items]    
Beginning balance 1,275
Granted
Expired or forfeited (1,275)
Ending balance
Exercisable as at end
P B I 2021 Equity Incentive Plan [Member]    
IfrsStatementLineItems [Line Items]    
Beginning balance 1,963,420 1,151,400
Granted 50,000
Expired or forfeited
Ending balance 1,963,420 1,201,400
Exercisable as at end 764,438 410,600
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK OPTION RESERVE (Details 2) - $ / shares
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Stock Options Two [Member]    
IfrsStatementLineItems [Line Items]    
Weighted average exercise price
P B I 2021 Equity Incentive Plan [Member]    
IfrsStatementLineItems [Line Items]    
Weighted average exercise price $ 10.53 $ 15.26
Weighted average remaining contractual life (in years) 8 years 7 months 9 days 8 years 10 months 24 days
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.23.2
STOCK OPTION RESERVE (Details Narrative)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 30, 2023
$ / shares
shares
Jul. 27, 2022
$ / shares
shares
Jun. 08, 2022
$ / shares
shares
Feb. 15, 2022
$ / shares
shares
Jan. 19, 2022
$ / shares
shares
Jan. 13, 2021
$ / shares
shares
Jun. 30, 2023
USD ($)
shares
Jun. 30, 2022
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2023
shares
IfrsStatementLineItems [Line Items]                    
Number of shares available for awards 746,120                  
Exercisable price | $ / shares $ 2.92                  
Number of shares available for awards 879,180                  
Expiration date Mar. 30, 2033                  
Number of shares purchased 14,600                  
Number of shares available for granted 87,600                  
Total of stock options granted to employees 651,020                  
Stock options granted to consultant 7,500                  
Share based compensation expense | $             $ 800 $ 1,200    
Vested Options [Member]                    
IfrsStatementLineItems [Line Items]                    
Options outstanding             7,500     7,500
Unvested Options [Member]                    
IfrsStatementLineItems [Line Items]                    
Options outstanding             738,620     738,620
Board Of Directors [Member]                    
IfrsStatementLineItems [Line Items]                    
Option issued           350,000        
Consultants [Member]                    
IfrsStatementLineItems [Line Items]                    
Option issued           518,000        
N 2021 Equity Incentive Plan [Member]                    
IfrsStatementLineItems [Line Items]                    
Option issued           868,000        
Exercise price | $ / shares           $ 17.75        
Restricted Stock Units [Member]                    
IfrsStatementLineItems [Line Items]                    
Number of shares available for awards           243,000        
Fair value per share | $ / shares           $ 17.75        
Compensation expense | $                 $ 4,300  
Amended And Restated 2021 Equity Incentive Plan [Member]                    
IfrsStatementLineItems [Line Items]                    
Number of shares available for awards         302,000          
Fair value per share | $ / shares         $ 10.22          
Number of shares available for awards 2,880,992                  
Share based compensation expense | $             $ 3,400      
Amended And Restated 2021 Equity Incentive Plan [Member] | Board Of Directors [Member]                    
IfrsStatementLineItems [Line Items]                    
Number of shares available for awards   15,900                
Exercisable price | $ / shares   $ 10.06                
Amended And Restated 2021 Equity Incentive Plan [Member] | Two Members [Member]                    
IfrsStatementLineItems [Line Items]                    
Number of shares available for awards         13,800          
Amended And Restated 2021 Equity Incentive Plan [Member] | Employees [Member]                    
IfrsStatementLineItems [Line Items]                    
Number of shares available for awards         288,200          
Amended And Restated 2021 Equity Incentive Plan [Member] | Directors [Member]                    
IfrsStatementLineItems [Line Items]                    
Number of shares available for awards       13,800 135,740          
Fair value per share | $ / shares       $ 8.59 $ 10.22          
Amended And Restated 2021 Equity Incentive Plan [Member] | Executive [Member]                    
IfrsStatementLineItems [Line Items]                    
Number of shares available for awards     50,000              
Exercisable price | $ / shares     $ 11.00              
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.23.2
(LOSS) PER SHARE (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Numerator (in 000’$)    
Net loss attributable to owners of the Company $ (5,919) $ (1,729)
Denominator (in 000’)    
Weighted average number of shares, Basic 17,701 13,351
Weighted average number of shares, Diluted 17,701 13,351
Basic earnings (loss) per share $ (0.33) $ (0.13)
Diluted earnings (loss) per share $ (0.33) $ (0.13)
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.23.2
(LOSS) PER SHARE (Details 1) - shares
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Share options [member]    
IfrsStatementLineItems [Line Items]    
Anti-dilutive effect on loss per share 1,963,420 1,201,400
Restricted share units [member]    
IfrsStatementLineItems [Line Items]    
Anti-dilutive effect on loss per share 378,740 378,740
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)
€ / shares in Units, $ in Thousands
3 Months Ended
Jul. 06, 2022
USD ($)
shares
Jun. 30, 2023
USD ($)
Jul. 13, 2022
EUR (€)
€ / shares
IfrsStatementLineItems [Line Items]      
Budget cost related to services | $   $ 12,100  
Convertible note | €     € 600,000
Interest rate     7.00%
Conversion of debt | €     € 20,000,000
Conversion of debt into shares | €     € 5,000,000
Share price, per share | € / shares     € 363.00
Number of ordinary shares issued | shares 94,508    
Lincoln [Member]      
IfrsStatementLineItems [Line Items]      
Aggregate value | $ $ 30,000    
Commitment fee | $ $ 900    
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
3 Months Ended
Dec. 31, 2022
Dec. 19, 2022
Dec. 15, 2021
Sep. 08, 2021
Jun. 30, 2023
Mar. 31, 2023
IfrsStatementLineItems [Line Items]            
Portage ordinary shares         1,070,000  
Base salary   $ 469,000 $ 618,000      
Annual base salary     $ 348,000      
Compensation committee $ 600,000          
Original annual targets percentage 73.50%          
Accounts payable and accrued expenses         $ 400,000 $ 400,000
Annual fees description         Additionally, the chairperson of each of the Audit Committee, Compensation Committee and Nominating Committee is entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members of those committees will be entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.  
Salva Rx [Member]            
IfrsStatementLineItems [Line Items]            
Issuance of unsecured notes, description       Company, through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price of £162. Simultaneously, the Company entered into an agreement with OSI, the holder of $0.15 million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for 820 shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets of IAS 39, “Financial Instruments: Recognition and Measurement,” and IFRIC 19, “Extinguishing Financial Liabilities with Equity Instruments,” and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%.    
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.23.2
FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details) - USD ($)
$ in Thousands
Jun. 30, 2023
Mar. 31, 2023
Jun. 30, 2022
Mar. 31, 2022
Financial assets        
Cash and cash equivalents $ 7,698 $ 10,545 $ 21,176 $ 23,352
Financial liabilities        
Lease liability - current 47    
Lease liability - non-current 249    
Deferred purchase price payable - Tarus 7,864 7,179    
Deferred obligation - iOx milestone 4,552 4,126    
Amortized Cost [Member]        
Financial assets        
Cash and cash equivalents 7,698 10,545    
Prepaid expenses and other receivables 2,752 2,689    
Convertible note receivable, including accrued interest, net of impairment    
Investment in associate    
Investment in public company    
Financial liabilities        
Accounts payable and accrued liabilities 2,591 1,865    
Lease liability - current 47    
Lease liability - non-current 249    
Deferred purchase price payable - Tarus    
Deferred obligation - iOx milestone    
Fair Value To Other Comprehensive Income [Member]        
Financial assets        
Cash and cash equivalents    
Prepaid expenses and other receivables    
Convertible note receivable, including accrued interest, net of impairment    
Investment in associate    
Investment in public company 3,855 2,087    
Fair Value Through Profit Or Loss [Member]        
Financial assets        
Cash and cash equivalents    
Prepaid expenses and other receivables    
Convertible note receivable, including accrued interest, net of impairment 442 442    
Investment in associate 756 806    
Investment in public company    
Financial liabilities        
Accounts payable and accrued liabilities    
Lease liability - current    
Lease liability - non-current    
Deferred purchase price payable - Tarus 7,864 7,179    
Deferred obligation - iOx milestone $ 4,552 $ 4,126    
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.23.2
FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
Sep. 12, 2022
Jun. 30, 2023
Mar. 31, 2023
IfrsStatementLineItems [Line Items]      
Impairment analysis     $ 607
Decreasing the carrying value     806
Notes receivable $ 614    
Unrealized gain     39
Increasing carrying value     653
Impairment of convertible note     211
Decreasing impairment carrying value     $ 442
Tarus [Member]      
IfrsStatementLineItems [Line Items]      
Loss on decrease in fair value of the liability   $ 685  
I O X [Member]      
IfrsStatementLineItems [Line Items]      
Loss on decrease in fair value of the liability   $ 426  
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.23.2
CAPITAL DISCLOSURES (Details Narrative) - USD ($)
$ in Thousands
Jun. 30, 2023
Mar. 31, 2023
Capital Disclosures    
Accounts payable and accrued liabilities $ 2,600 $ 1,900
Lease liability current 47
Current assets 10,900 13,700
Shareholders' equity attributable to owners $ 73,300 $ 76,000
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.23.2
NON-CONTROLLING INTEREST (Details) - USD ($)
$ in Thousands
3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
IfrsStatementLineItems [Line Items]    
Non-controlling interest, at beginning $ (650) $ 44,229
Net (loss) attributable to non-controlling interest (7) 104
Non-controlling interest, at ending (657) 44,333
I O X [Member]    
IfrsStatementLineItems [Line Items]    
Non-controlling interest, at beginning 44,701
Net (loss) attributable to non-controlling interest 175
Non-controlling interest, at ending 44,876
Saugatuck And Subsidiary [Member]    
IfrsStatementLineItems [Line Items]    
Non-controlling interest, at beginning (650) (472)
Net (loss) attributable to non-controlling interest (7) (71)
Non-controlling interest, at ending $ (657) $ (543)
XML 84 f6k_082923_htm.xml IDEA: XBRL DOCUMENT 0001095435 2023-04-01 2023-06-30 0001095435 2023-06-30 0001095435 2023-03-31 0001095435 2022-04-01 2022-06-30 0001095435 ifrs-full:IssuedCapitalMember 2023-03-31 0001095435 ptgef:StockOptionReserveMember 2023-03-31 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001095435 ifrs-full:RetainedEarningsMember 2023-03-31 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2023-03-31 0001095435 ifrs-full:NoncontrollingInterestsMember 2023-03-31 0001095435 ifrs-full:IssuedCapitalMember 2022-03-31 0001095435 ptgef:StockOptionReserveMember 2022-03-31 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001095435 ifrs-full:RetainedEarningsMember 2022-03-31 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2022-03-31 0001095435 ifrs-full:NoncontrollingInterestsMember 2022-03-31 0001095435 2022-03-31 0001095435 ifrs-full:IssuedCapitalMember 2023-04-01 2023-06-30 0001095435 ptgef:StockOptionReserveMember 2023-04-01 2023-06-30 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001095435 ifrs-full:RetainedEarningsMember 2023-04-01 2023-06-30 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2023-04-01 2023-06-30 0001095435 ifrs-full:NoncontrollingInterestsMember 2023-04-01 2023-06-30 0001095435 ifrs-full:IssuedCapitalMember 2022-04-01 2022-06-30 0001095435 ptgef:StockOptionReserveMember 2022-04-01 2022-06-30 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001095435 ifrs-full:RetainedEarningsMember 2022-04-01 2022-06-30 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2022-04-01 2022-06-30 0001095435 ifrs-full:NoncontrollingInterestsMember 2022-04-01 2022-06-30 0001095435 ifrs-full:IssuedCapitalMember 2023-06-30 0001095435 ptgef:StockOptionReserveMember 2023-06-30 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001095435 ifrs-full:RetainedEarningsMember 2023-06-30 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2023-06-30 0001095435 ifrs-full:NoncontrollingInterestsMember 2023-06-30 0001095435 ifrs-full:IssuedCapitalMember 2022-06-30 0001095435 ptgef:StockOptionReserveMember 2022-06-30 0001095435 ifrs-full:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001095435 ifrs-full:RetainedEarningsMember 2022-06-30 0001095435 ifrs-full:EquityAttributableToOwnersOfParentMember 2022-06-30 0001095435 ifrs-full:NoncontrollingInterestsMember 2022-06-30 0001095435 2022-06-30 0001095435 ptgef:SalvaRxLimitedMember 2018-08-13 0001095435 2021-09-01 2021-09-30 0001095435 ifrs-full:BottomOfRangeMember 2021-09-01 2021-09-30 0001095435 ifrs-full:TopOfRangeMember 2021-09-01 2021-09-30 0001095435 2023-07-31 0001095435 ptgef:CountryOfBritishVirginIslandsMember 2023-04-01 2023-06-30 0001095435 ptgef:CountryOfDelawareMember 2023-04-01 2023-06-30 0001095435 ptgef:SubsidiariesTwoMember 2023-04-01 2023-06-30 0001095435 ptgef:StimunitySAMember 2023-04-01 2023-06-30 0001095435 ptgef:StimunitySAMember 2022-04-01 2023-03-31 0001095435 ptgef:StimunitySAMember 2022-04-01 2022-06-30 0001095435 2023-07-12 2023-07-13 0001095435 2022-09-11 2022-09-12 0001095435 2022-04-01 2023-03-31 0001095435 ptgef:AcquisitionOfSalvaRxMember ptgef:IntensityMember 2023-04-01 2023-06-30 0001095435 ptgef:AcquisitionOfSalvaRxMember ptgef:IntensityMember 2023-06-30 0001095435 ptgef:AcquisitionOfIntensityHoldingLimitedMember ptgef:IntensityMember 2019-07-11 0001095435 2022-10-31 0001095435 2022-11-30 0001095435 2022-12-31 0001095435 2023-04-30 0001095435 ifrs-full:BottomOfRangeMember 2023-04-30 0001095435 ifrs-full:TopOfRangeMember 2023-04-30 0001095435 ptgef:OCIMember 2022-04-01 2023-03-31 0001095435 ptgef:OCIMember 2023-03-31 0001095435 ptgef:IntensityMember 2023-07-04 2023-07-05 0001095435 ptgef:IntensityMember 2023-04-01 2023-06-30 0001095435 ptgef:IntensityMember 2023-07-06 2023-07-07 0001095435 ptgef:IntensityMember 2023-07-07 0001095435 ptgef:TarusAcquisitionMember 2023-04-01 2023-06-30 0001095435 2022-07-01 0001095435 ptgef:TarusAcquisitionMember 2023-06-30 0001095435 ptgef:TarusAcquisitionMember 2022-04-01 2022-06-30 0001095435 ptgef:IMM60IOXMelanomaLungCancersMember 2023-06-30 0001095435 ptgef:IMM60IOXMelanomaLungCancersMember 2023-03-31 0001095435 ptgef:IMM65IOXMelanomaLungCancersMember 2023-06-30 0001095435 ptgef:IMM65IOXMelanomaLungCancersMember 2023-03-31 0001095435 ptgef:IOXMember 2023-06-30 0001095435 ptgef:IOXMember 2023-03-31 0001095435 ptgef:OncomerSaugatuckDNAAptamersMember 2023-06-30 0001095435 ptgef:OncomerSaugatuckDNAAptamersMember 2023-03-31 0001095435 ptgef:TarusAdenosineReceptorsMember 2023-06-30 0001095435 ptgef:TarusAdenosineReceptorsMember 2023-03-31 0001095435 ptgef:TarusAdenosineReceptors1Member 2023-06-30 0001095435 ptgef:TarusAdenosineReceptors1Member 2023-03-31 0001095435 ptgef:TarusAdenosineReceptors2Member 2023-06-30 0001095435 ptgef:TarusAdenosineReceptors2Member 2023-03-31 0001095435 ptgef:TarusMember 2023-06-30 0001095435 ptgef:TarusMember 2023-03-31 0001095435 ifrs-full:TopOfRangeMember ptgef:IoxIPRAndDMember 2023-04-01 2023-06-30 0001095435 ifrs-full:BottomOfRangeMember ptgef:IoxIPRAndDMember 2023-04-01 2023-06-30 0001095435 ifrs-full:TopOfRangeMember ptgef:TrusIPRAndDMember 2023-04-01 2023-06-30 0001095435 ifrs-full:BottomOfRangeMember ptgef:TrusIPRAndDMember 2023-04-01 2023-06-30 0001095435 ptgef:IOXMember 2023-06-30 0001095435 ptgef:IOXMember 2023-03-31 0001095435 2021-04-01 2022-03-31 0001095435 ptgef:UnitedStateMember 2023-06-30 0001095435 ptgef:BVIMember 2023-06-30 0001095435 ptgef:CountryOfUnitedKingdomMember 2023-06-30 0001095435 ptgef:UnitedStateMember 2022-06-30 0001095435 ptgef:BVIMember 2022-06-30 0001095435 ptgef:CountryOfUnitedKingdomMember 2022-06-30 0001095435 2022-07-15 2022-07-18 0001095435 2022-07-18 0001095435 2022-07-05 2022-07-06 0001095435 ptgef:ATMMember 2022-04-01 2023-03-31 0001095435 ptgef:LincolnMember 2022-04-01 2023-03-31 0001095435 ptgef:ATMMember 2023-04-01 2023-06-30 0001095435 ptgef:N2021EquityIncentivePlanMember 2021-01-13 0001095435 ptgef:BoardOfDirectorsMember 2021-01-13 0001095435 ptgef:ConsultantsMember 2021-01-13 0001095435 ptgef:RestrictedStockUnitsMember 2021-01-12 2021-01-13 0001095435 ptgef:RestrictedStockUnitsMember 2020-04-01 2021-03-31 0001095435 ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-01-18 2022-01-19 0001095435 ptgef:TwoMembersMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-01-18 2022-01-19 0001095435 ptgef:EmployeesMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-01-18 2022-01-19 0001095435 ptgef:DirectorsMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-01-18 2022-01-19 0001095435 ptgef:DirectorsMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-02-14 2022-02-15 0001095435 ptgef:ExecutiveMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-06-07 2022-06-08 0001095435 ptgef:BoardOfDirectorsMember ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2022-07-26 2022-07-27 0001095435 ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2023-03-25 2023-03-30 0001095435 2023-03-25 2023-03-30 0001095435 ptgef:VestedOptionsMember 2023-06-30 0001095435 ptgef:VestedOptionsMember 2023-03-31 0001095435 ptgef:UnvestedOptionsMember 2023-06-30 0001095435 ptgef:UnvestedOptionsMember 2023-03-31 0001095435 ptgef:AmendedAndRestated2021EquityIncentivePlanMember 2023-04-01 2023-06-30 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2023-03-31 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2022-03-31 0001095435 ptgef:StockOptionsTwoMember 2023-03-31 0001095435 ptgef:StockOptionsTwoMember 2022-03-31 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2023-04-01 2023-06-30 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2022-04-01 2022-06-30 0001095435 ptgef:StockOptionsTwoMember 2023-04-01 2023-06-30 0001095435 ptgef:StockOptionsTwoMember 2022-04-01 2022-06-30 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2023-06-30 0001095435 ptgef:PBI2021EquityIncentivePlanMember 2022-06-30 0001095435 ptgef:StockOptionsTwoMember 2023-06-30 0001095435 ptgef:StockOptionsTwoMember 2022-06-30 0001095435 ifrs-full:ShareOptionsMember 2023-04-01 2023-06-30 0001095435 ifrs-full:ShareOptionsMember 2022-04-01 2022-06-30 0001095435 ifrs-full:RestrictedShareUnitsMember 2023-04-01 2023-06-30 0001095435 ifrs-full:RestrictedShareUnitsMember 2022-04-01 2022-06-30 0001095435 2022-07-13 0001095435 ptgef:LincolnMember 2022-07-05 2022-07-06 0001095435 ptgef:SalvaRxMember 2021-09-07 2021-09-08 0001095435 2021-12-14 2021-12-15 0001095435 2022-12-18 2022-12-19 0001095435 2022-12-25 2022-12-31 0001095435 ptgef:AmortizedCostMember 2023-06-30 0001095435 ptgef:FairValueToOtherComprehensiveIncomeMember 2023-06-30 0001095435 ptgef:FairValueThroughProfitOrLossMember 2023-06-30 0001095435 ptgef:AmortizedCostMember 2023-03-31 0001095435 ptgef:FairValueToOtherComprehensiveIncomeMember 2023-03-31 0001095435 ptgef:FairValueThroughProfitOrLossMember 2023-03-31 0001095435 ptgef:TarusMember 2023-04-01 2023-06-30 0001095435 ptgef:IOXMember 2023-04-01 2023-06-30 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2023-03-31 0001095435 ptgef:IOXMember 2023-04-01 2023-06-30 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2023-04-01 2023-06-30 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2023-06-30 0001095435 ptgef:IOXMember 2022-03-31 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2022-03-31 0001095435 ptgef:IOXMember 2022-04-01 2022-06-30 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2022-04-01 2022-06-30 0001095435 ptgef:IOXMember 2022-06-30 0001095435 ptgef:SaugatuckAndSubsidiaryMember 2022-06-30 iso4217:USD shares iso4217:USD shares pure iso4217:EUR iso4217:EUR shares 6-K 001-40086 Portage Biotech Inc. Clarence Thomas Building P.O. Box 4649 Road Town Tortola VG1110 0001095435 false 6-K --03-31 2024 Q1 Portage Biotech Inc. 2023-06-30 7698000 10545000 2752000 2689000 442000 442000 10892000 13676000 756000 806000 3855000 2087000 81683000 81683000 839000 839000 293000 51000 38000 87477000 85453000 98369000 99129000 2591000 1865000 47000 2638000 1865000 249000 10416000 10564000 7864000 7179000 4552000 4126000 23081000 21869000 25719000 23734000 219425000 218782000 21973000 21204000 -2556000 -4325000 -165535000 -159616000 73307000 76045000 -657000 -650000 72650000 75395000 98369000 99129000 3627000 1876000 1370000 2211000 -4997000 -4087000 -1111000 -50000 -60000 1000 -18000 52000 11000 80000 21000 -6071000 -4177000 -145000 -2552000 -5926000 -1625000 1769000 -4157000 -1625000 -5919000 -1729000 -7000 104000 -5926000 -1625000 -4150000 -1729000 -7000 104000 -4157000 -1625000 -0.33 -0.33 -0.13 -0.13 17701 17701 13351 13351 17606 218782000 21204000 -4325000 -159616000 76045000 -650000 75395000 769000 769000 769000 171 632000 632000 632000 -19000 -19000 -19000 9 30000 30000 30000 1769000 1769000 1769000 -5919000 -5919000 -7000 -5926000 17786 219425000 21973000 -2556000 -165535000 73307000 -657000 72650000 13349 158324000 16928000 958000 -55005000 121205000 44229000 165434000 1176000 1176000 1176000 4 30000 30000 30000 -1729000 -1729000 104000 -1625000 13353 158354000 18104000 958000 -56734000 120682000 44333000 165015000 -5926000 -1625000 769000 1176000 -1111000 148000 2552000 -50000 -60000 30000 30000 11000 -1000 17000 44000 -50000 -408000 -10000 726000 1188000 1000 -3453000 -2176000 632000 19000 7000 606000 -2847000 -2176000 10545000 23352000 7698000 21176000 1769000 3000 303000 303000 <p id="xdx_80D_ecustom--NatureOfOperationsExplanatory_zFvaUtUqeQk" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 1. <span id="xdx_829_zurPJd8UMtSa">NATURE OF OPERATIONS</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Portage Biotech Inc. (the “Company” or “Portage”) is incorporated in the British Virgin Islands (“BVI”) with its registered office located at Clarence Thomas Building, P.O. Box 4649, Road Town, Tortola, BVI. Its USA agent, Portage Development Services Inc. (“PDS”), is located at 61 Wilton Road, Westport, CT, 06880, USA.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company is a foreign private issuer under the Securities and Exchange Commission (the “SEC”) rules. It is also a reporting issuer under the securities legislation of the provinces of Ontario and British Columbia. Its ordinary shares were listed on the Canadian Securities Exchange (“CSE”) under the symbol “PBT.U”. On February 25, 2021, the ordinary shares of the Company began trading on the Nasdaq Capital Market (“Nasdaq”) under the symbol “PRTG”. As the principal market for the Company’s ordinary shares is Nasdaq, the Company voluntarily delisted from the CSE on April 23, 2021.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Portage is a clinical-stage immuno-oncology company advancing therapies that target known checkpoint resistance pathways to improve long-term treatment response and quality of life in patients with invasive cancers. Portage’s access to next-generation technologies coupled with a deep understanding of biological mechanisms enable the identification of clinical therapies and product development strategies that accelerate these medicines through the translational pipeline. Portage’s portfolio consists of four diverse platforms, with lead programs consisting of invariant natural killer T-cell (“iNKT”) engagers and a suite of treatments targeting the adenosine pathway. Additional programs leverage delivery by intratumorals, nanoparticles, liposomes, aptamers, and virus-like particles. Within these four platforms, Portage has 9 product candidates currently in development with multiple clinical readouts expected through the end of calendar year 2024.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On August 13, 2018, the Company reached a definitive agreement to acquire <span id="xdx_90A_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20180813__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxLimitedMember_z3qrjILFiPB6" title="Percentage of acquire">100</span>% of SalvaRx Limited (“SalvaRx”) in exchange for <span id="xdx_905_ecustom--ExchangeOfOrdinaryShares_iI_c20180813__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxLimitedMember_zOueDL7nevfb" title="Exchange of ordinary shares">8,050,701</span> ordinary shares of the Company (the “SalvaRx Acquisition”). The SalvaRx Acquisition was completed on January 8, 2019 (the “Acquisition Date”) upon receiving shareholder and regulatory approval. In connection with the SalvaRx Acquisition, the Company acquired interests in SalvaRx’s five research and development invested entities and subsidiaries: iOx Therapeutics Ltd. (“iOx”) (60.49% interest), Nekonal Oncology Limited (“Nekonal”), Intensity Therapeutics, Inc. (“Intensity”), Saugatuck Therapeutics, Ltd. (“Saugatuck”) and Rift Biotherapeutics Inc.  The Company also acquired an option in Nekonal SARL, a Luxembourg-based company holding intellectual property rights for therapeutics and diagnostics in the field of autoimmune disorders and oncology, to participate in the funding of its autoimmune programs.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In September 2021, the Company, through SalvaRx, exchanged certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing <span id="xdx_90E_ecustom--PercentageOfOutstandingShares_pid_dp_c20210901__20210930_zPcF94imB7Z7" title="Percentage of outstanding shares">60.49</span>% of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from <span id="xdx_909_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zUr6xn4byVn4" title="Percentage of ownership subsidiary">60.49</span>% to <span id="xdx_905_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_ztrTnJrGdqa9" title="Percentage of ownership subsidiary">78.32</span>%. On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. <span style="background-color: white">See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx,” for a further discussion.</span></p> <p style="margin: 0pt 0; font-size: 10pt; color: #222222"> </p> 1 8050701 0.6049 0.6049 0.7832 <p id="xdx_807_eifrs-full--DisclosureOfGoingConcernExplanatory_zC68L8Nt5C33" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 2. <span id="xdx_824_za0JcvI2XIlb">GOING CONCERN</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; color: #222222"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of June 30, 2023, the Company had cash and cash equivalents of approximately $<span id="xdx_905_eifrs-full--Cash_iI_pn3n3_dm_c20230630_zKuR25EtEyr5" title="Cash and cash equivalents">7.7</span> million and total current liabilities of approximately $<span id="xdx_908_ecustom--TotalCurrentLiabilities_iI_pn3n3_dm_c20230630_zYxuoGKAIKng" title="Total current liabilities">2.6</span> million. For the three months ended June 30, 2023, the Company is reporting a net loss of approximately $<span id="xdx_908_ecustom--NetLossIncome_pn3n3_dm_c20230401__20230630_z2IVXPIi32M4" title="Net (loss) income">5.9</span> million and cash used in operating activities of approximately $<span id="xdx_90E_ecustom--CashUsedInOperatingActivities_pn3n3_dm_c20230401__20230630_zuVZsJbvDtjc" title="Cash used in operating activities">3.5</span> million. As of July 31, 2023, the Company had approximately $<span id="xdx_902_eifrs-full--CashOnHand_iI_pn3n3_dm_c20230731_zUerZgYIlhs5" title="Cash on hand">6.4</span> million of cash and cash equivalents on hand.</p> <p style="margin: 0pt 0; font-size: 10pt; color: #222222"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company’s cash and cash equivalents balance is decreasing, and the Company will not generate positive cash flows from operations for the fiscal year ending March 31, 2024.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company may have to delay, scale-back, or eliminate certain of its activities and other aspects of its operations until such time as the Company is successful in securing additional funding. The Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources. The future success of the Company is dependent upon its ability to obtain additional funding. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. As of the date of this filing, the Company currently anticipates that current cash and cash equivalents, excluding any potential proceeds from its ATM program and Committed Purchase Agreement with Lincoln Park, access to which are generally limited based on the Company’s Nasdaq trading volume, will be sufficient to meet its anticipated cash requirements through the end of October 2023. These factors raise significant doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has incurred significant operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future and may never become profitable. The losses result primarily from its conduct of research and development activities.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company historically has funded its operations principally from proceeds from issuances of equity and debt securities. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan, beyond the potential proceeds that could be reasonably generated from its ATM program and Committed Purchase Agreement with Lincoln Park given the Company’s current trading volume on Nasdaq. The Company's ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties and, future equity issuances would result in dilution to existing stockholders and any future debt securities may contain covenants that limit the Company's operations or ability to enter into certain transactions.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> 7700000 2600000 5900000 3500000 6400000 <p id="xdx_80C_eifrs-full--DisclosureOfBasisOfConsolidationExplanatory_zNPBLt1PJ8zj" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 3. <span id="xdx_82A_zTtZYWk95YBb">BASIS OF PRESENTATION</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b><i>Statement of Compliance and Basis of Presentation</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These condensed consolidated interim financial statements have been prepared in accordance with the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”), IAS 34 <i>Interim Financial Reporting</i> and interpretations of the International Financial Reporting Interpretations Committee. These condensed consolidated interim financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the audited consolidated financial statements of the Company for the year ended March 31, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These condensed consolidated interim financial statements have been prepared on an historical cost basis except for items disclosed herein at fair value (see Note 17, “Financial Instruments and Risk Management”). In addition, these condensed consolidated interim financial statements have been prepared using the accrual basis of accounting, except for cash flow information.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has only one reportable operating segment.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These condensed consolidated interim financial statements were approved and authorized for issuance by the Audit Committee and Board of Directors (the “Board”) on August 29, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Consolidation</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The condensed consolidated interim financial statements include the accounts of the Company and:</p> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(a)</td><td>SalvaRx, a wholly-owned subsidiary, incorporated on May 6, 2015 in the British Virgin Islands;</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><i> </i></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(b)</td><td>iOx, a wholly-owned subsidiary incorporated in the U.K. on February 10, 2015. In September 2021, the Company, through SalvaRx, exchanged certain notes, accrued interest, warrants and receivables in exchange for shares of iOx representing <span id="xdx_90B_ecustom--PercentageOfOutstandingShares_pid_dp_c20210901__20210930_z0pjpM8U2VP" title="Percentage of outstanding shares">60.49</span>% of the outstanding shares of iOx. As a result of this exchange, the Company, through SalvaRx, increased its ownership of iOx from <span id="xdx_907_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zFuKRjzCwenh" title="Percentage of ownership">60.49</span>% to <span id="xdx_908_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20210901__20210930__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zklnWcGyv4Hd" title="Percentage of ownership">78.32</span>%. On July 18, 2022, the Company purchased the remaining non-controlling interest of iOx. <span style="background-color: white">See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx,” for a further discussion;</span></td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(c)</td><td>Saugatuck, a <span id="xdx_90C_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20230401__20230630__ifrs-full--GeographicalAreasAxis__custom--CountryOfBritishVirginIslandsMember_z6IhNnHbQVI9" title="Percentage of ownership subsidiary">70</span>% owned subsidiary incorporated in the British Virgin Islands. Saugatuck and subsidiary refers to Saugatuck and Saugatuck Rx LLC;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(d)</td><td>PDS, a <span id="xdx_903_eifrs-full--ProportionOfOwnershipInterestInSubsidiary_pid_dp_c20230401__20230630__ifrs-full--GeographicalAreasAxis__custom--CountryOfDelawareMember_zytwZOl3MA15" title="Percentage of ownership subsidiary">100</span>% owned subsidiary incorporated in Delaware, which provides human resources, and other services to each operating subsidiary via a shared services agreement;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(e)</td><td>SalvaRx LLC, a wholly-owned subsidiary through SalvaRx;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(f)</td><td>Saugatuck Rx LLC, a wholly-owned subsidiary of Saugatuck; and</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(g)</td><td>Tarus Therapeutics, LLC (“Tarus”), a wholly-owned subsidiary of Portage.</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">All inter-company balances and transactions have been eliminated in consolidation.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">Non-controlling interest in the equity of a subsidiary is accounted for and reported as a component of stockholders’ equity. As of June 30, 2023, non-controlling interest represents the <span id="xdx_90A_eifrs-full--ProportionOfOwnershipInterestsHeldByNoncontrollingInterests_pip0_dp_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SubsidiariesTwoMember_z0279j1U3V27" title="Non-controlling interest">30</span>% shareholder ownership interest in Saugatuck and subsidiary, which is consolidated by the Company. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx” for a discussion of the Company’s purchase of the balance of the non-controlling interest in iOx.</p> <p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Functional and Presentation Currency</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company’s functional and presentation currency is the U.S. Dollar.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Use of Estimates and Judgments</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The preparation of the condensed consolidated interim financial statements in conformity with IFRS requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.</p> <p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Significant areas where estimates are made include valuation of financial instruments (including the Stimunity Convertible Note (as defined below), deferred tax assets and liabilities, research and development costs, fair value used for acquisition of intangible assets, contingent consideration assumed and measurement of share-based compensation. Significant areas where critical judgments are applied include assessment of impairment of investments, goodwill and in-process research and development and the determination of the accounting acquirer and acquiree in the business combination accounting.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> 0.6049 0.6049 0.7832 0.70 1 0.30 <p id="xdx_808_ecustom--DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory_zVGKYhS5PVIf" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 4.</b>  <b><span id="xdx_82A_z3rLDgwykt91">SIGNIFICANT ACCOUNTING POLICIES</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The accounting policies are set out in Note 4 to the Company’s audited consolidated financial statements for the fiscal year ended March 31, 2023 (“Fiscal 2023”). These policies have been applied consistently to all periods presented in these condensed consolidated interim financial statements.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p id="xdx_842_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zUgpBGr1FQrd" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_863_zTcH9nIV98c8">Recent Accounting Pronouncements</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>IFRS Pronouncements Issued</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b>Impact of Adoption of Significant New IFRS Standards in Fiscal 2023</b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 23.05pt"><b>(a)</b></td><td><b>Annual Improvements to IFRS Standards 2018-2020</b></td></tr></table> <p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The annual improvements process addresses issues in the 2018-2020 reporting cycles including changes to IFRS 9, “Financial Instruments,” IFRS 1, “First Time Adoption of IFRS,” IFRS 16, “Leases,” and IAS 41, “Biological Assets”.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">i)</td><td>The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition of financial liabilities.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">ii)</td><td>The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent to also measure cumulative translation differences using the amounts reported by the parent based on the parent’s date of transition to IFRS.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">iii)</td><td>The amendment to IFRS 16’s illustrative example 13 removes the illustration of payments from the lessor related to leasehold improvements.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These amendments were effective for annual periods beginning on or after January 1, 2022. The adoption of these amendments did not have a material effect on the Company’s annual consolidated financial statements or the condensed consolidated interim financial statements for the three months ended June 30, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b>New Accounting Standards, Interpretations and Amendments</b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Standards issued but not yet effective up to the date of issuance of the Company’s condensed consolidated interim financial statements are listed below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they become effective.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 23.05pt"><b>(a)</b></td><td><b>IAS 1: Presentation of Financial Statements</b></td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment to IAS 1 clarifies how to classify debt and other liabilities as either current or non-current. The amendment will be effective for annual periods beginning on or after January 1, 2024. The Company is currently evaluating the new guidance and impacts on its consolidated financial statements.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 23.05pt"><b>(b)</b></td><td><b>Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture</b></td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment addresses the conflict between IFRS 10, “Consolidated Financial Statements,” and IAS 28, “Investments in Associates and Joint Ventures,” in dealing with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, “Business Combinations,” between an investor and its associate or joint venture, is recognized in full. Any gain or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognized only to the extent of unrelated investors' interests in the associate or joint venture. The IASB has deferred the effective date of these amendments indefinitely, but an entity that early adopts the amendments must apply them prospectively. The Company is evaluating whether the adoption of the above amendment will have a material impact on its financial statements. </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p id="xdx_842_ecustom--DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory_zUgpBGr1FQrd" style="margin: 0pt 0; font-size: 10pt"><b><span id="xdx_863_zTcH9nIV98c8">Recent Accounting Pronouncements</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>IFRS Pronouncements Issued</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b>Impact of Adoption of Significant New IFRS Standards in Fiscal 2023</b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 23.05pt"><b>(a)</b></td><td><b>Annual Improvements to IFRS Standards 2018-2020</b></td></tr></table> <p style="margin: 0pt 0 0pt 23.05pt; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The annual improvements process addresses issues in the 2018-2020 reporting cycles including changes to IFRS 9, “Financial Instruments,” IFRS 1, “First Time Adoption of IFRS,” IFRS 16, “Leases,” and IAS 41, “Biological Assets”.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">i)</td><td>The amendment to IFRS 9 addresses which fees should be included in the 10% test for derecognition of financial liabilities.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">ii)</td><td>The amendment to IFRS 1 allows a subsidiary adopting IFRS at a later date than its parent to also measure cumulative translation differences using the amounts reported by the parent based on the parent’s date of transition to IFRS.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">iii)</td><td>The amendment to IFRS 16’s illustrative example 13 removes the illustration of payments from the lessor related to leasehold improvements.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">These amendments were effective for annual periods beginning on or after January 1, 2022. The adoption of these amendments did not have a material effect on the Company’s annual consolidated financial statements or the condensed consolidated interim financial statements for the three months ended June 30, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b>New Accounting Standards, Interpretations and Amendments</b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Standards issued but not yet effective up to the date of issuance of the Company’s condensed consolidated interim financial statements are listed below. This listing is of standards and interpretations issued, which the Company reasonably expects to be applicable at a future date. The Company intends to adopt those standards when they become effective.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 23.05pt"><b>(a)</b></td><td><b>IAS 1: Presentation of Financial Statements</b></td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment to IAS 1 clarifies how to classify debt and other liabilities as either current or non-current. The amendment will be effective for annual periods beginning on or after January 1, 2024. The Company is currently evaluating the new guidance and impacts on its consolidated financial statements.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 0"></td><td style="width: 23.05pt"><b>(b)</b></td><td><b>Amendments to IFRS 10 and IAS 28: Sale or Contribution of Assets between an Investor and Its Associate or Joint Venture</b></td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The amendment addresses the conflict between IFRS 10, “Consolidated Financial Statements,” and IAS 28, “Investments in Associates and Joint Ventures,” in dealing with the loss of control of a subsidiary that is sold or contributed to an associate or joint venture. The amendments clarify that the gain or loss resulting from the sale or contribution of assets that constitute a business, as defined in IFRS 3, “Business Combinations,” between an investor and its associate or joint venture, is recognized in full. Any gain or loss resulting from the sale or contribution of assets that do not constitute a business, however, is recognized only to the extent of unrelated investors' interests in the associate or joint venture. The IASB has deferred the effective date of these amendments indefinitely, but an entity that early adopts the amendments must apply them prospectively. The Company is evaluating whether the adoption of the above amendment will have a material impact on its financial statements. </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p id="xdx_80C_eifrs-full--DisclosureOfOtherAssetsExplanatory_zpOfJijnKX37" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 5. <span id="xdx_82F_zFc8TSEGN2E4">PREPAID EXPENSES AND OTHER RECEIVABLES</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_zlezYx9TKsak" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"><span id="xdx_8B3_zjjOB13ITE7c" style="display: none">Schedule of prepaid expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_494_20230630_zDKx7z89cIeh" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49D_20230331_zuVYDxtG3T7" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of <br/>June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of <br/>March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"> </td></tr> <tr id="xdx_40F_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_maCPz3YF_zdELFxB8hZsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Prepaid clinical research costs</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">1,783</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,653</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPz3YF_zPQXvdTYgSkc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Prepaid insurance</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">446</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">621</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3_maCPz3YF_zEVBCX4QW714" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Research &amp; development tax credits</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">186</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">169</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPz3YF_zjWPnNnT6y08" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Other prepaid expenses</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">151</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">56</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--TaxDeposits_iI_pn3n3_maCPz3YF_zrNGiLQ6XwOe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Tax deposits</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">115</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">119</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPz3YF_zWmb2cfcdHnc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">71</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">71</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPz3YF_z19abeB5Bz7e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,752</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,689</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"></p> <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock_pn3n3_zlezYx9TKsak" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"><span id="xdx_8B3_zjjOB13ITE7c" style="display: none">Schedule of prepaid expenses and other receivables</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_494_20230630_zDKx7z89cIeh" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49D_20230331_zuVYDxtG3T7" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of <br/>June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of <br/>March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: right"> </td></tr> <tr id="xdx_40F_eifrs-full--CurrentReceivablesFromSaleOfProperties_iI_maCPz3YF_zdELFxB8hZsc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Prepaid clinical research costs</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">1,783</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,653</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--CurrentAdvancesToSuppliers_iI_pn3n3_maCPz3YF_zPQXvdTYgSkc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Prepaid insurance</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">446</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">621</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--ResearchAndDevelopmentCredit_iI_pn3n3_maCPz3YF_zEVBCX4QW714" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Research &amp; development tax credits</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">186</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">169</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eifrs-full--CurrentPrepaidExpenses_iI_pn3n3_maCPz3YF_zjWPnNnT6y08" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Other prepaid expenses</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">151</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">56</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--TaxDeposits_iI_pn3n3_maCPz3YF_zrNGiLQ6XwOe" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Tax deposits</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">115</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">119</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--OtherCurrentReceivables_iI_pn3n3_maCPz3YF_zWmb2cfcdHnc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">71</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">71</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_eifrs-full--CurrentPrepayments_iTI_pn3n3_mtCPz3YF_z19abeB5Bz7e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">2,752</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,689</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> 1783000 1653000 446000 621000 186000 169000 151000 56000 115000 119000 71000 71000 2752000 2689000 <p id="xdx_80F_ecustom--InvestmentInAssociateDisclosureTextBlock_zLSFGQcubLG7" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 6. <span id="xdx_828_zGxYpZxdZNVf">INVESTMENT IN ASSOCIATE</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Details of the Company’s associate, Stimunity S.A. (“Stimunity”), as of June 30, 2023 and March 31, 2023 are as follows:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_zlJxhX1vVFnc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: left"><span id="xdx_8B7_zms8Ml2oK9Rg" style="display: none">Schedule of investment associate</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Name</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Principal Activity</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Place of Incorporation and <br/>Principal Place of Business</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Voting Rights Held as <br/>of June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Voting Rights Held as <br/>of March 31, 2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; font-size: 10pt; text-align: justify"><span id="xdx_902_eifrs-full--NameOfAssociate_c20230401__20230630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z8bhFYJHKWjl" title="Name">Associate: Stimunity S.A.</span></td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_905_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20230401__20230630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z7Bzct1DDK6j" title="Principal activity">Biotechnology</span></td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_902_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20230401__20230630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zvmThg4rPKwg" title="Place of Incorporation and principal place of business">Paris, France</span></td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_905_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20230401__20230630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zbtPyGVpyKQ4" title="Voting rights held">44.0</span>%</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90D_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20220401__20230331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zEFFCF8f8Xdi" title="Voting rights held">44.0</span>%</td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table is a roll-forward of the Company’s investment in Stimunity as of and for the three months ended June 30, 2023 and 2022:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_zDamfctTIeA4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span id="xdx_8B7_ziFHoK0rMla1" style="display: none">Schedule of investment in Stimunity S.A.</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of and for the Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20230401__20230630_z4WtMAg6wg8f" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance">806</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_980_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20220401__20220630_zcIx2wErSF72" style="width: 10%; font-size: 10pt; text-align: right" title="Beginning balance">1,673</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Share of loss</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_985_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20230401__20230630_zIZGDxHOkKa9" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share of loss">(50</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_980_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20220401__20220630_zLhenUIY2w9f" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share of loss">(60</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20230401__20230630_zEJjza7SpjX5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance">756</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20220401__20220630_zibRllCkuif3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">1,613</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company accounts for its investment in Stimunity under the equity method and, accordingly, records its share of Stimunity’s earnings or loss based on its ownership percentage. The Company recorded loss in equity in Stimunity of $<span id="xdx_909_ecustom--EquityInLossIncome_pn3n3_c20230401__20230630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zi2KqoHB2KH5" title="Equity in (loss) income">50,000</span> and $<span id="xdx_909_ecustom--EquityInLossIncome_pn3n3_c20220401__20220630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zsvNOdszCKe4" title="Equity in (loss) income">60,000</span> for the three months ended June 30, 2023 and 2022, respectively.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Under the Shareholders’ Agreement entered into on June 1, 2020, Portage has (i) a preferential subscription right to maintain its equity interest in Stimunity in the event of a capital increase from the issuance of new securities by Stimunity, except for issuances of new securities for stock options, under a merger plan or for an acquisition, and (ii) the right to vote against any (a) issuances of additional securities that would call for Portage to waive its preferential subscription right, or (b) any dilutive issuance.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 13, 2022,<span id="xdx_907_ecustom--ConvertibleNoteDescription_c20230712__20230713_z3JDUP6H0i4a" title="Convertible Note description"> the Company entered into a commitment with Stimunity to provide €600,000 under a convertible note (the “Stimunity Convertible Note”) with a maturity date of September 1, 2023 (the “Maturity Date”). The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible Note is automatically converted into Series A shares of Stimunity upon Stimunity completing a Series A round for at least €20 million. If such subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into Series A shares of Stimunity at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares (other than Common Shares or Series A shares) for at least €5 million (the “Minimum Raise”), the Company will have the right to convert the Stimunity Convertible Note and the historical Series A shares of Stimunity owned into the new category of shares. In the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the right to convert the Stimunity Convertible Note into Series A shares at €363.00 per share or the raise price less 15%, whichever is lower. The Stimunity Convertible Note was funded on September 12, 2022. See Note 15, “Commitments and Contingent Liabilities – Stimunity Convertible Note,” for a further discussion.</span></p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Stimunity Convertible Note was initially recorded at $<span id="xdx_901_ecustom--TranslatedValue_pn3n3_dm_c20220911__20220912_z05il1k6HhQe" title="Translated value">0.614</span> million to record the translated value of the Stimunity Convertible Note on September 12, 2022. The Company recognized an unrealized gain of $<span id="xdx_907_ecustom--UnrealizedGain_pn3n3_dm_c20220401__20230331_z0feYD1n80Qg" title="Unrealized gain">0.039</span> million through other comprehensive income (“OCI”) in Fiscal 2023 to reflect the change in translation rate for the Stimunity Convertible Note settleable in euros, increasing the carrying value of the Stimunity Convertible Note to $<span id="xdx_903_ecustom--IncreasingCarryingValue_pn3n3_dm_c20220401__20230331_zZojrofZNNpa" title="Increasing the carrying value">0.653</span> million.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of March 31, 2023, the Company determined that there were indications of impairment of both the investment in associate and the Stimunity Convertible Note receivable, based upon the inability of Stimunity to obtain financing. The Company performed an IAS 36 fair value analysis evaluating the likelihood of various scenarios given the then-current market conditions, the increasing cost of capital and development delays associated with Stimunity’s lack of liquidity. The Company recorded provisions of impairment of $<span id="xdx_90E_ecustom--ImpairmentAnalysis_pn3n3_dm_c20220401__20230331_zD08fTJHG2F" title="Impairment analysis">0.607</span> million and $<span id="xdx_909_ecustom--StimunityConvertibleNoteReceivable_pn3n3_dm_c20220401__20230331_zuZATVPpffl4" title="Stimunity convertible note receivable">0.211</span> million, with respect to the investment in associate and the Stimunity Convertible Note receivable, respectively, decreasing the carrying value of the investment in associate and the Stimunity Convertible Note to $<span id="xdx_906_ecustom--DecreasingCarryingValue_pn3n3_dm_c20220401__20230331_zcR339mrUUck" title="Decreasing the carrying value">0.806</span> million and $<span id="xdx_909_ecustom--StimunityConvertibleNote_pn3n3_dm_c20220401__20230331_z6raV5kblsIa" title="Stimunity convertible note">0.442</span> million, respectively, as of March 31, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">During the three months ended June 30, 2023, the Company recorded a loss of $<span id="xdx_90A_ecustom--LossOnSharesRecognize_pn3n3_dm_c20230401__20230630_z8JVrAZJFubc" title="Loss on shares recognize">0.05</span> million to recognize its share of Stimunity’s results of operations and recorded a marginal gain through OCI to reflect the translation rate effect on the Stimunity Convertible Note settleable in euros. The Company determined that there were <span id="xdx_90E_ecustom--ChangesInMarket_pn3n3_do_c20230401__20230630_z38YOQ4pAsR8" title="Changes in the market">no</span> significant changes in the market or Stimunity’s outlook from March 31, 2023 to June 30, 2023, and, accordingly, determined that the carrying value at June 30, 2023 was not further impaired.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--DisclosureOfInvestmentAssociatetableTextBlock_zlJxhX1vVFnc" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: left"><span id="xdx_8B7_zms8Ml2oK9Rg" style="display: none">Schedule of investment associate</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Name</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Principal Activity</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Place of Incorporation and <br/>Principal Place of Business</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Voting Rights Held as <br/>of June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Voting Rights Held as <br/>of March 31, 2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 20%; font-size: 10pt; text-align: justify"><span id="xdx_902_eifrs-full--NameOfAssociate_c20230401__20230630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z8bhFYJHKWjl" title="Name">Associate: Stimunity S.A.</span></td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_905_eifrs-full--PrincipalPlaceOfBusinessOfAssociate_c20230401__20230630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_z7Bzct1DDK6j" title="Principal activity">Biotechnology</span></td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_902_eifrs-full--CountryOfIncorporationOrResidenceOfAssociate_c20230401__20230630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zvmThg4rPKwg" title="Place of Incorporation and principal place of business">Paris, France</span></td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_905_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20230401__20230630__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zbtPyGVpyKQ4" title="Voting rights held">44.0</span>%</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 19%; font-size: 10pt; text-align: center"><span id="xdx_90D_eifrs-full--ProportionOfVotingPowerHeldInAssociate_pid_dp_c20220401__20230331__ifrs-full--SignificantInvestmentsInAssociatesAxis__custom--StimunitySAMember_zEFFCF8f8Xdi" title="Voting rights held">44.0</span>%</td></tr> </table> Associate: Stimunity S.A. Biotechnology Paris, France 0.440 0.440 <table cellpadding="0" cellspacing="0" id="xdx_881_ecustom--ScheduleOfInvestmentInStimunitySaTableTextBlock_pn3n3_zDamfctTIeA4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INVESTMENT IN ASSOCIATE (Details 1)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"><span id="xdx_8B7_ziFHoK0rMla1" style="display: none">Schedule of investment in Stimunity S.A.</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of and for the Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_984_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20230401__20230630_z4WtMAg6wg8f" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance">806</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_980_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iS_pn3n3_c20220401__20220630_zcIx2wErSF72" style="width: 10%; font-size: 10pt; text-align: right" title="Beginning balance">1,673</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Share of loss</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_985_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20230401__20230630_zIZGDxHOkKa9" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Share of loss">(50</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_980_eifrs-full--UnrecognisedShareOfLossesOfAssociates_iN_pn3n3_di_c20220401__20220630_zLhenUIY2w9f" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Share of loss">(60</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_980_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20230401__20230630_zEJjza7SpjX5" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance">756</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_eifrs-full--InvestmentsInSubsidiariesJointVenturesAndAssociates_iE_pn3n3_c20220401__20220630_zibRllCkuif3" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">1,613</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> 806000 1673000 50000 60000 756000 1613000 50000000 60000000 the Company entered into a commitment with Stimunity to provide €600,000 under a convertible note (the “Stimunity Convertible Note”) with a maturity date of September 1, 2023 (the “Maturity Date”). The Stimunity Convertible Note provides for simple interest at 7% per annum. The Stimunity Convertible Note is automatically converted into Series A shares of Stimunity upon Stimunity completing a Series A round for at least €20 million. If such subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into Series A shares of Stimunity at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares (other than Common Shares or Series A shares) for at least €5 million (the “Minimum Raise”), the Company will have the right to convert the Stimunity Convertible Note and the historical Series A shares of Stimunity owned into the new category of shares. In the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the right to convert the Stimunity Convertible Note into Series A shares at €363.00 per share or the raise price less 15%, whichever is lower. The Stimunity Convertible Note was funded on September 12, 2022. See Note 15, “Commitments and Contingent Liabilities – Stimunity Convertible Note,” for a further discussion. 614000 39000.000 653000 607000 211000 806000 442000 50000.00 0 <p id="xdx_80A_ecustom--DisclosureOfPublicCompaniesExplanatoryTextBlock_zVTVI2F8EEK4" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 7. <span id="xdx_829_zEoyqaVWSJUg">INVESTMENT IN PUBLIC COMPANY</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a discussion of the Company’s investment in Intensity Therapeutics, Inc. (“Intensity”) as of June 30, 2023 and March 31, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Intensity Therapeutics, Inc.</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In connection with the SalvaRx Acquisition in fiscal 2019, the Company acquired a $<span id="xdx_907_ecustom--PrivateInvestmentsInterest_pn3n3_dm_c20230401__20230630__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_z4cSnA8Ii7Rk" title="Investment">4.5</span> million interest in Intensity, a private clinical stage biotechnology company, of <span id="xdx_905_ecustom--InvestmentOwnedShares_iI_pid_dm_c20230630__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_zHklMxcr3Cni" title="Number of shares purchased">1.0</span> million shares, which represented a <span id="xdx_909_ecustom--InvestmentOwnershipPercentage_iI_pid_dp_c20230630__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfSalvaRxMember_zxKihq4yg487" title="Percentage of equity held">7.5</span>% equity interest in Intensity. The investment was recorded at fair value (which approximates cost) at the acquisition date. The investment in Intensity has been irrevocably designated as a financial asset recorded at fair value with gains and losses recorded through OCI. Upon Intensity’s IPO discussed below, effective June 30, 2023, the fair value of the asset is determined by quoted market price.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 11, 2019, the Company entered into an agreement with Fast Forward Innovations Limited (“Fast Forward”) to purchase Intensity Holdings Limited (“IHL”), a wholly-owned subsidiary of Fast Forward. The Company paid $<span id="xdx_909_eifrs-full--EquityInterestsOfAcquirer_iI_pn3n3_dm_c20190711__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zzOqR7DnIk4e" title="Equity interests of acquirer">1.3</span> million for IHL through the issuance of <span id="xdx_90B_ecustom--NumberOfInstrumentsOrInterestsIssuedOrIssuables_iI_pid_c20190711__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zaXwwkz6Nc7e" title="Number of ordinary shares issued in acquisition">129,806</span> ordinary shares of the Company. The sole asset of IHL consists of <span id="xdx_90B_ecustom--NumberOfPrivateCompanyShareConsistsInSoleAsset_iI_pid_c20190711__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zo5hVM2OcS0a" title="Number of private company share consists in sole asset">288,458</span> shares of Intensity. This transaction increased the Company’s ownership of Intensity to <span id="xdx_90C_eifrs-full--NumberOfSharesOutstanding_iI_pid_c20190711__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember__ifrs-full--BusinessCombinationsAxis__custom--AcquisitionOfIntensityHoldingLimitedMember_zPATgmr5Ud79" title="Number of shares outstanding">1,288,458</span> shares.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On October 28, 2021, Intensity filed a Form S-1 Registration Statement with the SEC to register shares for an initial public offering (“IPO”), which was declared effective by the SEC, but subsequently withdrawn prior to closing.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In October and November of 2022, Intensity filed amendments to its Form S-1 Registration Statement, which reflected a proposed offering price in the range of $<span id="xdx_909_eifrs-full--ParValuePerShare_iI_c20221031_zQCSSvPr6jt7" title="Per share price">4.00</span> - $<span id="xdx_90F_eifrs-full--ParValuePerShare_iI_c20221130_zMR4higFALjh" title="Per share price">5.00</span> per share, which is less than the Company’s carrying value, which was an external indication of impairment. Accordingly, the Company performed an IAS 36, “Impairment of Assets,” fair value analysis and determined a fair value of $<span id="xdx_90F_eifrs-full--PlanAssetsAtFairValue_iI_pn3n3_dm_c20221231_zm6fGAFNMbR5" title="Impairment asset fair value">3.363</span> million, which was $<span id="xdx_903_ecustom--ImpairmentAssetsCarringValue_iI_pn3n3_dm_c20221231_zwwHhOSkrcB4" title="Impairment assets carring value">4.046</span> million less than the then carrying value at December 31, 2022. Intensity continued to seek a successful IPO during the fourth quarter of fiscal year ended March 31, 2023. At March 31, 2023, the Company undertook an IAS 36 fair value analysis based on the continued existence of external indications of impairment. The analysis included evaluating the likelihood of a successful IPO and the timing of such an event, as well as the then lack of marketability of the shares and the continued uncertainty surrounding an IPO, or any type of financing.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In April 2023, Intensity completed a 1:2 reverse stock split, which reduced the Company’s holdings to <span id="xdx_909_ecustom--ReverseStockSplitHoldingShares_iI_pid_c20230430_zjpZlLxvD7g" title="Holding shares">644,229</span> shares. As the offering was priced at $<span id="xdx_905_ecustom--OfferingPerSharePrice_iI_c20230430__ifrs-full--RangeAxis__ifrs-full--BottomOfRangeMember_zWFlEwtpxT64" title="Offering price">4.00</span> to $<span id="xdx_907_ecustom--OfferingPerSharePrice_iI_c20230430__ifrs-full--RangeAxis__ifrs-full--TopOfRangeMember_zpiHiAuFkT6k" title="Offering price">5.00</span> per share, the Company determined the fair value of its interest to be $<span id="xdx_90D_eifrs-full--InterestReceivable_iI_pn3n3_dm_c20230630_zU51eiDoK2Fj" title="Fair value interest">2.087</span> million. In total, the Company recorded an unrealized loss of $<span id="xdx_90B_eifrs-full--ImpairmentLoss_pn3n3_dm_c20220401__20230331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--OCIMember_zEUK8yQv2fya" title="Impairment loss">5.322</span> million with respect to Intensity for the fiscal year ended March 31, 2023, which was recognized through OCI, reducing the Company’s carrying value in Intensity to $<span id="xdx_90C_ecustom--CashCarryingValue_iI_pn3n3_dm_c20230331__ifrs-full--ClassesOfIntangibleAssetsAndGoodwillAxis__custom--OCIMember_zlkKo0q27KV7" title="Cash carrying value">2.087</span> million as of March 31, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 5, 2023, Intensity completed an IPO of its common stock selling <span id="xdx_907_ecustom--NumberOfSharesSold_c20230704__20230705__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zZgGV5pGh9mf" title="Number of shares sold">3,900,000</span> shares at a price of $<span id="xdx_909_ecustom--PricePerShare_c20230704__20230705__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_z1jI7Z34rJL2" title="Price per share">5.00</span> per share generating net proceeds of approximately $<span id="xdx_900_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20230704__20230705__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zlRJCCx9quUj">16.2</span> million. In connection with the offering, Intensity’s common stock began trading on Nasdaq on June 30, 2023, under the ticker symbol “INTS.” The Intensity shares closed at a price of $<span id="xdx_900_ecustom--PricePerShare_c20230401__20230630__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zrBdSn34c7q1" title="Price per share">5.96</span> on June 30, 2023. The Company received an additional <span id="xdx_906_ecustom--AdditionalAntidilutionShares_c20230401__20230630__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zIv7FRuvZp6c" title="Additional antidilution shares">2,659</span> shares in connection with the offering pursuant to certain anti-dilution rights. Intensity sold its overallotment shares totaling <span id="xdx_901_ecustom--NumberOfSharesSold_c20230706__20230707__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_za42oH69uQHd" title="Number of shares sold">585,000</span> shares, which closed on July 7, 2023. At that date, the Company owned approximately <span id="xdx_907_eifrs-full--PercentageOfVotingEquityInterestsAcquired_iI_pid_dp_c20230707__ifrs-full--TypesOfInvestmentPropertyAxis__custom--IntensityMember_zX3aqgHS9022" title="Percentage of voting equity interests acquired">4.7</span>% of the issued and outstanding shares of Intensity. The Company recorded unrealized gain of $<span id="xdx_907_ecustom--UnrealizedGainOrLoss_pn3n3_dm_c20230401__20230630_zCHK1AkOMnw9" title="Unrealized gain or loss">1.768</span> million through OCI to reflect the difference between the market value of the Company’s ownership interest and its then carrying value, increasing the Company’s carrying value in Intensity to $<span id="xdx_909_ecustom--CashCarryingValue_iI_pn3n3_dm_c20230630_zqImO0rgpCQ6" title="Cash carrying value">3.855</span> million as of June 30, 2023. There was <span id="xdx_90D_ecustom--UnrealizedGainOrLoss_pn3n3_dmo_c20220401__20220630_zbut513k61Tg" title="Unrealized gain or loss">no</span> unrealized gain or loss with respect to the Company’s investment in Intensity during the three months ended June 30, 2022.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> 4500000 1000.0 0.075 1300000 129806 288458 1288458 4.00 5.00 3363000 4046000.000 644229 4.00 5.00 2087000.000 5322000 2087000.000 3900000 5.00 16200000 5.96 2659 585000 0.047 1768000 3855000 0 <p id="xdx_800_eifrs-full--DisclosureOfLeasesExplanatory_zdqjXIWIuyY7" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 8. <span id="xdx_827_zfg4RY7vGM1l">LEASE</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company entered into a lease of office space, which commenced on May 1, 2023. The lease provides for an original term of two years with an option to renew the lease for an additional term of three years. The Company has included the extension option in the lease analysis under IFRS 16, based upon management’s intentions. The Company calculated the lease liability using its incremental borrowing rate of 13%. The Company provided a $<span id="xdx_90E_eifrs-full--LongtermDeposits_iI_pn3n3_dm_c20230630_zjGf4m2auFTa" title="Security deposit">0.013</span> million security deposit. The lease liability is payable as follows (in thousands):</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_886_eifrs-full--DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_pn3n3_zMCRXOfyHzAk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"><span id="xdx_8B2_z4UvRTQ46X8e" style="display: none">Schedule of lease liability</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_495_20230630_zOLIJwSE9RW" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Twelve Months Ended June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr> <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentDueNextRollingTwelveMonths_iI_zXlE5oxLo1Pl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">2024</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">79</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LesseeOperatingLeaseLiabilityPaymentDueInRollingYearTwo_iI_zjTWUk7UauIl" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">2025</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">81</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--LesseeOperatingLeaseLiabilityPaymentDueInRollingYearThree_iI_zG3naKwiQwn4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">2026</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">83</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFour_iI_zzsz3GXjLBq7" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">2027</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">84</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFive_iI_znxqafSFJoId" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">2028</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">71</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityPaymentDue_iI_zTKdGgf0MoSf" style="vertical-align: bottom; background-color: White"> <td style="color: White; text-align: left; font-size: 10pt; padding-left: 5.4pt"> Total</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">398</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--LeaseLiabilityInterest_iI_zuk4OlR7E7c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less: interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(102</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr> <tr id="xdx_40E_eifrs-full--LeaseLiabilities_iI_zkmxHrySkVLh" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Total lease liability</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">296</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_400_eifrs-full--CurrentLeaseLiabilities_iI_zbnq03QkQ4Di" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Lease liability - current</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">47</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40D_eifrs-full--NoncurrentLeaseLiabilities_iI_znJZ3w0gkVOl" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Lease liability - non-current</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">249</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"> </p> 13000.000 <table cellpadding="0" cellspacing="0" id="xdx_886_eifrs-full--DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory_pn3n3_zMCRXOfyHzAk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - LEASE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"><span id="xdx_8B2_z4UvRTQ46X8e" style="display: none">Schedule of lease liability</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_495_20230630_zOLIJwSE9RW" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Twelve Months Ended June 30,</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr> <tr id="xdx_407_ecustom--LesseeOperatingLeaseLiabilityPaymentDueNextRollingTwelveMonths_iI_zXlE5oxLo1Pl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">2024</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">79</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LesseeOperatingLeaseLiabilityPaymentDueInRollingYearTwo_iI_zjTWUk7UauIl" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">2025</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">81</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--LesseeOperatingLeaseLiabilityPaymentDueInRollingYearThree_iI_zG3naKwiQwn4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">2026</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">83</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFour_iI_zzsz3GXjLBq7" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">2027</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">84</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFive_iI_znxqafSFJoId" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">2028</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">71</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LesseeOperatingLeaseLiabilityPaymentDue_iI_zTKdGgf0MoSf" style="vertical-align: bottom; background-color: White"> <td style="color: White; text-align: left; font-size: 10pt; padding-left: 5.4pt"> Total</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">398</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--LeaseLiabilityInterest_iI_zuk4OlR7E7c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Less: interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(102</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr> <tr id="xdx_40E_eifrs-full--LeaseLiabilities_iI_zkmxHrySkVLh" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Total lease liability</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">296</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_400_eifrs-full--CurrentLeaseLiabilities_iI_zbnq03QkQ4Di" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Lease liability - current</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">47</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40D_eifrs-full--NoncurrentLeaseLiabilities_iI_znJZ3w0gkVOl" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Lease liability - non-current</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">249</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> </table> 79000 81000 83000 84000 71000 398000 -102000 296000 47000 249000 <p id="xdx_80E_ecustom--AcquisitionsOfTarusExplanatory_zBaOePOqD3C1" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 9. <span id="xdx_824_zyzO5trDPU5g">ACQUISITION OF TARUS</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 1, 2022, the Company, its wholly-owned subsidiary, Portage Merger Sub I, Inc., its wholly-owned subsidiary, Portage Merger Sub II, LLC and Tarus Therapeutics, Inc., a Delaware corporation advancing adenosine receptor antagonists for the treatment of solid tumors, entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”). Under the structure of the Merger Agreement, Tarus Therapeutics, Inc. was ultimately merged into Portage Merger Sub II, LLC of the Company with the surviving entity renamed Tarus Therapeutics, LLC. The Tarus merger entitles the Company to the rights, know-how and/or ownership related to the assets developed by Tarus (the “Adenosine Compounds”), including:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">1.</td><td>All rights and obligations related to the License Agreement between Tarus and Impetis Biosciences Limited, dated October 29, 2019 (“Tarus License Agreement”), and the Call Option under the Tarus License Agreement, which was exercised on November 5, 2020;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">2.</td><td>All intellectual property and related documents owned or controlled by Tarus, including issued or pending patents, patent applications and trade secrets. Additionally, any draft submissions and/or correspondence with patent authorities;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">3.</td><td>All documents and supplies related to Adenosine Compounds (as defined in the Tarus License Agreement) including inventory, reagents, data, assays, reports, vendor agreements and other information related to the preclinical development;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">4.</td><td style="text-align: left">All clinical supplies, manufacturing know-how, batch records, regulatory documents pertaining to the Adenosine Compounds, certain reservations for manufacturing campaigns and any related agreements;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">5.</td><td style="text-align: left">All regulatory documents and correspondence pertaining to the Adenosine Compounds;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">6.</td><td style="text-align: left">All Contract Research Organization (“CRO”) agreements and protocol related documents for Adenosine Compounds;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">7.</td><td style="text-align: left">All current documents related to market research, forecasting, budgets and competitive intelligence; and</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">8.</td><td style="text-align: left">Rights to the use of Tarus Therapeutics’ name for regulatory purposes.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt">As consideration for Tarus, the Company issued to former Tarus shareholders an aggregate of <span id="xdx_902_ecustom--NumberOfShareIssued_c20230401__20230630_zrXNxIUN2keb" title="Number of share issued">2,425,999</span> ordinary shares of Portage, calculated on the basis of $<span id="xdx_90D_ecustom--OrdinarySharesValue_iI_pn3n3_dm_uUSD_c20230630_znNZnLUUrki9" title="Ordinary shares value">18</span> million divided by the 60-day volume weighted average price per share of ordinary shares of Portage. Such ordinary shares have not been registered with the SEC and were subject to lock-up agreements for terms ranging from six to twelve months, which expired on February 1, 2023 and July 1, 2023, respectively. Additionally, the ordinary shares that were subject to a twelve month lock-up period, are also subject to a three month dribble-out period, which commenced July 1, 2023. During the dribble out period, each holder may not sell more than 10% of the average trading volume of the Company’s ordinary shares for the rolling three month period prior to the date on which the holder executes a trade of the Company’s ordinary shares without its prior written consent (which the Company is permitted to withhold at its sole discretion). Additionally, milestone payments of up to $<span id="xdx_90B_eifrs-full--ProceedsFromIssueOfOrdinaryShares_pn3n3_dm_c20230401__20230630_zUsICgVatIJi" title="Proceeds from offering">32</span> million in cash or Portage ordinary shares (at the discretion of the Company) would be triggered upon achievement of future development and sales milestones, as described below. As a result of the transaction:</p> <p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td style="text-align: left">The Company also assumed $<span id="xdx_904_eifrs-full--ShorttermEmployeeBenefitsExpense_pn3n3_dm_c20230401__20230630_zwGUlgUFRWc" title="Short term debt">2</span> million in short-term debt held by Tarus and deferred license milestones obligations ($1 million plus interest). The short-term debt was repaid by the Company in July 2022.</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td style="text-align: left">Upon enrolling the first patient in a Phase 2 clinical trial utilizing Tarus’s adenosine receptor antagonists, the Company will pay an additional one-time milestone payment of $<span id="xdx_902_ecustom--MilestonePayment_pn3n3_dm_c20230401__20230630__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zjzWVPrJxWw9" title="Milestone payment">15</span> million to the former Tarus shareholders. Payment will be in the form of cash or Portage ordinary shares (at the discretion of the Company). The remaining $<span id="xdx_905_ecustom--MilestonePayment_pn3n3_dm_uUSD_c20230401__20230630_zH0ELLleiz0e" title="Milestone payment">17</span> million milestone is based on targeted commercial sales.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In connection with the acquisition of Tarus, the Company performed a fair value analysis of the assets acquired and liabilities assumed. The Company based the analysis on its clinical plan and timing of development events, and the probabilities of success determined primarily based upon empirical third party data and Company experience as well as the relevant cost of capital. In its fair value analysis, the Company used the Multi-Period Excess Earnings Method for PORT-6 and PORT-7 and the Replacement Cost Method for PORT-8 and PORT-9, determined based upon the maturity of the assets and the availability of sufficient data to measure fair value. The Company recorded the ordinary shares issued at $<span id="xdx_906_ecustom--OrdinarySharesIssuedValue_iI_pn3n3_dm_c20220701_zNyLiRZAlHYd" title="Ordinary shares issued Value">17.2</span> million, which represented the aggregate market value of the ordinary shares issued on July 1, 2022. The Company followed the guidance of IAS 3 and IAS 32 and recorded a deferred purchase price payable - Tarus of $<span id="xdx_901_ecustom--DeferredPurchasePricePayable_pn3n3_dm_uUSD_c20230401__20230630_zokMI7WiuPR3" title="Deferred purchase price payable">8.538</span> million, which reflected the estimated acquisition date fair value of contractual milestone obligations incurred. The principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount rate used. The Company recorded the obligation as a non-current liability, in accordance with the provisions IAS 32 with respect to the classification of financial assets and financial liabilities.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company will determine the fair value of the shares issuable upon achievement of future development and sales milestones at each balance sheet date. Any change to the fair value will be recorded in the Company’s statements of operations and other comprehensive income (loss).</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table summarizes the purchase price allocation to the fair value of assets acquired and liabilities assumed for Tarus:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_pn3n3_z843VCXRKrQ2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 5.4pt"><span id="xdx_8BD_zpw3G1uw9KP4" style="display: none">Schedule of fair value of assets acquired and liabilities assumed</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_49F_20230630__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zHglarFqWKLb" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--AssetsAbstract_iB" style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 5.4pt"><span style="text-decoration: underline">Assets:</span></td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">(In thousands)</td></tr> <tr id="xdx_40F_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Identifiable intangible assets</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">28,200</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40D_eifrs-full--Goodwill_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 5.4pt">Goodwill</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_eifrs-full--OtherTangibleOrIntangibleAssetsTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">28,738</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40E_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; padding-left: 5.4pt">Consideration:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-left: 5.4pt">Fair value of shares issued</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">17,200</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Liabilities assumed</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,000</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_403_eifrs-full--DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deferred purchase consideration at fair value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">8,538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40E_eifrs-full--ContingentLiabilitiesRecognisedInBusinessCombination_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total liabilities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">28,738</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Pro forma Information</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Summary unaudited pro forma condensed results of operations for the three months ended June 30, 2022, assuming the Tarus acquisition had occurred at the beginning of the earliest period presented, are as follows:</span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfProformaInformationTableTextBlock_pn3n3_zN57M8xVpPE8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details 1)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"><span id="xdx_8BB_zAt9XkKPUMK5" style="display: none">Schedule of Pro forma Information</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_495_20220401__20220630__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_za3v0lNNoug8" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left; padding-left: 5.4pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p> <p style="margin-top: 0; margin-bottom: 0">June 30, 2022</p></td></tr> <tr id="xdx_407_eifrs-full--ProfitLossFromContinuingOperations_zaxgn9UE6LEj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Loss from operations</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right">(3,788</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40D_eifrs-full--ProfitLossBeforeTax_zJtOFqi7PD64" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Loss before provision for income taxes</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,893</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40A_eifrs-full--ProfitLoss_zhlTq7YA27u4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net loss</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,341</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40B_eifrs-full--ComprehensiveIncome_zdJ6CBc0POVi" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total comprehensive loss for period</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,341</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_408_ecustom--EarningLossPerShare_pid_zG45AGhqFAL9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Loss per share</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.09</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">These pro forma results are not necessarily indicative of what would have occurred if the acquisition had been in effect for the period presented, and they may not be indicative of results expected in the future.</span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> 2425999 18000000 32000000 2000000 15000000 17000000 17200000 8538000 <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_pn3n3_z843VCXRKrQ2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 5.4pt"><span id="xdx_8BD_zpw3G1uw9KP4" style="display: none">Schedule of fair value of assets acquired and liabilities assumed</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_49F_20230630__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_zHglarFqWKLb" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--AssetsAbstract_iB" style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 5.4pt"><span style="text-decoration: underline">Assets:</span></td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: center">(In thousands)</td></tr> <tr id="xdx_40F_eifrs-full--IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Identifiable intangible assets</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">28,200</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40D_eifrs-full--Goodwill_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 5.4pt">Goodwill</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40C_eifrs-full--OtherTangibleOrIntangibleAssetsTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total assets</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">28,738</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40E_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; padding-left: 5.4pt">Consideration:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_eifrs-full--AcquisitiondateFairValueOfTotalConsiderationTransferred_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-left: 5.4pt">Fair value of shares issued</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">17,200</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--IdentifiableAssetsAcquiredLiabilitiesAssumed_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Liabilities assumed</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,000</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_403_eifrs-full--DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deferred purchase consideration at fair value</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">8,538</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr id="xdx_40E_eifrs-full--ContingentLiabilitiesRecognisedInBusinessCombination_iI_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total liabilities</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">28,738</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> </table> 28200000 538000 28738000 17200000 3000000 8538000 28738000 <table cellpadding="0" cellspacing="0" id="xdx_883_ecustom--ScheduleOfProformaInformationTableTextBlock_pn3n3_zN57M8xVpPE8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - ACQUISITION OF TARUS (Details 1)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"><span id="xdx_8BB_zAt9XkKPUMK5" style="display: none">Schedule of Pro forma Information</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_495_20220401__20220630__ifrs-full--TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis__custom--TarusAcquisitionMember_za3v0lNNoug8" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 10pt; text-align: left; padding-left: 5.4pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p> <p style="margin-top: 0; margin-bottom: 0">June 30, 2022</p></td></tr> <tr id="xdx_407_eifrs-full--ProfitLossFromContinuingOperations_zaxgn9UE6LEj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 87%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Loss from operations</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right">(3,788</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40D_eifrs-full--ProfitLossBeforeTax_zJtOFqi7PD64" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Loss before provision for income taxes</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(3,893</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40A_eifrs-full--ProfitLoss_zhlTq7YA27u4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net loss</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,341</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_40B_eifrs-full--ComprehensiveIncome_zdJ6CBc0POVi" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total comprehensive loss for period</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,341</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_408_ecustom--EarningLossPerShare_pid_zG45AGhqFAL9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Loss per share</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(0.09</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> </table> -3788000 -3893000 -1341000 -1341000 -0.09 <p id="xdx_801_ecustom--InProcessResearchAndDevelopmentAndDeferredTaxLiability_zpl7Ug1Xa7Ll" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 10. <span id="xdx_827_zLR3PnloFQvj">IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In-process research and development (“IPR&amp;D”) consists of the following projects (in thousands):</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_pn3n3_zBu9c5HkfXmg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 5.4pt"><span id="xdx_8B3_zlRYomU67cmj" style="display: none">Schedule of in-process research and development</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Value as of</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Project #</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Description</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-left: 5.4pt">iOx:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 25%; font-size: 10pt; padding-left: 5.4pt">PORT 2 (IMM60)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 24%; font-size: 10pt; text-align: left; padding-left: 5.4pt">Melanoma &amp; Lung Cancers</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98B_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_zfyhsR4pv2Bk" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">36,181</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_980_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_zEgljuQ1bEwj" style="width: 22%; font-size: 10pt; text-align: right" title="In-process research and development">36,181</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt">PORT 3 (IMM65)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Ovarian/Prostate Cancers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_983_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--IMM65IOXMelanomaLungCancersMember_z3IvRfDROne" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">21,709</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_985_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXMelanomaLungCancersMember_ztKF8Qw1RK89" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">21,709</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_982_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--IOXMember_znbnnsselCcj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">57,890</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98C_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--IOXMember_z04jKwGHRfIg" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">57,890</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 5.4pt">Oncomer/Saugatuck</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">DNA Aptamers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_983_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zdKqC1IhmrVe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">178</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zH1PCKlKtnw7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">178</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-left: 5.4pt">Tarus:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">PORT 6 &amp; PORT 7</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_987_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_zsZp1SYUZ8Mh" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">22,723</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_983_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_zE3NpobkDQZd" style="font-size: 10pt; text-align: right" title="In-process research and development">22,723</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 5.4pt">PORT 8</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_989_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_zGhnxVXfgT3h" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">420</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_982_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_zuzFbDwZGed2" style="font-size: 10pt; text-align: right" title="In-process research and development">420</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt">PORT 9</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_zycHcqKL48z6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">472</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_985_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_z7iWllSw7sed" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">472</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--TarusMember_zrGNQbqnBas3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">23,615</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--TarusMember_zwnpHGJFxQK5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">23,615</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">In-process research and development</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_c20230630_z8RJOor2Lot6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">81,683</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_ecustom--InprocessResearchAndDevelopment_iI_c20230331_zcyxZG0xEDR5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="In-process research and development">81,683</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Deferred tax liability</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--DeferredTaxesLiability_iI_c20230630_zUDMwQBOO1jk" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Deferred tax liability">13,510</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--DeferredTaxesLiability_iI_c20230331_zanLBd9gd5P8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax liability">13,195</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">At the end of each reporting period, the Company is required to assess whether there is any indication that an asset may be impaired. Pursuant to IAS 36, the Company evaluated the then-current capital markets, the increasing costs of capital, and the delays in the timing of asset development and concluded that provisions for impairment were required during the year ended March 31, 2023 with respect to the iOx IPR&amp;D and the Tarus IPR&amp;D. The Company recognized an impairment of $<span id="xdx_90F_ecustom--RecognizedImpairment_pn3n3_dm_c20230401__20230630_ztIYyW9HvGT8" title="Recognized an impairment">59.320</span> million with respect to the iOx assets, reducing the Company’s carrying value from $<span id="xdx_90F_ecustom--CarryingValue_pn3n3_dm_c20230401__20230630__ifrs-full--CounterpartiesAxis__custom--IoxIPRAndDMember__ifrs-full--BorrowingsByNameAxis__ifrs-full--TopOfRangeMember_zxmS5DlkYiD4" title="Carrying value">117.210</span> million to $<span id="xdx_90E_ecustom--CarryingValue_pn3n3_dm_c20230401__20230630__ifrs-full--CounterpartiesAxis__custom--IoxIPRAndDMember__ifrs-full--BorrowingsByNameAxis__ifrs-full--BottomOfRangeMember_z38NyueCNzy3" title="Carrying value">57.890</span> million and an impairment of $<span id="xdx_903_ecustom--Impairment_pn3n3_dm_c20230401__20230630_zEAw3rObreaj" title="Impairment">4.585</span> million with respect to the Tarus assets, reducing the Company’s carrying value from $<span id="xdx_90B_ecustom--CarryingValue_pn3n3_dm_c20230401__20230630__ifrs-full--CounterpartiesAxis__custom--TrusIPRAndDMember__ifrs-full--BorrowingsByNameAxis__ifrs-full--TopOfRangeMember_z4HDzAMjXdK7" title="Carrying value">28.2</span> million to $<span id="xdx_907_ecustom--CarryingValue_pn3n3_dm_c20230401__20230630__ifrs-full--CounterpartiesAxis__custom--TrusIPRAndDMember__ifrs-full--BorrowingsByNameAxis__ifrs-full--BottomOfRangeMember_zDkk1CEwCGk7" title="Carrying value">23.615</span> million. The deferred tax liability in the U.K. was reduced as a result of the IPR&amp;D impairment loss recognized by iOx for financial statement purposes.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Deferred tax liability represents iOx’s estimated tax on the difference between book and tax basis of the IPR&amp;D, which is taxable in the U.K, and the effect of usable net operating loss carryforwards.<br/> </p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ScheduleOfInProcessResearchAndDevelopmentTableTextBlock_pn3n3_zBu9c5HkfXmg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 5.4pt"><span id="xdx_8B3_zlRYomU67cmj" style="display: none">Schedule of in-process research and development</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Value as of</td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Project #</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold">Description</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">March 31, 2023</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-left: 5.4pt">iOx:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 25%; font-size: 10pt; padding-left: 5.4pt">PORT 2 (IMM60)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 24%; font-size: 10pt; text-align: left; padding-left: 5.4pt">Melanoma &amp; Lung Cancers</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98B_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_zfyhsR4pv2Bk" style="width: 22%; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">36,181</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_980_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--IMM60IOXMelanomaLungCancersMember_zEgljuQ1bEwj" style="width: 22%; font-size: 10pt; text-align: right" title="In-process research and development">36,181</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt">PORT 3 (IMM65)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Ovarian/Prostate Cancers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_983_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--IMM65IOXMelanomaLungCancersMember_z3IvRfDROne" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">21,709</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_985_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--IMM65IOXMelanomaLungCancersMember_ztKF8Qw1RK89" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">21,709</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_982_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--IOXMember_znbnnsselCcj" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">57,890</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98C_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--IOXMember_z04jKwGHRfIg" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">57,890</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt; padding-left: 5.4pt">Oncomer/Saugatuck</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">DNA Aptamers</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_983_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zdKqC1IhmrVe" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">178</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--OncomerSaugatuckDNAAptamersMember_zH1PCKlKtnw7" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">178</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-left: 5.4pt">Tarus:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">PORT 6 &amp; PORT 7</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_987_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_zsZp1SYUZ8Mh" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">22,723</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_983_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptorsMember_zE3NpobkDQZd" style="font-size: 10pt; text-align: right" title="In-process research and development">22,723</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 5.4pt">PORT 8</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left; padding-left: 5.4pt">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_989_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_zGhnxVXfgT3h" style="font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">420</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_982_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors1Member_zuzFbDwZGed2" style="font-size: 10pt; text-align: right" title="In-process research and development">420</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt">PORT 9</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Adenosine Receptors</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98E_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_zycHcqKL48z6" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">472</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_985_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--TarusAdenosineReceptors2Member_z7iWllSw7sed" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">472</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_c20230630__ifrs-full--CounterpartiesAxis__custom--TarusMember_zrGNQbqnBas3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">23,615</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98D_ecustom--InprocessResearchAndDevelopment_iI_c20230331__ifrs-full--CounterpartiesAxis__custom--TarusMember_zwnpHGJFxQK5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="In-process research and development">23,615</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">In-process research and development</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="text-align: left; padding-bottom: 2.5pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98A_ecustom--InprocessResearchAndDevelopment_iI_c20230630_z8RJOor2Lot6" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="In-process research and development">81,683</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98B_ecustom--InprocessResearchAndDevelopment_iI_c20230331_zcyxZG0xEDR5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="In-process research and development">81,683</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Deferred tax liability</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_ecustom--DeferredTaxesLiability_iI_c20230630_zUDMwQBOO1jk" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Deferred tax liability">13,510</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--DeferredTaxesLiability_iI_c20230331_zanLBd9gd5P8" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Deferred tax liability">13,195</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> 36181000 36181000 21709000 21709000 57890000 57890000 178000 178000 22723000 22723000 420000 420000 472000 472000 23615000 23615000 81683000 81683000 13510000 13195000 59320000 117210000 57890000 4585000 28200000 23615000 <p id="xdx_80B_eifrs-full--DisclosureOfIncomeTaxExplanatory_zOH1cYlYMWQf" style="margin: 0pt 0; font-size: 10pt"><span style="background-color: white"><b>NOTE 11. <span id="xdx_820_zTyN782uVRt8">INCOME TAXES</span></b></span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company is a BVI business company. The BVI government does not, under existing legislation, impose any income or corporate tax on corporations.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">PDS is a U.S. corporation and is subject to U.S. federal, state and local income taxes, as applicable.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">iOx is subject to U.K. taxes.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The (expense) benefit from income taxes consists of the following for the three months ended June 30, 2023 and 2022 (U.S. Dollars in thousands):</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zoqSmVLMDwmg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold"><span id="xdx_8BE_zChqTykMyt7i" style="display: none">Schedule of income taxes benefit</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_499_20230401_20230630" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_497_20220401_20220630" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">For the Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">Current:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--CurrentFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 74%; font-size: 10pt; font-weight: bold">Federal</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(3</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0789">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--CurrentStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">State and local</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--CurrentForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_eifrs-full--CurrentTaxExpenseIncome_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(3</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">Deferred:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold">Federal</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">State and local</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0806">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">148</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,552</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_eifrs-full--AdjustmentsForDeferredTaxExpense_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total deferred</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">148</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,552</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_pn3n3_di_zMjB5icmuYq8" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Benefit from income taxes</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">145</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,552</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a reconciliation of the U.S. taxes to the effective income tax rates for the three months ended June 30, 2023 and 2022 (U.S. Dollars in thousands):</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z4s0dODqmh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BA_zXdTLkA2KKSf" style="display: none">Schedule of reconciliation income tax rates</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_49E_20230401__20230630_zvOrKnFtVgVk" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_490_20220401__20220630_z272SGLu3BI1" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr id="xdx_40D_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_zf746Mqzrv3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">(Loss) income on ordinary activities before tax</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(605</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">34</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_zqbLBZPwwIDh" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Statutory U.S. income tax rate</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">21.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr> <tr id="xdx_408_ecustom--IncomeTaxBenefitExpenseAtStatutoryIncomeTaxRate_zLA5XG1f1E13" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Income tax benefit (expense) at statutory income tax rate</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">127</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(7</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--SharebasedCompensationExpenseRecognizedForFinancialStatementPurposes_zPIGAAuD8e6a" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Share-based compensation expense recognized for financial statement purposes</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">(142</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--OtherLossesRecognized_zNVyynNBZjsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Other losses recognized</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">7</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_zVviSreJ657c" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Utilization of losses not previously benefitted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">12</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--IncomeTaxExpense_zS7cKD2h2i73" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Income tax (expense)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(3</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of June 30, 2023, the Company had $<span id="xdx_901_ecustom--FederalNetOperatingLosses_iI_pn3n3_dm_c20230630_zzTtYxk1XI5j" title="Federal net operating losses">0.6</span> million of federal net operating losses, which carryforward indefinitely but are limited to 80% of taxable income when utilized and $0.4 million of items deducted for financial statements but not tax, excluding share-based compensation. As of each of June 30, 2023 and March 31, 2023, the Company had U.S. deferred tax assets of $<span id="xdx_90D_eifrs-full--DeferredTaxAssets_iI_pn3n3_dm_c20230630_zk4jVXALG9Fg" title="Deferred tax assets"><span id="xdx_902_eifrs-full--DeferredTaxAssets_iI_pn3n3_dm_c20230331_zVjO4ZstZGp1" title="Deferred tax assets">0.2</span></span> million.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a reconciliation of the U.K. taxes to the effective income tax rates for the three months ended June 30, 2023 and 2022 (U.S. Dollars in thousands):</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ScheduleOfIncomeTaxExplanatory_pn3n3_zEETdp6LTVka" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BF_zYCOOupkKJg1" style="display: none">Schedule of effective income tax rates</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_49F_20230401__20230630_z7ocZRUqpYEd" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_496_20220401__20220630_zvFfgm8Bgz39" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr id="xdx_407_eifrs-full--AccountingProfit_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Loss on ordinary activities before tax</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">1,576</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,743</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eifrs-full--ApplicableTaxRate_pid_dp_zCAeKPePWHpk" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Statutory U.K. income tax rate</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">25.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr> <tr id="xdx_400_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Loss at statutory income tax rate</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">394</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">331</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--ChangeIncreaseInDeferredIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Change from increase in deferred income tax rate</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">105</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--RecognitionOfDeferredTaxAssets_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Recognition of deferred tax assets</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ForeignCurrencyEffect_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Foreign currency effect</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(246</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,116</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--TaxEffectOfTaxLosses_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Income tax benefit</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">148</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,552</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Research and development credit receivables of $<span id="xdx_903_ecustom--ResearchAndDevelopmentCreditReceivables_iI_pn3n3_dm_c20230630_z8hd7Zjxrh8c" title="Research and development credit receivables"><span id="xdx_902_ecustom--ResearchAndDevelopmentCreditReceivables_iI_pn3n3_dm_c20230331_z0xLZqKe4xu" title="Research and development credit receivables">0.2</span></span> million were included in prepaid expenses and other receivables on the condensed consolidated interim statements of financial position as of each of June 30, 2023 and March 31, 2023. The receivable was collected in July 2023.</span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following is a reconciliation of financial statement income (loss) to tax basis income (loss) (in thousands):</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock_pn3n3_zm7XzwBudW4g" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8B0_zOuaRQRdg0s7" style="display: none">Schedule of reconciliation of financial statement loss to tax basis loss</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_490_20230630__ifrs-full--GeographicalAreasAxis__custom--UnitedStateMember_zcZJje0y94Ai" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_498_20230630__ifrs-full--GeographicalAreasAxis__custom--BVIMember_zhTmQFLwOY44" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_490_20230630__ifrs-full--GeographicalAreasAxis__custom--CountryOfUnitedKingdomMember_zlylIqrpXNM3" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_491_20230630_zUwUkGU6JXvb" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_492_20220630__ifrs-full--GeographicalAreasAxis__custom--UnitedStateMember_zpuSgWFGvbm7" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_499_20220630__ifrs-full--GeographicalAreasAxis__custom--BVIMember_zeZr54Or83I9" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_498_20220630__ifrs-full--GeographicalAreasAxis__custom--CountryOfUnitedKingdomMember_zRaFVYVTHxTk" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_492_20220630_zP3jwtTWm1ph" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="31" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>States</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">BVI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>Kingdom</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>States</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">BVI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr id="xdx_401_ecustom--PretaxIncomeLoss_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Pre-tax loss</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(609</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(3,886</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(1,576</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(6,071</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">34</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(2,468</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(1,743</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(4,177</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--SharebasedCompensationExpenseForFinancialStatementPurposesForWhichNoBenefitWasTaken_iI_pn3n3_zuJs3AQxCYtd" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based compensation expense for financial statement purposes for which no benefit was taken</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">683</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">683</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LossesNotSubjectToTax_iI_pn3n3_zoBkl70aaI7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Losses not subject to tax</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,886</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,886</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,468</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,468</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--UtilizationOfLossNotPreviouslyBenefitted_pn3n3_zMyyyTSejM6d" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Utilization of losses not previously benefitted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(59</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(59</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(34</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(34</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--PretaxLossSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Taxable income (loss)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">15</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(1,576</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(1,561</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0919">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,743</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,743</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">As of June 30, 2023 and March 31, 2023, the Company’s deferred tax assets and liabilities in the U.K. consisted of the effects of temporary differences attributable to the following (U.S. Dollars in thousands):</span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureOfDeferredTaxAssetsExplanatory_pn3n3_zEzvmfEBNHM3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt"><span id="xdx_8BA_zeB48A1WOibh" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_491_20230630" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_499_20230331_znnDaHw7LUce" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30,</td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Deferred tax assets:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzLpY_zai0j5yNrsGh" style="vertical-align: bottom; background-color: White"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Net operating loss</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(4,594</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(4,131</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetUnrecognized_i01I_pn3n3_maNDTAzLpY_zexekBAxagY3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deferred tax asset (unrecognized)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,500</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,500</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_eifrs-full--NetDeferredTaxAssets_iTI_pn3n3_mtNDTAzLpY_msNDTLzujE_zzYCpgi6kBKi" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deferred tax asset</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(3,094</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,631</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxLiabiltiesAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Deferred tax liabilities:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxLiabilitiesInProcessRAndD_i01I_pn3n3_maDTLz5vf_zJwfE4B6xBuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">In-process research and development</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">13,510</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,195</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DeferredTaxLiability1_iTI_pn3n3_mtDTLz5vf_maNDTLzujE_zhZi0AdH8Qec" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deferred tax liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">13,510</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,195</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eifrs-full--NetDeferredTaxLiabilities_iI_pn3n3_zj5eQ77fibcl" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net deferred tax liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">10,416</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">10,564</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">iOx generated no research and development cash credits recorded for the three months ended June 30, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of June 30, 2023 and March 31, 2023, iOx had a net deferred tax liability of approximately $<span id="xdx_90C_eifrs-full--DeferredTaxLiabilities_iI_pn3n3_dm_c20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zFV0jZsg7gp4" title="Deferred tax liabilities">10.4</span> million and approximately $<span id="xdx_90D_eifrs-full--DeferredTaxLiabilities_iI_pn3n3_dm_c20230331__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zYLarDg77Iv9" title="Deferred tax liabilities">10.6</span> million, respectively. On January 8, 2019, the Company originally recognized a $19.8 million deferred tax liability, reflecting the then prevailing U.K. tax rate of 17% on the difference between the book and income tax basis of IPR&amp;D acquired as part of the SalvaRx Acquisition. In the fiscal 2022, the Company recorded a $<span id="xdx_903_eifrs-full--DeferredTaxExpenseIncome_pn3n3_dm_c20220401__20220630_z8IjTWDqgTA7" title="Deferred income taxes">7.0</span> million increase in deferred income taxes to reflect a future change in the U.K. income tax rate to 25% effective April 1, 2023 and recognized $<span id="xdx_90D_ecustom--CurrentYearLosses_pn3n3_dm_c20230401__20230630_zmdAjVRJjTH6" title="Current year losses">0.7</span> million of current year losses and $0.8 million of prior year losses. The Company also recognized a $<span id="xdx_909_eifrs-full--IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset_pn3n3_dm_c20210401__20220331_zNU3XTlqL0vl" title="Increase (Decrease) in deferred tax liability">1.1</span> million decrease in deferred tax liability in fiscal 2022 to reflect the effect of the change in exchange rates on the liability settleable in British pound sterling. For the year ended March 31, 2023, the Company recognized an aggregate reduction in net deferred tax liability of $17.9 million, comprised of $11.3 million to recognized the deferred tax effect of loss on impairment recognized with respect to the iOx IPR&amp;D, $0.7 million related to other current year losses, $3.8 million to reflect the change related to the future U.K. tax rates and $2.1 million to reflect the effect of the change in exchange rates on the liability settleable in British pound sterling. For the three months ended June 30, 2023, the Company recognized a net decrease in the deferred tax liability of $<span id="xdx_902_ecustom--DeferredTaxLiability_iI_pn3n3_dm_c20230630_z9mZdbI2KnVl" title="Deferred tax liability">0.1</span> million comprised of $<span id="xdx_90F_eifrs-full--TaxEffectFromChangeInTaxRate_pn3n3_dm_c20230401__20230630_zR1iRG6Rkov2" title="Change in exchange rates on the liability">0.3</span> million to reflect the effect of the change in exchange rates on the liability in the period and recognized $<span id="xdx_907_ecustom--ExchangeRatesLosses_pn3n3_dm_c20230401__20230630_zcioU3OSLbui" title="Exchange rates losses">0.4</span> million of current period losses.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">There is no expiration date for accumulated tax losses in the U.K. entities<span style="font-size: 10pt">.</span></p> <p style="margin: 0pt 0; font-size: 10pt"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ScheduleOfIncomeTaxesBenefitTableTextBlock_pn3n3_zoqSmVLMDwmg" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold"><span id="xdx_8BE_zChqTykMyt7i" style="display: none">Schedule of income taxes benefit</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_499_20230401_20230630" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_497_20220401_20220630" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">For the Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr id="xdx_40F_eifrs-full--CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">Current:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--CurrentFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; width: 74%; font-size: 10pt; font-weight: bold">Federal</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(3</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0789">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--CurrentStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">State and local</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0792">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--CurrentForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0794">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0795">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_eifrs-full--CurrentTaxExpenseIncome_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total current</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(3</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0798">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eifrs-full--DeferredTaxExpenseIncomeAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold">Deferred:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredFederalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold">Federal</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredStateAndLocalIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; text-align: left">State and local</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0806">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0807">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_ecustom--DeferredForeignIncomeTaxBenefit_i01_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; font-size: 10pt; font-weight: bold; padding-bottom: 1pt">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">148</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,552</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_407_eifrs-full--AdjustmentsForDeferredTaxExpense_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt">Total deferred</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">148</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,552</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_eifrs-full--IncomeTaxExpenseContinuingOperations_iN_pn3n3_di_zMjB5icmuYq8" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Benefit from income taxes</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">145</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,552</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> -3000 -3000 148000 2552000 148000 2552000 -145000 -2552000 <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock_pn3n3_z4s0dODqmh" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 1)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BA_zXdTLkA2KKSf" style="display: none">Schedule of reconciliation income tax rates</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_49E_20230401__20230630_zvOrKnFtVgVk" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_490_20220401__20220630_z272SGLu3BI1" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr id="xdx_40D_ecustom--IncomeLossOnOrdinaryActivitiesBeforeTax_zf746Mqzrv3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">(Loss) income on ordinary activities before tax</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(605</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">34</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--StatutoryU.s.IncomeTaxRate_pid_dp_zqbLBZPwwIDh" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Statutory U.S. income tax rate</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">21.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">21.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr> <tr id="xdx_408_ecustom--IncomeTaxBenefitExpenseAtStatutoryIncomeTaxRate_zLA5XG1f1E13" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Income tax benefit (expense) at statutory income tax rate</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">127</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(7</td><td style="white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--SharebasedCompensationExpenseRecognizedForFinancialStatementPurposes_zPIGAAuD8e6a" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Share-based compensation expense recognized for financial statement purposes</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">(142</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0830">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--OtherLossesRecognized_zNVyynNBZjsl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Other losses recognized</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">7</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--UtilizationOfLossesNotPreviouslyBenefitted_zVviSreJ657c" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Utilization of losses not previously benefitted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">12</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0836">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--IncomeTaxExpense_zS7cKD2h2i73" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Income tax (expense)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(3</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> -605000 34000 0.210 0.210 127000 -7000 -142000 7000 12000 -3000 600000 200000 200000 <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--ScheduleOfIncomeTaxExplanatory_pn3n3_zEETdp6LTVka" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 2)"> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"><span id="xdx_8BF_zYCOOupkKJg1" style="display: none">Schedule of effective income tax rates</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_49F_20230401__20230630_z7ocZRUqpYEd" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" id="xdx_496_20220401__20220630_zvFfgm8Bgz39" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr id="xdx_407_eifrs-full--AccountingProfit_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Loss on ordinary activities before tax</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">1,576</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,743</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eifrs-full--ApplicableTaxRate_pid_dp_zCAeKPePWHpk" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Statutory U.K. income tax rate</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">25.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">%</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">19.0</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">%</td></tr> <tr id="xdx_400_eifrs-full--TaxExpenseIncomeAtApplicableTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Loss at statutory income tax rate</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">394</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">331</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--ChangeIncreaseInDeferredIncomeTaxRate_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Change from increase in deferred income tax rate</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0861">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">105</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--RecognitionOfDeferredTaxAssets_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Recognition of deferred tax assets</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0864">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0865">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--ForeignCurrencyEffect_i_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Foreign currency effect</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(246</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">2,116</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--TaxEffectOfTaxLosses_i_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Income tax benefit</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">148</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">2,552</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> 1576000 1743000 0.250 0.190 394000 331000 105000 -246000 2116000 148000 2552000 200000 200000 <table cellpadding="0" cellspacing="0" id="xdx_882_ecustom--ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock_pn3n3_zm7XzwBudW4g" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 3)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8B0_zOuaRQRdg0s7" style="display: none">Schedule of reconciliation of financial statement loss to tax basis loss</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_490_20230630__ifrs-full--GeographicalAreasAxis__custom--UnitedStateMember_zcZJje0y94Ai" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_498_20230630__ifrs-full--GeographicalAreasAxis__custom--BVIMember_zhTmQFLwOY44" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_490_20230630__ifrs-full--GeographicalAreasAxis__custom--CountryOfUnitedKingdomMember_zlylIqrpXNM3" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_491_20230630_zUwUkGU6JXvb" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_492_20220630__ifrs-full--GeographicalAreasAxis__custom--UnitedStateMember_zpuSgWFGvbm7" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_499_20220630__ifrs-full--GeographicalAreasAxis__custom--BVIMember_zeZr54Or83I9" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_498_20220630__ifrs-full--GeographicalAreasAxis__custom--CountryOfUnitedKingdomMember_zRaFVYVTHxTk" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_492_20220630_zP3jwtTWm1ph" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="31" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">June 30, 2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>States</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">BVI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>Kingdom</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">United <br/>States</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">BVI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Foreign</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr id="xdx_401_ecustom--PretaxIncomeLoss_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Pre-tax loss</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(609</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(3,886</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(1,576</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 4%; font-size: 10pt; font-weight: bold; text-align: right">(6,071</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">34</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(2,468</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(1,743</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 4%; font-size: 10pt; text-align: right">(4,177</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--SharebasedCompensationExpenseForFinancialStatementPurposesForWhichNoBenefitWasTaken_iI_pn3n3_zuJs3AQxCYtd" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Share-based compensation expense for financial statement purposes for which no benefit was taken</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">683</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0890">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">683</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0892">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0894">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--LossesNotSubjectToTax_iI_pn3n3_zoBkl70aaI7b" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Losses not subject to tax</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0897">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,886</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0899">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,886</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,468</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,468</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--UtilizationOfLossNotPreviouslyBenefitted_pn3n3_zMyyyTSejM6d" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Utilization of losses not previously benefitted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(59</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0907">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0908">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(59</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(34</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0912">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(34</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_402_ecustom--PretaxLossSubjectToTax_iI_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Taxable income (loss)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">15</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(1,576</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">(1,561</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0919">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0920">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,743</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">(1,743</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> </table> -609000 -3886000 -1576000 -6071000 34000 -2468000 -1743000 -4177000 683000 683000 3886000 3886000 2468000 2468000 -59000 -59000 -34000 -34000 15000 -1576000 -1561000 -1743000 -1743000 <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureOfDeferredTaxAssetsExplanatory_pn3n3_zEzvmfEBNHM3" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - INCOME TAXES (Details 4)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt"><span id="xdx_8BA_zeB48A1WOibh" style="display: none">Schedule of deferred tax assets and liabilities</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_491_20230630" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_499_20230331_znnDaHw7LUce" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30,</td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td></tr> <tr id="xdx_409_ecustom--DeferredTaxAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Deferred tax assets:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_405_ecustom--DeferredTaxAssetsNetOperatingLossCarryforward_i01I_pn3n3_maNDTAzLpY_zai0j5yNrsGh" style="vertical-align: bottom; background-color: White"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Net operating loss</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(4,594</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">(4,131</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_404_ecustom--DeferredTaxAssetUnrecognized_i01I_pn3n3_maNDTAzLpY_zexekBAxagY3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deferred tax asset (unrecognized)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">1,500</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">1,500</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_eifrs-full--NetDeferredTaxAssets_iTI_pn3n3_mtNDTAzLpY_msNDTLzujE_zzYCpgi6kBKi" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deferred tax asset</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">(3,094</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(2,631</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--DeferredTaxLiabiltiesAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt">Deferred tax liabilities:</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DeferredTaxLiabilitiesInProcessRAndD_i01I_pn3n3_maDTLz5vf_zJwfE4B6xBuj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">In-process research and development</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">13,510</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,195</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_ecustom--DeferredTaxLiability1_iTI_pn3n3_mtDTLz5vf_maNDTLzujE_zhZi0AdH8Qec" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Deferred tax liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right">13,510</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">13,195</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 1pt; padding-left: 5.4pt"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right"> </td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_402_eifrs-full--NetDeferredTaxLiabilities_iI_pn3n3_zj5eQ77fibcl" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net deferred tax liability</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">10,416</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">10,564</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> -4594000 -4131000 1500000 1500000 -3094000 -2631000 13510000 13195000 13510000 13195000 10416000 10564000 10400000 10600000 7000000.0 700000 1100000 100000 300000 400000 <p id="xdx_802_ecustom--CapitalStockTextBlock_zKhoJDDKWUt" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 12. <span id="xdx_82C_ztQI45XW1cQ2">CAPITAL STOCK</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(a)</td><td>Authorized ordinary shares<b>: </b>Unlimited number of Portage ordinary shares without par value.</td></tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(b)</td><td>The following is a roll-forward of Portage ordinary shares for the years ended June 30, 2023 and 2022:</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_z2Yui7vKGvzk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8B4_zxRDrfMyYJaf" style="display: none">Schedule of unlimited number of common shares without par value</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Ordinary<br/> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Ordinary <br/> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000’</td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000’$</td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000’</td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000’$</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98F_ecustom--CommonStockShares_iS_pid_c20230401__20230630_zTxEZc6Ra6Jh" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance, Shares">17,606</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--CommonStockValues_iS_pn3n3_c20230401__20230630_zLXNRxdqZ6ef" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance, Amount">218,782</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_985_ecustom--CommonStockShares_iS_pid_c20220401__20220630_zIf4LQvmMoWa" style="width: 10%; font-size: 10pt; text-align: right" title="Beginning balance, Shares">13,349</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--CommonStockValues_iS_pn3n3_c20220401__20220630_zC9bSGOXFy6e" style="width: 10%; font-size: 10pt; text-align: right" title="Beginning balance, Amount">158,324</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued under public offering and ATM, net of issue costs</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_982_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostShares_pid_c20230401__20230630_zb9iLZx1s11c" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue cost, shares">171</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_984_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20230401__20230630_zAPCOXx80B8b" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue costs">613</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_985_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostShares_pid_c20220401__20220630_z8ost6m83478" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue cost, shares"><span style="-sec-ix-hidden: xdx2ixbrl0986">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_989_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20220401__20220630_zMpctgZ2pZfi" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue costs"><span style="-sec-ix-hidden: xdx2ixbrl0988">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Shares issued or accrued for services</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98F_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pid_c20230401__20230630_zKlonSXHPOWf" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services, shares">9</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_987_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20230401__20230630_zUZhiS1jz5T" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services">30</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pid_c20220401__20220630_z0dJYNI8yNM1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued or accrued for services, shares">4</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_984_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20220401__20220630_zp1E7ch75YDf" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued or accrued for services">30</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98A_ecustom--CommonStockShares_iE_pid_c20230401__20230630_zbZAg85rz943" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance, Shares">17,786</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_ecustom--CommonStockValues_iE_pn3n3_c20230401__20230630_z3BsDMqTSD1c" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance, Amount">219,425</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_986_ecustom--CommonStockShares_iE_pid_c20220401__20220630_z7TuXLumcJ6l" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance, Shares">13,353</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--CommonStockValues_iE_pn3n3_c20220401__20220630_zmmYzDrq6t13" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance, Amount">158,354</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A6_zjSY7QlGvl2l" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Portage filed a shelf registration statement with the SEC under which it may sell ordinary shares, debt securities, warrants and units in one or more offerings from time to time, which became effective on March 8, 2021 (“Registration Statement”). In connection with the Registration Statement, Portage has filed with the SEC:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>a base prospectus, which covers the offering, issuance and sale by Portage of up to $200,000,000 in the aggregate of the securities identified above from time to time in one or more offerings;</td></tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>a prospectus supplement, which covers the offer, issuance and sale by Portage in an “at-the-market” (“ATM”) offering of up to a maximum aggregate offering price of $<span id="xdx_90E_ecustom--MaximumAggregateOfferingPrice_pn3n3_c20230401__20230630_zdLrk2YCWHCd" title="Maximum aggregate offering price">50,000,000</span> of Portage’s ordinary shares that may be issued and sold from time to time under a Controlled Equity Offering Sales Agreement, dated February 24, 2021 (the “Sales Agreement”), with Cantor Fitzgerald &amp; Co., the sales agent (“Cantor Fitzgerald”);</td></tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>a prospectus supplement dated June 24, 2021, for the offer, issuance and sale by Portage of <span id="xdx_902_ecustom--IssuanceAndSalesShares_pid_c20230401__20230630_zAV8VwzAl2U9" title="Issuance and sales, shares">1,150,000</span> ordinary shares for gross proceeds of approximately $<span id="xdx_90B_ecustom--GrossProceedsFromStock_pn3n3_dm_c20230401__20230630_zpmZbdjbCuhh" title="Gross proceeds from stock">26.5</span> million in a firm commitment underwritten public offering with Cantor Fitzgerald; and</td></tr></table> <p style="margin-top: 0; margin-bottom: 0"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>a prospectus supplement dated August 19, 2022, for the resale of up to $30,000,000 in ordinary shares that Portage may sell from time to time to Lincoln Park Capital Fund, LLC (“Lincoln”) and an additional 94,508 shares that were issued to Lincoln.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span id="xdx_90F_ecustom--CashFundDescription_c20230401__20230630_z3rpcXtS4gN1" title="Cash fund, description">The Sales Agreement permits the Company to sell in an ATM program up to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered, issued and sold by the Company under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Upon termination of the Sales Agreement, any portion of the $50,000,000 included in the Sales Agreement prospectus that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus.</span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">During Fiscal 2022, the Company sold <span id="xdx_90C_ecustom--NumberOfStockSold_pid_c20210401__20220331_zVAeJgyoNEte" title="Number of stock sold">90,888</span> ordinary shares under the ATM program, generating gross proceeds of approximately $<span id="xdx_908_ecustom--GrossProceedsFromStockSold_pn3n3_dm_c20210401__20220331_z28AY5xP4IHe" title="Gross proceeds from stock sold">2.6</span> million ($<span id="xdx_904_ecustom--NetProceedsFromStockSold_pn3n3_dm_c20210401__20220331_zUav7uTl8Rhj" title="Net proceeds from stock sold">2.5</span> million, net of commissions).</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has issued <span id="xdx_908_ecustom--NumberOfSharesSold_pid_c20230401__20230630_znPAygLK8bPk" title="Number of shares sold">2,425,999</span> ordinary shares in connection with the acquisition of Tarus Therapeutics, Inc. and in connection with the Tarus Therapeutics, Inc.’s acquisition it may issue additional ordinary shares. <span style="background-color: white">See Note 9, “Acquisition of Tarus,” for a further discussion.</span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 18, 2022, the Company entered into the iOx Share Exchange Agreement under which it exchanged <span id="xdx_904_ecustom--NumberOfSharesExchanged_pid_c20220715__20220718_zXYndI5YPZ02" title="Number of shares exchanged">1,070,000</span> ordinary shares of the Company for the remaining minority interest of <span id="xdx_90A_ecustom--MinorityInterestPercentage_iI_pid_dp_c20220718_zOXaakEuKgtf" title="Minority interest, percentage">21.68</span>% of iOx. <span style="background-color: white">See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx,” for a further discussion.</span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 6, 2022, the Company entered into a Purchase Agreement (the “Committed Purchase Agreement”) with Lincoln, under which it may require Lincoln to purchase ordinary shares of the Company having an aggregate value of up to $30 million (the “Purchase Shares”) over a period of 36 months. Upon execution of the Committed Purchase Agreement, the Company issued to Lincoln <span id="xdx_903_ecustom--NumberOfOrdinaryShareIssued_pid_c20220705__20220706_zukZJ6D78E7b" title="Number of ordinary share issued">94,508</span> ordinary shares, representing a 3% commitment fee. Pursuant to the Committed Purchase Agreement, Lincoln will be obligated to purchase the Purchase Shares in three different scenarios that are based on various market criteria and share amounts. The Company has the right to terminate the Committed Purchase Agreement for any reason, effective upon one business day prior written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The requirement that Lincoln must make a purchase will be suspended based on various criteria such as there not being an effective registration statement for Lincoln to be able to resell the ordinary shares it is committed to purchase and market criteria such as the Company continuing to be Depository Trust Company eligible, among other things. The Committed Purchase Agreement does not impose any financial or business covenants on the Company, and there are no limitations on the use of proceeds. The Company may raise capital from other sources in its sole discretion; provided, however, that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like securities until the three-year anniversary of the date of the Committed Purchase Agreement, excluding, however, an ATM transaction with a registered broker-dealer, which includes any sales under the Sales Agreement with Cantor Fitzgerald.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">As discussed in Note 2, “Going Concern,” the Company’s access to the ATM program and the Committed Purchase Agreement is generally limited based on the Company’s trading volume on Nasdaq.</span> See Note 15, “Commitments and Contingent Liabilities – Committed Purchase Agreement,” for a further discussion.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In Fiscal 2023, the Company sold <span id="xdx_90A_ecustom--NumberOfSharesSold_pid_c20220401__20230331__ifrs-full--CounterpartiesAxis__custom--ATMMember_zyzGCN1tn9i3" title="Number of shares sold">166,145</span> ordinary shares under the ATM program, generating net proceeds of approximately $<span id="xdx_90B_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20220401__20230331__ifrs-full--CounterpartiesAxis__custom--ATMMember_ze0yiUZcIfi3" title="Net proceeds from sale">0.9</span> million. Separately, in Fiscal 2023, the Company sold <span id="xdx_907_ecustom--NumberOfSharesSold_pid_c20220401__20230331__ifrs-full--CounterpartiesAxis__custom--LincolnMember_z312WYUZcCZ1" title="Number of shares sold">480,000</span> ordinary shares to Lincoln under the Committed Purchase Agreement for net proceeds totaling approximately $<span id="xdx_909_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20220401__20230331__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zfY5nwmAvHTh" title="Net proceeds from sale">2.0</span> million. From April 1, 2023 through June 30, 2023, the Company sold <span id="xdx_901_ecustom--NumberOfSharesSold_pid_c20230401__20230630__ifrs-full--CounterpartiesAxis__custom--ATMMember_zV9tkPiaC5Ee" title="Number of shares sold">171,504</span> ordinary shares under the ATM program, generating net proceeds of approximately $<span id="xdx_90F_eifrs-full--ProceedsFromSalesOfBiologicalAssets_pn3n3_dm_c20230401__20230630__ifrs-full--CounterpartiesAxis__custom--ATMMember_zwDT3aP1Wxb" title="Net proceeds from sale">0.6</span> million.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock_pn3n3_z2Yui7vKGvzk" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - CAPITAL STOCK (Details)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8B4_zxRDrfMyYJaf" style="display: none">Schedule of unlimited number of common shares without par value</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Ordinary<br/> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Ordinary <br/> Shares</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amount</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000’</td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000’$</td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000’</td><td style="font-size: 10pt; font-weight: bold"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">In 000’$</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98F_ecustom--CommonStockShares_iS_pid_c20230401__20230630_zTxEZc6Ra6Jh" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance, Shares">17,606</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--CommonStockValues_iS_pn3n3_c20230401__20230630_zLXNRxdqZ6ef" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance, Amount">218,782</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_985_ecustom--CommonStockShares_iS_pid_c20220401__20220630_zIf4LQvmMoWa" style="width: 10%; font-size: 10pt; text-align: right" title="Beginning balance, Shares">13,349</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98D_ecustom--CommonStockValues_iS_pn3n3_c20220401__20220630_zC9bSGOXFy6e" style="width: 10%; font-size: 10pt; text-align: right" title="Beginning balance, Amount">158,324</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt">Shares issued under public offering and ATM, net of issue costs</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_982_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostShares_pid_c20230401__20230630_zb9iLZx1s11c" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue cost, shares">171</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_984_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20230401__20230630_zAPCOXx80B8b" style="font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued under public offering and ATM, net of issue costs">613</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_985_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostShares_pid_c20220401__20220630_z8ost6m83478" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue cost, shares"><span style="-sec-ix-hidden: xdx2ixbrl0986">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_989_ecustom--SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts_pn3n3_c20220401__20220630_zMpctgZ2pZfi" style="font-size: 10pt; text-align: right" title="Shares issued under public offering and ATM, net of issue costs"><span style="-sec-ix-hidden: xdx2ixbrl0988">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Shares issued or accrued for services</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98F_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pid_c20230401__20230630_zKlonSXHPOWf" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services, shares">9</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_987_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20230401__20230630_zUZhiS1jz5T" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Shares issued or accrued for services">30</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eifrs-full--IncreaseDecreaseInNumberOfOrdinarySharesIssued_pid_c20220401__20220630_z0dJYNI8yNM1" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued or accrued for services, shares">4</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_984_eifrs-full--SaleOrIssueOfTreasuryShares_pn3n3_c20220401__20220630_zp1E7ch75YDf" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Shares issued or accrued for services">30</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98A_ecustom--CommonStockShares_iE_pid_c20230401__20230630_zbZAg85rz943" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance, Shares">17,786</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98F_ecustom--CommonStockValues_iE_pn3n3_c20230401__20230630_z3BsDMqTSD1c" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance, Amount">219,425</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_986_ecustom--CommonStockShares_iE_pid_c20220401__20220630_z7TuXLumcJ6l" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance, Shares">13,353</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_989_ecustom--CommonStockValues_iE_pn3n3_c20220401__20220630_zmmYzDrq6t13" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance, Amount">158,354</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> 17606 218782000 13349 158324000 171 613000 9 30000 4 30000 17786 219425000 13353 158354000 50000000000 1150000 26500000 The Sales Agreement permits the Company to sell in an ATM program up to $50,000,000 of ordinary shares from time to time, the amount of which is included in the $200,000,000 of securities that may be offered, issued and sold by the Company under the base prospectus. The sales under the prospectus will be deemed to be made pursuant to an ATM program as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. Upon termination of the Sales Agreement, any portion of the $50,000,000 included in the Sales Agreement prospectus that is not sold pursuant to the Sales Agreement will be available for sale in other offerings pursuant to the base prospectus. 90888 2600000 2500000 2425999 1070000 0.2168 94508 166145 900000 480000 2000000.0 171504 600000 <p id="xdx_80D_eifrs-full--DisclosureOfSharebasedPaymentArrangementsExplanatory_ziEmAKvxvrrd" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 13. <span id="xdx_82D_z66oMC57Z3q3">STOCK OPTION RESERVE</span></b></p> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(a)</td><td>The following table provides the activity for the Company’s stock option reserve for the three months ended June 30, 2023 and 2022:</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_zxmG2GZnXcN4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8B7_zHhuyrxD5EA9" style="display: none">Schedule of terms stock option reserve explanatory</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-Controlling Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-Controlling Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98D_ecustom--StockOptionReserve_iS_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zuemiCzGZgrg" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Begiining balance"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_983_ecustom--StockOptionReserve_iS_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z0MEqh6nmLP8" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Begiining balance">21,204</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_z2TySL3goAX" style="width: 10%; font-size: 10pt; text-align: right" title="Begiining balance">11,659</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zWaylfJtaed3" style="width: 10%; font-size: 10pt; text-align: right" title="Begiining balance">16,928</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_znZ6PoGCyGr4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_985_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zVIymicy0jk3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense">769</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zZRD4Ite2hZd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_985_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zotfFns8IvJb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense">1,176</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--StockOptionReserve_iE_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zUmtKGdqMc02" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z9Z6QQXnUhfe" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance">21,973</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_984_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zDS4Zk8KNcC2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">11,659</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zm6a1usn7169" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">18,104</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Stock Options</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 25, 2020, at the annual meeting of shareholders, the Company’s incentive stock option plan (the “2020 Stock Option Plan”) was approved, which authorized the Company’s directors to fix the option exercise price and to issue stock options under the plan as appropriate. The Company’s 2020 Stock Option Plan was a 10% rolling stock option plan under which the Company’s directors were authorized to grant up to a maximum of 10% of the issued and outstanding ordinary shares on the date of grant.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Effective January 13, 2021, the Company amended and restated its 2020 Stock Option Plan to permit the grant of additional types of equity compensation securities, including restricted stock units (“RSUs”) and dividend equivalent rights (the “2021 Equity Incentive Plan”). The aggregate number of equity securities, which may be issued under the 2021 Equity Incentive Plan has not been changed.  Pursuant to the 2021 Equity Incentive Plan, on January 13, 2021, the Company granted an aggregate of <span id="xdx_907_eifrs-full--NumberOfSharesIssued_iI_pid_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_zzX99pReAkR1" title="Option issued">868,000</span> stock options exercisable at a price of $<span id="xdx_909_eifrs-full--ExercisePriceOfOutstandingShareOptions2019_iI_pid_c20210113__ifrs-full--DefinedBenefitPlansAxis__custom--N2021EquityIncentivePlanMember_z4IhH1p7Pqx4" title="Exercise price">17.75</span> per share, representing the closing price of the shares on the day immediately preceding the grant date, which expire on January 13, 2031 to various directors, officers and consultants of the Company. <span id="xdx_908_eifrs-full--NumberOfSharesIssued_iI_pid_c20210113__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember_zSM5oIV96cI3" title="Option issued">350,000</span> options granted to members of the Board vest 1/3 on grant date, 1/3 on the first anniversary of the grant and 1/3 on the second anniversary of the grant. <span id="xdx_90E_eifrs-full--NumberOfSharesIssued_iI_pid_c20210113__ifrs-full--CounterpartiesAxis__custom--ConsultantsMember_zeNlm4h41Gdk" title="Option issued">518,000</span> options granted to consultants (one of whom is also a director of the Company) vest 1/3 on each of the first three anniversaries of the grant date.</span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Additionally, the Company granted <span id="xdx_903_ecustom--StockGranted_pid_c20210112__20210113__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_z7aFgVF4XXEb" title="Stock granted">243,000</span> RSUs on January 13, 2021, with a fair value of $<span id="xdx_90E_ecustom--FairValuePerShare_pid_c20210112__20210113__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_z5GcT9Vd4SR5" title="Fair value per share">17.75</span> per share, which was the closing price on the day immediately preceding the grant date. The RSUs vested on the date of grant, but underlying shares cannot be sold until one of four of the following conditions are met: (1) a Change in Control (as defined in the Amended and Restated 2021 Equity Incentive Plan (defined below)), (2) the participant’s Separation from Service (as defined in the Amended and Restated 2021 Equity Incentive Plan), (3) the participant’s death, or (4) the participant’s Disability (as defined in the Amended and Restated 2021 Equity Incentive Plan).  In accordance with IFRS 2, “Share-based Payment,” the Company recognized compensation expense of $<span id="xdx_908_eifrs-full--CommunicationExpense_pn3n3_dm_c20200401__20210331__ifrs-full--DefinedBenefitPlansAxis__custom--RestrictedStockUnitsMember_ze2t1EcWScBd" title="Compensation expense">4.3</span> million in the year ended March 31, 2021, in connection with the RSU grants.</span></p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Amended and Restated 2021 Equity Incentive Plan and Grants of Stock Options and Restricted Stock Units</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On January 19, 2022, the Board unanimously approved the Amended and Restated 2021 Equity Incentive Plan (the “Amended and Restated 2021 Equity Incentive Plan”). The Amended and Restated 2021 Equity Incentive Plan provides for:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-size: 10pt"><b>(1)</b></span></td><td>An increase of aggregate number of ordinary shares available for awards to 2,001,812, which is equal to 15% of the issued and outstanding ordinary shares of the Company as of January 19, 2022 subject to discretionary annual increases (on a cumulative basis) as may be approved by the Board in future years by a number of ordinary shares not to exceed an additional 5% of the aggregate number of shares then outstanding;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-size: 10pt"><b>(2)</b></span></td><td>The authorization of incentive stock options under the Amended and Restated 2021 Equity Incentive Plan; and</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-size: 10pt"><b>(3)</b></span></td><td>The provision of dividend equivalent rights to be issued when authorized.</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Pursuant to the Amended and Restated 2021 Equity Incentive Plan, on January 19, 2022, the Company granted an aggregate of <span id="xdx_90F_ecustom--StockGranted_pid_c20220118__20220119__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zS2J8ifR4Mc6" title="Stock granted">302,000</span> stock options exercisable at a price of $<span id="xdx_903_ecustom--FairValuePerShare_pid_c20220118__20220119__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zpzam1tISvTa" title="Fair value per share">10.22</span> per share, representing the average price of the Company’s ordinary shares on the grant date, which expire on January 19, 2032, to various directors, officers and consultants of the Company. A total of <span id="xdx_902_ecustom--StockGranted_pid_c20220118__20220119__ifrs-full--CounterpartiesAxis__custom--TwoMembersMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zJY7r4vVurxa" title="Stock granted">13,800</span> of the 302,000 stock options were granted to two members of the Board and vest on the first anniversary of the grant date. The balance of <span id="xdx_902_ecustom--StockGranted_pid_c20220118__20220119__ifrs-full--CounterpartiesAxis__custom--EmployeesMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_z9xGaTbaClm9" title="Stock granted">288,200</span> stock options was granted to employees (one of whom is also a director of the Company), and a consultant, and such stock options vest ratably on each of the first four annual anniversaries of the grant date.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">Additionally, the Company granted <span id="xdx_901_ecustom--StockGranted_pid_c20220118__20220119__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zl5tbrylbBB9" title="Stock granted">135,740</span> RSUs to employees (one of whom is also a director of the Company) on January 19, 2022, with a fair value of $<span id="xdx_90C_ecustom--FairValuePerShare_c20220118__20220119__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zj6jgw0M6zI9" title="Fair value per share">10.22</span> per share, representing the average price of the shares on the grant date. The RSUs were </span>fully vested and nonforfeitable as of the <span style="background-color: white">grant date and will expire on January 19, 2032.</span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On February 15, 2022, James Mellon, Linda Kozick and Mark Simon were appointed to the Board. Mr. Mellon owned approximately 23.9% of the Company’s outstanding shares at that date. Additionally, Mr. Mellon had previously served as a member of the Board from 2016 to August 14, 2020. On February 15, 2022, in connection with the appointments, each of these directors was granted <span id="xdx_90F_ecustom--StockGranted_pid_c20220214__20220215__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_z6EImWARslRd" title="Stock granted">13,800</span> non-qualified stock options, which vest ratably monthly over a three-year period. The options have an exercise price of $<span id="xdx_90C_ecustom--FairValuePerShare_pid_c20220214__20220215__ifrs-full--CounterpartiesAxis__custom--DirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zvPOK44o9js9" title="Fair value per share">8.59</span> per share, representing the average price of the shares on the grant date, and will expire, if unexercised, on February 15, 2032.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On June 8, 2022, the Company granted <span id="xdx_900_ecustom--StockGranted_pid_c20220607__20220608__ifrs-full--CounterpartiesAxis__custom--ExecutiveMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zCzDozCGWZSk" title="Stock granted">50,000</span> options to purchase shares to an executive of the Company. The options have an exercise price of $<span id="xdx_901_ecustom--ExercisablePrice_pid_c20220607__20220608__ifrs-full--CounterpartiesAxis__custom--ExecutiveMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_z8uFrmb4ajye" title="Exercisable price">11.00</span>, the average price of the stock on that date, vest ratably on each of the first four anniversaries of the grant date and will expire, if unexercised, on June 8, 2032.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 27, 2022, the Company granted <span id="xdx_909_ecustom--StockGranted_pid_c20220726__20220727__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zsRNHfoDKvIc" title="Stock granted">15,900</span> options to purchase shares to a member of the Board. The options have an exercise price of $<span id="xdx_907_ecustom--ExercisablePrice_pid_c20220726__20220727__ifrs-full--CounterpartiesAxis__custom--BoardOfDirectorsMember__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zNX71eQkgYyd" title="Exercisable price">10.06</span>, the average price of the stock on that date, vest ratably on each monthly anniversary of the grant date in the three year period following the grant date and will expire, if unexercised, on July 27, 2032.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On March 30, 2023, the Board unanimously approved to increase the maximum number of ordinary shares reserved for issuance under the Amended and Restated 2021 Equity Incentive Plan. The aggregate number of shares available for awards under the Amended and Restated 2021 Equity Incentive Plan was increased to <span id="xdx_90F_ecustom--NumberOfShareOptionsAvailableInSharebasedPaymentArrangement_pid_c20230325__20230330__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zQLXUkONjN0h" title="Number of shares available for awards">2,880,992</span>, which represented a 5% increase (or <span id="xdx_907_ecustom--NumberOfShareOptionsAvailableInSharebasedPaymentArrangement_pid_c20230325__20230330_zPnTd18GRbHj" title="Number of shares available for awards">879,180</span> shares) based on ordinary shares outstanding on March 29, 2023, which is equal to 16% of the issued and outstanding ordinary shares in the capital of the Company as of this date.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On March 30, 2023, the Company granted an aggregate of <span id="xdx_904_ecustom--StockGranted_pid_c20230325__20230330_zZYrhOy6fQJ3" title="Number of shares available for awards">746,120</span> stock options exercisable at a price of $<span id="xdx_907_ecustom--ExercisablePrice_pid_c20230325__20230330_z0vi8hmFuE7c" title="Exercisable price">2.92</span> per share, representing the average price of the shares on the grant date, which expire on <span id="xdx_90A_ecustom--ExpirationDateOfGrantOfSharebasedPaymentArrangement_dd_c20230325__20230330_zOYpJikTSKS" title="Expiration date">March 30, 2033</span>, to various directors, officers and a consultant of the Company. <span id="xdx_905_ecustom--NumberOfSharesPurchased_pid_c20230325__20230330_z0QJez7LRwug" title="Number of shares purchased">14,600</span> options to purchase ordinary shares, totaling <span id="xdx_900_ecustom--NumberOfSharesAvailableForGranted_pid_c20230325__20230330_zLN0llnkWxSf" title="Number of shares available for granted">87,600</span>, were granted to each non-executive member of the Board and vest on the first anniversary of the grant date. A total of <span id="xdx_909_ecustom--NumberOfSharesAvailableForGrants_pid_c20230325__20230330_zcfjfQFWTHCb" title="Total of stock options granted to employees">651,020</span> stock options were granted to employees (including Mr. Walters, who is Chairman of the Board of Directors), and a consultant, and such stock options vest ratably on each of the first four annual anniversaries of the grant date. The balance of <span id="xdx_905_ecustom--NumberOfSharesAvailableForOptionGranted_pid_c20230325__20230330_ziioYAF2ZGpj" title="Stock options granted to consultant">7,500</span> stock options were also granted to a consultant, which was fully vested as of the <span style="background-color: white">grant date.</span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(b)</td><td>The changes in the number of options issued for the three months ended June 30, 2023 and 2022 were:</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_zLuiuIzJVFaa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8B2_zWjFJGovytH" style="display: none">Schedule of outstanding stock options</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right" title="Granted"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right" title="Granted"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated <br/>2021 Equity Incentive Plan</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx Option Plan<br/> (Subsidiary Plan)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zJ3ZiG6WUPOa" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance">1,963,420</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98B_ecustom--NumberOfOutstandingShareOption_iS_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zqmRFdt1I9fk" style="width: 10%; font-size: 10pt; text-align: right" title="Beginning balance">1,151,400</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iS_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zxOR7ABEIk1f" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1142">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfOutstandingShareOption_iS_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_z1H29vrjgpp4" style="width: 10%; font-size: 10pt; text-align: right" title="Beginning balance">1,275</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Granted</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zxlIQLSltcF9" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1146">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zNIL9OtkFaF7" style="font-size: 10pt; text-align: right" title="Granted">50,000</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_981_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zw1Ny6nK72y7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zHuMVyn3gAKb" style="font-size: 10pt; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1152">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Expired or forfeited</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z8UNMreoizJ9" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zHGP2JpIbJRk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_981_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zYaE1B0aJZPl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_982_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zeDpO88ZomJ9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited">(1,275</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, end of year</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_980_ecustom--NumberOfOutstandingShareOption_iE_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zHarurziOAQ9" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance">1,963,420</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iE_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zPB5e1XuLR7i" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">1,201,400</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zMPiFiyHBvll" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance"><span style="font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1166">-</span></b></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iE_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zpAx5PqDD868" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Exercisable, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z6U2XlyOQv6l" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end">764,438</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zA9583XZNEgj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end">410,600</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98B_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zakLzNFrHpMg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"><span style="-sec-ix-hidden: xdx2ixbrl1174">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_984_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zNO8XqaGDdKe" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(c)</td><td>The following is the weighted average exercise price and the remaining contractual life for outstanding options by plan as of June 30, 2023 and 2022:</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 0.3in"> </p> <table cellpadding="0" cellspacing="0" id="xdx_889_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zifjebvJakJ" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8BB_zInGiUkBmu7d" style="display: none">Schedule of weighted average exercise price and remaining contractual life</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated <br/>2021 Equity Incentive Plan</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx Option Plan<br/> (Subsidiary Plan)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Weighted average exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5EI1GMjKWm4" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price">10.53</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zSL6GABU5SBc" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Weighted average exercise price">15.26</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zEpaGheTqQj1" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zUf5QWKd2Yx8" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Weighted average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Weighted average remaining contractual life (in years)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zS60tTNfhN61" title="Weighted average remaining contractual life (in years)">8.61</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_901_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z8bivkfjlyRg" title="Weighted average remaining contractual life (in years)">8.90</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The vested options can be exercised at any time in accordance with the applicable option agreement. The exercise price was greater than the market price for all options outstanding as of June 30, 2023 and March 31, 2023, except <span id="xdx_901_eifrs-full--NumberOfOutstandingShareOptions_iI_uShares_c20230630__ifrs-full--MeasurementAxis__custom--VestedOptionsMember_zkHZL1UDU5e3" title="Options outstanding"><span id="xdx_903_eifrs-full--NumberOfOutstandingShareOptions_iI_uShares_c20230331__ifrs-full--MeasurementAxis__custom--VestedOptionsMember_zCU04f1eUTBf" title="Options outstanding">7,500</span></span> vested options and <span id="xdx_905_eifrs-full--NumberOfOutstandingShareOptions_iI_uShares_c20230630__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_zEQ3aJJpc9pk" title="Options outstanding"><span id="xdx_905_eifrs-full--NumberOfOutstandingShareOptions_iI_uShares_c20230331__ifrs-full--MeasurementAxis__custom--UnvestedOptionsMember_z1uXFRQuwSkk" title="Options outstanding">738,620</span></span> unvested options as of each date.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company recorded approximately $<span id="xdx_901_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_dm_c20230401__20230630_zGZGEjmuttJ3" title="Share based compensation expense">0.8</span> million and $<span id="xdx_90E_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_dm_c20220401__20220630_zN7XPKSZyQC6" title="Share based compensation expense">1.2</span> million of share-based compensation expense with respect to the Amended and Restated 2021 Equity Incentive Plan in the three months ended June 30, 2023 and 2022, respectively. The Company expects to record additional share-based compensation expense of approximately $<span id="xdx_90D_eifrs-full--KeyManagementPersonnelCompensationSharebasedPayment_pn3n3_dm_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--AmendedAndRestated2021EquityIncentivePlanMember_zxtkgTsn4Ue" title="Share based compensation expense">3.4</span> million through March 2027 with respect to the Amended and Restated 2021 Equity Incentive Plan.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of June 30, 2022, the Company’s iOx stock option plan was fully vested. The iOx stock option plan expired on May 5, 2022 and all outstanding stock option awards issued under the iOx stock option plan expired.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_88E_ecustom--DisclosureOfTermsStockOptionReserveExplanatory_pn3n3_zxmG2GZnXcN4" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8B7_zHhuyrxD5EA9" style="display: none">Schedule of terms stock option reserve explanatory</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt; white-space: nowrap; font-size: 10pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-Controlling Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Non-Controlling Interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Stock Option Reserve</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98D_ecustom--StockOptionReserve_iS_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zuemiCzGZgrg" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Begiining balance"><span style="-sec-ix-hidden: xdx2ixbrl1050">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_983_ecustom--StockOptionReserve_iS_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z0MEqh6nmLP8" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Begiining balance">21,204</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_z2TySL3goAX" style="width: 10%; font-size: 10pt; text-align: right" title="Begiining balance">11,659</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_98E_ecustom--StockOptionReserve_iS_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zWaylfJtaed3" style="width: 10%; font-size: 10pt; text-align: right" title="Begiining balance">16,928</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Share-based compensation expense</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98A_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_znZ6PoGCyGr4" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl1058">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_985_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zVIymicy0jk3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Stock based compensation expense">769</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98D_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zZRD4Ite2hZd" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense"><span style="-sec-ix-hidden: xdx2ixbrl1062">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_985_eifrs-full--AdjustmentsForSharebasedPayments_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zotfFns8IvJb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Stock based compensation expense">1,176</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_ecustom--StockOptionReserve_iE_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zUmtKGdqMc02" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1066">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_981_ecustom--StockOptionReserve_iE_pn3n3_c20230401__20230630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_z9Z6QQXnUhfe" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance">21,973</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_984_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__ifrs-full--NoncontrollingInterestsMember_zDS4Zk8KNcC2" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">11,659</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_987_ecustom--StockOptionReserve_iE_pn3n3_c20220401__20220630__ifrs-full--ComponentsOfEquityAxis__custom--StockOptionReserveMember_zm6a1usn7169" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">18,104</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> 21204000 11659000 16928000 769000 1176000 21973000 11659000 18104000 868000 17.75 350000 518000 243000 17.75 4300000 302000 10.22 13800 288200 135740 10.22 13800 8.59 50000 11.00 15900 10.06 2880992 879180 746120 2.92 2033-03-30 14600 87600 651020 7500 <table cellpadding="0" cellspacing="0" id="xdx_888_ecustom--DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory_zLuiuIzJVFaa" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 1)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8B2_zWjFJGovytH" style="display: none">Schedule of outstanding stock options</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right" title="Granted"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right" title="Granted"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated <br/>2021 Equity Incentive Plan</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx Option Plan<br/> (Subsidiary Plan)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Balance, beginning of period</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iS_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zJ3ZiG6WUPOa" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance">1,963,420</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98B_ecustom--NumberOfOutstandingShareOption_iS_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zqmRFdt1I9fk" style="width: 10%; font-size: 10pt; text-align: right" title="Beginning balance">1,151,400</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iS_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zxOR7ABEIk1f" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Beginning balance"><span style="-sec-ix-hidden: xdx2ixbrl1142">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfOutstandingShareOption_iS_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_z1H29vrjgpp4" style="width: 10%; font-size: 10pt; text-align: right" title="Beginning balance">1,275</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-indent: -9pt; padding-left: 9pt">Granted</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98F_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zxlIQLSltcF9" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1146">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_983_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zNIL9OtkFaF7" style="font-size: 10pt; text-align: right" title="Granted">50,000</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_981_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zw1Ny6nK72y7" style="font-size: 10pt; font-weight: bold; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1150">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_980_ecustom--NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zHuMVyn3gAKb" style="font-size: 10pt; text-align: right" title="Granted"><span style="-sec-ix-hidden: xdx2ixbrl1152">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; text-indent: -9pt; padding-left: 9pt">Expired or forfeited</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z8UNMreoizJ9" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1154">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zHGP2JpIbJRk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1156">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_981_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zYaE1B0aJZPl" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Expired or forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1158">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_982_ecustom--NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zeDpO88ZomJ9" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Expired or forfeited">(1,275</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Balance, end of year</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_980_ecustom--NumberOfOutstandingShareOption_iE_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zHarurziOAQ9" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance">1,963,420</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_988_ecustom--NumberOfOutstandingShareOption_iE_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zPB5e1XuLR7i" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance">1,201,400</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98E_ecustom--NumberOfOutstandingShareOption_iE_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zMPiFiyHBvll" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Ending balance"><span style="font-size: 10pt"><b><span style="-sec-ix-hidden: xdx2ixbrl1166">-</span></b></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_98A_ecustom--NumberOfOutstandingShareOption_iE_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zpAx5PqDD868" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Ending balance"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Exercisable, end of period</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_987_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z6U2XlyOQv6l" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end">764,438</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_988_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zA9583XZNEgj" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end">410,600</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98B_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zakLzNFrHpMg" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Exercisable as at end"><span style="-sec-ix-hidden: xdx2ixbrl1174">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_984_ecustom--NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zNO8XqaGDdKe" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Exercisable as at end"><span style="-sec-ix-hidden: xdx2ixbrl1176">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> 1963420 1151400 1275 50000 -1275 1963420 1201400 764438 410600 <table cellpadding="0" cellspacing="0" id="xdx_889_eifrs-full--DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory_zifjebvJakJ" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - STOCK OPTION RESERVE (Details 2)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; text-indent: -9pt; padding-left: 9pt"><span id="xdx_8BB_zInGiUkBmu7d" style="display: none">Schedule of weighted average exercise price and remaining contractual life</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="15" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">PBI Amended and Restated <br/>2021 Equity Incentive Plan</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx Option Plan<br/> (Subsidiary Plan)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 48%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Weighted average exercise price</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z5EI1GMjKWm4" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price">10.53</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_98B_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zSL6GABU5SBc" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Weighted average exercise price">15.26</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_989_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zEpaGheTqQj1" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Weighted average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1184">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019_pid_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__custom--StockOptionsTwoMember_zUf5QWKd2Yx8" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Weighted average exercise price"><span style="-sec-ix-hidden: xdx2ixbrl1186">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt">Weighted average remaining contractual life (in years)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_90F_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20230401__20230630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_zS60tTNfhN61" title="Weighted average remaining contractual life (in years)">8.61</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_901_eifrs-full--WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019_dtY_c20220401__20220630__ifrs-full--DefinedBenefitPlansAxis__custom--PBI2021EquityIncentivePlanMember_z8bivkfjlyRg" title="Weighted average remaining contractual life (in years)">8.90</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right">-</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right">-</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> 10.53 15.26 P8Y7M9D P8Y10M24D 7500 7500 738620 738620 800000 1200000 3400000 <p id="xdx_807_eifrs-full--EarningsPerShareExplanatory_z7iro5Q7eNe7" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 14. <span id="xdx_829_zhxb2IWeGWfj">(LOSS) PER SHARE</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Basic earnings per share (“EPS”) is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Diluted EPS is calculated by dividing the net income (loss) attributable to ordinary equity holders of the Company by the weighted average number of ordinary shares outstanding during the period plus the weighted average number of ordinary shares that would be issued on conversion of all the dilutive potential ordinary shares into ordinary shares.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table reflects the loss and share data used in the basic and diluted EPS calculations (U.S. Dollars in thousands, except per share amounts):</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--ScheduleOfEarningsPerShareTableTextBlock_pn3n3_zwHslk4PfCU8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left; padding-left: 5.4pt"><span id="xdx_8BA_zRvmyJuCVezg" style="display: none">Schedule of basic and diluted EPS calculations</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_495_20230401__20230630_zXWMTCwYH0N5" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_491_20220401__20220630_zMtpDOaFlSZa" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt"><i>Numerator (in 000’$)</i></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net loss attributable to owners of the Company</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(5,919</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right">(1,729</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left; padding-left: 5.4pt">Denominator (in 000’)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Weighted average number of shares – Basic and Diluted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--WeightedAverageNumberOfSharesBasic_pid_c20230401__20230630_zYe5ceFCzxY9" title="Weighted average number of shares, Basic"><span id="xdx_90B_ecustom--WeightedAverageNumberOfSharesDiluted_pid_c20230401__20230630_zKRozzzVNKP5" title="Weighted average number of shares, Diluted">17,701</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_ecustom--WeightedAverageNumberOfSharesBasic_pid_c20220401__20220630_zSQd878bqmV6" title="Weighted average number of shares, Basic"><span id="xdx_902_ecustom--WeightedAverageNumberOfSharesDiluted_pid_c20220401__20220630_zVNRGwGoCVW7" title="Weighted average number of shares, Diluted">13,351</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Basic and diluted (loss) per share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_908_eifrs-full--BasicEarningsLossPerShare_pid_c20230401__20230630_zJ7b9ngPPfs3" title="Basic earnings (loss) per share"><span id="xdx_90F_eifrs-full--DilutedEarningsLossPerShare_pid_c20230401__20230630_z2WekAEubOK1" title="Diluted earnings (loss) per share">(0.33</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--BasicEarningsLossPerShare_pid_c20220401__20220630_ziSz1NK4yq3c" title="Basic earnings (loss) per share"><span id="xdx_90C_eifrs-full--DilutedEarningsLossPerShare_pid_c20220401__20220630_zQIaLNp4YXC" title="Diluted earnings (loss) per share">(0.13</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The inclusion of the Company’s stock options, RSUs and share purchase warrants in the computation of diluted loss per share would have an anti-dilutive effect on loss per share and are therefore excluded from the computation. Consequently, there is no difference between basic loss per share and diluted loss per share for the three months ended June 30, 2023 and 2022. The following table reflects the Company's outstanding securities by year that would have an anti-dilutive effect on loss per share and, accordingly, were excluded from the calculation.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_zMMkWpu8LdS" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B1_zqzbMiPQe28i" style="display: none">Schedule of anti-dilutive share</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Stock options</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_985_ecustom--AntidilutiveEffectOnLossPerShare_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--ShareOptionsMember_z0kIzaLroicd" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,963,420</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_986_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--ShareOptionsMember_z83Lb60fSBzd" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">1,201,400</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_z1vA4i3UkS9i" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">378,740</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zju2W2IlBH28" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">378,740</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <table cellpadding="0" cellspacing="0" id="xdx_884_ecustom--ScheduleOfEarningsPerShareTableTextBlock_pn3n3_zwHslk4PfCU8" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left; padding-left: 5.4pt"><span id="xdx_8BA_zRvmyJuCVezg" style="display: none">Schedule of basic and diluted EPS calculations</span></td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_495_20230401__20230630_zXWMTCwYH0N5" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_491_20220401__20220630_zMtpDOaFlSZa" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Three Months Ended June 30,</td></tr> <tr id="xdx_403_ecustom--NumeratorAbstract_iB" style="vertical-align: bottom"> <td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt"><i>Numerator (in 000’$)</i></td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt"> </td></tr> <tr id="xdx_40C_eifrs-full--ProfitLossAttributableToOwnersOfParent_i01_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Net loss attributable to owners of the Company</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right">(5,919</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right">(1,729</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td></tr> <tr id="xdx_403_ecustom--DenominatorAbstract_iB" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; font-style: italic; text-align: left; padding-left: 5.4pt">Denominator (in 000’)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Weighted average number of shares – Basic and Diluted</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_906_ecustom--WeightedAverageNumberOfSharesBasic_pid_c20230401__20230630_zYe5ceFCzxY9" title="Weighted average number of shares, Basic"><span id="xdx_90B_ecustom--WeightedAverageNumberOfSharesDiluted_pid_c20230401__20230630_zKRozzzVNKP5" title="Weighted average number of shares, Diluted">17,701</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_902_ecustom--WeightedAverageNumberOfSharesBasic_pid_c20220401__20220630_zSQd878bqmV6" title="Weighted average number of shares, Basic"><span id="xdx_902_ecustom--WeightedAverageNumberOfSharesDiluted_pid_c20220401__20220630_zVNRGwGoCVW7" title="Weighted average number of shares, Diluted">13,351</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Basic and diluted (loss) per share</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right"><span id="xdx_908_eifrs-full--BasicEarningsLossPerShare_pid_c20230401__20230630_zJ7b9ngPPfs3" title="Basic earnings (loss) per share"><span id="xdx_90F_eifrs-full--DilutedEarningsLossPerShare_pid_c20230401__20230630_z2WekAEubOK1" title="Diluted earnings (loss) per share">(0.33</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span id="xdx_907_eifrs-full--BasicEarningsLossPerShare_pid_c20220401__20220630_ziSz1NK4yq3c" title="Basic earnings (loss) per share"><span id="xdx_90C_eifrs-full--DilutedEarningsLossPerShare_pid_c20220401__20220630_zQIaLNp4YXC" title="Diluted earnings (loss) per share">(0.13</span></span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td></tr> </table> -5919000 -1729000 17701 17701 13351 13351 -0.33 -0.33 -0.13 -0.13 <table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfAntiDilutiveEffectTableTextBlock_zMMkWpu8LdS" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - (LOSS) PER SHARE (Details 1)"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8B1_zqzbMiPQe28i" style="display: none">Schedule of anti-dilutive share</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30,</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">2022</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 74%; font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Stock options</td><td style="width: 1%; font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_985_ecustom--AntidilutiveEffectOnLossPerShare_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--ShareOptionsMember_z0kIzaLroicd" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">1,963,420</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; width: 1%; font-size: 10pt; text-align: left"> </td><td id="xdx_986_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--ShareOptionsMember_z83Lb60fSBzd" style="border-bottom: Black 2.5pt double; width: 10%; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">1,201,400</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 2.5pt">Restricted stock units</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_982_ecustom--AntidilutiveEffectOnLossPerShare_c20230401__20230630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_z1vA4i3UkS9i" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Anti-dilutive effect on loss per share">378,740</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"> </td><td id="xdx_983_ecustom--AntidilutiveEffectOnLossPerShare_c20220401__20220630__ifrs-full--TypesOfAntidilutiveInstrumentsAxis__ifrs-full--RestrictedShareUnitsMember_zju2W2IlBH28" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Anti-dilutive effect on loss per share">378,740</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> 1963420 1201400 378740 378740 <p id="xdx_809_eifrs-full--DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory_zPIyvTSqi2L" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 15. <span id="xdx_828_zkcraavzzXVb">COMMITMENTS AND CONTINGENT LIABILITIES</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Effective March 15, 2022, iOx entered into a Master Services Agreement (the “MSA”) with Parexel International (IRE) Limited (“Parexel”) under which Parexel agreed to act as clinical service provider (CRO) pursuant to a work order (“Work Order”) effective June 1, 2022. Pursuant to such Work Order, Parexel will operate a Phase 2 trial of IMM60 and pembrolizumab in advanced melanoma and non-small lung cancer (“NSCLC”). The MSA provides for a five-year term, and the Work Order provides for a term to be ended upon the completion of the services required. The budget provides for service fees and pass-through expenses and clinical sites totaling $11.5 million. During Fiscal 2023, the Company executed two change orders resulting in a $0.6 million increase in the overall estimated budgeted costs.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On March 1, 2023, the Company, through Tarus, entered into a clinical service agreement with Fortrea Inc. (formerly Labcorp Drug Development Inc.), a third-party CRO. The term of the agreement is through the earlier of August 14, 2025 or the completion of provision of services and the payment of contractual obligations. The budgeted costs for the services to be provided is approximately $<span id="xdx_90D_ecustom--CostAndExpenses_pn3n3_dm_c20230401__20230630_zuu5A1gV9pQf" title="Budget cost related to services">12.1</span> million.</p> <p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0in"><b><i>Stimunity Convertible Note</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 13, 2022, the Company entered into a commitment with Stimunity to provide €<span id="xdx_902_ecustom--ConvertibleNote_iI_uEUR_c20220713_ze21bIYhxPzh" title="Convertible note">600,000</span> under the Stimunity Convertible Note. The Stimunity Convertible Note provides for simple interest at <span id="xdx_905_eifrs-full--BorrowingsInterestRate_iI_pid_dp_c20220713_zdlU3ZrX4EI7" title="Interest rate">7</span>% per annum. The Stimunity Convertible Note is automatically converted into Series A shares of Stimunity upon Stimunity completing a Series A round for at least €<span id="xdx_903_ecustom--ConversionOfDebt_iI_pn3n3_dm_uEUR_c20220713_ziRdQY6Ynl87" title="Conversion of debt">20</span> million. If such subscription round is completed prior to the Maturity Date, the Company will be entitled to convert the Stimunity Convertible Note into Series A shares of Stimunity at the subscription share price less 15%. Additionally, if Stimunity completes a financing with a new category of shares (other than Common Shares or Series A shares of Stimunity) for at least €<span id="xdx_903_ecustom--ConversionOfDebtIntoShares_iI_pn3n3_dm_uEUR_c20220713_z6hywy0VbuTi" title="Conversion of debt into shares">5</span> million (the “Minimum Raise”), the Company will have the right to convert the Stimunity Convertible Note and the historical Series A shares of Stimunity owned into the new category of shares. In the event that Stimunity does not close a financing prior to the Maturity Date or raises less than the Minimum Raise, the Company will have the right to convert the Stimunity Convertible Note into Series A shares of Stimunity at €<span id="xdx_906_ecustom--SharePricePerShare_iI_pid_uEURPShares_c20220713_zFrSqfChetsf" title="Share price, per share">363.00</span> per share or the raise price less 15%, whichever is lower. The Stimunity Convertible Note was funded by the Company on September 12, 2022. In addition, the Company has not reflected the interest earned on the Stimunity Convertible Note in reporting its consolidated financial results. See Note 6, “Investment in Associate,” for a further discussion.</p> <p style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Committed Purchase Agreement</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 6, 2022 (the “Signing Date”), the Company entered into the Committed Purchase Agreement with Lincoln, pursuant to which the Company may require Lincoln to purchase ordinary shares having an aggregate value of up to $<span id="xdx_90F_ecustom--AggregateValue_pn3n3_dm_c20220705__20220706__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zig6uYtpEdhi" title="Aggregate value">30</span> million over a period of 36 months. Pursuant to the Committed Purchase Agreement, Lincoln will be obligated to purchase the Company’s ordinary shares in three different scenarios that are based on various market criteria and share amounts.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Upon execution of the Committed Purchase Agreement, the Company issued to Lincoln <span id="xdx_907_ecustom--NumberOfOrdinaryShareIssued_pid_c20220705__20220706_zw21fsFLNIyj" title="Number of ordinary shares issued">94,508</span> ordinary shares, representing a 3% commitment fee valued at $<span id="xdx_90F_ecustom--CommitmentFee_pn3n3_dm_c20220705__20220706__ifrs-full--CounterpartiesAxis__custom--LincolnMember_zNrNw4YlSUt2" title="Commitment fee">0.9</span> million. The Company has the right to terminate the Committed Purchase Agreement for any reason, effective upon one business day prior written notice to Lincoln. Lincoln has no right to terminate the Committed Purchase Agreement. The Company is accounting for the commitment fee as a deferred commitment fee on the consolidated statement of financial position as of June 30, 2023 and March 31, 2023 and will amortize it pro-rata against equity sold under the Committed Purchase Agreement. Any unamortized balance will be written-off to operations at the expiration of the commitment.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Committed Purchase Agreement does not impose any financial or business covenants on the Company and there are no limitations on the use of proceeds received by the Company from Lincoln. The Company may raise capital from other sources in its sole discretion; provided, however, that the Company shall not enter into any similar agreement for the issuance of variable priced equity-like securities until the three-year anniversary of the Signing Date, excluding, however, an at-the-market transaction with a registered broker-dealer.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">In connection with the Committed Purchase Agreement, the Company and Lincoln entered into a Registration Rights Agreement, dated July 6, 2022 (the “Registration Rights Agreement”). Pursuant to the Registration Rights Agreement, the Company agreed to file with the SEC the prospectus supplement to the Company’s shelf registration statement pursuant to Rule 424(b) for the purpose of registering for resale the ordinary shares to be issued to Lincoln under the Committed Purchase Agreement. The prospectus supplement was filed on August 19, 2022.</p> <p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt">The Company is obligated under the Tarus Merger Agreement and the iOx Share Exchange Agreement to pay certain third party earnouts based on the achievement of certain milestones. See Note 9, “Acquisition of Tarus,” and Note 16<span style="background-color: white">, “Related Party Transactions – Share Exchange Agreement – iOx,”</span> respectively, for further discussions.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> 12100000 600000 0.07 20000000 5000000 363.00 30000000 94508 900000 <p id="xdx_80B_eifrs-full--DisclosureOfTransactionsBetweenRelatedPartiesExplanatory_zKZqFjxb5jW1" style="margin: 0pt 0; font-size: 10pt; text-align: justify"><b>NOTE 16. <span id="xdx_82D_zytj2eMmn9ke">RELATED PARTY TRANSACTIONS</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>SalvaRx Acquisition</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Two of the Company’s directors are also directors of SalvaRx Group plc, a company which owns approximately 4.1% of the Company’s issued and outstanding ordinary shares as of June 30, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Investments</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company has entered into related party transactions and certain services agreements with its investees.  Key management personnel of the Company have also entered into related party transactions with investees. Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the activities of the Company, including directors and senior management of the Company.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following subsidiaries and associates are considered related parties:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(a)</td><td><b>Stimunity</b>. The CEO of Portage is one of three members of the board of directors of Stimunity (see Note 6, “Investment in Associate,” and Note 15, “Commitments and Contingent Liabilities – Stimunity Convertible Note”).</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(b)</td><td><b>iOx</b>. Upon execution of the iOx Share Exchange on July 18, 2022, the non-Portage director resigned from the iOx board leaving two Portage insiders as directors. The CEO of Portage is also the CEO of iOx, and the management team of Portage comprises the management team of iOx. See below for a discussion of the Company’s purchase of the non-controlling interest in iOx through its wholly-owned subsidiary SalvaRx.</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(c)</td><td><b>Saugatuck</b>. One of the three directorships on the board of directors of Saugatuck is controlled by Portage. Additionally, the CEO of Portage is also the CEO of Saugatuck, and the management team of Portage comprises the management team of Saugatuck.</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(d)</td><td><b>Intensity</b>. The CEO of Portage previously served as a part-time officer of Intensity until becoming a consultant in 2023. Additionally, Intensity provided services (primarily rent) to Portage through April 2023.</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(e)</td><td><b>Portage Development Services Inc</b>. PDS provides human resources and other services to each operating subsidiary of Portage through a shared services agreement.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following are related party balances and transactions other than those disclosed elsewhere in the condensed consolidated interim financial statements:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Transactions between the parent company and its subsidiaries, which are related parties, have been eliminated in consolidation and are not disclosed in this note.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">On September 8, 2021, the <span id="xdx_902_ecustom--IssuanceOfUnsecuredNotesDescription_c20210907__20210908__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SalvaRxMember_zS6Bnd2kQ7Ng" title="Issuance of unsecured notes, description">Company, through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price of £162. Simultaneously, the Company entered into an agreement with OSI, the holder of $0.15 million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for 820 shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets of IAS 39, “Financial Instruments: Recognition and Measurement,” and IFRIC 19, “Extinguishing Financial Liabilities with Equity Instruments,” and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%.</span></span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Share Exchange Agreement – iOx</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On July 18, 2022, the Company and SalvaRx entered into a Share Exchange Agreement (the “Share Exchange Agreement”) with each of the minority shareholders of iOx (the “Sellers”) resulting in the acquisition of the outstanding non-controlling ownership interest (approximately 22%) of iOx, which is developing the iNKT engager platform. The Company followed IFRS 3, “Business Combinations,” and IAS 27, “Separate Financial Statements,” (which substantially replaced IAS 3) to account for this transaction. The Company achieved control of iOx, as defined, on January 8, 2019 upon the completion of the SalvaRx Acquisition. Further transactions whereby the parent entity acquires further equity interests from non-controlling interests, or disposes of equity interests but without losing control, are accounted for as equity transactions (i.e., transactions with owners in their capacity as owners). As such:</p> <p style="margin: 0pt 0; font-size: 10pt"><b> </b></p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>the carrying amounts of the controlling and non-controlling interests are adjusted to reflect the changes in their relative interests in the subsidiary;</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>any difference between the amount by which the non-controlling interests is adjusted and the fair value of the consideration paid or received is recognized directly in equity and attributed to the owners of the parent; and</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>there is no consequential adjustment to the carrying amount of goodwill, and no gain or loss is recognized in profit or loss.</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company now owns the worldwide rights to its small molecule iNKT engagers, including lead programs PORT-2 and PORT-3. Under the terms of the Share Exchange Agreement, each Seller sold to the Company, and the Company acquired from each Seller, legal and beneficial ownership of the number of iOx shares held by each Seller, free and clear of any share encumbrances, in exchange for the issuance in an aggregate of <span id="xdx_90A_ecustom--PortageOrdinaryShares_pid_c20230401__20230630_zsjYcxst0vZi" title="Portage ordinary shares">1,070,000</span> Portage ordinary shares to be allocated among the Sellers based upon their relative ownership. As a result of the Share Exchange Agreement, the Company owns 100% of the issued and outstanding shares of iOx through its wholly-owned subsidiary, SalvaRx.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt">As additional consideration for the sale of the iOx shares to the Company under the Share Exchange Agreement, the Sellers shall have the contingent right to receive additional shares (“Earnout Shares”) from the Company having an aggregate value equal to $25 million calculated at the Per Share Earnout Price, as defined in the Share Exchange Agreement, upon the achievement of certain milestones defined as the dosing of the first patient in a Phase 3 clinical trial for either PORT-2 (IMM60 iNKT cell activator/engager) or PORT-3 (PLGA-nanoparticle formulation of IMM60 combined with a NY-ESO-1 peptide vaccine). The Company shall have the option, in its sole and absolute discretion, to settle the Earnout Shares in cash. The Company followed IFRS 3 and IAS 32, “Financial Instruments: Presentation,” to account for the fair value of the Earnout Shares. The principal assumptions for determining the fair value include the timing of development events, the probabilities of success and the discount rate used. The fundamental principle of IAS 32 is that a financial instrument should be classified as either a financial liability or an equity instrument according to the substance of the contract, not its legal form, and the definitions of financial liability and equity instrument. A financial instrument is an equity instrument if, and only if, both conditions (a) and (b) below are met:</p> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-align: left; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(a)</td><td style="text-align: left">the instrument includes no contractual obligation to deliver cash or another financial asset to another entity, and</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(b)</td><td style="text-align: left">if the instrument will or may be settled in the Company’s own equity instruments, it is either:</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 41.05pt"></td><td style="width: 18pt">(i)</td><td style="text-align: left">a non-derivative that includes no contractual obligation for the Company to deliver a variable number of its own equity instruments; or</td></tr></table> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 41.05pt"></td><td style="width: 18pt">(ii)</td><td style="text-align: left">a derivative that will be settled only by the issuer exchanging a fixed amount of cash or another financial asset for a fixed number of its own equity instruments.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">When a derivative financial instrument gives one party a choice over how it is settled (for instance, the Company or the holder can choose settlement net in cash or by exchanging shares for cash), it is a financial asset or a financial liability unless all of the settlement alternatives would result in it being an equity instrument. The financial instrument includes the exclusive right of the Company to settle the obligation with cash or equity and, accordingly, accounted for the fair value of the Earnout Shares as a non-current liability.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company recorded $5.478 million as the fair value estimate of the Earnout Shares, which is reflected as deferred obligation - iOx milestone on the condensed consolidated interim statements of financial position included herein. The Company will determine the fair value of the Earnout Shares at each balance sheet date. Any change to the fair value will be recorded in the Company’s statements of operations and other comprehensive income (loss). The Company recorded a (loss) from the change (increase) in fair value of the liability of $0.685 million for the three months ended June 30, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Employment Agreements</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">PDS entered into a Services Agreement with the Company’s CEO effective December 15, 2021 (the “CEO Services Agreement”). The CEO Services Agreement originally provided for a base salary of $<span id="xdx_907_eifrs-full--WagesAndSalaries_c20211214__20211215_zH5A6u4xxsh" title="Base salary">618,000</span>, plus cost-of-living increases. On December 19, 2022, the Compensation Committee approved the CEO’s compensation of $642,700 for Fiscal 2024. The CEO Services Agreement provides for annual increases based upon the review of the base salary by the Board prior to the anniversary of the CEO Services Agreement provided that the annual increase cannot be less than the cost-of-living increase. The CEO Services Agreement also provides that the CEO is eligible to receive an annual performance-based bonus targeted at 59% of the applicable year’s base salary, which bonus is earned based on the achievement of performance targets, as determined annually by the Board and communicated to the CEO in the first quarter of the year. Any annual bonus, to the extent earned, is to be paid no later than March 15 of the following year. The CEO Services Agreement is for an initial term of three years, after which it will automatically renew annually unless terminated in accordance with the CEO Services Agreement.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Under the CEO Services Agreement, the CEO may terminate his employment with PDS at any time for Good Reason (as defined in the CEO Services Agreement). PDS may terminate the CEO’s employment immediately upon his death, upon a period of disability or without Just Cause (as defined in the CEO Services Agreement). In the event that the CEO’s employment is terminated due to his death or Disability (as defined in the CEO Services Agreement), for Good Reason or without Just Cause, he will be entitled to accrued obligations (accrued unpaid portion of base salary, accrued unused vacation time and any unpaid expenses). Additionally, he may be entitled to Severance Benefits (as defined in the CEO Services Agreement), which include his then current base salary and the average of his annual bonus for the prior two completed performance years, paid over 12 monthly installments. Additionally, the CEO will be entitled to life insurance benefits and medical and dental benefits for a period of 12 months at the same rate the CEO and PDS shared such costs during his period of employment.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Additionally, all stock options (and any other unvested equity incentive award) held by the CEO relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as defined in the CEO Services Agreement), and the exercise period for such stock options will be increased by a period of two years from the Termination Date.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">If the CEO’s employment by PDS is terminated by PDS or any successor entity without Just Cause (not including termination by virtue of the CEO’s death or Disability) or by the CEO for Good Reason within 12 months following the effective date of a Change in Control (as defined in the CEO Services Agreement), then, in addition to paying or providing the CEO with the Accrued Obligations (as defined in the CEO Services Agreement), the Company will provide the following Change in Control Severance Benefits (as defined in the CEO Services Agreement):</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(1)</td><td>PDS will pay the base salary continuation benefit for 18 months;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(2)</td><td>PDS will pay the life insurance benefit for 18 months;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(3)</td><td>PDS will pay an additional amount equivalent to the CEO’s target annual bonus calculated using the bonus percentage for the performance year in which the CEO’s termination occurs. This bonus will be paid in 12 equal installments commencing on the first payroll date that is more than 60 days following the date of termination of the CEO’s employment, with the remaining installments occurring on the first day of the month for the 11 months thereafter;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(4)</td><td>PDS will provide the CEO with continued medical and dental benefits, as described above, for 18 months; and</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(5)</td><td>All stock options (and any other unvested equity incentive award) held by the CEO relating to shares of PDS or the Company will be deemed fully vested and exercisable on the Termination Date, as defined, and the exercise period for such stock options will be increased by a period of two years from the Termination Date.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">PDS entered into services agreements (individually, an “Executive Service Agreement,” and collectively, the “Executive Service Agreements”) with each of the Company’s five other members of senior management (individually, “Executive” and collectively, “Executives”), three of which are dated as of December 1, 2021, one of which is dated December 15, 2021 and one of which is dated June 1, 2022. Each of the Executive Services Agreements provides for an initial term of two years that is automatically renewed for one-year periods (except two of the Executive Services Agreement, which provides for an initial term of one year and that is automatically renewed for one-year periods). The Executive Services Agreements initially provided for annual base salaries ranging from $175,000 to $<span id="xdx_905_ecustom--AnnualBaseSalary_c20211214__20211215_zfHFoiF0SLFd" title="Annual base salary">348,000</span> (pro-rated for services rendered) and annual bonus targets ranging from 30% to 40%. They also provide for long-term incentives in the form of equity awards from time to time under the Portage Biotech Inc. Amended and Restated 2021 Equity Incentive Plan.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On December 19, 2022, the Compensation Committee approved executive compensation for Fiscal 2024 for annual base salaries ranging from $183,750 to $<span id="xdx_903_eifrs-full--WagesAndSalaries_c20221218__20221219_z4BLDMeolhi1" title="Base salary">469,000</span> (pro-rated for services rendered) and annual bonus targets ranging from 30% to 40%.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Executive Services Agreements can be terminated by PDS without Just Cause, by death or Disability, or by the Executive (except one) for Good Reason (each as defined in the respective Executive Services Agreements). In such instances, the Executive Services Agreements provide for the payment of accrued obligations (accrued unpaid portion of base salary, accrued unused vacation time and any unpaid expenses). Additionally, the Executives (except two) are entitled to 50% of base salary plus 50% of average annual bonus earned over the prior two performance years, as well as prevailing life insurance benefits for a period of six months and medical and dental benefits for a period of six months at the prevailing rate PDS and the Executive were sharing such expenses.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Additionally, all stock options (and any other unvested equity incentive award) held by the Executives relating to shares of the Company will be deemed fully vested and exercisable on the Termination Date (as defined in the respective Executive Services Agreements), and the exercise period for such stock options will be increased by a period of two years from the Termination Date.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">If an Executive’s employment by PDS is terminated by the Company or any successor entity without Just Cause (not including termination by virtue of the Executive’s death or Disability) or by the Executive (except one) for Good Reason within 12 months following the effective date of a Change in Control (as defined in the respective Executive Services Agreements), then, in addition to paying or providing the Executive with the Accrued Obligations (as defined in the respective Executive Services Agreements), the Company will provide the following Change in Control Severance Benefits (as defined in the respective Executive Services Agreements), except in two cases in which the Executive is entitled to Item (5) and 50% of Items (1) and (3) below:</p> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(1)</td><td>PDS will pay the Base Salary continuation benefit for 12 months;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(2)</td><td>PDS will pay the life insurance benefit for 12 months;</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(3)</td><td>The Company will pay an additional amount equivalent to the Executive’s target annual bonus calculated using the bonus percentage for the performance year in which the Executive’s termination occurs. This bonus will be payable in 12 equal installments commencing on the first payroll date that is more than 60 days following the date of termination of the Executive’s employment, with the remaining installments occurring on the first day of the month for the 11 months thereafter;</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(4)</td><td>PDS will provide the Executive with continued medical and dental benefits, as described above, for 12 months; and</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt">(5)</td><td>All stock options (and any other unvested equity incentive award) held by the Executive relating to shares of PDS or the Company will be deemed fully vested and exercisable on the Termination Date and the exercise period for such stock options will be increased by a period of two years from the Termination Date.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Executive Services Agreements also include customary confidentiality, as well as provisions relating to assignment of inventions. The Executive Services Agreements also includes non-competition and non-solicitation of employees and customers provision that run during the Executive’s employment with PDS and for a period of one year after termination of employment.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><span style="background-color: white"><b><i>Bonuses &amp; Board Compensation Arrangements</i></b></span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><span style="background-color: white">In December 2022, the Board approved executive performance bonuses, as recommended by the Compensation Committee, totaling $<span id="xdx_905_ecustom--CompensationCommittee_pn3n3_dm_c20221225__20221231_zwNIOx8VueGb" title="Compensation committee">0.6</span> million, which is equivalent to <span id="xdx_905_ecustom--OriginalAnnualTargetsPercentage_pid_dp_c20221225__20221231_zVIZf75M4PDj" title="Original annual targets percentage">73.5</span>% of original annual targets established by the Board in December 2021. The bonuses were approved based upon the original performance targets established. The Board further approved a payment structure of 25% of approved bonuses, which were paid in January 2023, with the balance of amounts due payable upon a new financing. The accrued, unpaid amount of approximately $<span id="xdx_900_ecustom--AccountsPayableAndAccruedExpenses_iI_pn3n3_dm_c20230630_z7M5Yt0eWZgb" title="Accounts payable and accrued expenses"><span id="xdx_901_ecustom--AccountsPayableAndAccruedExpenses_iI_pn3n3_dm_c20230331_zFfA54edLcg4" title="Accounts payable and accrued expenses">0.4</span></span> million is included in accounts payable and accrued expenses on the condensed consolidated statements of financial position as of each of June 30, 2023 and March 31, 2023. </span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Effective January 1, 2022, each non-employee Board member are entitled to receive cash Board fees of $40,000 per annum, payable quarterly in arrears. Additionally, each non-employee Board member is entitled to an annual grant of 6,900 options to purchase Portage ordinary shares, which would vest the first annual anniversary of the grant date. The Company incurred Board fees totaling $82,500 and $75,000 during the three months ended June 30, 2023 and 2022, respectively.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Non-employee Board chairpersons are entitled to an annual cash fee of $30,000, payable quarterly in arrears. In lieu of a non-executive chairperson, the lead director is entitled to an annual cash fee of $20,000 per annum paid quarterly in arrears. <span id="xdx_90A_ecustom--AnnualFeesdescription_c20230401__20230630_zktDG1Ibwqsg" title="Annual fees description">Additionally, the chairperson of each of the Audit Committee, Compensation Committee and Nominating Committee is entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members of those committees will be entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears.</span></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> Company, through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price of £162. Simultaneously, the Company entered into an agreement with OSI, the holder of $0.15 million notes plus accrued interest under which OSI exchanged the notes plus accrued interest for 820 shares of iOx. The Company followed the guidance provided by an IFRS Discussion Group Public Meeting dated November 29, 2016, following the general tenets of IAS 39, “Financial Instruments: Recognition and Measurement,” and IFRIC 19, “Extinguishing Financial Liabilities with Equity Instruments,” and recorded the exchange at historical cost. Additionally, no profit or loss was recorded in connection with the exchange. As a result of these transactions, the Company, through SalvaRx, increased its ownership of iOx from 60.49% to 78.32%. 1070000 618000 348000 469000 600000 0.735 400000 400000 Additionally, the chairperson of each of the Audit Committee, Compensation Committee and Nominating Committee is entitled to annual fees of $15,000, $12,000 and $8,000, respectively, payable quarterly in arrears. Members of those committees will be entitled to annual fees of $7,500, $6,000 and $4,000, respectively, payable quarterly in arrears. <p id="xdx_80E_eifrs-full--DisclosureOfFinancialInstrumentsExplanatory_zDCsSF7niIkb" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 17. <span id="xdx_827_zaX68kmxTHh3">FINANCIAL INSTRUMENTS AND RISK MANAGEMENT</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company’s financial instruments recognized in the Company’s condensed consolidated interim statements of financial position consist of the following:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Fair value estimates are made at a specific point in time, based on relevant market information and information about financial instruments. These estimates are subject to and involve uncertainties and matters of significant judgment; and therefore, these estimates cannot be determined with precision. Changes in assumptions could significantly affect these estimates.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following table summarizes the Company’s financial instruments as of June 30, 2023 and March 31, 2023:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory_pn3n3_zhl1gFE35mD2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BD_zEAfaWQQMGC5" style="display: none">Schedule of financial instruments</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_49B_20230630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zJfH4CL9PSDj" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_499_20230630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zkKY2bwcL57b" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_49B_20230630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zwGJUQtLMSS" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49F_20230331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zXlNAAcpFVO6" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_499_20230331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zRVu8RpmfwR8" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49D_20230331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z8D5qJpt5BXh" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial assets</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">7,698</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">10,545</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1330">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">2,752</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1334">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,689</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1337">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ConvertibleNoteReceivableIncludingAccruedInterestNetOfImpairment_i01I_pn3n3_zW1tbRhb7Jy1" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Convertible note receivable, including accrued interest, net of impairment</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1339">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">442</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1342">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">442</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--CurrentInvestments_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment in associate</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">756</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1349">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1350">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">806</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--InvestmentInPrivateCompany_i01I_pn3n3_zSsBcSbKdQjc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment in public company</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,855</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1355">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,087</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1358">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_498_20230630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zHU4ypz61Qm6" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_493_20230630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zmyMlrsJz2Ia" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_495_20230331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_ziD0A1UAF5Gc" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49C_20230331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zNPRgEPbjTSk" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr> <tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">2,591</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1366">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,865</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_eifrs-full--CurrentLeaseLiabilities_i01I_pn3n3_zWrS9YDuCTJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Lease liability - current</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">47</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1373">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--NoncurrentLeaseLiabilities_i01I_pn3n3_zZP745YExMl5" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Lease liability - non-current</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">249</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1378">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredPurchasePricePayableTarus_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred purchase price payable - Tarus</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1380">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">7,864</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">7,179</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DeferredObligationIoxMilestone_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred obligation - iOx milestone</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1385">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">4,552</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1387">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">4,126</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A7_zEOxJferGpIa" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">A summary of the Company’s risk exposures as it relates to financial instruments are reflected below.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Fair value of Financial Instruments</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company’s financial assets and liabilities are comprised of cash and cash equivalents, receivables and investments in equities and private and public entities, accounts payable, lease liability, deferred purchase price payable, deferred obligation and unsecured notes payable.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company classifies the fair value of these transactions according to the following fair value hierarchy based on the amount of observable inputs used to value the instrument:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>Level 1 – Values are based on unadjusted quoted prices available in active markets for identical assets or liabilities as of the reporting date.</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>Level 2 – Values are based on inputs, including quoted forward prices for commodities, time value and volatility factors, which can be substantially observed or corroborated in the marketplace. Prices in Level 2 are either directly or indirectly observable as of the reporting date.</td></tr></table> <p style="margin: 0pt 0 0pt 41.05pt; font-size: 10pt; text-indent: -0.25in"> </p> <table cellpadding="0" cellspacing="0" style="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top"> <td style="width: 23.05pt"></td><td style="width: 18pt"><span style="font-family: Symbol">·</span></td><td>Level 3 – Values are based on prices or valuation techniques that are not based on observable market data. Investments are classified as Level 3 financial instrument.</td></tr></table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Assessment of the significance of a particular input to the fair value measurement requires judgment and may affect the placement within the fair value hierarchy.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Management has assessed that the fair values of cash and cash equivalents, other receivables and accounts payable approximate their carrying amounts largely due to the short-term maturities of these instruments.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The following methods and assumptions were used to estimate their fair values:</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Investment in Associate:</b> The fair value of the Stimunity investment was determined based on an IAS 36 fair value analysis evaluating the likelihood of various scenarios given the then-current market conditions, the increasing cost of capital and development delays associated with Stimunity’s lack of liquidity (Level 3). The Company recorded a provision of impairment of $<span id="xdx_907_ecustom--ImpairmentAnalysis_pn3n3_dm_c20220401__20230331_zET081uWU0Yi" title="Impairment analysis">0.607</span> million with respect to the investment in associate decreasing the carrying value of the investment in associate to $<span id="xdx_908_ecustom--DecreasingCarryingValue_pn3n3_dm_c20220401__20230331_zBkNPWRumhz8" title="Decreasing the carrying value">0.806</span> million as of March 31, 2023. There was no provision for impairment recorded in the three months ended June 30, 2023. See Note 6, “Investment in Associate,” for a further discussion.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Convertible Note Receivable:</b> The fair value of the Stimunity Convertible Note receivable denominated in euros at initial recognition is the transaction price for the instrument adjusted for the effect of the currency translation rate on the reporting date (Level 3) (see Note 15, “Commitments and Contingent Liabilities – Stimunity Convertible Note”). The Stimunity Convertible Note was initially recorded at $<span id="xdx_906_ecustom--NotesReceivable_pn3n3_dm_c20220911__20220912_zk5mpJXoncqb" title="Notes receivable">0.614</span> million to record the translated value of the Stimunity Convertible Note on September 12, 2022. The Company recognized an unrealized gain of $<span id="xdx_902_ecustom--UnrealizedGains_pn3n3_dm_c20220401__20230331_zxXC5HQTgAtk" title="Unrealized gain">0.039</span> million through OCI in Fiscal 2023 to reflect the change in translation rate for the Stimunity Convertible Note settleable in euros, increasing the carrying value of the Stimunity Convertible Note to $<span id="xdx_906_ecustom--IncreasingCarryingValue_pn3n3_dm_c20220401__20230331_zNTmdw7CILvf" title="Increasing carrying value">0.653</span> million. As of March 31, 2023, the Company determined that there were indications of impairment, based upon the inability of Stimunity to obtain financing. The Company performed an IAS 36 fair value analysis evaluating the likelihood of various scenarios given the then-current market conditions, the increasing cost of capital and development delays associated with Stimunity’s lack of liquidity. The Company recorded an impairment of $<span id="xdx_90B_eifrs-full--ReversalOfImpairmentLoss_pn3n3_dm_c20220401__20230331_z3d8c3k1xaG7" title=" Impairment of convertible note">0.211</span> million resulting from the impairment analysis decreasing the carrying value of the Stimunity Convertible Note to $<span id="xdx_90E_ecustom--DecreasingImpairmentCarryingValue_pn3n3_dm_c20220401__20230331_zql4zLh0aap" title="Decreasing impairment carrying value">0.442</span> million as of March 31, 2023. The Company recorded a nominal unrealized gain in the three months ended June 30, 2023 with respect to the Stimunity Convertible Note.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Investment in Public Company</b>: Upon Intensity’s IPO effective June 30, 2023, the fair value of the investment is determined by the quoted market price (Level 1).</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Accrued Equity Issuable: </b>The fair value is estimated based on the average of the quoted market prices for the period in which the shares were earned (Level 1).</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Lease Liability - Current</b>: The lease liability - current represents the present value of the lease payments due over the next twelve months discounted at the Company’s incremental borrowing rate (Level 2).</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Lease Liability - Non-Current:</b> The lease liability - non-current represents the present value of the lease payments due under the lease less the current portion of such payments discounted at the Company’s incremental borrowing rate (Level 2).</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Deferred Purchase Price Payable - Tarus:</b> The fair value is the estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 at acquisition date, adjusted at each reporting date for any change in fair value (Level 3) (see Note 9, “Acquisition of Tarus”). The fair value was determined using the Income Approach and was based upon the analysis on the Tarus clinical plan, the timing of development events and the probabilities of success determined primarily based upon empirical third party data and Company experience, as well as the relevant cost of capital. The Company recorded a (loss) from the change (increase) in fair value of the liability of $<span id="xdx_90B_ecustom--LossOnDecreaseInFairValueOfLiability_pn3n3_dm_c20230401__20230630__ifrs-full--CounterpartiesAxis__custom--TarusMember_z2dM9I7soHse" title="Loss on decrease in fair value of the liability">0.685</span> million for the three months ended June 30, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b>Deferred Obligation - iOx Milestone:</b> The fair value is the estimated value of a future contingent obligation based upon a fair value analysis performed in accordance with IFRS 3 as of July 18, 2022, the date of the Share Exchange Agreement, adjusted at each reporting date for any change in fair value (Level 3) (see Note 16, “Related Party Transactions – Share Exchange Agreement – iOx”). The fair value was determined using the Income Approach and based on factors including the clinical plan, the timing of development events and the probabilities of success determined primarily based upon empirical third party data and Company experience, as well as the relevant cost of capital. The Company recorded a (loss) from the change (increase) in fair value of the liability of $<span id="xdx_90E_ecustom--LossOnDecreaseInFairValueOfLiability_pn3n3_dm_c20230401__20230630__ifrs-full--CounterpartiesAxis__custom--IOXMember_z83o7eRtR1P4" title="Loss on decrease in fair value of the liability">0.426</span> million for the three months ended June 30, 2023.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="text-align: left; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><b><i>Fair Value Hierarchy</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b></b>The investment in public company (Intensity) was transferred from Level 3 to Level 1 of the fair value hierarchy for the three months ended June 30, 2023 as the result of Intensity’s IPO. For the year ended March 31, 2023, the fair value of the investment was determined based on an IAS 36 impairment analysis after determining there were external indications of impairment (Level 3). See Note 7, “Investment in Public Company.”</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company’s financial instruments are exposed to certain financial risks: Credit Risk, Liquidity Risk and Foreign Currency Risk.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Credit Risk</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Credit risk is the risk of loss associated with a counterparty’s inability to fulfill its payment obligations. The credit risk is attributable to various financial instruments, as noted below. The credit risk is limited to the carrying value as reflected in the Company’s condensed consolidated interim statements of financial position.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b><i>Cash and cash equivalents</i>.</b> Cash and cash equivalents comprise cash on hand and amounts invested in underlying Treasury and money market funds that are readily convertible to a known amount of cash with three months or less from date of acquisition and are subject to an insignificant risk of change in value. <span style="background-color: white">As of June 30, 2023 and March 31, 2023, cash equivalents was comprised of a money market account with maturities less than 90 days from the date of purchase. </span>Cash and cash equivalents are held with major international financial institutions and therefore the risk of loss is minimal.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Liquidity Risk</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Liquidity risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company’s approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when due, under both normal and stressed conditions without incurring unacceptable losses or risking harm to the Company’s reputation. The Company holds sufficient cash and cash equivalents to satisfy current obligations under accounts payable and accruals.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company monitors its liquidity position regularly to assess whether it has the funds necessary to meet its operating needs and needs for investing in new projects.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As a biotech company at an early stage of development and without significant internally generated cash flows, there are inherent liquidity risks, including the possibility that additional financing may not be available to the Company, or that actual drug development expenditures may exceed those planned. The current uncertainty in global markets could have an impact on the Company’s future ability to access capital on terms that are acceptable to the Company. There can be no assurance that required financing will be available to the Company. See Note 2, “Going Concern,” and Note 12, “Capital Stock,” for a discussion of the Company’s share offering and Note 15, “Commitments and Contingent Liabilities – Committed Purchase Agreement,” for a further discussion.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <p style="margin: 0pt 0; font-size: 10pt"><b><i>Foreign Currency Risk</i></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">While the Company operates in various jurisdictions, substantially all of the Company’s transactions are denominated in the U.S. Dollar, except the deferred tax liability in the U.K. settleable in British pound sterling and the Stimunity Convertible Note receivable settleable in euros.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_893_ecustom--DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory_pn3n3_zhl1gFE35mD2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left"><span id="xdx_8BD_zEAfaWQQMGC5" style="display: none">Schedule of financial instruments</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_49B_20230630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zJfH4CL9PSDj" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_499_20230630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zkKY2bwcL57b" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_49B_20230630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zwGJUQtLMSS" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49F_20230331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zXlNAAcpFVO6" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_499_20230331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueToOtherComprehensiveIncomeMember_zRVu8RpmfwR8" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49D_20230331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_z8D5qJpt5BXh" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="11" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTOCI</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt"> </td> <td colspan="3" style="white-space: nowrap; font-size: 10pt; text-align: center"> </td></tr> <tr id="xdx_40C_eifrs-full--CategoriesOfFinancialAssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial assets</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_408_eifrs-full--CashAndCashEquivalents_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="width: 34%; font-size: 10pt; font-weight: bold; text-align: left">Cash and cash equivalents</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right">7,698</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1326">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 8%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1327">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right">10,545</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1329">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 8%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1330">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_401_ecustom--PrepaidExpensesAndOtherReceivable_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Prepaid expenses and other receivables</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">2,752</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1333">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1334">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,689</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1336">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1337">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--ConvertibleNoteReceivableIncludingAccruedInterestNetOfImpairment_i01I_pn3n3_zW1tbRhb7Jy1" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Convertible note receivable, including accrued interest, net of impairment</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1339">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1340">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">442</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1342">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1343">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">442</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40A_eifrs-full--CurrentInvestments_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment in associate</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1347">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">756</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1349">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1350">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">806</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--InvestmentInPrivateCompany_i01I_pn3n3_zSsBcSbKdQjc" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Investment in public company</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1353">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">3,855</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1355">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">2,087</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1358">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_498_20230630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_zHU4ypz61Qm6" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_493_20230630__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zmyMlrsJz2Ia" style="font-size: 10pt; font-weight: bold; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_495_20230331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--AmortizedCostMember_ziD0A1UAF5Gc" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td id="xdx_49C_20230331__ifrs-full--LevelsOfFairValueHierarchyAxis__custom--FairValueThroughProfitOrLossMember_zNPRgEPbjTSk" style="font-size: 10pt; text-align: center"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="7" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">As of March 31, 2023</td></tr> <tr style="vertical-align: bottom"> <td style="white-space: nowrap; font-size: 10pt; text-align: center"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Amortized <br/>Cost</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">FVTPL</td></tr> <tr id="xdx_40A_eifrs-full--CategoriesOfFinancialLiabilitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-decoration: underline; font-size: 10pt; font-weight: bold; text-align: left">Financial liabilities</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AccountsPayableAndAccruedLiabilities_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="width: 48%; font-size: 10pt; font-weight: bold; text-align: left">Accounts payable and accrued liabilities</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right">2,591</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1366">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right">1,865</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 10%; font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1368">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40E_eifrs-full--CurrentLeaseLiabilities_i01I_pn3n3_zWrS9YDuCTJl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Lease liability - current</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">47</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1371">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1372">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1373">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_40B_eifrs-full--NoncurrentLeaseLiabilities_i01I_pn3n3_zZP745YExMl5" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Lease liability - non-current</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">249</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1376">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1377">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1378">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DeferredPurchasePricePayableTarus_i01I_pn3n3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred purchase price payable - Tarus</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1380">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">7,864</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1382">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">7,179</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DeferredObligationIoxMilestone_i01I_pn3n3" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left">Deferred obligation - iOx milestone</td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1385">-</span></td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left">$</td><td style="font-size: 10pt; font-weight: bold; text-align: right">4,552</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1387">-</span></td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">4,126</td><td style="white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> 7698000 10545000 2752000 2689000 442000 442000 756000 806000 3855000 2087000 2591000 1865000 47000 249000 7864000 7179000 4552000 4126000 607000 806000 614000 39000.000 653000 211000 442000 685000 426000 <p id="xdx_804_ecustom--DisclosureOfCapitalManagementExplanatoryTextBlock_zec6IwqXUU39" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 18. <span id="xdx_82E_zdeT6nypcTg3">CAPITAL DISCLOSURES</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company considers the items included in shareholders’ equity as capital. The Company had accounts payable and accrued liabilities of approximately $<span id="xdx_902_ecustom--AccountsPayableAndAccruedLiability_iI_pn3n3_dm_c20230630_ziz7Vq4Dhmuj" title="Accounts payable and accrued liabilities">2.6</span> million and lease liability - current of $<span id="xdx_904_eifrs-full--CurrentLeaseLiabilities_iI_pn3n3_dm_c20230630_zGIg95hqBZrh" title="Lease liability current">0.047</span> million as of June 30, 2023 (accounts payable and accrued liabilities of approximately $<span id="xdx_90A_ecustom--AccountsPayableAndAccruedLiability_iI_pn3n3_dm_c20230331_zeACjbLJgFUe" title="Accounts payable and accrued liabilities">1.9</span> million as of March 31, 2023) and current assets of approximately $<span id="xdx_909_ecustom--CurrentAsset_iI_pn3n3_dm_c20230630_z5S6zoOhLUY2" title="Current assets">10.9</span> million as of June 30, 2023 (approximately $<span id="xdx_908_ecustom--CurrentAsset_iI_pn3n3_dm_c20230331_z4BC4Vt6PVJ2" title="Current assets">13.7</span> million as of March 31, 2023). The Company’s objectives when managing capital are to safeguard the Company’s ability to continue as a going concern in order to pursue new business opportunities and to maintain a flexible capital structure, which optimizes the costs of capital at an acceptable risk.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"><b> </b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">As of June 30, 2023, shareholders’ equity attributable to the owners of the company was approximately $<span id="xdx_90D_ecustom--ShareholdersEquityAttributableToOwners_iI_pn3n3_dm_c20230630_ztUVbZVyH3Ie" title="Shareholders' equity attributable to owners">73.3</span> million (approximately $<span id="xdx_901_ecustom--ShareholdersEquityAttributableToOwners_iI_pn3n3_dm_c20230331_zoL3DsGngjZ7" title="Shareholders' equity attributable to owners">76.0</span> million as of March 31, 2023).</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">The Company is not subject to any externally imposed capital requirements and does not presently utilize any quantitative measures to monitor its capital. There have been no changes to the Company’s approach to capital management during the three months ended June 30, 2023 and 2022.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> 2600000 47000.000 1900000 10900000 13700000 73300000 76000000.0 <p id="xdx_803_eifrs-full--DisclosureOfInterestsInOtherEntitiesExplanatory_ziLXgCqLQg28" style="margin: 0pt 0; font-size: 10pt"><b>NOTE 19. <span id="xdx_82A_zZrEm1RgkcJd">NON-CONTROLLING INTEREST</span></b></p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zpkJck7wgsX2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt"><span id="xdx_8BA_z0YWwqhHAKZ" style="display: none">Schedule of non-controlling interest</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Saugatuck <br/>and subsidiary</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; font-weight: bold; padding-left: 5.4pt">Non-controlling interest as of April 1, 2023</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_z5KpaGbpFHg5" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning"><span style="-sec-ix-hidden: xdx2ixbrl1443">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_987_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_zfvVA1s2GKfl" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">(650</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20230630_zFOJkoh4AqPc" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">(650</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Net loss attributable to non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_986_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zOKJQo6Gd1Ig" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net (loss) attributable to non-controlling interest"><span style="-sec-ix-hidden: xdx2ixbrl1449">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98E_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_z0E39TVdOXvd" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net (loss) attributable to non-controlling interest">(7</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_985_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20230630_z2ZyXsbNafT2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net (loss) attributable to non-controlling interest">(7</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Non-controlling interest as of June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zty0PQ3sfaph" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"><span style="-sec-ix-hidden: xdx2ixbrl1455">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_zvXPCW9yja1c" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(657</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20230401__20230630_zwU3QLifdK93" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(657</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Saugatuck <br/>and subsidiary</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; padding-left: 5.4pt">Non-controlling interest as of April 1, 2022</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_z7da0KK5xL2l" style="width: 10%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">44,701</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_zPDM6hJaUXC1" style="width: 10%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">(472</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20220630_zZvUBZiQiV1f" style="width: 10%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">44,229</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Net income (loss) attributable to non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98E_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zlMsOpTVIoOi" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest">175</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_981_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_zLf4E0y59Jyb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest">(71</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98D_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20220401__20220630_zg23rNJuODL5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest">104</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">Non-controlling interest as of June 30, 2022</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_z31VGfm2DzY5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending">44,876</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_zUObxxd5y5Yl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending">(543</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20220630_z0IEyYpbNIla" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending">44,333</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> <p id="xdx_8A2_zqzFZtjkoyR8" style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">On September 8, 2021, the Company, through SalvaRx, completed a settlement of loans (including interest) to and receivables from iOx for services rendered in exchange for 23,772 ordinary shares of iOx at a price of £162. On July 18, 2022, the Company completed the acquisition of the remaining non-controlling interest in iOx, by issuing 1,070,000 shares of its ordinary shares and assuming certain milestone obligations. See Note 16, “Related Party Transactions – Share Exchange Agreement – iOx” for a discussion of the Company’s purchase of the balance of the non-controlling interest in iOx.</p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt"> </p> <p style="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt">Saugatuck and subsidiary includes Saugatuck and its wholly-owned subsidiary, Saugatuck Rx LLC.</p> <p style="margin: 0pt 0; font-size: 10pt"> </p> <table cellpadding="0" cellspacing="0" id="xdx_89A_ecustom--ScheduleOfNoncontrollingInterestTableTextBlock_pn3n3_zpkJck7wgsX2" style="border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NON-CONTROLLING INTEREST (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-left: 5.4pt"><span id="xdx_8BA_z0YWwqhHAKZ" style="display: none">Schedule of non-controlling interest</span></td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold"> </td> <td style="font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; text-align: right"> </td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Saugatuck <br/>and subsidiary</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; font-weight: bold; padding-left: 5.4pt">Non-controlling interest as of April 1, 2023</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98C_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_z5KpaGbpFHg5" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning"><span style="-sec-ix-hidden: xdx2ixbrl1443">-</span></td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_987_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_zfvVA1s2GKfl" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">(650</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="width: 1%; font-size: 10pt; font-weight: bold"> </td> <td style="width: 1%; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_98E_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20230401__20230630_zFOJkoh4AqPc" style="width: 10%; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at beginning">(650</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; font-weight: bold; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Net loss attributable to non-controlling interest</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_986_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zOKJQo6Gd1Ig" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net (loss) attributable to non-controlling interest"><span style="-sec-ix-hidden: xdx2ixbrl1449">-</span></td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_98E_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_z0E39TVdOXvd" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net (loss) attributable to non-controlling interest">(7</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: left"> </td><td id="xdx_985_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20230401__20230630_z2ZyXsbNafT2" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: right" title="Net (loss) attributable to non-controlling interest">(7</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Non-controlling interest as of June 30, 2023</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_986_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zty0PQ3sfaph" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending"><span style="-sec-ix-hidden: xdx2ixbrl1455">-</span></td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20230401__20230630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_zvXPCW9yja1c" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(657</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: left">$</td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20230401__20230630_zwU3QLifdK93" style="border-bottom: Black 2.5pt double; font-size: 10pt; font-weight: bold; text-align: right" title="Non-controlling interest, at ending">(657</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: left">)</td></tr> </table> <p style="margin: 0pt 0; font-size: 10pt"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">(In thousands)</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">iOx</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Saugatuck <br/>and subsidiary</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="3" style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center">Total</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 61%; font-size: 10pt; padding-left: 5.4pt">Non-controlling interest as of April 1, 2022</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_983_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_z7da0KK5xL2l" style="width: 10%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">44,701</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_984_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_zPDM6hJaUXC1" style="width: 10%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">(472</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 1%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td id="xdx_982_eifrs-full--NoncontrollingInterests_iS_pn3n3_c20220401__20220630_zZvUBZiQiV1f" style="width: 10%; font-size: 10pt; text-align: right" title="Non-controlling interest, at beginning">44,229</td><td style="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Net income (loss) attributable to non-controlling interest</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98E_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_zlMsOpTVIoOi" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest">175</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_981_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_zLf4E0y59Jyb" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest">(71</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left"> </td><td id="xdx_98D_ecustom--NetLossAttributableToNoncontrollingInterest_pn3n3_c20220401__20220630_zg23rNJuODL5" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right" title="Net (loss) attributable to non-controlling interest">104</td><td style="border-bottom: Black 1pt solid; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; padding-bottom: 2.5pt; padding-left: 5.4pt">Non-controlling interest as of June 30, 2022</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98C_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--IOXMember_z31VGfm2DzY5" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending">44,876</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_988_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20220630__ifrs-full--CategoriesOfRelatedPartiesAxis__custom--SaugatuckAndSubsidiaryMember_zUObxxd5y5Yl" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending">(543</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left">$</td><td id="xdx_98A_eifrs-full--NoncontrollingInterests_iE_pn3n3_c20220401__20220630_z0IEyYpbNIla" style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right" title="Non-controlling interest, at ending">44,333</td><td style="border-bottom: Black 2.5pt double; white-space: nowrap; font-size: 10pt; text-align: left"> </td></tr> </table> -650000 -650000 -7000 -7000 -657000 -657000 44701000 -472000 44229000 175000 -71000 104000 44876000 -543000 44333000 EXCEL 85 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

-8?20$3;8T.P6BP^0"X99K>]9!:G-:2I4[^W+C)QO!P.&" M=*ZN.'NNFQ]W=?V#_-R653L;W7?=P^EXW*[NQ39O_ZH?1"7W;.IFFW=RL_D^ M;A\:D:_;>R&Z;3FV)Q-_O,V+:G1^MC]7THS5C;H3JZZH*]G8-]P6XKD][.\W MR5/1%G=%673_SD;#_U*,R+:HBFWQ2ZQGH\F(M/?U\W7=%+_JJLM+OFKJLIR- MK-V.6]%TQ>J/9MY#9OE=.[1T^5V:2Y#9R)_($VZ*INV&(X;SYY+Q2GD7;(J5F->KQZVH MNET<&U'V@%5[7SRT(U+E6S$;A?63:/K[D1>@Z]V]=1)*B51S6L@=#5T/>)@H MU5I4K5@3^:^MRV(M.=:$5C).Q98HD#8 :1\1\A];@70 2.>8D(X"Z0*0[C$A M7072 R"]8T)Z"J0/0/JXD"S(EFE$XDL2)U$:9#1F7"&; F137+*KF+(K$L8L MC%*F('T"D#[A(ET$G/(^5DD:\8AE0[@4M,\ VF=<-$ZO&+VD8< R$H1AO&19 M'[XD7M"01NHCM2;0,#W!Q92!2P(Z)]'7)&(\XB1@PVXMF-?,2$,A)P'H4D[[[MIWWRQ(EUJ7@"QA(6N"LH])&H<1YZ0?58(TO!YZ MQ3RZC19QHF)"GK"014&9?,$B&;JO^F@"&<)"5D08)#0+%H1GMOZ)IK=:/X D82%;XF01<_Z!2-,3?AVD*I<-:<%&UH)\M6[H,*#M MC""MW^NK'^ 6-+A0,2$MV,A:2*.%M,"<)$&:?2-9&C >A*]3)AN<82";X9*R M@$E7+:08>)8N#R%-*?^BS8,@.=C8DXR7CCNG/)2OI,Q M0A"JK"15<%B]K%_ M_=)XL>@S*,JR2.)E*A^D"QM9%V"BITTB;4@7-K(NP$1/QX0,8B,;Y(U$CYQD MN01I54S(*3:R4X9D:@_U0:6";&(CV\2459D@'4@M#K):P/1*+[I :G'09QR' M],H80\@J#G;A2LVSC'1@P0I9)J:$RP@):<5!ULKKS,L("'G%0?8*F#GH_03R MBH-=KWI#SR_Q5#$AKSC(7C&5U?"3 MB@F)QD$6C;'N=L!5:]*0:MQC%K?TTCFD&ON M&PA36ZN%=..AZT:=@!EZC@=9QD.WC(&.6!H?I!<5']@I(J243/N05']DK,*8Z/_ AP?A'*:*976(:@J)B0='UDZ M<.54S<-]2#X^LGQ@3#4/GT+RF6)_"O#GTK!J2A43LL\4V3YOUZ%?5Z>FD'VF M@WW&P\'M^=E:;(I*K)F\1"O;5WFY2AK2_^R^.7.]_O.1S6-9AK(MKA9UOMY_ M^KW_;/W\/U!+ P04 " I@!U7K&U05SP" "O*@ &@ 'AL+U]R96QS M+W=O0,UYOVR'IJO9=%MZ Y*> M?- DBL>A[=U/2!?)([.83?%9R5%\_8/P0]3'EWQHQWUW*KM]7Q:?Q\.IK*K= M./:_ZKJL=_G8EKNNSZ?SD4TW'-OQO!RV==^NW]MMKF6YC'JXG5$]/=[.7+Q^ M]?E_)G:;S7Z=?W?K/\=\&O\QN/[HAO>RRWFL%J_ML,WCJJH_#]?=I;YLTMUY M"<"O07U%@*]!?46 KUE\K!-H+>@WD*@MZ#>0J"WH-Y" MH+>@WD*@MZ#>0J"WH-Y"H+>@WD*@MZ+>2J"WHMY*H+>BWDJ@MTY>EA#HK:BW M$NBMJ+<2Z*VHMQ+HK:BW$NBMJ+<2Z*VHMQ+H;:BW$>AMJ+<1Z&VHMQ'H;:BW M$>AMDY?=!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z.^KM!'H[ZNT$>COJ M[01Z.^KM!'H[ZNT$>OOD8R6!WHYZ.X'>CGH[@=Z.>CN!WHYZ.X'>@7H'@=Z! M>@>!WH%Z!X'>@7H'@=Z!>@>!WH%Z!X'>,?G9A$#O0+V#0.] O8- [T"]@T#O M!O5N"/1N4.^&0.\&]6Y^4N\R?AURN?9\K_'Z/TGU>#XW7R]_67[OG-R7"\[U M;45Y^@M02P,$% @ *8 =5T!K%[H @ QBD !, !;0V]N=&5N=%]4 M>7!E&ULS=I-3L,P$ 7@JU39HL;U;P%1-L 66' !DTS;J$ELV0;*[7%2 M0 )!!2H2;].HM3UOXI&^5<_NGCW%R;9K^[@HUBGY4\9BM:;.QM)YZO/*TH7. MIOPUK)BWU<:NB(G9S+#*]8GZ-$U#C>+\[)*6]J%-DZMM_CDVKE\4@=I83"YV M&X>L16&];YO*IKS.'OOZ4\KT-:',)\<]<=WX>)0W%.S+A&'E^X#7/%$)3 MT^36AG1MN[R+;5L6TW-+L=Q?XHL>W7+95%2[ZJ'+1\KH ]DZKHE2UY:[HD?[ MDU.^8=I]\H/SQS+[ O/.V^!\S!,+]/NXMY$,IZ<^%Z*0FOVO^)Z82Q_\?C1, MNZ;ZA]GY>I])[@ "L" 1 " :\ !D M;V-097)PC$ 8 )PG 3 M " &UL4$L! A0#% M @ *8 =5Y$7U\UM P 5 P !@ ("!#0@ 'AL+W=OHAS&RA@8 $<= 8 M " @; + !X;"]W;W)K&PO M=V]R:W-H965T&UL4$L! A0#% @ *8 =5\D! O;M @ M'P@ !@ ("!%!@ 'AL+W=O(U&PO=V]R:W-H965T&UL4$L! A0#% @ *8 =5\+WS]&[!@ &PX !@ M ("!BBD 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ *8 =5SNDX-5G!P Q!( !D ("!VCX 'AL+W=O&UL4$L! A0#% @ *8 =5VOQ87M[ M! QPD !D ("!=U$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *8 =5V5$_0#V! QPH !D M ("!@F, 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ *8 =5Z9)"\ ""0 $!D !D ("!9G< M 'AL+W=O&PO=V]R:W-H965TX2@-1B < '<1 9 M " @9B% !X;"]W;W)K&UL4$L! A0#% @ M*8 =5[^<.3,+%0 M$, !D ("!5XT 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *8 =5_RL><([! MQ D !D ("!NK$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *8 =5Z2DEIKE @ \ 8 !D M ("!7\ 'AL+W=O8-(L" "C!0 &0 @(%[PP >&PO=V]R:W-H M965T&UL4$L! M A0#% @ *8 =5_$I3Z!* P (P< !D ("!LLD 'AL M+W=O&PO=V]R:W-H965T#<%*UZ@( 'D& 9 " M@<_2 !X;"]W;W)K&UL4$L! A0#% @ *8 = M5T!M1[G+ P *PH !D ("!\-4 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *8 =5U?,HQ?: @ X@8 M !D ("!)>$ 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *8 =5UIKVY/' P )Q0 !D M ("!_.H 'AL+W=O1_OP(# #\" &0 @('Z[@ >&PO=V]R:W-H965T M;=2VAX@( )@( 9 M " @3/R !X;"]W;W)K&UL4$L! A0# M% @ *8 =5W-7S$V9 @ T08 !D ("!3/4 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ *8 =5RUE M@W$, P ]PL !D ("!Z@D! 'AL+W=O&PO=V]R:W-H965TU%[\8TP( ,$' 9 " @70/ 0!X;"]W;W)K&UL4$L! A0#% @ *8 =5W[L1WUX P )@T !D M ("!?A(! 'AL+W=O&PO M=V]R:W-H965T,%2A3D00 M *<; 9 " @>X9 0!X;"]W;W)K&UL4$L! A0#% @ *8 =5ZQ\(+1F P (@T !D ("! MMAX! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ *8 =5U*+>1-> P -@H !D ("!72D! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *8 =5\R+__UH M! AD !D ("!Y#0! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ *8 =5T00@_-M P 'PX !D M ("!WT,! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ *8 =5^!:CY[!# $,$ !D ("!H$X! M 'AL+W=O&PO=V]R:W-H965T 0!X;"]W;W)K&UL4$L! A0#% @ M*8 =5UK.Z9(J! Y1( !D ("!\F$! 'AL+W=O&PO=V]R:W-H965T< 1 < + _ 9 " @8YM 0!X;"]W M;W)K&UL4$L! A0#% @ *8 =5_&]3PHF! M2Q4 !D ("!"74! 'AL+W=O0$ >&PO=V]R:W-H965T&UL4$L! A0#% @ *8 =5X*!OU\Y P ZA( T M ( !(( ! 'AL+W-T>6QE&PO=V]R:V)O M;VLN>&UL4$L! A0#% @ *8 =5ZQM4%<\ @ KRH !H M ( !](D! 'AL+U]R96QS+W=O<&5S72YX;6Q02P4& % 4 #G%0 F8X! end XML 86 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 87 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 88 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 169 329 1 false 56 0 false 6 false false R1.htm 00000001 - Document - Cover Sheet http://portagebiotech.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited) Sheet http://portagebiotech.com/role/InterimStatementsOfFinancialPosition Condensed Consolidated Interim Statements of Financial Position (Unaudited) Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) Sheet http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) (Parenthetical) Sheet http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLossParenthetical Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) (Parenthetical) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) Sheet http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited) Sheet http://portagebiotech.com/role/InterimStatementsOfCashFlows Condensed Consolidated Interim Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - NATURE OF OPERATIONS Sheet http://portagebiotech.com/role/NatureOfOperations NATURE OF OPERATIONS Notes 7 false false R8.htm 00000008 - Disclosure - GOING CONCERN Sheet http://portagebiotech.com/role/GoingConcern GOING CONCERN Notes 8 false false R9.htm 00000009 - Disclosure - BASIS OF PRESENTATION Sheet http://portagebiotech.com/role/BasisOfPresentation BASIS OF PRESENTATION Notes 9 false false R10.htm 00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://portagebiotech.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 00000011 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES Sheet http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables PREPAID EXPENSES AND OTHER RECEIVABLES Notes 11 false false R12.htm 00000012 - Disclosure - INVESTMENT IN ASSOCIATE Sheet http://portagebiotech.com/role/InvestmentInAssociate INVESTMENT IN ASSOCIATE Notes 12 false false R13.htm 00000013 - Disclosure - INVESTMENT IN PUBLIC COMPANY Sheet http://portagebiotech.com/role/InvestmentInPublicCompany INVESTMENT IN PUBLIC COMPANY Notes 13 false false R14.htm 00000014 - Disclosure - LEASE Sheet http://portagebiotech.com/role/Lease LEASE Notes 14 false false R15.htm 00000015 - Disclosure - ACQUISITION OF TARUS Sheet http://portagebiotech.com/role/AcquisitionOfTarus ACQUISITION OF TARUS Notes 15 false false R16.htm 00000016 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY Sheet http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY Notes 16 false false R17.htm 00000017 - Disclosure - INCOME TAXES Sheet http://portagebiotech.com/role/IncomeTaxes INCOME TAXES Notes 17 false false R18.htm 00000018 - Disclosure - CAPITAL STOCK Sheet http://portagebiotech.com/role/CapitalStock CAPITAL STOCK Notes 18 false false R19.htm 00000019 - Disclosure - STOCK OPTION RESERVE Sheet http://portagebiotech.com/role/StockOptionReserve STOCK OPTION RESERVE Notes 19 false false R20.htm 00000020 - Disclosure - (LOSS) PER SHARE Sheet http://portagebiotech.com/role/LossPerShare (LOSS) PER SHARE Notes 20 false false R21.htm 00000021 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES Sheet http://portagebiotech.com/role/CommitmentsAndContingentLiabilities COMMITMENTS AND CONTINGENT LIABILITIES Notes 21 false false R22.htm 00000022 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://portagebiotech.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 22 false false R23.htm 00000023 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT Sheet http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement FINANCIAL INSTRUMENTS AND RISK MANAGEMENT Notes 23 false false R24.htm 00000024 - Disclosure - CAPITAL DISCLOSURES Sheet http://portagebiotech.com/role/CapitalDisclosures CAPITAL DISCLOSURES Notes 24 false false R25.htm 00000025 - Disclosure - NON-CONTROLLING INTEREST Sheet http://portagebiotech.com/role/Non-controllingInterest NON-CONTROLLING INTEREST Notes 25 false false R26.htm 00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 26 false false R27.htm 00000027 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables) Sheet http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables PREPAID EXPENSES AND OTHER RECEIVABLES (Tables) Tables http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables 27 false false R28.htm 00000028 - Disclosure - INVESTMENT IN ASSOCIATE (Tables) Sheet http://portagebiotech.com/role/InvestmentInAssociateTables INVESTMENT IN ASSOCIATE (Tables) Tables http://portagebiotech.com/role/InvestmentInAssociate 28 false false R29.htm 00000029 - Disclosure - LEASE (Tables) Sheet http://portagebiotech.com/role/LeaseTables LEASE (Tables) Tables http://portagebiotech.com/role/Lease 29 false false R30.htm 00000030 - Disclosure - ACQUISITION OF TARUS (Tables) Sheet http://portagebiotech.com/role/AcquisitionOfTarusTables ACQUISITION OF TARUS (Tables) Tables http://portagebiotech.com/role/AcquisitionOfTarus 30 false false R31.htm 00000031 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables) Sheet http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables) Tables http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability 31 false false R32.htm 00000032 - Disclosure - INCOME TAXES (Tables) Sheet http://portagebiotech.com/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://portagebiotech.com/role/IncomeTaxes 32 false false R33.htm 00000033 - Disclosure - CAPITAL STOCK (Tables) Sheet http://portagebiotech.com/role/CapitalStockTables CAPITAL STOCK (Tables) Tables http://portagebiotech.com/role/CapitalStock 33 false false R34.htm 00000034 - Disclosure - STOCK OPTION RESERVE (Tables) Sheet http://portagebiotech.com/role/StockOptionReserveTables STOCK OPTION RESERVE (Tables) Tables http://portagebiotech.com/role/StockOptionReserve 34 false false R35.htm 00000035 - Disclosure - (LOSS) PER SHARE (Tables) Sheet http://portagebiotech.com/role/LossPerShareTables (LOSS) PER SHARE (Tables) Tables http://portagebiotech.com/role/LossPerShare 35 false false R36.htm 00000036 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables) Sheet http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables) Tables http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement 36 false false R37.htm 00000037 - Disclosure - NON-CONTROLLING INTEREST (Tables) Sheet http://portagebiotech.com/role/Non-controllingInterestTables NON-CONTROLLING INTEREST (Tables) Tables http://portagebiotech.com/role/Non-controllingInterest 37 false false R38.htm 00000038 - Disclosure - NATURE OF OPERATIONS (Details Narrative) Sheet http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative NATURE OF OPERATIONS (Details Narrative) Details http://portagebiotech.com/role/NatureOfOperations 38 false false R39.htm 00000039 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://portagebiotech.com/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://portagebiotech.com/role/GoingConcern 39 false false R40.htm 00000040 - Disclosure - BASIS OF PRESENTATION (Details Narrative) Sheet http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative BASIS OF PRESENTATION (Details Narrative) Details http://portagebiotech.com/role/BasisOfPresentation 40 false false R41.htm 00000041 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details) Sheet http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails PREPAID EXPENSES AND OTHER RECEIVABLES (Details) Details http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables 41 false false R42.htm 00000042 - Disclosure - INVESTMENT IN ASSOCIATE (Details) Sheet http://portagebiotech.com/role/InvestmentInAssociateDetails INVESTMENT IN ASSOCIATE (Details) Details http://portagebiotech.com/role/InvestmentInAssociateTables 42 false false R43.htm 00000043 - Disclosure - INVESTMENT IN ASSOCIATE (Details 1) Sheet http://portagebiotech.com/role/InvestmentInAssociateDetails1 INVESTMENT IN ASSOCIATE (Details 1) Details http://portagebiotech.com/role/InvestmentInAssociateTables 43 false false R44.htm 00000044 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative) Sheet http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative INVESTMENT IN ASSOCIATE (Details Narrative) Details http://portagebiotech.com/role/InvestmentInAssociateTables 44 false false R45.htm 00000045 - Disclosure - INVESTMENT IN PUBLIC COMPANY (Details Narrative) Sheet http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative INVESTMENT IN PUBLIC COMPANY (Details Narrative) Details http://portagebiotech.com/role/InvestmentInPublicCompany 45 false false R46.htm 00000046 - Disclosure - LEASE (Details) Sheet http://portagebiotech.com/role/LeaseDetails LEASE (Details) Details http://portagebiotech.com/role/LeaseTables 46 false false R47.htm 00000047 - Disclosure - LEASE (Details Narrative) Sheet http://portagebiotech.com/role/LeaseDetailsNarrative LEASE (Details Narrative) Details http://portagebiotech.com/role/LeaseTables 47 false false R48.htm 00000048 - Disclosure - ACQUISITION OF TARUS (Details) Sheet http://portagebiotech.com/role/AcquisitionOfTarusDetails ACQUISITION OF TARUS (Details) Details http://portagebiotech.com/role/AcquisitionOfTarusTables 48 false false R49.htm 00000049 - Disclosure - ACQUISITION OF TARUS (Details 1) Sheet http://portagebiotech.com/role/AcquisitionOfTarusDetails1 ACQUISITION OF TARUS (Details 1) Details http://portagebiotech.com/role/AcquisitionOfTarusTables 49 false false R50.htm 00000050 - Disclosure - ACQUISITION OF TARUS (Details Narrative) Sheet http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative ACQUISITION OF TARUS (Details Narrative) Details http://portagebiotech.com/role/AcquisitionOfTarusTables 50 false false R51.htm 00000051 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details) Sheet http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details) Details http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables 51 false false R52.htm 00000052 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative) Sheet http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative) Details http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables 52 false false R53.htm 00000053 - Disclosure - INCOME TAXES (Details) Sheet http://portagebiotech.com/role/IncomeTaxesDetails INCOME TAXES (Details) Details http://portagebiotech.com/role/IncomeTaxesTables 53 false false R54.htm 00000054 - Disclosure - INCOME TAXES (Details 1) Sheet http://portagebiotech.com/role/IncomeTaxesDetails1 INCOME TAXES (Details 1) Details http://portagebiotech.com/role/IncomeTaxesTables 54 false false R55.htm 00000055 - Disclosure - INCOME TAXES (Details 2) Sheet http://portagebiotech.com/role/IncomeTaxesDetails2 INCOME TAXES (Details 2) Details http://portagebiotech.com/role/IncomeTaxesTables 55 false false R56.htm 00000056 - Disclosure - INCOME TAXES (Details 3) Sheet http://portagebiotech.com/role/IncomeTaxesDetails3 INCOME TAXES (Details 3) Details http://portagebiotech.com/role/IncomeTaxesTables 56 false false R57.htm 00000057 - Disclosure - INCOME TAXES (Details 4) Sheet http://portagebiotech.com/role/IncomeTaxesDetails4 INCOME TAXES (Details 4) Details http://portagebiotech.com/role/IncomeTaxesTables 57 false false R58.htm 00000058 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://portagebiotech.com/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://portagebiotech.com/role/IncomeTaxesTables 58 false false R59.htm 00000059 - Disclosure - CAPITAL STOCK (Details) Sheet http://portagebiotech.com/role/CapitalStockDetails CAPITAL STOCK (Details) Details http://portagebiotech.com/role/CapitalStockTables 59 false false R60.htm 00000060 - Disclosure - CAPITAL STOCK (Details Narrative) Sheet http://portagebiotech.com/role/CapitalStockDetailsNarrative CAPITAL STOCK (Details Narrative) Details http://portagebiotech.com/role/CapitalStockTables 60 false false R61.htm 00000061 - Disclosure - STOCK OPTION RESERVE (Details) Sheet http://portagebiotech.com/role/StockOptionReserveDetails STOCK OPTION RESERVE (Details) Details http://portagebiotech.com/role/StockOptionReserveTables 61 false false R62.htm 00000062 - Disclosure - STOCK OPTION RESERVE (Details 1) Sheet http://portagebiotech.com/role/StockOptionReserveDetails1 STOCK OPTION RESERVE (Details 1) Details http://portagebiotech.com/role/StockOptionReserveTables 62 false false R63.htm 00000063 - Disclosure - STOCK OPTION RESERVE (Details 2) Sheet http://portagebiotech.com/role/StockOptionReserveDetails2 STOCK OPTION RESERVE (Details 2) Details http://portagebiotech.com/role/StockOptionReserveTables 63 false false R64.htm 00000064 - Disclosure - STOCK OPTION RESERVE (Details Narrative) Sheet http://portagebiotech.com/role/StockOptionReserveDetailsNarrative STOCK OPTION RESERVE (Details Narrative) Details http://portagebiotech.com/role/StockOptionReserveTables 64 false false R65.htm 00000065 - Disclosure - (LOSS) PER SHARE (Details) Sheet http://portagebiotech.com/role/LossPerShareDetails (LOSS) PER SHARE (Details) Details http://portagebiotech.com/role/LossPerShareTables 65 false false R66.htm 00000066 - Disclosure - (LOSS) PER SHARE (Details 1) Sheet http://portagebiotech.com/role/LossPerShareDetails1 (LOSS) PER SHARE (Details 1) Details http://portagebiotech.com/role/LossPerShareTables 66 false false R67.htm 00000067 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) Sheet http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative) Details http://portagebiotech.com/role/CommitmentsAndContingentLiabilities 67 false false R68.htm 00000068 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://portagebiotech.com/role/RelatedPartyTransactions 68 false false R69.htm 00000069 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details) Sheet http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details) Details http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables 69 false false R70.htm 00000070 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative) Sheet http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative) Details http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables 70 false false R71.htm 00000071 - Disclosure - CAPITAL DISCLOSURES (Details Narrative) Sheet http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative CAPITAL DISCLOSURES (Details Narrative) Details http://portagebiotech.com/role/CapitalDisclosures 71 false false R72.htm 00000072 - Disclosure - NON-CONTROLLING INTEREST (Details) Sheet http://portagebiotech.com/role/Non-controllingInterestDetails NON-CONTROLLING INTEREST (Details) Details http://portagebiotech.com/role/Non-controllingInterestTables 72 false false All Reports Book All Reports exh_991.htm f6k_082923.htm exh_992.htm ptgef-20230630.xsd ptgef-20230630_cal.xml ptgef-20230630_def.xml ptgef-20230630_lab.xml ptgef-20230630_pre.xml http://xbrl.sec.gov/dei/2023 https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full true true JSON 90 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "exh_991.htm f6k_082923.htm": { "axisCustom": 0, "axisStandard": 15, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 16, "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 339 }, "contextCount": 169, "dts": { "calculationLink": { "local": [ "ptgef-20230630_cal.xml" ] }, "definitionLink": { "local": [ "ptgef-20230630_def.xml" ] }, "inline": { "local": [ "exh_991.htm", "f6k_082923.htm" ] }, "labelLink": { "local": [ "ptgef-20230630_lab.xml" ] }, "presentationLink": { "local": [ "ptgef-20230630_pre.xml" ] }, "schema": { "local": [ "ptgef-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 512, "entityCount": 1, "hidden": { "http://portagebiotech.com/20230630": 100, "http://xbrl.sec.gov/dei/2023": 6, "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 44, "total": 150 }, "keyCustom": 191, "keyStandard": 138, "memberCustom": 44, "memberStandard": 9, "nsprefix": "ptgef", "nsuri": "http://portagebiotech.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://portagebiotech.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentPeriodEndDate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "10", "role": "http://portagebiotech.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES", "menuCat": "Notes", "order": "11", "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables", "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:InvestmentInAssociateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - INVESTMENT IN ASSOCIATE", "menuCat": "Notes", "order": "12", "role": "http://portagebiotech.com/role/InvestmentInAssociate", "shortName": "INVESTMENT IN ASSOCIATE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:InvestmentInAssociateDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfPublicCompaniesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - INVESTMENT IN PUBLIC COMPANY", "menuCat": "Notes", "order": "13", "role": "http://portagebiotech.com/role/InvestmentInPublicCompany", "shortName": "INVESTMENT IN PUBLIC COMPANY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfPublicCompaniesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - LEASE", "menuCat": "Notes", "order": "14", "role": "http://portagebiotech.com/role/Lease", "shortName": "LEASE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfLeasesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:AcquisitionsOfTarusExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - ACQUISITION OF TARUS", "menuCat": "Notes", "order": "15", "role": "http://portagebiotech.com/role/AcquisitionOfTarus", "shortName": "ACQUISITION OF TARUS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:AcquisitionsOfTarusExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY", "menuCat": "Notes", "order": "16", "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability", "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "17", "role": "http://portagebiotech.com/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:CapitalStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - CAPITAL STOCK", "menuCat": "Notes", "order": "18", "role": "http://portagebiotech.com/role/CapitalStock", "shortName": "CAPITAL STOCK", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:CapitalStockTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - STOCK OPTION RESERVE", "menuCat": "Notes", "order": "19", "role": "http://portagebiotech.com/role/StockOptionReserve", "shortName": "STOCK OPTION RESERVE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Interim Statements of Financial Position (Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition", "shortName": "Condensed Consolidated Interim Statements of Financial Position (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "lang": null, "name": "ifrs-full:TradeAndOtherCurrentReceivables", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - (LOSS) PER SHARE", "menuCat": "Notes", "order": "20", "role": "http://portagebiotech.com/role/LossPerShare", "shortName": "(LOSS) PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES", "menuCat": "Notes", "order": "21", "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "22", "role": "http://portagebiotech.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT", "menuCat": "Notes", "order": "23", "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement", "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - CAPITAL DISCLOSURES", "menuCat": "Notes", "order": "24", "role": "http://portagebiotech.com/role/CapitalDisclosures", "shortName": "CAPITAL DISCLOSURES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - NON-CONTROLLING INTEREST", "menuCat": "Notes", "order": "25", "role": "http://portagebiotech.com/role/Non-controllingInterest", "shortName": "NON-CONTROLLING INTEREST", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "26", "role": "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ptgef:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfOtherAssetsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)", "menuCat": "Tables", "order": "27", "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables", "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfOtherAssetsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ptgef:InvestmentInAssociateDisclosureTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfInvestmentAssociatetableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - INVESTMENT IN ASSOCIATE (Tables)", "menuCat": "Tables", "order": "28", "role": "http://portagebiotech.com/role/InvestmentInAssociateTables", "shortName": "INVESTMENT IN ASSOCIATE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ptgef:InvestmentInAssociateDisclosureTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfInvestmentAssociatetableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - LEASE (Tables)", "menuCat": "Tables", "order": "29", "role": "http://portagebiotech.com/role/LeaseTables", "shortName": "LEASE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)", "menuCat": "Statements", "order": "3", "role": "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss", "shortName": "Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - ACQUISITION OF TARUS (Tables)", "menuCat": "Tables", "order": "30", "role": "http://portagebiotech.com/role/AcquisitionOfTarusTables", "shortName": "ACQUISITION OF TARUS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)", "menuCat": "Tables", "order": "31", "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables", "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "32", "role": "http://portagebiotech.com/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ptgef:CapitalStockTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - CAPITAL STOCK (Tables)", "menuCat": "Tables", "order": "33", "role": "http://portagebiotech.com/role/CapitalStockTables", "shortName": "CAPITAL STOCK (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ptgef:CapitalStockTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfTermsStockOptionReserveExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - STOCK OPTION RESERVE (Tables)", "menuCat": "Tables", "order": "34", "role": "http://portagebiotech.com/role/StockOptionReserveTables", "shortName": "STOCK OPTION RESERVE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfTermsStockOptionReserveExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ifrs-full:EarningsPerShareExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ScheduleOfEarningsPerShareTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - (LOSS) PER SHARE (Tables)", "menuCat": "Tables", "order": "35", "role": "http://portagebiotech.com/role/LossPerShareTables", "shortName": "(LOSS) PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:EarningsPerShareExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ScheduleOfEarningsPerShareTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)", "menuCat": "Tables", "order": "36", "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables", "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - NON-CONTROLLING INTEREST (Tables)", "menuCat": "Tables", "order": "37", "role": "http://portagebiotech.com/role/Non-controllingInterestTables", "shortName": "NON-CONTROLLING INTEREST (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "p", "ptgef:NatureOfOperationsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2021-09-012021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:PercentageOfOutstandingShares", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - NATURE OF OPERATIONS (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "shortName": "NATURE OF OPERATIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ptgef:NatureOfOperationsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2018-08-13_custom_SalvaRxLimitedMember", "decimals": "INF", "lang": null, "name": "ifrs-full:PercentageOfVotingEquityInterestsAcquired", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGoingConcernExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - GOING CONCERN (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://portagebiotech.com/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfGoingConcernExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:BasicEarningsLossPerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "4", "role": "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLossParenthetical", "shortName": "Condensed Consolidated Interim Statements of Operations and Other Comprehensive Income (Loss) (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "INF", "lang": null, "name": "ptgef:WeightedAverageSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "p", "ptgef:NatureOfOperationsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2021-09-012021-09-30", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:PercentageOfOutstandingShares", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - BASIS OF PRESENTATION (Details Narrative)", "menuCat": "Details", "order": "40", "role": "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "shortName": "BASIS OF PRESENTATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-012023-06-30_custom_SubsidiariesTwoMember", "decimals": "INF", "lang": null, "name": "ifrs-full:ProportionOfOwnershipInterestsHeldByNoncontrollingInterests", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock", "ifrs-full:DisclosureOfOtherAssetsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentReceivablesFromSaleOfProperties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - PREPAID EXPENSES AND OTHER RECEIVABLES (Details)", "menuCat": "Details", "order": "41", "role": "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails", "shortName": "PREPAID EXPENSES AND OTHER RECEIVABLES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock", "ifrs-full:DisclosureOfOtherAssetsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CurrentReceivablesFromSaleOfProperties", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ptgef:DisclosureOfInvestmentAssociatetableTextBlock", "ptgef:InvestmentInAssociateDisclosureTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-012023-06-30_custom_StimunitySAMember", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:NameOfAssociate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - INVESTMENT IN ASSOCIATE (Details)", "menuCat": "Details", "order": "42", "role": "http://portagebiotech.com/role/InvestmentInAssociateDetails", "shortName": "INVESTMENT IN ASSOCIATE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ptgef:DisclosureOfInvestmentAssociatetableTextBlock", "ptgef:InvestmentInAssociateDisclosureTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-012023-06-30_custom_StimunitySAMember", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:NameOfAssociate", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000043 - Disclosure - INVESTMENT IN ASSOCIATE (Details 1)", "menuCat": "Details", "order": "43", "role": "http://portagebiotech.com/role/InvestmentInAssociateDetails1", "shortName": "INVESTMENT IN ASSOCIATE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfInvestmentInStimunitySaTableTextBlock", "ptgef:InvestmentInAssociateDisclosureTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "lang": null, "name": "ifrs-full:InvestmentsInSubsidiariesJointVenturesAndAssociates", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "p", "ptgef:InvestmentInAssociateDisclosureTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-07-122023-07-13", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ConvertibleNoteDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000044 - Disclosure - INVESTMENT IN ASSOCIATE (Details Narrative)", "menuCat": "Details", "order": "44", "role": "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative", "shortName": "INVESTMENT IN ASSOCIATE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ptgef:InvestmentInAssociateDisclosureTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-07-122023-07-13", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:ConvertibleNoteDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "p", "ptgef:DisclosureOfPublicCompaniesExplanatoryTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2022-11-30", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000045 - Disclosure - INVESTMENT IN PUBLIC COMPANY (Details Narrative)", "menuCat": "Details", "order": "45", "role": "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "shortName": "INVESTMENT IN PUBLIC COMPANY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ptgef:DisclosureOfPublicCompaniesExplanatoryTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2022-11-30", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:ParValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:LesseeOperatingLeaseLiabilityPaymentDueNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000046 - Disclosure - LEASE (Details)", "menuCat": "Details", "order": "46", "role": "http://portagebiotech.com/role/LeaseDetails", "shortName": "LEASE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:LesseeOperatingLeaseLiabilityPaymentDueNextRollingTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LongtermDeposits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000047 - Disclosure - LEASE (Details Narrative)", "menuCat": "Details", "order": "47", "role": "http://portagebiotech.com/role/LeaseDetailsNarrative", "shortName": "LEASE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfLeasesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:LongtermDeposits", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30_custom_TarusAcquisitionMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000048 - Disclosure - ACQUISITION OF TARUS (Details)", "menuCat": "Details", "order": "48", "role": "http://portagebiotech.com/role/AcquisitionOfTarusDetails", "shortName": "ACQUISITION OF TARUS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30_custom_TarusAcquisitionMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossBeforeTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000049 - Disclosure - ACQUISITION OF TARUS (Details 1)", "menuCat": "Details", "order": "49", "role": "http://portagebiotech.com/role/AcquisitionOfTarusDetails1", "shortName": "ACQUISITION OF TARUS (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfProformaInformationTableTextBlock", "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2022-04-012022-06-30_custom_TarusAcquisitionMember", "decimals": "-3", "lang": null, "name": "ifrs-full:ProfitLossFromContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2022-03-31_ifrs-full_IssuedCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "shortName": "Condensed Consolidated Interim Statements of Changes in Shareholders' Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2022-03-31_ifrs-full_IssuedCapitalMember", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:Equity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "p", "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:NumberOfShareIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000050 - Disclosure - ACQUISITION OF TARUS (Details Narrative)", "menuCat": "Details", "order": "50", "role": "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative", "shortName": "ACQUISITION OF TARUS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ptgef:AcquisitionsOfTarusExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:NumberOfShareIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:InprocessResearchAndDevelopment", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000051 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)", "menuCat": "Details", "order": "51", "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfInProcessResearchAndDevelopmentTableTextBlock", "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "lang": null, "name": "ptgef:DeferredTaxesLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "p", "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:RecognizedImpairment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000052 - Disclosure - IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)", "menuCat": "Details", "order": "52", "role": "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative", "shortName": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ptgef:InProcessResearchAndDevelopmentAndDeferredTaxLiability", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:RecognizedImpairment", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:CurrentFederalIncomeTaxBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000053 - Disclosure - INCOME TAXES (Details)", "menuCat": "Details", "order": "53", "role": "http://portagebiotech.com/role/IncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfIncomeTaxesBenefitTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:CurrentFederalIncomeTaxBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000054 - Disclosure - INCOME TAXES (Details 1)", "menuCat": "Details", "order": "54", "role": "http://portagebiotech.com/role/IncomeTaxesDetails1", "shortName": "INCOME TAXES (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:IncomeLossOnOrdinaryActivitiesBeforeTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfIncomeTaxExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AccountingProfit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000055 - Disclosure - INCOME TAXES (Details 2)", "menuCat": "Details", "order": "55", "role": "http://portagebiotech.com/role/IncomeTaxesDetails2", "shortName": "INCOME TAXES (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfIncomeTaxExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AccountingProfit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:PretaxIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000056 - Disclosure - INCOME TAXES (Details 3)", "menuCat": "Details", "order": "56", "role": "http://portagebiotech.com/role/IncomeTaxesDetails3", "shortName": "INCOME TAXES (Details 3)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:PretaxIncomeLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfDeferredTaxAssetsExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:DeferredTaxAssetsNetOperatingLossCarryforward", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000057 - Disclosure - INCOME TAXES (Details 4)", "menuCat": "Details", "order": "57", "role": "http://portagebiotech.com/role/IncomeTaxesDetails4", "shortName": "INCOME TAXES (Details 4)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfDeferredTaxAssetsExplanatory", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:DeferredTaxAssetsNetOperatingLossCarryforward", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:FederalNetOperatingLosses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000058 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "58", "role": "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfIncomeTaxExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:FederalNetOperatingLosses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock", "ptgef:CapitalStockTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:CommonStockShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000059 - Disclosure - CAPITAL STOCK (Details)", "menuCat": "Details", "order": "59", "role": "http://portagebiotech.com/role/CapitalStockDetails", "shortName": "CAPITAL STOCK (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock", "ptgef:CapitalStockTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:CommonStockShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Interim Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "shortName": "Condensed Consolidated Interim Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "lang": null, "name": "ptgef:ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ptgef:CapitalStockTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:MaximumAggregateOfferingPrice", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000060 - Disclosure - CAPITAL STOCK (Details Narrative)", "menuCat": "Details", "order": "60", "role": "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "shortName": "CAPITAL STOCK (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ptgef:CapitalStockTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:MaximumAggregateOfferingPrice", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:AdjustmentsForSharebasedPayments", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000061 - Disclosure - STOCK OPTION RESERVE (Details)", "menuCat": "Details", "order": "61", "role": "http://portagebiotech.com/role/StockOptionReserveDetails", "shortName": "STOCK OPTION RESERVE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfTermsStockOptionReserveExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2022-03-31_ifrs-full_NoncontrollingInterestsMember", "decimals": "-3", "lang": null, "name": "ptgef:StockOptionReserve", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2022-03-31_custom_StockOptionsTwoMember", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:NumberOfOutstandingShareOption", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000062 - Disclosure - STOCK OPTION RESERVE (Details 1)", "menuCat": "Details", "order": "62", "role": "http://portagebiotech.com/role/StockOptionReserveDetails1", "shortName": "STOCK OPTION RESERVE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2022-03-31_custom_StockOptionsTwoMember", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:NumberOfOutstandingShareOption", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-012023-06-30_custom_PBI2021EquityIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000063 - Disclosure - STOCK OPTION RESERVE (Details 2)", "menuCat": "Details", "order": "63", "role": "http://portagebiotech.com/role/StockOptionReserveDetails2", "shortName": "STOCK OPTION RESERVE (Details 2)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ifrs-full:DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-012023-06-30_custom_PBI2021EquityIncentivePlanMember", "decimals": "INF", "first": true, "lang": null, "name": "ifrs-full:WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-03-252023-03-30", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:StockGranted", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000064 - Disclosure - STOCK OPTION RESERVE (Details Narrative)", "menuCat": "Details", "order": "64", "role": "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative", "shortName": "STOCK OPTION RESERVE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-03-252023-03-30", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:StockGranted", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:ProfitLossAttributableToOwnersOfParent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000065 - Disclosure - (LOSS) PER SHARE (Details)", "menuCat": "Details", "order": "65", "role": "http://portagebiotech.com/role/LossPerShareDetails", "shortName": "(LOSS) PER SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "ptgef:ScheduleOfEarningsPerShareTableTextBlock", "ifrs-full:EarningsPerShareExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "INF", "lang": null, "name": "ptgef:WeightedAverageNumberOfSharesBasic", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock", "ifrs-full:EarningsPerShareExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-012023-06-30_ifrs-full_ShareOptionsMember", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:AntidilutiveEffectOnLossPerShare", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000066 - Disclosure - (LOSS) PER SHARE (Details 1)", "menuCat": "Details", "order": "66", "role": "http://portagebiotech.com/role/LossPerShareDetails1", "shortName": "(LOSS) PER SHARE (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfAntiDilutiveEffectTableTextBlock", "ifrs-full:EarningsPerShareExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-012023-06-30_ifrs-full_ShareOptionsMember", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:AntidilutiveEffectOnLossPerShare", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:CostAndExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000067 - Disclosure - COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)", "menuCat": "Details", "order": "67", "role": "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENT LIABILITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:CostAndExpenses", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:PortageOrdinaryShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000068 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "68", "role": "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "ptgef:PortageOrdinaryShares", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000069 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)", "menuCat": "Details", "order": "69", "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30_custom_AmortizedCostMember", "decimals": "-3", "lang": null, "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:NatureOfOperationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - NATURE OF OPERATIONS", "menuCat": "Notes", "order": "7", "role": "http://portagebiotech.com/role/NatureOfOperations", "shortName": "NATURE OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ptgef:NatureOfOperationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "ptgef:InvestmentInAssociateDisclosureTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2022-04-012023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:ImpairmentAnalysis", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000070 - Disclosure - FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)", "menuCat": "Details", "order": "70", "role": "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "shortName": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2022-09-112022-09-12", "decimals": "-3", "lang": null, "name": "ptgef:NotesReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "p", "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:AccountsPayableAndAccruedLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000071 - Disclosure - CAPITAL DISCLOSURES (Details Narrative)", "menuCat": "Details", "order": "71", "role": "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative", "shortName": "CAPITAL DISCLOSURES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ptgef:DisclosureOfCapitalManagementExplanatoryTextBlock", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-06-30", "decimals": "-3", "first": true, "lang": null, "name": "ptgef:AccountsPayableAndAccruedLiability", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "ifrs-full:NoncontrollingInterests", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000072 - Disclosure - NON-CONTROLLING INTEREST (Details)", "menuCat": "Details", "order": "72", "role": "http://portagebiotech.com/role/Non-controllingInterestDetails", "shortName": "NON-CONTROLLING INTEREST (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "ptgef:ScheduleOfNoncontrollingInterestTableTextBlock", "ifrs-full:DisclosureOfInterestsInOtherEntitiesExplanatory", "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "AsOf2022-03-31", "decimals": "-3", "lang": null, "name": "ifrs-full:NoncontrollingInterests", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGoingConcernExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - GOING CONCERN", "menuCat": "Notes", "order": "8", "role": "http://portagebiotech.com/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfGoingConcernExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - BASIS OF PRESENTATION", "menuCat": "Notes", "order": "9", "role": "http://portagebiotech.com/role/BasisOfPresentation", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "exh_991.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfConsolidationExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 56, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r163", "r165", "r166" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r152" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r167" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r158" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r168" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r154" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r159" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r160" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r153" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r161" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r170" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://portagebiotech.com/role/Cover" ], "xbrltype": "booleanItemType" }, "ifrs-full_AccountingProfit": { "auth_ref": [ "r30", "r31" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of profit (loss) for a period before deducting tax expense. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Loss on ordinary activities before tax" } } }, "localname": "AccountingProfit", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncome": { "auth_ref": [ "r176" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of accumulated items of income and expense (including reclassification adjustments) that are not recognised in profit or loss as required or permitted by other IFRSs. [Refer: IFRSs [member]; Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r174" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Accumulated other comprehensive income [member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred": { "auth_ref": [ "r112" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Fair value of shares issued" } } }, "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferred", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consideration:" } } }, "localname": "AcquisitiondateFairValueOfTotalConsiderationTransferredAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherAssets": { "auth_ref": [ "r189" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 11.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in other assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Other assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInOtherAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": { "auth_ref": [ "r189" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 10.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in prepaid expenses", "verboseLabel": "Prepaid expenses and other receivables" } } }, "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDeferredTaxExpense": { "auth_ref": [ "r189" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for deferred tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred tax expense (income); Profit (loss)]" } }, "en-us": { "role": { "label": "Total deferred" } } }, "localname": "AdjustmentsForDeferredTaxExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "auth_ref": [ "r188" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } }, "en-us": { "role": { "label": "Depreciation" } } }, "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInOtherLiabilities": { "auth_ref": [ "r189" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 13.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in other liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Other liabilities; Profit (loss)]" } }, "en-us": { "role": { "label": "Other" } } }, "localname": "AdjustmentsForIncreaseDecreaseInOtherLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": { "auth_ref": [ "r187" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 12.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade accounts payable", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments for non-cash items:" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r188" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Stock based compensation expense", "verboseLabel": "Share-based compensation expense" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/StockOptionReserveDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedMeasurementMember": { "auth_ref": [ "r58", "r61", "r91" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } } }, "localname": "AggregatedMeasurementMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "auth_ref": [ "r36", "r92" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } } }, "localname": "AllLevelsOfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AntidilutiveInstrumentsMember": { "auth_ref": [ "r52" ], "lang": { "en": { "role": { "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used." } } }, "localname": "AntidilutiveInstrumentsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2" ], "xbrltype": "domainItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r31" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Statutory U.K. income tax rate" } } }, "localname": "ApplicableTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "xbrltype": "percentItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r13", "r91", "r92", "r93", "r125", "r127" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r50", "r51" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLossParenthetical", "http://portagebiotech.com/role/LossPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_BorrowingsByNameAxis": { "auth_ref": [ "r192" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Borrowings by name [axis]" } } }, "localname": "BorrowingsByNameAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_BorrowingsByNameMember": { "auth_ref": [ "r192" ], "lang": { "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } } }, "localname": "BorrowingsByNameMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_BorrowingsInterestRate": { "auth_ref": [ "r192" ], "lang": { "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Interest rate" } } }, "localname": "BorrowingsInterestRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "xbrltype": "percentItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r95", "r103", "r108", "r142", "r144", "r192" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom of range [member]" } } }, "localname": "BottomOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_BusinessCombinationsAxis": { "auth_ref": [ "r114" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Business combinations [axis]" } } }, "localname": "BusinessCombinationsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "Cash", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r8", "r64", "r86" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r62", "r65" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r62", "r65" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashOnHand": { "auth_ref": [ "r190" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash held by the entity. This does not include demand deposits." } }, "en-us": { "role": { "label": "Cash on hand" } } }, "localname": "CashOnHand", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfFinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial assets" } } }, "localname": "CategoriesOfFinancialAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Financial liabilities" } } }, "localname": "CategoriesOfFinancialLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r39" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "http://portagebiotech.com/role/Non-controllingInterestDetails", "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": { "auth_ref": [ "r184" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets and goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_CommunicationExpense": { "auth_ref": [ "r175" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from communication." } }, "en-us": { "role": { "label": "Compensation expense" } } }, "localname": "CommunicationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/StockOptionReserveDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r1", "r22", "r67", "r69", "r84", "r140" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Total comprehensive loss for period", "totalLabel": "Total comprehensive loss for period" } } }, "localname": "ComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails1", "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Comprehensive (loss) income attributable to:" } } }, "localname": "ComprehensiveIncomeAttributableToAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": { "auth_ref": [ "r1", "r25" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]" } }, "en-us": { "role": { "label": "Comprehensive income, attributable to non-controlling interests", "verboseLabel": "Non-controlling interest" } } }, "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "auth_ref": [ "r1", "r26" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } }, "en-us": { "role": { "label": "Comprehensive income, attributable to owners of parent", "verboseLabel": "Owners of the Company" } } }, "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination": { "auth_ref": [ "r115" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]]" } }, "en-us": { "role": { "label": "Total liabilities" } } }, "localname": "ContingentLiabilitiesRecognisedInBusinessCombination", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CounterpartiesAxis": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Counterparties [axis]" } } }, "localname": "CounterpartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_CounterpartiesMember": { "auth_ref": [ "r120" ], "lang": { "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } } }, "localname": "CounterpartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_CountryOfIncorporationOrResidenceOfAssociate": { "auth_ref": [ "r43", "r47", "r77" ], "lang": { "en": { "role": { "documentation": "The country in which an associate of the entity is incorporated. [Refer: Associates [member]]" } }, "en-us": { "role": { "label": "Place of Incorporation and principal place of business" } } }, "localname": "CountryOfIncorporationOrResidenceOfAssociate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentAdvancesToSuppliers": { "auth_ref": [ "r175" ], "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "order": 2.0, "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current advances made to suppliers before goods or services are received." } }, "en-us": { "role": { "label": "Prepaid insurance" } } }, "localname": "CurrentAdvancesToSuppliers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r15", "r80", "r140" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets [Default Label]", "totalLabel": "Total current assets" } } }, "localname": "CurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentInvestments": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current investments." } }, "en-us": { "role": { "label": "Current investments", "verboseLabel": "Investment in associate" } } }, "localname": "CurrentInvestments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLeaseLiabilities": { "auth_ref": [ "r98" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Lease liability - current, including interest", "terseLabel": "Lease liability current", "verboseLabel": "Lease liability - current" } } }, "localname": "CurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition", "http://portagebiotech.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r16", "r82", "r140" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities [Default Label]", "totalLabel": "Total current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentPrepaidExpenses": { "auth_ref": [ "r175" ], "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "order": 4.0, "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised." } }, "en-us": { "role": { "label": "Other prepaid expenses" } } }, "localname": "CurrentPrepaidExpenses", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentPrepayments": { "auth_ref": [ "r134" ], "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current prepayments. [Refer: Prepayments]" } }, "en-us": { "role": { "label": "Current prepayments", "totalLabel": "Total prepaid expenses and other receivables" } } }, "localname": "CurrentPrepayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentReceivablesFromSaleOfProperties": { "auth_ref": [ "r177" ], "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "order": 1.0, "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current receivables from sale of properties. [Refer: Receivables from sale of properties]" } }, "en-us": { "role": { "label": "Prepaid clinical research costs" } } }, "localname": "CurrentReceivablesFromSaleOfProperties", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxExpenseIncome": { "auth_ref": [ "r137" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period." } }, "en-us": { "role": { "label": "Total current" } } }, "localname": "CurrentTaxExpenseIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current:" } } }, "localname": "CurrentTaxExpenseIncomeAndAdjustmentsForCurrentTaxOfPriorPeriodsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DeferredTaxAssets": { "auth_ref": [ "r10", "r14", "r32" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Deferred tax assets" } } }, "localname": "DeferredTaxAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxExpenseIncome": { "auth_ref": [ "r33" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tax expense (income) relating to changes in deferred tax liabilities and deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Deferred income taxes" } } }, "localname": "DeferredTaxExpenseIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred:" } } }, "localname": "DeferredTaxExpenseIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DeferredTaxLiabilities": { "auth_ref": [ "r10", "r14", "r32" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } }, "en-us": { "role": { "label": "Deferred tax liability", "verboseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate": { "auth_ref": [ "r191" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount recognised as of the acquisition date for deferred tax liabilities assumed in a business combination. [Refer: Deferred tax liabilities; Business combinations [member]]" } }, "en-us": { "role": { "label": "Deferred purchase consideration at fair value" } } }, "localname": "DeferredTaxLiabilitiesRecognisedAsOfAcquisitionDate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DefinedBenefitPlansAxis": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Defined benefit plans [axis]" } } }, "localname": "DefinedBenefitPlansAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_DefinedBenefitPlansMember": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used." } } }, "localname": "DefinedBenefitPlansMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_DepreciationAndAmortisationExpense": { "auth_ref": [ "r0", "r28", "r87", "r123", "r129", "r131" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 6.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation and amortisation expense. Depreciation and amortisation are the systematic allocations of depreciable amounts of assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation and amortisation expense", "negatedLabel": "Depreciation expense" } } }, "localname": "DepreciationAndAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r50", "r51" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLossParenthetical", "http://portagebiotech.com/role/LossPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfBasisOfConsolidationExplanatory": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for consolidation." } }, "en-us": { "role": { "label": "BASIS OF PRESENTATION" } } }, "localname": "DisclosureOfBasisOfConsolidationExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments and contingent liabilities. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "COMMITMENTS AND CONTINGENT LIABILITIES" } } }, "localname": "DisclosureOfCommitmentsAndContingentLiabilitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } }, "en-us": { "role": { "label": "Disclosure of defined benefit plans [table]" } } }, "localname": "DisclosureOfDefinedBenefitPlansTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "auth_ref": [ "r192" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": { "auth_ref": [ "r96" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers." } }, "en-us": { "role": { "label": "Disclosure of disaggregation of revenue from contracts with customers [table]" } } }, "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFairValueMeasurementOfAssetsTable": { "auth_ref": [ "r94" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the fair value measurement of assets." } }, "en-us": { "role": { "label": "Disclosure of fair value measurement of assets [table]" } } }, "localname": "DisclosureOfFairValueMeasurementOfAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r121" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for financial instruments." } }, "en-us": { "role": { "label": "FINANCIAL INSTRUMENTS AND RISK MANAGEMENT" } } }, "localname": "DisclosureOfFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagement" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfGoingConcernExplanatory": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "The disclosure of the entity's ability to continue as a going concern." } }, "en-us": { "role": { "label": "GOING CONCERN" } } }, "localname": "DisclosureOfGoingConcernExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r34" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "label": "Disclosure of instruments with potential future dilutive effect not included in calculation of diluted earnings per share [table]" } } }, "localname": "DisclosureOfInstrumentsWithPotentialFutureDilutiveEffectNotIncludedInCalculationOfDilutedEarningsPerShareTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails1" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInterestsInOtherEntitiesExplanatory": { "auth_ref": [ "r71" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for interests in other entities." } }, "en-us": { "role": { "label": "NON-CONTROLLING INTEREST" } } }, "localname": "DisclosureOfInterestsInOtherEntitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/Non-controllingInterest" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInvestmentPropertyTable": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of investment property." } }, "en-us": { "role": { "label": "Disclosure of detailed information about investment property [table]" } } }, "localname": "DisclosureOfInvestmentPropertyTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfLeasesExplanatory": { "auth_ref": [ "r101", "r102" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for leases." } }, "en-us": { "role": { "label": "LEASE" } } }, "localname": "DisclosureOfLeasesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/Lease" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory": { "auth_ref": [ "r100" ], "lang": { "en": { "role": { "documentation": "The disclosure of a maturity analysis of operating lease payments. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset." } }, "en-us": { "role": { "label": "Schedule of lease liability" } } }, "localname": "DisclosureOfMaturityAnalysisOfOperatingLeasePaymentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/LeaseTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory": { "auth_ref": [ "r108" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Schedule of weighted average exercise price and remaining contractual life" } } }, "localname": "DisclosureOfNumberAndWeightedAverageRemainingContractualLifeOfOutstandingShareOptionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOffsettingOfFinancialAssetsTable": { "auth_ref": [ "r119" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the offsetting of financial assets." } }, "en-us": { "role": { "label": "Disclosure of offsetting of financial assets [table]" } } }, "localname": "DisclosureOfOffsettingOfFinancialAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOtherAssetsExplanatory": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "The disclosure of other assets. [Refer: Other assets]" } }, "en-us": { "role": { "label": "PREPAID EXPENSES AND OTHER RECEIVABLES" } } }, "localname": "DisclosureOfOtherAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r104" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "STOCK OPTION RESERVE" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserve" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSignificantInvestmentsInAssociatesTable": { "auth_ref": [ "r45", "r49", "r90" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to associates." } }, "en-us": { "role": { "label": "Disclosure of associates [table]" } } }, "localname": "DisclosureOfSignificantInvestmentsInAssociatesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetails", "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesExplanatory": { "auth_ref": [ "r38" ], "lang": { "en": { "role": { "documentation": "The disclosure of transactions between the entity and its related parties. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r39" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "http://portagebiotech.com/role/Non-controllingInterestDetails", "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable": { "auth_ref": [ "r113" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions recognised separately from the acquisition of assets and the assumption of liabilities in business combinations." } }, "en-us": { "role": { "label": "Disclosure of transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [table]" } } }, "localname": "DisclosureOfTransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails", "http://portagebiotech.com/role/AcquisitionOfTarusDetails1", "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Loss per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r50" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "(LOSS) PER SHARE" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/LossPerShare" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EntitysTotalForAssociatesMember": { "auth_ref": [ "r45", "r49", "r90" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } } }, "localname": "EntitysTotalForAssociatesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetails", "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForBusinessCombinationsMember": { "auth_ref": [ "r114", "r117" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Business combinations' axis if no other member is used." } } }, "localname": "EntitysTotalForBusinessCombinationsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r39" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "http://portagebiotech.com/role/Non-controllingInterestDetails", "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r13", "r18", "r66", "r68", "r91", "r92", "r93" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total equity" } } }, "localname": "Equity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shareholders\u2019 Equity" } } }, "localname": "EquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r13" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total liabilities and equity" } } }, "localname": "EquityAndLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAttributableToOwnersOfParent": { "auth_ref": [ "r12" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } }, "en-us": { "role": { "label": "Equity attributable to owners of parent", "totalLabel": "Total equity attributable to owners of the Company" } } }, "localname": "EquityAttributableToOwnersOfParent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } }, "en-us": { "role": { "label": "Equity attributable to owners of parent [member]" } } }, "localname": "EquityAttributableToOwnersOfParentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_EquityInterestsOfAcquirer": { "auth_ref": [ "r111" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value, at the acquisition date, of equity interests of the acquirer transferred as consideration in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Equity interests of acquirer" } } }, "localname": "EquityInterestsOfAcquirer", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } } }, "localname": "EquityMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/StockOptionReserveDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": { "auth_ref": [ "r108" ], "lang": { "en": { "role": { "documentation": "The exercise price of outstanding share options." } }, "en-us": { "role": { "label": "Exercise price" } } }, "localname": "ExercisePriceOfOutstandingShareOptions2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r175" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeographicalAreasAxis": { "auth_ref": [ "r130", "r138", "r145", "r147" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Geographical areas [axis]" } } }, "localname": "GeographicalAreasAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "xbrltype": "stringItemType" }, "ifrs-full_GeographicalAreasMember": { "auth_ref": [ "r130", "r138", "r145", "r147" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used." } } }, "localname": "GeographicalAreasMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ifrs-full_Goodwill": { "auth_ref": [ "r6", "r55", "r56", "r116" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognised. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IdentifiableAssetsAcquiredLiabilitiesAssumed": { "auth_ref": [ "r148", "r149" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as of the acquisition date for net identifiable assets acquired or liabilities assumed in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Liabilities assumed" } } }, "localname": "IdentifiableAssetsAcquiredLiabilitiesAssumed", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate": { "auth_ref": [ "r148", "r149" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as of the acquisition date for identifiable intangible assets acquired in a business combination. [Refer: Intangible assets other than goodwill; Business combinations [member]]" } }, "en-us": { "role": { "label": "Identifiable intangible assets" } } }, "localname": "IdentifiableIntangibleAssetsRecognisedAsOfAcquisitionDate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ImpairmentLoss": { "auth_ref": [ "r53", "r54" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Impairment loss" } } }, "localname": "ImpairmentLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r27", "r29", "r30", "r31", "r40", "r89", "r124" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax benefit", "negatedTerseLabel": "Benefit from income taxes" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails", "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalents": { "auth_ref": [ "r64" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents after the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents after effect of exchange rate changes", "totalLabel": "Decrease in cash and cash equivalents during period" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInDeferredTaxLiabilityAsset": { "auth_ref": [ "r180" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in a deferred tax liability (asset). [Refer: Deferred tax liability (asset)]" } }, "en-us": { "role": { "label": "Increase (decrease) in deferred tax liability (asset)", "negatedLabel": "Decrease in deferred tax liability" } } }, "localname": "IncreaseDecreaseInDeferredTaxLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": { "auth_ref": [ "r175" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Increase (decrease) in number of ordinary shares issued", "verboseLabel": "Shares issued or accrued for services, shares" } } }, "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset": { "auth_ref": [ "r180" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in deferred tax liability (asset) resulting from business combinations. [Refer: Deferred tax liability (asset)]" } }, "en-us": { "role": { "label": "Increase (Decrease) in deferred tax liability" } } }, "localname": "IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r3" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Share-based compensation expense" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwillMember": { "auth_ref": [ "r184" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]" } } }, "localname": "IntangibleAssetsAndGoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestReceivable": { "auth_ref": [ "r175" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of interest recognised as a receivable." } }, "en-us": { "role": { "label": "Fair value interest" } } }, "localname": "InterestReceivable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentProperty": { "auth_ref": [ "r5", "r59", "r60" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of property (land or a building - or part of a building - or both) held (by the owner or by the lessee as a right-of-use asset) to earn rentals or for capital appreciation or both, rather than for: (a) use in the production or supply of goods or services or for administrative purposes; or (b) sale in the ordinary course of business." } }, "en-us": { "role": { "label": "Investment in public company" } } }, "localname": "InvestmentProperty", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentPropertyMember": { "auth_ref": [ "r141", "r143", "r175" ], "lang": { "en": { "role": { "documentation": "This member stands for investment property. It also represents the standard value for the 'Types of investment property' axis if no other member is used. [Refer: Investment property]" } } }, "localname": "InvestmentPropertyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_InvestmentsInSubsidiariesJointVenturesAndAssociates": { "auth_ref": [ "r41" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of investments in subsidiaries, joint ventures and associates in an entity's separate financial statements. [Refer: Associates [member]; Joint ventures [member]; Subsidiaries [member]; Investments in subsidiaries reported in separate financial statements]" } }, "en-us": { "role": { "label": "Investment in associate", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "InvestmentsInSubsidiariesJointVenturesAndAssociates", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition", "http://portagebiotech.com/role/InvestmentInAssociateDetails1" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r135" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Capital stock" } } }, "localname": "IssuedCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital [member]" } } }, "localname": "IssuedCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r37" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Share based compensation expense" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r98" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Total lease liability" } } }, "localname": "LeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "auth_ref": [ "r36", "r92" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]" } } }, "localname": "LevelsOfFairValueHierarchyAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_Liabilities": { "auth_ref": [ "r13", "r91", "r92", "r93", "r125", "r128" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LongtermDeposits": { "auth_ref": [ "r176" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of long-term deposits held by the entity." } }, "en-us": { "role": { "label": "Security deposit" } } }, "localname": "LongtermDeposits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/LeaseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MeasurementAxis": { "auth_ref": [ "r58", "r61", "r91" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Measurement [axis]" } } }, "localname": "MeasurementAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_NameOfAssociate": { "auth_ref": [ "r42", "r46", "r76" ], "lang": { "en": { "role": { "documentation": "The name of an associate. [Refer: Associates [member]]" } }, "en-us": { "role": { "label": "Name" } } }, "localname": "NameOfAssociate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NetDeferredTaxAssets": { "auth_ref": [ "r179" ], "calculation": { "http://portagebiotech.com/role/IncomeTaxesDetails4": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Net deferred tax assets", "totalLabel": "Deferred tax asset" } } }, "localname": "NetDeferredTaxAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetDeferredTaxLiabilities": { "auth_ref": [ "r179" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Net deferred tax liability" } } }, "localname": "NetDeferredTaxLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncontrollingInterests": { "auth_ref": [ "r11", "r70", "r74" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Non-controlling interest", "periodEndLabel": "Non-controlling interest, at ending", "periodStartLabel": "Non-controlling interest, at beginning" } } }, "localname": "NoncontrollingInterests", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition", "http://portagebiotech.com/role/Non-controllingInterestDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncontrollingInterestsMember": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } }, "en-us": { "role": { "label": "Non-controlling interests [member]" } } }, "localname": "NoncontrollingInterestsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/StockOptionReserveDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r15", "r81", "r140" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets [Default Label]", "totalLabel": "Total non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentLeaseLiabilities": { "auth_ref": [ "r98" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Lease liability - non-current" } } }, "localname": "NoncurrentLeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition", "http://portagebiotech.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r16", "r83", "r140" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities [Default Label]", "totalLabel": "Total non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NotesAndOtherExplanatoryInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes and other explanatory information [abstract]" } } }, "localname": "NotesAndOtherExplanatoryInformationAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r105", "r107", "r108" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Options outstanding" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r173" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Option issued" } } }, "localname": "NumberOfSharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r20" ], "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ifrs-full_OtherAssets": { "auth_ref": [ "r176" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 6.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other assets, including equipment, net" } } }, "localname": "OtherAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_OtherCurrentReceivables": { "auth_ref": [ "r134" ], "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "order": 6.0, "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other receivables" } } }, "localname": "OtherCurrentReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReserves": { "auth_ref": [ "r135" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing reserves within equity, not including retained earnings. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Stock option reserve" } } }, "localname": "OtherReserves", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherTangibleOrIntangibleAssetsTransferred": { "auth_ref": [ "r110" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value, at acquisition date, of other tangible or intangible assets (including a business or subsidiary of the acquirer) transferred as consideration in a business combination, that the entity does not separately disclose in the same note. [Refer: Intangible assets other than goodwill; Business combinations [member]; Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Total assets" } } }, "localname": "OtherTangibleOrIntangibleAssetsTransferred", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r19" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Per share price" } } }, "localname": "ParValuePerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ifrs-full_PaymentsForShareIssueCosts": { "auth_ref": [ "r186" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for share issue costs." } }, "en-us": { "role": { "label": "Payments for share issue costs", "negatedLabel": "Share issuance costs" } } }, "localname": "PaymentsForShareIssueCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "auth_ref": [ "r109" ], "lang": { "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Percentage of acquire", "verboseLabel": "Percentage of voting equity interests acquired" } } }, "localname": "PercentageOfVotingEquityInterestsAcquired", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "ifrs-full_PlanAssetsAtFairValue": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The fair value of defined benefit plan assets. Plan assets comprise assets held by a long-term employee benefit fund and qualifying insurance policies. [Refer: At fair value [member]]" } }, "en-us": { "role": { "label": "Impairment asset fair value" } } }, "localname": "PlanAssetsAtFairValue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PrincipalPlaceOfBusinessOfAssociate": { "auth_ref": [ "r43", "r47", "r77" ], "lang": { "en": { "role": { "documentation": "The principal place of business of an associate. [Refer: Principal place of business; Associates [member]]" } }, "en-us": { "role": { "label": "Principal activity" } } }, "localname": "PrincipalPlaceOfBusinessOfAssociate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "auth_ref": [ "r186" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Proceeds from offering" } } }, "localname": "ProceedsFromIssueOfOrdinaryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromSalesOfBiologicalAssets": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from sales of biological assets. [Refer: Biological assets]" } }, "en-us": { "role": { "label": "Proceeds from sales of biological assets", "verboseLabel": "Net proceeds from sale" } } }, "localname": "ProceedsFromSalesOfBiologicalAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r2", "r21", "r63", "r67", "r69", "r125", "r126", "r140", "r146" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 }, "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Net (loss) income for period", "terseLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss for the period" } } }, "localname": "ProfitLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails1", "http://portagebiotech.com/role/InterimStatementsOfCashFlows", "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expenses" } } }, "localname": "ProfitLossAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ProfitLossAttributableToAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net (loss) income attributable to:" } } }, "localname": "ProfitLossAttributableToAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "auth_ref": [ "r23", "r73" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to non-controlling interests", "verboseLabel": "Non-controlling interest" } } }, "localname": "ProfitLossAttributableToNoncontrollingInterests", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Owners of the Company", "verboseLabel": "Net loss attributable to owners of the Company" } } }, "localname": "ProfitLossAttributableToOwnersOfParent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss", "http://portagebiotech.com/role/LossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r118", "r131", "r132", "r150", "r151" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Loss before provision for income taxes", "totalLabel": "Loss before (provision) benefit for income taxes" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails1", "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromContinuingOperations": { "auth_ref": [ "r21", "r85", "r125", "r126" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing operations. [Refer: Continuing operations [member]; Profit (loss)]" } }, "en-us": { "role": { "label": "Loss from operations" } } }, "localname": "ProfitLossFromContinuingOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails1" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r139", "r178" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Loss from operations" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProportionOfOwnershipInterestInSubsidiary": { "auth_ref": [ "r44", "r48", "r75" ], "lang": { "en": { "role": { "documentation": "The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Percentage of ownership subsidiary" } } }, "localname": "ProportionOfOwnershipInterestInSubsidiary", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "ifrs-full_ProportionOfOwnershipInterestsHeldByNoncontrollingInterests": { "auth_ref": [ "r72" ], "lang": { "en": { "role": { "documentation": "The proportion of ownership interests in a subsidiary held by non-controlling interests. [Refer: Subsidiaries [member]; Non-controlling interests]" } }, "en-us": { "role": { "label": "Proportion of ownership interests held by non-controlling interests", "verboseLabel": "Non-controlling interest" } } }, "localname": "ProportionOfOwnershipInterestsHeldByNoncontrollingInterests", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "percentItemType" }, "ifrs-full_ProportionOfVotingPowerHeldInAssociate": { "auth_ref": [ "r44", "r48", "r78" ], "lang": { "en": { "role": { "documentation": "The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]]" } }, "en-us": { "role": { "label": "Voting rights held" } } }, "localname": "ProportionOfVotingPowerHeldInAssociate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r95", "r103", "r108", "r142", "r144", "r192" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r95", "r103", "r108", "r142", "r144", "r192" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } } }, "localname": "RangesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related party transactions [abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r57" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RestrictedShareUnitsMember": { "auth_ref": [ "r183" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of antidilutive instrument representing restricted share units." } }, "en-us": { "role": { "label": "Restricted share units [member]" } } }, "localname": "RestrictedShareUnitsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails1" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarnings": { "auth_ref": [ "r135", "r136" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Accumulated deficit" } } }, "localname": "RetainedEarnings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r4", "r133" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings [member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RevenueFromInterest": { "auth_ref": [ "r88", "r122", "r129", "r175" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 7.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from interest." } }, "en-us": { "role": { "label": "Interest income, net" } } }, "localname": "RevenueFromInterest", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReversalOfImpairmentLoss": { "auth_ref": [ "r53", "r54" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount recognised as an increase of the carrying amount of an asset or cash-generating unit to its recoverable amount when an impairment loss had been previously recognised. [Refer: Impairment loss]" } }, "en-us": { "role": { "label": "Impairment of convertible note" } } }, "localname": "ReversalOfImpairmentLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r97", "r99" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Right to use asset" } } }, "localname": "RightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SaleOrIssueOfTreasuryShares": { "auth_ref": [ "r173" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Sale or issue of treasury shares", "verboseLabel": "Shares issued or accrued for services" } } }, "localname": "SaleOrIssueOfTreasuryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": { "auth_ref": [ "r178" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Associates [member]; Investments accounted for using equity method; Profit (loss)]" } }, "en-us": { "role": { "label": "Share of loss in associate accounted for using equity method" } } }, "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ShareOptionsMember": { "auth_ref": [ "r183" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of antidilutive instrument representing share options." } }, "en-us": { "role": { "label": "Share options [member]" } } }, "localname": "ShareOptionsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails1" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermEmployeeBenefitsExpense": { "auth_ref": [ "r175" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from employee benefits (other than termination benefits) that are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services." } }, "en-us": { "role": { "label": "Short term debt" } } }, "localname": "ShorttermEmployeeBenefitsExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "auth_ref": [ "r45", "r49", "r90" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Associates [axis]" } } }, "localname": "SignificantInvestmentsInAssociatesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetails", "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "localname": "StatementOfChangesInEquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r4" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/StockOptionReserveDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxEffectFromChangeInTaxRate": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to changes in the tax rate. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Change in exchange rates on the liability" } } }, "localname": "TaxEffectFromChangeInTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfTaxLosses": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Income tax benefit" } } }, "localname": "TaxEffectOfTaxLosses", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "auth_ref": [ "r30" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Loss at statutory income tax rate" } } }, "localname": "TaxExpenseIncomeAtApplicableTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r95", "r103", "r108", "r142", "r144", "r192" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [member]" } } }, "localname": "TopOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayables": { "auth_ref": [ "r9" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } }, "en-us": { "role": { "label": "Accounts payable and accrued liabilities" } } }, "localname": "TradeAndOtherCurrentPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentReceivables": { "auth_ref": [ "r7", "r17" ], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } }, "en-us": { "role": { "label": "Prepaid expenses and other receivables" } } }, "localname": "TradeAndOtherCurrentReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis": { "auth_ref": [ "r113" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination [axis]" } } }, "localname": "TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails", "http://portagebiotech.com/role/AcquisitionOfTarusDetails1", "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember": { "auth_ref": [ "r113" ], "lang": { "en": { "role": { "documentation": "This member stands for transactions that are recognised separately from the acquisition of assets and assumption of liabilities in business combinations. It also represents the standard value for the 'Transactions recognised separately from acquisition of assets and assumption of liabilities in business combination' axis if no other member is used. [Refer: Business combinations [member]]" } } }, "localname": "TransactionsRecognisedSeparatelyFromAcquisitionOfAssetsAndAssumptionOfLiabilitiesInBusinessCombinationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails", "http://portagebiotech.com/role/AcquisitionOfTarusDetails1", "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": { "auth_ref": [ "r52" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of antidilutive instruments [axis]" } } }, "localname": "TypesOfAntidilutiveInstrumentsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfInvestmentPropertyAxis": { "auth_ref": [ "r175" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of investment property [axis]" } } }, "localname": "TypesOfInvestmentPropertyAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "stringItemType" }, "ifrs-full_UnrecognisedShareOfLossesOfAssociates": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of the unrecognised share of associates' losses if the entity has stopped recognising its share of losses when applying the equity method. [Refer: Associates [member]]" } }, "en-us": { "role": { "label": "Unrecognised share of losses of associates", "negatedLabel": "Share of loss" } } }, "localname": "UnrecognisedShareOfLossesOfAssociates", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetails1" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r182" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Base salary" } } }, "localname": "WagesAndSalaries", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019": { "auth_ref": [ "r106" ], "lang": { "en": { "role": { "documentation": "The weighted average exercise price of share options exercised in a share-based payment arrangement. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average exercise price" } } }, "localname": "WeightedAverageExercisePriceOfShareOptionsExercisedInSharebasedPaymentArrangement2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails2" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019": { "auth_ref": [ "r108" ], "lang": { "en": { "role": { "documentation": "The weighted average remaining contractual life of outstanding share options. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average remaining contractual life (in years)" } } }, "localname": "WeightedAverageRemainingContractualLifeOfOutstandingShareOptions2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails2" ], "xbrltype": "durationItemType" }, "ifrs-full_WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding" } } }, "localname": "WeightedAverageSharesAndAdjustedWeightedAverageSharesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "stringItemType" }, "ptgef_ATMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "A T M [Member]" } } }, "localname": "ATMMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_AccountsPayableAndAccruedExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses" } } }, "localname": "AccountsPayableAndAccruedExpenses", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_AccountsPayableAndAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts Payable And Accrued Liabilities", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilities", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_AccountsPayableAndAccruedLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "AccountsPayableAndAccruedLiability", "verboseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiability", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_AcquisitionOfIntensityHoldingLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition Of Intensity Holding Limited [Member]" } } }, "localname": "AcquisitionOfIntensityHoldingLimitedMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_AcquisitionOfSalvaRxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition Of Salva Rx [Member]" } } }, "localname": "AcquisitionOfSalvaRxMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_AcquisitionsOfTarusExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ACQUISITION OF TARUS" } } }, "localname": "AcquisitionsOfTarusExplanatory", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarus" ], "xbrltype": "textBlockItemType" }, "ptgef_AdditionalAntidilutionShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Additional antidilution shares" } } }, "localname": "AdditionalAntidilutionShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_AggregateValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Aggregate value" } } }, "localname": "AggregateValue", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_AmendedAndRestated2021EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amended And Restated 2021 Equity Incentive Plan [Member]" } } }, "localname": "AmendedAndRestated2021EquityIncentivePlanMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_AmortizedCostMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amortized Cost [Member]" } } }, "localname": "AmortizedCostMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "domainItemType" }, "ptgef_AnnualBaseSalary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Annual base salary" } } }, "localname": "AnnualBaseSalary", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_AnnualFeesdescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Annual fees description" } } }, "localname": "AnnualFeesdescription", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ptgef_AntidilutiveEffectOnLossPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Anti-dilutive effect on loss per share" } } }, "localname": "AntidilutiveEffectOnLossPerShare", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails1" ], "xbrltype": "sharesItemType" }, "ptgef_BVIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "B V I [Member]" } } }, "localname": "BVIMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ptgef_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board Of Directors [Member]" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_CapitalStockTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CAPITAL STOCK" } } }, "localname": "CapitalStockTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStock" ], "xbrltype": "textBlockItemType" }, "ptgef_CarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Carrying value" } } }, "localname": "CarryingValue", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_CashCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash carrying value" } } }, "localname": "CashCarryingValue", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_CashFundDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash fund, description" } } }, "localname": "CashFundDescription", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "stringItemType" }, "ptgef_CashPaidForInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash paid for interest" } } }, "localname": "CashPaidForInterest", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptgef_CashUsedInOperatingActivities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cash used in operating activities" } } }, "localname": "CashUsedInOperatingActivities", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in fair value of deferred purchase price payable - Tarus and deferred obligation - iOx milestone" } } }, "localname": "ChangeInFairValueOfDeferredPurchasePricePayableTarusAndDeferredObligationIoxMilestone", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ptgef_ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone", "negatedLabel": "Change in fair value of deferred purchase price payable \u2013 Tarus and deferred obligation \u2013 iOx milestone" } } }, "localname": "ChangeInFairValueOfDeferredsPurchasePricePayableTarusAndDeferredObligationIoxMilestone", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptgef_ChangeIncreaseInDeferredIncomeTaxRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change from increase in deferred income tax rate" } } }, "localname": "ChangeIncreaseInDeferredIncomeTaxRate", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ptgef_ChangesInMarket": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Changes in the market" } } }, "localname": "ChangesInMarket", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_CommitmentAndContingencies": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Commitments and Contingent Liabilities (Note 15)" } } }, "localname": "CommitmentAndContingencies", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ptgef_CommitmentFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Commitment fee" } } }, "localname": "CommitmentFee", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of unlimited number of common shares without par value" } } }, "localname": "CommonSharesUnlimitedNumberOfCommonSharesWithoutParValueTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockTables" ], "xbrltype": "textBlockItemType" }, "ptgef_CommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStockShares", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares" } } }, "localname": "CommonStockShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "xbrltype": "sharesItemType" }, "ptgef_CommonStockValues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common Stock Values", "periodEndLabel": "Ending balance, Amount", "periodStartLabel": "Beginning balance, Amount" } } }, "localname": "CommonStockValues", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_CompensationCommittee": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Compensation committee" } } }, "localname": "CompensationCommittee", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_ConsultantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Consultants [Member]" } } }, "localname": "ConsultantsMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_ConversionOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of debt" } } }, "localname": "ConversionOfDebt", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_ConversionOfDebtIntoShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of debt into shares" } } }, "localname": "ConversionOfDebtIntoShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_ConvertibleNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Convertible note" } } }, "localname": "ConvertibleNote", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_ConvertibleNoteDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Convertible Note description" } } }, "localname": "ConvertibleNoteDescription", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "stringItemType" }, "ptgef_ConvertibleNoteReceivable": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Convertible note receivable" } } }, "localname": "ConvertibleNoteReceivable", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ptgef_ConvertibleNoteReceivableIncludingAccruedInterestNetOfImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Convertible note receivable, including accrued interest, net of impairment" } } }, "localname": "ConvertibleNoteReceivableIncludingAccruedInterestNetOfImpairment", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_CostAndExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Budget cost related to services" } } }, "localname": "CostAndExpenses", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_CountryOfBritishVirginIslandsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Country Of British Virgin Islands [Member]" } } }, "localname": "CountryOfBritishVirginIslandsMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_CountryOfDelawareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Country Of Delaware [Member]" } } }, "localname": "CountryOfDelawareMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_CountryOfUnitedKingdomMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United Kingdom [Member]" } } }, "localname": "CountryOfUnitedKingdomMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ptgef_CurrentAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Current Asset", "verboseLabel": "Current assets" } } }, "localname": "CurrentAsset", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_CurrentFederalIncomeTaxBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Federal" } } }, "localname": "CurrentFederalIncomeTaxBenefit", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_CurrentForeignIncomeTaxBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Foreign" } } }, "localname": "CurrentForeignIncomeTaxBenefit", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_CurrentStateAndLocalIncomeTaxBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "State and local" } } }, "localname": "CurrentStateAndLocalIncomeTaxBenefit", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_CurrentYearLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Current year losses" } } }, "localname": "CurrentYearLosses", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_DecreasingCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Decreasing the carrying value" } } }, "localname": "DecreasingCarryingValue", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_DecreasingImpairmentCarryingValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Decreasing impairment carrying value" } } }, "localname": "DecreasingImpairmentCarryingValue", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredCommitmentFee": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred commitment fee" } } }, "localname": "DeferredCommitmentFee", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredFederalIncomeTaxBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Federal Income Tax Benefit", "verboseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxBenefit", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredForeignIncomeTaxBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Foreign Income Tax Benefit", "verboseLabel": "Foreign" } } }, "localname": "DeferredForeignIncomeTaxBenefit", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredObligationIoxMilestone": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred obligation - iOx milestone" } } }, "localname": "DeferredObligationIoxMilestone", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredPurchasePricePayable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred purchase price payable" } } }, "localname": "DeferredPurchasePricePayable", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredPurchasePricePayableTarus": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred purchase price payable - Tarus" } } }, "localname": "DeferredPurchasePricePayableTarus", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredStateAndLocalIncomeTaxBenefit": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred State And Local Income Tax Benefit", "verboseLabel": "State and local" } } }, "localname": "DeferredStateAndLocalIncomeTaxBenefit", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredTaxAssetUnrecognized": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/IncomeTaxesDetails4": { "order": 2.0, "parentTag": "ifrs-full_NetDeferredTaxAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Deferred tax asset (unrecognized)" } } }, "localname": "DeferredTaxAssetUnrecognized", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredTaxAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsAbstract", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "xbrltype": "stringItemType" }, "ptgef_DeferredTaxAssetsNetOperatingLossCarryforward": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/IncomeTaxesDetails4": { "order": 1.0, "parentTag": "ifrs-full_NetDeferredTaxAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Net operating loss" } } }, "localname": "DeferredTaxAssetsNetOperatingLossCarryforward", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredTaxLiabilitiesInProcessRAndD": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/IncomeTaxesDetails4": { "order": 1.0, "parentTag": "ptgef_DeferredTaxLiability1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities In Process R And D", "verboseLabel": "In-process research and development" } } }, "localname": "DeferredTaxLiabilitiesInProcessRAndD", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredTaxLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "DeferredTaxLiability", "verboseLabel": "Deferred tax liability" } } }, "localname": "DeferredTaxLiability", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredTaxLiability1": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/IncomeTaxesDetails4": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Deferred Tax Liability1", "totalLabel": "Deferred tax liability" } } }, "localname": "DeferredTaxLiability1", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "xbrltype": "monetaryItemType" }, "ptgef_DeferredTaxLiabiltiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax liabilities:" } } }, "localname": "DeferredTaxLiabiltiesAbstract", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails4" ], "xbrltype": "stringItemType" }, "ptgef_DeferredTaxesLiability": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "DeferredTaxesLiability", "verboseLabel": "Deferred tax liability" } } }, "localname": "DeferredTaxesLiability", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Denominator (in 000\u2019)" } } }, "localname": "DenominatorAbstract", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails" ], "xbrltype": "stringItemType" }, "ptgef_DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Recent Accounting Pronouncements" } } }, "localname": "DescriptionOfAccountingPolicyForAdoptionOfNewStandardsExplanatory", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ptgef_DirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Directors [Member]" } } }, "localname": "DirectorsMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_DisclosureAcquisitionOfTarusAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition Of Tarus" } } }, "localname": "DisclosureAcquisitionOfTarusAbstract", "nsuri": "http://portagebiotech.com/20230630", "xbrltype": "stringItemType" }, "ptgef_DisclosureCapitalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Disclosures" } } }, "localname": "DisclosureCapitalDisclosuresAbstract", "nsuri": "http://portagebiotech.com/20230630", "xbrltype": "stringItemType" }, "ptgef_DisclosureCapitalStockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capital Stock" } } }, "localname": "DisclosureCapitalStockAbstract", "nsuri": "http://portagebiotech.com/20230630", "xbrltype": "stringItemType" }, "ptgef_DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "In-process Research And Development And Deferred Tax Liability" } } }, "localname": "DisclosureInprocessResearchAndDevelopmentAndDeferredTaxLiabilityAbstract", "nsuri": "http://portagebiotech.com/20230630", "xbrltype": "stringItemType" }, "ptgef_DisclosureInvestmentInAssociateAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Associate" } } }, "localname": "DisclosureInvestmentInAssociateAbstract", "nsuri": "http://portagebiotech.com/20230630", "xbrltype": "stringItemType" }, "ptgef_DisclosureInvestmentInPublicCompanyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment In Public Company" } } }, "localname": "DisclosureInvestmentInPublicCompanyAbstract", "nsuri": "http://portagebiotech.com/20230630", "xbrltype": "stringItemType" }, "ptgef_DisclosureNatureOfOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nature Of Operations" } } }, "localname": "DisclosureNatureOfOperationsAbstract", "nsuri": "http://portagebiotech.com/20230630", "xbrltype": "stringItemType" }, "ptgef_DisclosureOfCapitalManagementExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CAPITAL DISCLOSURES" } } }, "localname": "DisclosureOfCapitalManagementExplanatoryTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalDisclosures" ], "xbrltype": "textBlockItemType" }, "ptgef_DisclosureOfDeferredTaxAssetsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of deferred tax assets and liabilities" } } }, "localname": "DisclosureOfDeferredTaxAssetsExplanatory", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "ptgef_DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of prepaid expenses and other receivables" } } }, "localname": "DisclosureOfDetailedInformationAboutPrepaidExpensesAndOtherReceivableTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesTables" ], "xbrltype": "textBlockItemType" }, "ptgef_DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of financial instruments" } } }, "localname": "DisclosureOfFinancialAssetsAndFinancialLiabilitiesExplanatory", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementTables" ], "xbrltype": "textBlockItemType" }, "ptgef_DisclosureOfInvestmentAssociatetableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of investment associate" } } }, "localname": "DisclosureOfInvestmentAssociatetableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateTables" ], "xbrltype": "textBlockItemType" }, "ptgef_DisclosureOfPublicCompaniesExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTMENT IN PUBLIC COMPANY" } } }, "localname": "DisclosureOfPublicCompaniesExplanatoryTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompany" ], "xbrltype": "textBlockItemType" }, "ptgef_DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of outstanding stock options" } } }, "localname": "DisclosureOfShareBasedCompensationStockOptionsActivityExplanatory", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveTables" ], "xbrltype": "textBlockItemType" }, "ptgef_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "ptgef_DisclosureOfTermsStockOptionReserveExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of terms stock option reserve explanatory" } } }, "localname": "DisclosureOfTermsStockOptionReserveExplanatory", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveTables" ], "xbrltype": "textBlockItemType" }, "ptgef_DisclosureSignificantAccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "DisclosureSignificantAccountingPoliciesAbstract", "nsuri": "http://portagebiotech.com/20230630", "xbrltype": "stringItemType" }, "ptgef_EarningLossPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EarningLossPerShare", "verboseLabel": "Loss per share" } } }, "localname": "EarningLossPerShare", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails1" ], "xbrltype": "perShareItemType" }, "ptgef_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employees [Member]" } } }, "localname": "EmployeesMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_EquityInLossIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Equity in (loss) income" } } }, "localname": "EquityInLossIncome", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_ExchangeOfOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exchange of ordinary shares" } } }, "localname": "ExchangeOfOrdinaryShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_ExchangeRatesLosses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Exchange rates losses" } } }, "localname": "ExchangeRatesLosses", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_ExecutiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Executive [Member]" } } }, "localname": "ExecutiveMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_ExercisablePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercisable price" } } }, "localname": "ExercisablePrice", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ptgef_ExpirationDateOfGrantOfSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expiration date" } } }, "localname": "ExpirationDateOfGrantOfSharebasedPaymentArrangement", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "dateItemType" }, "ptgef_FairValueOfStockIssuedForServices": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Fair value of shares issued for services" } } }, "localname": "FairValueOfStockIssuedForServices", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptgef_FairValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair value per share" } } }, "localname": "FairValuePerShare", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ptgef_FairValueThroughProfitOrLossMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Through Profit Or Loss [Member]" } } }, "localname": "FairValueThroughProfitOrLossMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "domainItemType" }, "ptgef_FairValueToOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value To Other Comprehensive Income [Member]" } } }, "localname": "FairValueToOtherComprehensiveIncomeMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "domainItemType" }, "ptgef_FederalNetOperatingLosses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Federal net operating losses" } } }, "localname": "FederalNetOperatingLosses", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_ForeignCurrencyEffect": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Foreign currency effect" } } }, "localname": "ForeignCurrencyEffect", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ptgef_ForeignExchangeTransactionGainLoss": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 5.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "ForeignExchangeTransactionGainLoss", "negatedLabel": "Foreign exchange transaction gain (loss)" } } }, "localname": "ForeignExchangeTransactionGainLoss", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ptgef_GainsLossesOnChangeInFairValueOfWarrants": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 4.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Change in fair value of warrant liability" } } }, "localname": "GainsLossesOnChangeInFairValueOfWarrants", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ptgef_GrossProceedsFromStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Gross proceeds from stock" } } }, "localname": "GrossProceedsFromStock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_GrossProceedsFromStockSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Gross proceeds from stock sold" } } }, "localname": "GrossProceedsFromStockSold", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_IMM60IOXMelanomaLungCancersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "I M M 60 I O X Melanoma Lung Cancers [Member]" } } }, "localname": "IMM60IOXMelanomaLungCancersMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "xbrltype": "domainItemType" }, "ptgef_IMM65IOXMelanomaLungCancersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "I M M 65 I O X Melanoma Lung Cancers [Member]" } } }, "localname": "IMM65IOXMelanomaLungCancersMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "xbrltype": "domainItemType" }, "ptgef_IOXMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "I O X [Member]" } } }, "localname": "IOXMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "http://portagebiotech.com/role/Non-controllingInterestDetails" ], "xbrltype": "domainItemType" }, "ptgef_IfrsStatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IfrsStatementLineItems [Line Items]" } } }, "localname": "IfrsStatementLineItems", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails", "http://portagebiotech.com/role/AcquisitionOfTarusDetails1", "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative", "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails", "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative", "http://portagebiotech.com/role/IncomeTaxesDetails3", "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative", "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/InvestmentInAssociateDetails", "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative", "http://portagebiotech.com/role/LossPerShareDetails1", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative", "http://portagebiotech.com/role/Non-controllingInterestDetails", "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative", "http://portagebiotech.com/role/StockOptionReserveDetails", "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2", "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "stringItemType" }, "ptgef_Impairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Impairment" } } }, "localname": "Impairment", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_ImpairmentAnalysis": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Impairment analysis" } } }, "localname": "ImpairmentAnalysis", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_ImpairmentAssetsCarringValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Impairment assets carring value" } } }, "localname": "ImpairmentAssetsCarringValue", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_InProcessResearchAndDevelopmentAndDeferredTaxLiability": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IN-PROCESS RESEARCH AND DEVELOPMENT AND DEFERRED TAX LIABILITY" } } }, "localname": "InProcessResearchAndDevelopmentAndDeferredTaxLiability", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiability" ], "xbrltype": "textBlockItemType" }, "ptgef_IncomeLossOnOrdinaryActivitiesBeforeTax": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "(Loss) income on ordinary activities before tax" } } }, "localname": "IncomeLossOnOrdinaryActivitiesBeforeTax", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "ptgef_IncomeOnFairValueOfWarrantLiability": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IncomeOnFairValueOfWarrantLiability", "verboseLabel": "Change in fair value of warrant liability" } } }, "localname": "IncomeOnFairValueOfWarrantLiability", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptgef_IncomeTaxBenefitExpenseAtStatutoryIncomeTaxRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Income tax benefit (expense) at statutory income tax rate" } } }, "localname": "IncomeTaxBenefitExpenseAtStatutoryIncomeTaxRate", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "ptgef_IncomeTaxExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Income tax (expense)" } } }, "localname": "IncomeTaxExpense", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "ptgef_IncreaseDecreaseInShareOfLossInAssociate": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "IncreaseDecreaseInShareOfLossInAssociate", "negatedLabel": "Share of loss in associate" } } }, "localname": "IncreaseDecreaseInShareOfLossInAssociate", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptgef_IncreasingCarryingValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Increasing the carrying value", "verboseLabel": "Increasing carrying value" } } }, "localname": "IncreasingCarryingValue", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_IncreasingDecreasingAccountsReceivable": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "IncreasingDecreasingAccountsReceivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreasingDecreasingAccountsReceivable", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptgef_InprocessResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "In-process research and development" } } }, "localname": "InprocessResearchAndDevelopment", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails", "http://portagebiotech.com/role/InterimStatementsOfFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ptgef_IntensityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Intensity [Member]" } } }, "localname": "IntensityMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_InvestmentInAssociateDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INVESTMENT IN ASSOCIATE" } } }, "localname": "InvestmentInAssociateDisclosureTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociate" ], "xbrltype": "textBlockItemType" }, "ptgef_InvestmentInPrivateCompany": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "InvestmentInPrivateCompany", "verboseLabel": "Investment in public company" } } }, "localname": "InvestmentInPrivateCompany", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_InvestmentOwnedShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of shares purchased" } } }, "localname": "InvestmentOwnedShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_InvestmentOwnershipPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of equity held" } } }, "localname": "InvestmentOwnershipPercentage", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "percentItemType" }, "ptgef_IoxIPRAndDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Iox I P R And D [Member]" } } }, "localname": "IoxIPRAndDMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_IssuanceAndSalesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance and sales, shares" } } }, "localname": "IssuanceAndSalesShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_IssuanceOfUnsecuredNotesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of unsecured notes, description" } } }, "localname": "IssuanceOfUnsecuredNotesDescription", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "ptgef_LeaseLiabilityIncurred": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Lease liability incurred" } } }, "localname": "LeaseLiabilityIncurred", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptgef_LeaseLiabilityInterest": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Less: interest" } } }, "localname": "LeaseLiabilityInterest", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentDue", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFive": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "2028" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFive", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFour": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentDueInRollingYearFour", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDueInRollingYearThree": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentDueInRollingYearThree", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDueInRollingYearTwo": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentDueInRollingYearTwo", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_LesseeOperatingLeaseLiabilityPaymentDueNextRollingTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentDueNextRollingTwelveMonths", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LeaseDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_LincolnMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lincoln [Member]" } } }, "localname": "LincolnMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_LossOnDecreaseInFairValueOfLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loss on decrease in fair value of the liability" } } }, "localname": "LossOnDecreaseInFairValueOfLiability", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_LossOnSharesRecognize": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loss on shares recognize" } } }, "localname": "LossOnSharesRecognize", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_LossesNotSubjectToTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Losses not subject to tax" } } }, "localname": "LossesNotSubjectToTax", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "ptgef_MaximumAggregateOfferingPrice": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Maximum aggregate offering price" } } }, "localname": "MaximumAggregateOfferingPrice", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_MilestonePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Milestone payment" } } }, "localname": "MilestonePayment", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_MinorityInterestPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Minority interest, percentage" } } }, "localname": "MinorityInterestPercentage", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "percentItemType" }, "ptgef_N2021EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "N 2021 Equity Incentive Plan [Member]" } } }, "localname": "N2021EquityIncentivePlanMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_NatureOfOperationsExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NATURE OF OPERATIONS" } } }, "localname": "NatureOfOperationsExplanatory", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/NatureOfOperations" ], "xbrltype": "textBlockItemType" }, "ptgef_NetChangeInWorkingCapitalComponentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating working capital:" } } }, "localname": "NetChangeInWorkingCapitalComponentsAbstract", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ptgef_NetLossAttributableToNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net (loss) attributable to non-controlling interest" } } }, "localname": "NetLossAttributableToNoncontrollingInterest", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/Non-controllingInterestDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_NetLossIncome": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net (loss) income" } } }, "localname": "NetLossIncome", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_NetProceedsFromStockSold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net proceeds from stock sold" } } }, "localname": "NetProceedsFromStockSold", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_NetUnrealizedGainOnInvestment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "NetUnrealizedGainOnInvestment", "verboseLabel": "Net unrealized gain on investments" } } }, "localname": "NetUnrealizedGainOnInvestment", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ptgef_NetUnrealizedGainOnInvestmentInIntensity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net unrealized gain on investment in Intensity" } } }, "localname": "NetUnrealizedGainOnInvestmentInIntensity", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptgef_NetUnrealizedGainOnInvestments": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Net unrealized gain on investments" } } }, "localname": "NetUnrealizedGainOnInvestments", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLoss" ], "xbrltype": "monetaryItemType" }, "ptgef_NoncashInvestingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingItemsAbstract", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ptgef_NotesReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Notes receivable" } } }, "localname": "NotesReceivable", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_NumberOfInstrumentsOrInterestsIssuedOrIssuables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of ordinary shares issued in acquisition" } } }, "localname": "NumberOfInstrumentsOrInterestsIssuedOrIssuables", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfOrdinaryShareIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of ordinary share issued", "verboseLabel": "Number of ordinary shares issued" } } }, "localname": "NumberOfOrdinaryShareIssued", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfOutstandingShareOption": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number Of Outstanding Share Option", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "NumberOfOutstandingShareOption", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfPrivateCompanyShareConsistsInSoleAsset": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of private company share consists in sole asset" } } }, "localname": "NumberOfPrivateCompanyShareConsistsInSoleAsset", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfShareIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of share issued" } } }, "localname": "NumberOfShareIssued", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfShareOptionsAvailableInSharebasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumberOfShareOptionsAvailableInSharebasedPaymentArrangement", "verboseLabel": "Number of shares available for awards" } } }, "localname": "NumberOfShareOptionsAvailableInSharebasedPaymentArrangement", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Exercisable as at end" } } }, "localname": "NumberOfShareOptionsExercisableInSharebasedPaymentsArrangements", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expired or forfeited" } } }, "localname": "NumberOfShareOptionsExpiredOrForfeitedInSharebasedPaymentsArrangement", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Granted" } } }, "localname": "NumberOfShareOptionsGrantedInSharebasedPaymentsArrangement", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfSharesAvailableForGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of shares available for granted" } } }, "localname": "NumberOfSharesAvailableForGranted", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfSharesAvailableForGrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Total of stock options granted to employees" } } }, "localname": "NumberOfSharesAvailableForGrants", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfSharesAvailableForOptionGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock options granted to consultant" } } }, "localname": "NumberOfSharesAvailableForOptionGranted", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfSharesExchanged": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of shares exchanged" } } }, "localname": "NumberOfSharesExchanged", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumberOfSharesPurchased", "verboseLabel": "Number of shares purchased" } } }, "localname": "NumberOfSharesPurchased", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfSharesSold": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of shares sold" } } }, "localname": "NumberOfSharesSold", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative", "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumberOfStockSold": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of stock sold" } } }, "localname": "NumberOfStockSold", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Numerator (in 000\u2019$)" } } }, "localname": "NumeratorAbstract", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails" ], "xbrltype": "stringItemType" }, "ptgef_OCIMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "O C I [Member]" } } }, "localname": "OCIMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_OfferingPerSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Offering price" } } }, "localname": "OfferingPerSharePrice", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ptgef_OncomerSaugatuckDNAAptamersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Oncomer Saugatuck D N A Aptamers [Member]" } } }, "localname": "OncomerSaugatuckDNAAptamersMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "xbrltype": "domainItemType" }, "ptgef_OrdinarySharesIssuedValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Ordinary shares issued Value" } } }, "localname": "OrdinarySharesIssuedValue", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_OrdinarySharesValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Ordinary shares value" } } }, "localname": "OrdinarySharesValue", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_OriginalAnnualTargetsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Original annual targets percentage" } } }, "localname": "OriginalAnnualTargetsPercentage", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "percentItemType" }, "ptgef_OtherLossesRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Other losses recognized" } } }, "localname": "OtherLossesRecognized", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "ptgef_PBI2021EquityIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "P B I 2021 Equity Incentive Plan [Member]" } } }, "localname": "PBI2021EquityIncentivePlanMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2" ], "xbrltype": "domainItemType" }, "ptgef_PercentageOfOutstandingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of outstanding shares" } } }, "localname": "PercentageOfOutstandingShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative", "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "percentItemType" }, "ptgef_PortageOrdinaryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Portage ordinary shares" } } }, "localname": "PortageOrdinaryShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_PrepaidExpensesAndOtherReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Prepaid Expenses And Other Receivable", "verboseLabel": "Prepaid expenses and other receivables" } } }, "localname": "PrepaidExpensesAndOtherReceivable", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_PrepaidExpensesAndOtherReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses And Other Receivables" } } }, "localname": "PrepaidExpensesAndOtherReceivablesAbstract", "nsuri": "http://portagebiotech.com/20230630", "xbrltype": "stringItemType" }, "ptgef_PretaxIncomeLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Pre-tax loss" } } }, "localname": "PretaxIncomeLoss", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "ptgef_PretaxLossSubjectToTax": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Taxable income (loss)" } } }, "localname": "PretaxLossSubjectToTax", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "ptgef_PricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Price per share" } } }, "localname": "PricePerShare", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_PrivateInvestmentsInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Investment" } } }, "localname": "PrivateInvestmentsInterest", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from shares issued under ATM and Committed Purchase Agreement" } } }, "localname": "ProceedsFromSharesIssuedUnderAtmAndCommittedPurchaseAgreement", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptgef_RecognitionOfDeferredTaxAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Recognition of deferred tax assets" } } }, "localname": "RecognitionOfDeferredTaxAssets", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails2" ], "xbrltype": "monetaryItemType" }, "ptgef_RecognizedImpairment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Recognized an impairment" } } }, "localname": "RecognizedImpairment", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_RepaymentOfLeaseLiability": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/InterimStatementsOfCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "RepaymentOfLeaseLiability", "negatedLabel": "Repayment of lease liability" } } }, "localname": "RepaymentOfLeaseLiability", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptgef_ResearchAndDevelopmentCredit": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "order": 3.0, "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Research & development tax credits" } } }, "localname": "ResearchAndDevelopmentCredit", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_ResearchAndDevelopmentCreditReceivables": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Research and development credit receivables" } } }, "localname": "ResearchAndDevelopmentCreditReceivables", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_RestrictedStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Restricted Stock Units [Member]" } } }, "localname": "RestrictedStockUnitsMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_ReverseStockSplitHoldingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Holding shares" } } }, "localname": "ReverseStockSplitHoldingShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_RightToUseAssetAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Right to use asset acquired" } } }, "localname": "RightToUseAssetAcquired", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "ptgef_SalvaRxLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Salva Rx Limited [Member]" } } }, "localname": "SalvaRxLimitedMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/NatureOfOperationsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_SalvaRxMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Salva Rx [Member]" } } }, "localname": "SalvaRxMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_SaugatuckAndSubsidiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Saugatuck And Subsidiary [Member]" } } }, "localname": "SaugatuckAndSubsidiaryMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/Non-controllingInterestDetails" ], "xbrltype": "domainItemType" }, "ptgef_ScheduleOfAntiDilutiveEffectTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of anti-dilutive share" } } }, "localname": "ScheduleOfAntiDilutiveEffectTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "ptgef_ScheduleOfEarningsPerShareTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of basic and diluted EPS calculations" } } }, "localname": "ScheduleOfEarningsPerShareTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LossPerShareTables" ], "xbrltype": "textBlockItemType" }, "ptgef_ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of fair value of assets acquired and liabilities assumed" } } }, "localname": "ScheduleOfFairValueOfAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusTables" ], "xbrltype": "textBlockItemType" }, "ptgef_ScheduleOfInProcessResearchAndDevelopmentTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of in-process research and development" } } }, "localname": "ScheduleOfInProcessResearchAndDevelopmentTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityTables" ], "xbrltype": "textBlockItemType" }, "ptgef_ScheduleOfIncomeTaxExplanatory": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of effective income tax rates" } } }, "localname": "ScheduleOfIncomeTaxExplanatory", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "ptgef_ScheduleOfIncomeTaxesBenefitTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of income taxes benefit" } } }, "localname": "ScheduleOfIncomeTaxesBenefitTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "ptgef_ScheduleOfInvestmentInStimunitySaTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of investment in Stimunity S.A." } } }, "localname": "ScheduleOfInvestmentInStimunitySaTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateTables" ], "xbrltype": "textBlockItemType" }, "ptgef_ScheduleOfNoncontrollingInterestTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of non-controlling interest" } } }, "localname": "ScheduleOfNoncontrollingInterestTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/Non-controllingInterestTables" ], "xbrltype": "textBlockItemType" }, "ptgef_ScheduleOfProformaInformationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of Pro forma Information" } } }, "localname": "ScheduleOfProformaInformationTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusTables" ], "xbrltype": "textBlockItemType" }, "ptgef_ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation income tax rates" } } }, "localname": "ScheduleOfReconciliationEffectiveIncomeTaxratesTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "ptgef_ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of reconciliation of financial statement loss to tax basis loss" } } }, "localname": "ScheduleOfReconciliationOfFinancialStatementLossToTaxBasisLossTableTextBlock", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "ptgef_ShareIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Share issuance costs" } } }, "localname": "ShareIssuanceCosts", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ptgef_SharePricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share price, per share" } } }, "localname": "SharePricePerShare", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CommitmentsAndContingentLiabilitiesDetailsNarrative" ], "xbrltype": "perShareItemType" }, "ptgef_SharebasedCompensationExpenseForFinancialStatementPurposesForWhichNoBenefitWasTaken": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Share-based compensation expense for financial statement purposes for which no benefit was taken" } } }, "localname": "SharebasedCompensationExpenseForFinancialStatementPurposesForWhichNoBenefitWasTaken", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "ptgef_SharebasedCompensationExpenseRecognizedForFinancialStatementPurposes": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Share-based compensation expense recognized for financial statement purposes" } } }, "localname": "SharebasedCompensationExpenseRecognizedForFinancialStatementPurposes", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "ptgef_ShareholdersEquityAttributableToOwners": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shareholders' equity attributable to owners" } } }, "localname": "ShareholdersEquityAttributableToOwners", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalDisclosuresDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_SharesIssuedOrAccruedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued or accrued for services" } } }, "localname": "SharesIssuedOrAccruedForServices", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ptgef_SharesIssuedOrAccruedForServicesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued or accrued for services, shares" } } }, "localname": "SharesIssuedOrAccruedForServicesShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "ptgef_SharesIssuedUnderAtm": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued under ATM" } } }, "localname": "SharesIssuedUnderAtm", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "xbrltype": "monetaryItemType" }, "ptgef_SharesIssuedUnderAtmShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued under ATM, shares" } } }, "localname": "SharesIssuedUnderAtmShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity" ], "xbrltype": "sharesItemType" }, "ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Shares issued under public offering and ATM, net of issue cost, shares" } } }, "localname": "SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCostShares", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "xbrltype": "sharesItemType" }, "ptgef_SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shares issued under public offering and ATM, net of issue costs" } } }, "localname": "SharesIssuedUnderPublicOfferingAndAtmNetOfIssueCosts", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/CapitalStockDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_StatutoryU.s.IncomeTaxRate": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statutory U.S. income tax rate" } } }, "localname": "StatutoryU.s.IncomeTaxRate", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "xbrltype": "percentItemType" }, "ptgef_StimunityConvertibleNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stimunity convertible note" } } }, "localname": "StimunityConvertibleNote", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_StimunityConvertibleNoteReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Stimunity convertible note receivable" } } }, "localname": "StimunityConvertibleNoteReceivable", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_StimunitySAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stimunity S A [Member]" } } }, "localname": "StimunitySAMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetails", "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_StockGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of shares available for awards" } } }, "localname": "StockGranted", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "sharesItemType" }, "ptgef_StockOptionReserve": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Stock Option Reserve", "periodEndLabel": "Ending balance", "periodStartLabel": "Begiining balance" } } }, "localname": "StockOptionReserve", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_StockOptionReserveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Option Reserve [Member]" } } }, "localname": "StockOptionReserveMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfChangesInShareholdersEquity", "http://portagebiotech.com/role/StockOptionReserveDetails" ], "xbrltype": "domainItemType" }, "ptgef_StockOptionsTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock Options Two [Member]" } } }, "localname": "StockOptionsTwoMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetails1", "http://portagebiotech.com/role/StockOptionReserveDetails2" ], "xbrltype": "domainItemType" }, "ptgef_SubsidiariesTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsidiaries Two [Member]" } } }, "localname": "SubsidiariesTwoMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/BasisOfPresentationDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_SupplementalCashFlowInformationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of cash flow information:" } } }, "localname": "SupplementalCashFlowInformationsAbstract", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "ptgef_TarusAcquisitionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tarus Acquisition [Member]" } } }, "localname": "TarusAcquisitionMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/AcquisitionOfTarusDetails", "http://portagebiotech.com/role/AcquisitionOfTarusDetails1", "http://portagebiotech.com/role/AcquisitionOfTarusDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_TarusAdenosineReceptors1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tarus Adenosine Receptors 1 [Member]" } } }, "localname": "TarusAdenosineReceptors1Member", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "xbrltype": "domainItemType" }, "ptgef_TarusAdenosineReceptors2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tarus Adenosine Receptors 2 [Member]" } } }, "localname": "TarusAdenosineReceptors2Member", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "xbrltype": "domainItemType" }, "ptgef_TarusAdenosineReceptorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tarus Adenosine Receptors [Member]" } } }, "localname": "TarusAdenosineReceptorsMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "xbrltype": "domainItemType" }, "ptgef_TarusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Tarus [Member]" } } }, "localname": "TarusMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative", "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetails" ], "xbrltype": "domainItemType" }, "ptgef_TaxDeposits": { "auth_ref": [], "calculation": { "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails": { "order": 5.0, "parentTag": "ifrs-full_CurrentPrepayments", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Tax deposits" } } }, "localname": "TaxDeposits", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/PrepaidExpensesAndOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ptgef_TotalCurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Total current liabilities" } } }, "localname": "TotalCurrentLiabilities", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_TranslatedValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Translated value" } } }, "localname": "TranslatedValue", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_TrusIPRAndDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trus I P R And D [Member]" } } }, "localname": "TrusIPRAndDMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/In-processResearchAndDevelopmentAndDeferredTaxLiabilityDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_TwoMembersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Two Members [Member]" } } }, "localname": "TwoMembersMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_UnitedStateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "United State [Member]" } } }, "localname": "UnitedStateMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "xbrltype": "domainItemType" }, "ptgef_UnrealizedGain": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unrealized gain" } } }, "localname": "UnrealizedGain", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInAssociateDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_UnrealizedGainOrLoss": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Unrealized gain or loss" } } }, "localname": "UnrealizedGainOrLoss", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InvestmentInPublicCompanyDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_UnrealizedGains": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "UnrealizedGains", "verboseLabel": "Unrealized gain" } } }, "localname": "UnrealizedGains", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/FinancialInstrumentsAndRiskManagementDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "ptgef_UnvestedOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Unvested Options [Member]" } } }, "localname": "UnvestedOptionsMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_UtilizationOfLossNotPreviouslyBenefitted": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "UtilizationOfLossNotPreviouslyBenefitted", "verboseLabel": "Utilization of losses not previously benefitted" } } }, "localname": "UtilizationOfLossNotPreviouslyBenefitted", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails3" ], "xbrltype": "monetaryItemType" }, "ptgef_UtilizationOfLossesNotPreviouslyBenefitted": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Utilization of losses not previously benefitted" } } }, "localname": "UtilizationOfLossesNotPreviouslyBenefitted", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/IncomeTaxesDetails1" ], "xbrltype": "monetaryItemType" }, "ptgef_VestedOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vested Options [Member]" } } }, "localname": "VestedOptionsMember", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/StockOptionReserveDetailsNarrative" ], "xbrltype": "domainItemType" }, "ptgef_WeightedAverageNumberOfSharesBasic": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of shares, Basic" } } }, "localname": "WeightedAverageNumberOfSharesBasic", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" }, "ptgef_WeightedAverageNumberOfSharesDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average number of shares, Diluted" } } }, "localname": "WeightedAverageNumberOfSharesDiluted", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/LossPerShareDetails" ], "xbrltype": "sharesItemType" }, "ptgef_WeightedAverageSharesOutstandingBasic": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding, basic" } } }, "localname": "WeightedAverageSharesOutstandingBasic", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLossParenthetical" ], "xbrltype": "sharesItemType" }, "ptgef_WeightedAverageSharesOutstandingDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding, diluted" } } }, "localname": "WeightedAverageSharesOutstandingDiluted", "nsuri": "http://portagebiotech.com/20230630", "presentation": [ "http://portagebiotech.com/role/InterimStatementsOfOperationsAndOtherComprehensiveIncomeLossParenthetical" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_104&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r10": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r100": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_97&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "16", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g51-60_TI", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "16", "Section": "Presentation", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS16_g47-50_TI", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "17", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Clause": "iv", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iv&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Clause": "vi", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r110": { "Clause": "ii", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_ii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Clause": "iv", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f_iv&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_l&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B67&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "13C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_13C&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r120": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "7", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_e&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r130": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r132": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r133": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r134": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r135": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r136": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r137": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_80_a&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r138": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "19", "Paragraph": "138", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138_a&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r139": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r14": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_56&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r140": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r141": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_94&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r142": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r143": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE60", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE60&doctype=Illustrative%20Examples", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r144": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r145": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "B89", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r146": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r147": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "17", "Paragraph": "96", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_96_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r148": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r149": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "IE72", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_IE72&doctype=Illustrative%20Examples", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r15": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r150": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r151": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r152": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r153": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r154": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r155": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r156": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r157": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r158": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r159": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r160": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r161": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r162": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r163": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r164": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r165": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r166": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r167": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r168": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r169": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r170": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r171": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r172": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r173": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r174": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r175": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r176": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r177": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r178": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r179": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r18": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r180": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r181": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "19", "Paragraph": "57", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_57_a&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r182": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_9&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r183": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r184": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r185": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "7", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r186": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r187": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r188": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r189": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r19": { "Clause": "iii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r190": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r191": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2023-en-r&anchor=para_B64_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r192": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r2": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r20": { "Clause": "iv", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Clause": "ii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Clause": "ii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_79&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Clause": "iii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r30": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Clause": "ii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Clause": "ii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS12_g79-88_TI", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "19", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_138&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "19", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "24", "Paragraph": "18", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_18&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r40": { "Clause": "viii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2023-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "27", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Clause": "ii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_ii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Clause": "iii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Clause": "ii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_ii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Clause": "iii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2023-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r50": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_c&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Clause": "ii", "IssueDate": "2023-01-01", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "36", "Paragraph": "134", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_134_a&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "36", "Paragraph": "135", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2023-en-r&anchor=para_135_a&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "40", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_76&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r60": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Clause": "ii", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r70": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "10", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "1", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_1&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_c&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "19B", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_19B_c&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "21", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Clause": "iii", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "21", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iii&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Clause": "iv", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "21", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "22", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_22_c&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r80": { "Clause": "i", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Clause": "ii", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Clause": "iii", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Clause": "iv", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Clause": "ix", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Clause": "vi", "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_vi&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "IssueDate": "2023-01-01", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r90": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "13", "Paragraph": "93", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "IssueDate": "2023-01-01", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2023-03-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 91 0001171843-23-005467-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001171843-23-005467-xbrl.zip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end